Study: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

Summary: This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Detailed Description: NA

Results: Outcome: Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density. Time frame: From Baseline (Month 0) to Month 12. Description: Relative change in Bone Mineral Density (BMD) is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 12 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 12. Participants available at particular time point for assessment were included in the analysis.. Parameters: Mean Difference (Final Values) = 0.615 (p = 0.045, CI 0.013-1.216); Mean Difference (Final Values) = 0.297 (p = 0.338, CI -0.312-0.906); Mean Difference (Final Values) = 1 (p = 0.001, CI 0.395-1.605). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Summary: This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Detailed Description: NA

Results: Outcome: Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months. Time frame: Baseline and Month 12. Description: BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 12. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline). Parameters: Mean Difference (Final Values) = 1.257 (p = 0.001, CI 0.701-1.814); Mean Difference (Final Values) = 1.025 (p = 0.001, CI 0.471-1.578). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Summary: This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

Detailed Description: NA

Results: Outcome: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24. Time frame: 24 Months. Description: Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.. Parameters: Mean Difference (Final Values) = 7 (p = 1e-04, CI 6.2-7.8). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia

Summary: This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

Detailed Description: NA

Results: Outcome: Percentage of Responders. Time frame: Up to 12 months. Description: Percent responders were defined as follows: Participants with a) lumbar spine (LS) BMD, equal to or above Baseline at Month 12 b) proximal femur BMD, equal to or above Baseline at Month 12 c) Both lumbar spine and proximal femur BMD, equal or above Baseline at Month 12. BMD of the lumbar spine was defined as the BMD of at least two vertebrae (L2-L4) that were not fractured and not affected by an osteoarthritic process, or a scanning artifact that could not be removed to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center. Proximal femur included total hip, trochanter and femoral neck sites.. Parameters: Odds Ratio (OR) = 12.51 (p = NA, CI 5.12-30.56); Odds Ratio (OR) = 8.59 (p = NA, CI 3.8-19.42); Odds Ratio (OR) = 13.8 (p = NA, CI 5.17-36.79). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12. Time frame: Baseline and Month 12. Description: BMD was measured by a single dual-energy x-ray absorptiometry (DEXA) scan of the lumbar spine at the time of screening and at Month 12. A BMD measurement was considered unsuitable in case of detection of a fracture, an osteoarthritic process, or a scanning artifact that could not be removed to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at baseline) / (BMD at baseline). Parameters: Mean Difference (Net) = 4.1226 (p = 1e-04, CI 2.9613-5.2838). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Vitamin K Supplementation in Post-Menopausal Osteopenia

Summary: The purpose of this study is to determine whether supplementation with 5 mg vitamin K daily over a 2-year period will prevent bone loss in post-menopausal women with osteopenia.

Detailed Description: Osteoporosis is major cause of morbidity and mortality in Canadian postmenopausal women. It is a systemic disease characterized by low bone mass and deterioration of bone microarchitecture, resulting in bone fragility and an increased risk of fractures. One in six women over the age of 50 have osteoporosis. The lifetime risk of an osteoporotic fracture for an average 50 year-old Canadian woman is \>40%. The annual health care costs for osteoporotic fractures in Canada have been estimated to exceed $1.3 billion.

Recent data suggest that vitamin K supplements may decrease bone loss and prevent fractures. Vitamin K is a co-factor of gamma-glutamyl carboxylase, an enzyme that catalyzes the gamma-carboxylation of glutamic acid residues in bone matrix proteins such as osteocalcin. Vitamin K has been reported to enhance bone formation in both in vitro studies and in vivo studies in animals. Vitamin K levels are low in individuals with osteoporosis and in patients with osteoporotic fractures. The few studies examining vitamin K supplementation in humans have showed promising results with no significant side effects, but these studies had significant methodological shortcomings such as inadequate sample size and lack of randomization.

The primary objective of our study is to examine whether vitamin K supplementation will increase bone mineral density in postmenopausal women with osteopenia. Our secondary objectives are to examine the possible adverse effects from long-term vitamin K supplementation, to investigate whether vitamin K will decrease risk of fractures and to determine if vitamin K affects quality of life. Our hypotheses are that vitamin K increases bone mineral density in postmenopausal women, and that there are no significant adverse effects from vitamin K supplementation.

Results: Outcome: Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.. Time frame: 0 to 24 months. Description: BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.. Time frame: 0 to 24 months. Description: BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.
Study: Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

Summary: To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.

Detailed Description: NA

Results: Outcome: Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Mineral Content BMC (Percentage) Change in Collum Femoris After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0.174, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Mineral Content BMC (Percentage) Change in Lumber Spine After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0.869, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Mineral Density BMD (Percentage) Change in Collum Femoris After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0.19, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0.26, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Mineral Density BMD (Percentage) Change in Trochiter After 12 Months. Time frame: Baseline and 12 months. Description: NA. Parameters: NA = NA (p = 0.31, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Summary: The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age. The main area of interest in the study is the pattern of any vaginal bleeding that occurs.

Detailed Description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.

Results: Outcome: Assessment of QOL as Measured by Women's Health Questionnaire. Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Women's Health Questionnaire (Total Score). For the Total score, the minimum is 36 and maximum is 144. A higher score means the distress and dysfunction are less pronounced.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 1: Hot Flushes (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 4: Sleep Problems (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 5: Irritability (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 6: Breast Tension (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.175, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Bleeding Days. Time frame: Last 90 days in Contraception Phase and first 360 days in Hormone-Replacement Therapy (HRT) Phase. Description: Measured by using Subject Diaries (Subject Reported Data). Parameters: NA = NA (p = 0.128, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Spotting Days. Time frame: Last 90 days in Contraception Phase and first 360 days in HRT Phase. Description: Measured by using Subject Diaries (Subject Reported Data). Parameters: NA = NA (p = 0.296, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS)). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 4: Nausea (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 5: Edema (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.054, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 7: Hair Loss (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.062, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS). Time frame: Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase. Description: Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)

Summary: The objective of the active surveillance study is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral continuous combined HRT products. The primary focus is the assessment of pertinent cardiovascular outcomes (such as venous and arterial thromboembolism) in new HRT users for up to 8.5 years.

Detailed Description: The safety of a novel drug product containing a new chemical entity should be assessed in an extensive post marketing safety surveillance program. It is also prudent to assess both, the safety outcomes that relate specifically to the targeted population, as well as those that could potentially be related to the special pharmacological characteristics of the novel drug product. Differentiating between the inherent background population risk and a potential incremental risk due to treatment is often challenging. Active safety surveillance using valid epidemiological study designs has been proven to be a pertinent and reliable method to approach this endeavour.

The primary objective of the study, the European Active Surveillance Study of Women taking HRT (EURAS-HRT), is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral continuous combined HRT products. This active surveillance study will assess pertinent cardiovascular outcomes in new HRT users over a study period of up to 8.5 years. Also, all other serious adverse events will be reported.

The new drug product under surveillance in the EURAS - HRT study contains the novel synthetic progestagen drospirenone (DRSP) combined with estradiol.

As estrogen/progestagen combinations increase the risk for thromboembolism, all new drug products that contain a novel estrogen or progestagen should be investigated for their influence on venous and arterial thromboembolic events rates. A large, prospective, controlled cohort study of OC users (EURAS OC study), which compared DRSP-containing OC users with other OC users, demonstrated that DRSP is not associated with an increased incidence for any of the above-mentioned adverse events in OC users. However, because OC users are two to three decades younger than the typical HRT user the results of the OC study can only partially be extrapolated to older age groups.

The participating women will complete a baseline survey using a self-administered questionnaire to describe the baseline risk. After 6 months, 12 months, and then on an annual basis, they will fill out a questionnaire in which they record complaints and events during the use of the prescribed HRTs. All adverse outcomes (including cancer) occurring during the observational period will be evaluated additionally. Reported serious adverse events will be validated and analyzed. As study participants may switch from oral continuous combined products to other oral or non-oral HRT products the outcomes for these preparation are recorded too. However, these results represent not the scientific focus of the study.

Based on experience obtained in previous HRT studies, complex sources of bias and confounding are expected. Multivariate methods will therefore be used to adjust for confounding.

Results: Outcome: Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke). Time frame: within 8.5 years. Description: Arterial thromboembolism (ATE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.. Parameters: Hazard Ratio (HR) = 0.5 (p = NA, CI 0.3-0.8). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism). Time frame: within 8.5 years. Description: Venous thromboembolism (VTE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.. Parameters: Hazard Ratio (HR) = 0.8 (p = NA, CI 0.5-1.3). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: A Study of Monthly Risedronate for Osteoporosis

Summary: The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Detailed Description: The comparator arms of this risedronate study are 150 mg monthly and 5 mg daily.

Results: Outcome: Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population. Time frame: Baseline to Month 12. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.. Parameters: LS Mean Difference = -5e-04 (p = NA, CI -0.0035-0.0024). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.. Parameters: Mean Difference (Final Values) = -9e-04 (p = NA, CI -0.0048-0.0029). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum BAP at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by ELISA (enzyme-linked immunosorbent assay). Parameters: Mean Difference (Final Values) = 0.12 (p = NA, CI -0.45-0.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay). Parameters: Mean Difference (Final Values) = 0.17 (p = NA, CI -0.29-0.64). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum CTX at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by electrochemiluminescent immunoassay.. Parameters: Mean Difference (Final Values) = -0.02 (p = NA, CI -0.06-0.01). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.. Parameters: Mean Difference (Final Values) = -0.02 (p = NA, CI -0.05-0). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Urine NTX/Cr at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \& 24.. Parameters: Mean Difference (Final Values) = 1 (p = NA, CI -2.54-4.53). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \& 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine. Parameters: Mean Difference (Final Values) = 0.23 (p = NA, CI -2.83-3.28). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With New Vertebral Fracture at Month 12, ITT Population. Time frame: Baseline to Month 12. Description: At least 1 new fractured vertebra. Parameters: Risk Ratio (RR) = 0.96 (p = 1, CI 0.36-2.54). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With New Vertebral Fracture at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: At least 1 new fractured vertebra. Parameters: Risk Ratio (RR) = 0.98 (p = 1, CI 0.47-2.03). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population. Time frame: Baseline to Month 12. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.. Parameters: LS Mean Difference = -0.076 (p = NA, CI -0.475-0.323). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.. Parameters: Mean Difference (Final Values) = -0.085 (p = NA, CI -0.609-0.439). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24). Time frame: Baseline to Month 24 - Endpoint. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).. Parameters: LS Mean Difference = -0.239 (p = NA, CI -0.727-0.249). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population. Time frame: Baseline to Month 12 - Endpoint. Description: BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).. Parameters: Least Square (LS) Mean Difference = -0.115 (p = NA, CI -0.505-0.274). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum BAP at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by ELISA (enzyme-linked immunosorbent assay). Parameters: Mean Difference (Final Values) = -0.77 (p = NA, CI -3.96-2.43). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum BAP at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: Assayed by ELISA (enzyme-linked immunosorbent assay). Parameters: Mean Difference (Final Values) = 1.31 (p = NA, CI -0.85-3.48). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum CTX at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by electrochemiluminescent immunoassay.. Parameters: Mean Difference (Final Values) = -5.69 (p = NA, CI -12.04-0.66). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum CTX at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: Assayed by electrochemiluminescent immunoassay.. Parameters: Mean Difference (Final Values) = -4.17 (p = NA, CI -7.98--0.36). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population. Time frame: Baseline to Month 24. Description: Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \& 24.. Parameters: Mean Difference (Final Values) = -2.83 (p = NA, CI -6.45-0.8). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population. Time frame: Baseline to Month 6. Description: Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \& 24.. Parameters: Mean Difference (Final Values) = -1.57 (p = NA, CI -4.47-1.33). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Summary: This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.

Detailed Description: NA

Results: Outcome: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12. Time frame: 12 months. Description: Cortical Thickness measured by XtremeCT.. Parameters: Mean Difference (Final Values) = 4.1 (p = NA, CI 2.6-5.7); Mean Difference (Final Values) = 1 (p = NA, CI -0.6-2.6). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Summary: This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is approximately 7 months, and the target sample size is \<100 individuals.

Detailed Description: NA

Results: Outcome: Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX) From Baseline to Day 3. Time frame: Baseline (Visit 1) and Day 3. Description: Serum C-terminal Telopeptide of Type 1 Collagen (sCTX) is a biochemical marker for bone turnover that has been shown to detect increased bone resorption, a process by which bone is broken down within the body. It is measured in units of nanograms (ng) per milliliter (mL). The relative change in sCTX was defined as the relative difference between the value at each time point and the value at Baseline, using the following formula: Relative change = (sCTX time point- sCTX Baseline) / (sCTX Baseline) \* 100. The sCTX value used for Baseline was the average of the results from the 2 blood samples taken at screening. If 1 of these 2 samples was nonquantifiable or missing, then the Baseline sCTX was the result from the non-missing sample. Baseline visit was defined as Visit 1.. Parameters: Difference in median = -64.2 (p = 1e-04, CI -80.28--46.21). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Summary: The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.

Detailed Description: NA

Results: Outcome: Change From Baseline to 12-Month Endpoint in the Roland-Morris Disability Questionnaire.. Time frame: Baseline, 12 Months. Description: Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).. Parameters: NA = NA (p = 0.932, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 12-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO). Time frame: Baseline, 12 Months. Description: QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.. Parameters: NA = NA (p = 0.572, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 18-Month Endpoint in European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO). Time frame: Baseline, 18 Months. Description: QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.. Parameters: NA = NA (p = 0.553, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 18-Month Endpoint in the Roland-Morris Disability Questionnaire.. Time frame: Baseline, 18 Months. Description: Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability). Pooled site, baseline glucocorticoid usage status (yes/no) and baseline score were controlled for.. Parameters: NA = NA (p = 0.943, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 3-Month Endpoint in the Roland-Morris Disability Questionnaire.. Time frame: Baseline, 3 Months. Description: Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).. Parameters: NA = NA (p = 0.968, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 6-Month Endpoint in the Roland-Morris Disability Questionnaire.. Time frame: Baseline, 6 Months. Description: Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).. Parameters: NA = NA (p = 0.568, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to 6-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO). Time frame: Baseline, 6 Months. Description: QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.. Parameters: NA = NA (p = 0.814, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 12-Month Endpoint. Time frame: 12 Months. Description: 24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 12-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.986, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 18-Month Endpoint. Time frame: 18 Months. Description: 24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 18-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.399, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 6-Month Endpoint. Time frame: 6 Months. Description: 24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 6-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.809, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 12-Month Endpoint. Time frame: 12 Months. Description: 24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 12-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.683, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 18-Month Endpoint. Time frame: 18 Months. Description: 24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 18-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.6, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint. Time frame: 6 Months. Description: 24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 6-month last observation carried forward (LOCF) endpoint.. Parameters: NA = NA (p = 0.642, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 12 Months. Time frame: Days 0, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600. Description: Time to first occurrence of \>= 30% pain reduction in worst back pain from baseline to 12 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.03 (p = 0.719, CI 0.86-1.25). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 18 Months. Time frame: Baseline through 18 Months. Description: Time to first occurrence of \>= 30% pain reduction in worst back pain from baseline to 18 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.07 (p = 0.453, CI 0.89-1.28). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 6 Months. Time frame: Days 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300. Description: Time to first occurrence of \>= 30% pain reduction in worst back pain from baseline to 6 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.03 (p = 0.746, CI 0.85-1.26). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 12 Months. Time frame: Days 0, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600. Description: Time to first occurrence of \>= 30% pain reduction in average back pain from baseline to 12 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.02 (p = 0.789, CI 0.86-1.23). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 18 Months. Time frame: Baseline through 18 Months. Description: Time to first occurrence of \>=30% pain reduction in average back pain from baseline to 18 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.09 (p = 0.353, CI 0.91-1.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 6 Months. Time frame: Days 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300. Description: Time to first occurrence of \>=30% pain reduction in average back pain from baseline to 6 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.. Parameters: Hazard Ratio (HR) = 1.04 (p = 0.681, CI 0.86-1.26). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

Summary: This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12 weeks; they will then cross over to receive the alternative treatment for a further 12 weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Detailed Description: NA

Results: Outcome: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing. Time frame: at 6 months. Description: Patients who had taken at least one dose of each study medication were asked to answer a Preference Questionnaire (answered by patients before any study procedures took place at the 6 month visit or at the early termination visit). The questionnaire included three questions on the preferred dosing schedule, and one question asking which schedule was more convenient. No assistance was allowed in completing the questionnaire.. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Study of Transitioning From Alendronate to Denosumab

Summary: The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density. Time frame: Baseline, 12 months. Description: Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.. Parameters: Mean Difference (Final Values) = 1.18 (p = 1e-04, CI 0.63-1.73). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I). Time frame: Baseline, 3 months. Description: Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \[(3 month value - baseline value) / baseline value\]\*100.. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Total Hip Bone Mineral Density. Time frame: Baseline, 12 months. Description: Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.. Parameters: Mean Difference (Final Values) = 0.85 (p = 1e-04, CI 0.44-1.25). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Summary: This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.

Eligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen.

Treatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa.

After taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.

Detailed Description: NA

Results: Outcome: Mean Percent Change of Serum C-terminal Telopeptide (CTx) From Baseline to Visit 3 for Once-monthly Dosing of Ibandronate & Once-weekly Dosing of Risedronate. Time frame: Baseline (Week 0) and Visit 3 (Week 12). Description: The difference of change in serum CTX from basal value between the two sequences was tested using ANCOVA at 95% confidence interval at 3 months (Visit 3) after the administration. Analysis was done with PP population. Baseline was value at Week 0, Change from baseline was calculated by subtracting Baseline value from value at specified time point.. Parameters: NA = NA (p = 0.9456, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants Choosing Ibandronate or Risedronate as Their Preferred Treatment Based on Convenience of Administration. Time frame: Visit 4 (Week 24). Description: Participant's preference for convenient treatment was compared between monthly ibandronate and weekly risedronate. Analysis population was mITT. Preference for convenient treatment was calculated as percentage. Percentage of participants who think once-monthly ibandronate dosing is more convenient over once-weekly risedronate dosing were presented. Those participants who answered the two treatments equally convenient were excluded while reporting.. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants Who Prefer the Once-monthly Dosing of Ibandronate to the Once-weekly Dosing of Risedronate. Time frame: Visit 4 (Week 24). Description: Preference of monthly ibandronate and weekly risedronate was compared. Modified-intention-to-treat (mITT) population was used for analysis. Any participant randomly assigned, received the study drug, and participants were asked to fill the preference questionnaire on completion of study. Preference was calculated as percentage. Data for percentage of participants with preference to once-monthly dosing of ibandronate to the once-weekly dosing of risedronate was presented.. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

Summary: The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq and Prempro on blood pressure in post-menopausal women with prehypertension.

Detailed Description: This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.

Results: Outcome: Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population. Time frame: Baseline to Week 8. Description: The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP.. Parameters: NA = NA (p = 0.0702, CI NA-NA); NA = NA (p = 0.5777, CI NA-NA); NA = NA (p = 0.198, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population. Time frame: Baseline to Week 8. Description: The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP.. Parameters: NA = NA (p = 0.6929, CI NA-NA); NA = NA (p = 0.1182, CI NA-NA); NA = NA (p = 0.2224, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Postmenopausal Women Estrogen and Progesterone Infusion

Summary: The purpose of the study is to study the effects of aging, estrogen and progesterone on the brain. Specifically, we want to look at how the hypothalamus and pituitary (two small glands in the brain) respond to estrogen. The pituitary gland is controlled by the hypothalamus. The hypothalamus secretes GnRH (Gonadotropin-Releasing Hormone) that signals the pituitary to secrete the reproductive hormones, LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone). These hormones act on the ovaries and signal the ovaries to produce estrogen and progesterone. Estrogen in the bloodstream then acts on the brain to modulate this system with changes in LH and FSH. Early changes associated with low levels of estrogen are inhibitory (estrogen negative feedback) while higher levels of estrogen (such as those present when a follicle in the ovary is ready to ovulate) stimulate LH to cause ovulation (positive feedback). This study will determine: 1) hypothalamic and pituitary levels of glucose uptake (as a measure of brain metabolic activity) at baseline and in association with estrogen negative feedback on LH (24 hr) and estrogen positive feedback on LH (72 hr); and 2) the effect of aging on estrogen feedback on LH, assessing negative feedback (nadir \~ 24 hr) and positive feedback (peak between 72 and 96 hr).

Detailed Description: The transition to menopause is characterized by a decline in the numbers of functional ovarian follicles followed by a decrease in levels of inhibin A and B and complex changes in estradiol, which include an initial increase followed by an inevitable decrease. Therefore, there are dynamic changes in the hypothalamic-pituitary feedback from the aging ovary, prior to the ultimate loss of feedback that occurs with the complete cessation of ovarian function. While there is ample evidence that the loss of ovarian function is a major contributor to the menopause, there is evidence from animal models that primary age-related neuroendocrine changes may also contribute to reproductive aging. Specifically, there is evidence for changes in the hypothalamic and pituitary responses to estrogen negative and positive feedback. An understanding of the age-related changes in the physiology of the hypothalamic and pituitary responsiveness to gonadal steroid feedback is critical in determining whether hypothalamic and pituitary changes per se contribute to the menopause and the impact of the loss of reproductive function on the brain.

Results: Outcome: 18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback. Time frame: 0 vs 24 hr. Description: Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.. Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: 18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback. Time frame: 24 vs 72 hr. Description: Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.. Parameters: NA = NA (p = 0.07, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: 18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback. Time frame: Baseline vs 24 hr after the onset of steroid infusion. Description: Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.. Parameters: NA = NA (p = 0.49, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: 18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback. Time frame: 24 hr vs 72 hr. Description: Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.. Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Effect of Aging on Estrogen Negative Feedback on LH. Time frame: Baseline at 0 time before infusion, nadir occurred between 8 and 60 hr (mean 24 hr). Description: Difference between baseline LH (average of 3 samples drawn 15 min apart) and nadir LH based on a 3-point moving average of blood samples drawn every 4 hours over 120 hr, expressed as a percent of baseline (% baseline).. Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Effect of Aging on Estrogen Negative Feedback on LH. Time frame: Baseline at 0 time before infusion, nadir occurred between 8 and 60 hr (mean 24 hr). Description: Difference between baseline LH (average of 3 samples drawn 15 min apart) and nadir LH based on a 3-point moving average of blood samples drawn every 4 hours over 120 hr, expressed as a percent of baseline (% baseline).. Parameters: NA = NA (p = 0.9, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Effect of Aging on Estrogen Positive Feedback on LH. Time frame: Onset of surge (average of 61 hr from beginnning of infusion until the end of the study (120 hr). Description: LH area under the curve in response to estrogen positive feedback. Area under the curve was calculated from blood samples drawn every 4 hours from the onset of positive feedback until the end of the study (120 min). The onset of positive feedback is defined as the time when LH first exceeds mean + 2SD of the previous three time points and shows a sustained rise.. Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Effect of Race on Gonadotropin Responses

Summary: The purpose of this study is to attempt to determine why estrogen levels are increased in African-American women as compared to Caucasian women by evaluating estrogen feedback on the brain. African-American women have increased bone mineral density, higher rates of twins, greater incidence of fibroids, and increased incidence of breast cancer below 40 years of age as compared to Caucasian women. These traits or illnesses are all believed to be estrogen-dependent. In fact, previous research has demonstrated increased estrogen levels in African-American women as compared to Caucasian women. However, the reason for these differences in estrogen levels has not been studied in humans. One possibility is that estrogen feedback on the brain differs between African-American and Caucasian women. Two small glands in the brain (hypothalamus and pituitary) respond to estrogen. The hypothalamus secretes GnRH (Gonadotropin-Releasing Hormone) that signals the pituitary to secrete the reproductive hormones, LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone). These hormones act on the ovaries and signal the ovaries to produce estrogen and progesterone. Estrogen in the bloodstream then acts on the brain to stop this system when the blood has enough estrogen levels. This is called estrogen feedback. This study will determine whether there are differences in estrogen feedback between African-American and Caucasian women.

Detailed Description: Several independent lines of evidence have suggested that reproductive endocrine dynamics may differ between African-American (AAW) and Caucasian (CW) women. There is an increased incidence of dizygotic twinning in African-American women and a further increase in the incidence reported in African women compared to Caucasian, Hispanic and Asian populations. While the etiology of dizygotic twinning is not well understood, an increase in its incidence may imply an alteration in the integrated control of the reproductive axis which usually favors development of a single ovulatory follicle. It is widely appreciated that the incidence of leiomyomas is increased in African-American women. Growth factors are likely to play a role in their control, but there is also ample evidence that leiomyomas are responsive to gonadal steroids, decreasing in size following the menopause and in response to hypoestrogenism caused by gonadotropin downregulation. African-American women under 40 years of age have a higher risk of breast cancer than women of all other ethnicities in that age group, again raising the question of whether there are also differences in reproductive hormone dynamics. Finally, bone density is increased in African-American women. In a cross-sectional study of 54 African-American and 39 Caucasian women between the ages of 20 and 90, Perry et al found that the increase in bone density in AAW was associated with increased serum levels of both estradiol and testosterone. Woods et al also described increased levels of estradiol, estrone and androstenedione levels in AAW compared with control women on a controlled low-fat, high-fiber diet. In contrast, a recent longitudinal cohort study has suggested that AAW have lower levels of estradiol with increasing age and BMI in comparison with CW. We have compared reproductive hormone levels in AAW and CW \< 35 years old with a history of regular ovulatory cycles. Our preliminary data indicate that in comparison to age and BMI matched CW, estradiol levels are consistently elevated across the cycle in AAW in the absence of changes in LH, FSH, progesterone, inhibin A or inhibin B. These relationships suggest both altered negative and forward feedback interrelationships between FSH and LH and estradiol in the setting of normal inhibin levels. In the current protocol we will seek to understand the mechanisms underlying these feedback differences, which have never been addressed in these populations.

A graded infusion of estradiol and progesterone can be used to assess differences in negative and positive feedback of gonadal steroids on LH and FSH. We have hypothesized that differences exist in feedback regulation of the hypothalamus and pituitary as a function of African-American or Caucasian race in reproductive aged women.

Results: Outcome: LH Peak in Response to Estrogen Positive Feedback. Time frame: 5 days of estradiol and progesterone infusion. Description: Estradiol levels are consistently higher in African-American vs Caucasian women across the menstrual cycle. This study was designed to determine if African-American women are more sensitive to estrogen positive feedback to generate the preovulatory LH surge using a controlled estrogen infusion paradigm.. Parameters: NA = NA (p = 0.69, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Endometrial Safety Study

Summary: The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).

Detailed Description: NA

Results: Outcome: Number of Participants With Amenorrhea During Month 1 to 3 of Treatment. Time frame: Month 1 to Month 3. Description: The women were to record daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.. Parameters: proportion = 0.687 (p = NA, CI 0.637-0.734); proportion = 0.593 (p = NA, CI 0.496-0.684). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Amenorrhea During Month 10 to 12 of Treatment. Time frame: Month 10 to Month 12. Description: The women were to record any bleeding daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.. Parameters: proportion = 0.789 (p = NA, CI 0.743-0.83); proportion = 0.84 (p = NA, CI 0.756-0.904). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment). Time frame: Up to one year. Description: The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.. Parameters: proportion = 0 (p = NA, CI 0-0.0119). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Summary: The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in an observational follow-up study, MK-0822-083 (EudraCT number: 2007-002693-66) .

Detailed Description: NA

Results: Outcome: Base Study + First Extension: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication. Time frame: Up to approximately 74 months of observation. Description: Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study + first extension were adjudicated against both ASBMR 2010 \& 2013 criteria. All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.. Parameters: Difference in rates = 0.03 (p = NA, CI 0.02-0.06). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication. Time frame: Up to approximately 74 months of observation. Description: The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study + first extension. Results are expressed as number of participants with an event per 100 person-years of follow-up.. Parameters: Difference in rates = 0.06 (p = NA, CI 0.03-0.11). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm. Time frame: Baseline and once yearly, up to approximately 74 months of observation. Description: BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study + first extension-dbp) in an approximate 10% random subset of participants at selected sites.. Parameters: Difference in Least Squares Means = 1.1 (p = 0.001, CI 0.66-1.54); Difference in Least Squares Means = 1.36 (p = 0.001, CI 0.87-1.85); Difference in Least Squares Means = 1.96 (p = 0.001, CI 1.42-2.5); Difference in Least Squares Means = 2.18 (p = 0.001, CI 1.4-2.96); Difference in Least Squares Means = 2.33 (p = 0.001, CI 1.54-3.11). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Femoral Neck. Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation. Description: BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).. Parameters: Difference in Least Squares Means = 1.47 (p = 0.001, CI 0.92-2.01); Difference in Least Squares Means = 2.21 (p = 0.001, CI 2.05-2.37); Difference in Least Squares Means = 4.39 (p = 0.001, CI 4.2-4.57); Difference in Least Squares Means = 6.5 (p = 0.001, CI 6.28-6.72); Difference in Least Squares Means = 8.29 (p = 0.001, CI 8.02-8.57); Difference in Least Squares Means = 10.05 (p = 0.001, CI 9.72-10.38). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Lumbar Spine. Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation. Description: BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses.. Parameters: Difference in Least Squares Means = 2.9 (p = 0.001, CI 2.4-3.39); Difference in Least Squares Means = 4.01 (p = 0.001, CI 3.87-4.15); Difference in Least Squares Means = 5.93 (p = 0.001, CI 5.75-6.11); Difference in Least Squares Means = 7.7 (p = 0.001, CI 7.48-7.91); Difference in Least Squares Means = 9.34 (p = 0.001, CI 9.08-9.61); Difference in Least Squares Means = 10.87 (p = 0.001, CI 10.55-11.19). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Total Hip. Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation. Description: BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).. Parameters: Difference in Least Squares Means = 1.34 (p = 0.001, CI 0.94-1.74); Difference in Least Squares Means = 2.5 (p = 0.001, CI 2.38-2.62); Difference in Least Squares Means = 4.47 (p = 0.001, CI 4.31-4.62); Difference in Least Squares Means = 6.46 (p = 0.001, CI 6.26-6.65); Difference in Least Squares Means = 8.48 (p = 0.001, CI 8.24-8.73); Difference in Least Squares Means = 10.29 (p = 0.001, CI 9.99-10.59). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Trochanter. Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation. Description: BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).. Parameters: Difference in Least Squares Means = 1.74 (p = 0.001, CI 1.06-2.42); Difference in Least Squares Means = 3.5 (p = 0.001, CI 3.31-3.7); Difference in Least Squares Means = 6.41 (p = 0.001, CI 6.16-6.65); Difference in Least Squares Means = 9.25 (p = 0.001, CI 8.95-9.54); Difference in Least Squares Means = 12.14 (p = 0.001, CI 11.76-12.51); Difference in Least Squares Means = 14.56 (p = 0.001, CI 14.11-15.01). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Rate of Adverse Events. Time frame: Up to approximately 74 months of observation. Description: An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.. Parameters: Difference in rates = 0.88 (p = NA, CI -2.3-4.07). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse Event. Time frame: Up to approximately 74 months of observation. Description: An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.. Parameters: Difference in rates = 0.11 (p = NA, CI -0.16-0.37). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture. Time frame: Up to approximately 74 months of observation. Description: Morphometric vertebral fractures were confirmed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant SQ Grade 1-3) (T4 to L4) were confirmed by QM and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).. Parameters: Hazard Ratio (HR) = 0.48 (p = 0.001, CI 0.42-0.55). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated). Time frame: Up to approximately 74 months of observation. Description: Osteoporotic clinical fractures (combining vertebral and non-vertebral) were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.67 (p = 0.001, CI 0.6-0.75). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated). Time frame: Up to approximately 74 months of observation. Description: Osteoporotic clinical hip fractures was confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.52 (p = 0.001, CI 0.4-0.67). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated). Time frame: Up to approximately 74 months of observation. Description: Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur and shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.74 (p = 0.001, CI 0.66-0.83). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated). Time frame: Up to approximately 74 months of observation. Description: Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.33 (p = 0.001, CI 0.24-0.45). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.17 (p = 0.029, CI 1.02-1.36). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First 4-Point MACE Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.14 (p = 0.159, CI 0.99-1.31). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First All-Cause Death Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated all-cause death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.05 (p = 0.341, CI 0.95-1.17). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.22 (p = 0.059, CI 0.99-1.5). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Cardiovascular Death Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated cardiovascular death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.13 (p = 0.246, CI 0.92-1.4). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 0.8 (p = 0.638, CI 0.32-2.03). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Fatal Stroke Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.61 (p = 0.114, CI 0.89-2.9). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 0.94 (p = 0.798, CI 0.7-1.26). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.37 (p = 0.005, CI 1.1-1.71). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 0.79 (p = 0.366, CI 0.47-1.33). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.17 (p = 0.178, CI 0.93-1.46). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 74 months of observation. Description: The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.23 (p = 0.198, CI 0.9-1.68). Non-inferiority type: OTHER. Outcome: Base Study: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication. Time frame: Up to approximately 60 months of observation. Description: Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study were adjudicated against both ASBMR 2010 and 2013 criteria. All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.. Parameters: Difference in rates = 0.02 (p = NA, CI 0.01-0.05). Non-inferiority type: OTHER. Outcome: Base Study: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication. Time frame: Up to approximately 60 months of observation. Description: The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study. Results are expressed as number of participants with an event per 100 person-years of follow-up.. Parameters: Difference in rates = 0.04 (p = NA, CI -0.01-0.09). Non-inferiority type: OTHER. Outcome: Base Study: Number of Participants With Height Loss of > 1 cm. Time frame: Baseline and once yearly, up to approximately 60 months of observation. Description: Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.. Parameters: Odds Ratio (OR) = 0.89 (p = 0.014, CI 0.81-0.98). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm. Time frame: Baseline and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of participants at selected sites.. Parameters: Difference in Least Squares Means = 1.11 (p = 0.001, CI 0.67-1.55); Difference in Least Squares Means = 1.35 (p = 0.001, CI 0.85-1.84); Difference in Least Squares Means = 1.93 (p = 0.001, CI 1.38-2.47); Difference in Least Squares Means = 2.2 (p = 0.001, CI 0.89-3.51); Difference in Least Squares Means = 3.5 (p = 0.001, CI 1.46-5.54). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm in Bisphosphonate-Intolerant Participants. Time frame: Baseline and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of bisphosphonate-intolerant participants at selected sites. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.. Parameters: Difference in Least Squares Means = 1.08 (p = 0.083, CI -0.14-2.31); Difference in Least Squares Means = 1.05 (p = 0.129, CI -0.31-2.4); Difference in Least Squares Means = 1.21 (p = 0.104, CI -0.25-2.67); Difference in Least Squares Means = 1.55 (p = 0.617, CI -4.92-8.02). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).. Parameters: Difference in Least Squares Means = 1.49 (p = 0.001, CI 0.95-2.03); Difference in Least Squares Means = 2.21 (p = 0.001, CI 2.05-2.37); Difference in Least Squares Means = 4.38 (p = 0.001, CI 4.19-4.57); Difference in Least Squares Means = 6.46 (p = 0.001, CI 6.24-6.68); Difference in Least Squares Means = 8.42 (p = 0.001, CI 7.82-9.02); Difference in Least Squares Means = 8.53 (p = 0.001, CI 7.54-9.53). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck in Bisphosphonate-Intolerant Participants. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA in bisphosphonate-intolerant participants at the femoral neck-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.. Parameters: Difference in Least Squares Means = 2.21 (p = 0.001, CI 1.83-2.59); Difference in Least Squares Means = 4.33 (p = 0.001, CI 3.87-4.78); Difference in Least Squares Means = 6.09 (p = 0.001, CI 5.56-6.62); Difference in Least Squares Means = 9.08 (p = 0.001, CI 6.97-11.19). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine. Time frame: Baseline, Month 6, and once yearly, approximately 60 months of observation. Description: BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses.

at. Parameters: Difference in Least Squares Means = 2.96 (p = 0.001, CI 2.47-3.46); Difference in Least Squares Means = 4.07 (p = 0.001, CI 3.93-4.22); Difference in Least Squares Means = 6.05 (p = 0.001, CI 5.87-6.23); Difference in Least Squares Means = 7.84 (p = 0.001, CI 7.62-8.06); Difference in Least Squares Means = 9.72 (p = 0.001, CI 9.16-10.27); Difference in Least Squares Means = 11.23 (p = 0.001, CI 10.23-12.23). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine in Bisphosphonate-Intolerant Participants. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA in bisphosphonate-intolerant participants at the lumbar spine at randomization, and at yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.. Parameters: Difference in Least Squares Means = 5.79 (p = 0.001, CI 5.37-6.2); Difference in Least Squares Means = 4.02 (p = 0.001, CI 3.67-4.37); Difference in Least Squares Means = 7.62 (p = 0.001, CI 7.11-8.13); Difference in Least Squares Means = 9.51 (p = 0.001, CI 7.96-11.06). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).. Parameters: Difference in Least Squares Means = 1.32 (p = 0.001, CI 0.9-1.75); Difference in Least Squares Means = 2.49 (p = 0.001, CI 2.37-2.61); Difference in Least Squares Means = 4.47 (p = 0.001, CI 4.31-4.62); Difference in Least Squares Means = 6.44 (p = 0.001, CI 6.25-6.64); Difference in Least Squares Means = 8.62 (p = 0.001, CI 8.11-9.12); Difference in Least Squares Means = 9.49 (p = 0.001, CI 8.7-10.29). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip in Bisphosphonate-Intolerant Participants. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA in bisphosphonate-intolerant participants at the total hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.. Parameters: Difference in Least Squares Means = 2.4 (p = 0.001, CI 2.11-2.68); Difference in Least Squares Means = 4.21 (p = 0.001, CI 3.84-4.57); Difference in Least Squares Means = 5.86 (p = 0.001, CI 5.41-6.3); Difference in Least Squares Means = 8.54 (p = 0.001, CI 7-10.09). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).. Parameters: Difference in Least Squares Means = 12.44 (p = 0.001, CI 11.66-13.22); Difference in Least Squares Means = 13.81 (p = 0.001, CI 12.58-15.04); Difference in Least Squares Means = 1.74 (p = 0.001, CI 1.03-2.46); Difference in Least Squares Means = 3.5 (p = 0.001, CI 3.31-3.7); Difference in Least Squares Means = 6.41 (p = 0.001, CI 6.17-6.65); Difference in Least Squares Means = 9.27 (p = 0.001, CI 8.98-9.57). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter in Bisphosphonate-Intolerant Participants. Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation. Description: BMD was measured by DXA in bisphosphonate-intolerant participants at the trochanter-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.. Parameters: Difference in Least Squares Means = 3.44 (p = 0.001, CI 2.98-3.9); Difference in Least Squares Means = 6.03 (p = 0.001, CI 5.47-6.59); Difference in Least Squares Means = 8.49 (p = 0.001, CI 7.81-9.16); Difference in Least Squares Means = 11.76 (p = 0.001, CI 9.15-14.36). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP) After Log-Transformation. Time frame: Baseline, Month 6, and once yearly up to 4 years. Description: BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Mean Difference (Final Values) = -7.64 (p = 0.001, CI -11.87--3.41); Mean Difference (Final Values) = -0.77 (p = 0.896, CI -12.34-10.79); Mean Difference (Final Values) = -14.13 (p = 0.001, CI -17--11.27); Mean Difference (Final Values) = -12.01 (p = 0.001, CI -15.22--8.79); Mean Difference (Final Values) = -9.29 (p = 0.001, CI -13.45--5.13). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in N-Terminal Propeptide of Type 1 Collagen (P1NP) After Log-Transformation. Time frame: Baseline, Month 6, and once yearly up to 4 years. Description: P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Mean Difference (Final Values) = -29.43 (p = 0.001, CI -33.47--25.39); Mean Difference (Final Values) = -25.94 (p = 0.001, CI -30.54--21.34); Mean Difference (Final Values) = -16.26 (p = 0.001, CI -21.41--11.12); Mean Difference (Final Values) = -12.11 (p = 0.001, CI -18.03--6.19); Mean Difference (Final Values) = -3.34 (p = 0.61, CI -16.12-9.45). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Serum C-Telopeptides of Type I Collagen (s-CTx) After Log-Transformation. Time frame: Baseline, Month 6, and once yearly up to 4 years. Description: s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -58.99 (p = 0.001, CI -64.68--53.3); Difference in Least Squares Means = -60.01 (p = 0.001, CI -66.4--53.61); Difference in Least Squares Means = -46.7 (p = 0.001, CI -53.23--40.17); Difference in Least Squares Means = -44.67 (p = 0.05, CI -52.62--36.72); Difference in Least Squares Means = -18.73 (p = 0.05, CI -37.44--0.01). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio After Log-Transformation. Time frame: Baseline, Month 6, and once yearly up to 4 years. Description: u-NTx, a biochemical marker of bone resorption, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. Urine NTx measurements (in bone collagen equivalents \[BCE\]) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -51.7 (p = 0.001, CI -56.11--47.28); Difference in Least Squares Means = -53.59 (p = 0.001, CI -58.39--48.79); Difference in Least Squares Means = -56.68 (p = 0.001, CI -62.52--50.84); Difference in Least Squares Means = -59.14 (p = 0.001, CI -66.04--52.23); Difference in Least Squares Means = -44.54 (p = 0.001, CI -61.72--27.36). Non-inferiority type: OTHER. Outcome: Base Study: Rate of Adverse Events. Time frame: Up to approximately 60 months of observation. Description: An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.. Parameters: Difference in rates = 1.52 (p = NA, CI -1.8-4.84). Non-inferiority type: OTHER. Outcome: Base Study: Rate of Discontinuation From Study Treatment Due to an Adverse Event. Time frame: Up to approximately 60 months of observation. Description: An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.. Parameters: Difference in rates = 0.27 (p = NA, CI -0.04-0.58). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture. Time frame: Up to approximately 60 months of observation. Description: Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant semiquantitative \[SQ\] Grade 1-3) (T4 to L4) were confirmed by quantitative morphometric (QM) and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).. Parameters: Hazard Ratio (HR) = 0.46 (p = 0.001, CI 0.4-0.53). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated). Time frame: Up to approximately 60 months of observation. Description: Osteoporotic clinical hip fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.53 (p = 0.001, CI 0.39-0.71). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated). Time frame: Up to approximately 60 months of observation. Description: Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.77 (p = 0.001, CI 0.68-0.87). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated). Time frame: Up to approximately 60 months of observation. Description: Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.. Parameters: Hazard Ratio (HR) = 0.28 (p = 0.001, CI 0.19-0.4). Non-inferiority type: OTHER. Outcome: Base Study: Time to First 3-Point Major Adverse Cardiac Event (MACE) Confirmed by Thrombolysis in Myocardial Infarction Study Group (TIMI) Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.12 (p = 0.182, CI 0.95-1.34). Non-inferiority type: OTHER. Outcome: Base Study: Time to First 4-Point MACE Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.12 (p = 0.127, CI 0.97-1.29). Non-inferiority type: OTHER. Outcome: Base Study: Time to First All-Cause Death Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated all-cause death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.12 (p = 0.127, CI 0.97-1.29). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.25 (p = 0.074, CI 0.98-1.6). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Cardiovascular Death Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated cardiovascular death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.16 (p = 0.277, CI 0.89-1.52). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 0.86 (p = 0.794, CI 0.29-2.57). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Fatal Stroke Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.91 (p = 0.081, CI 0.93-3.97). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 0.82 (p = 0.256, CI 0.58-1.15). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.32 (p = 0.034, CI 1.02-1.7). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.06 (p = 0.857, CI 0.59-1.89). Non-inferiority type: OTHER. Outcome: Base Study: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.18 (p = 0.235, CI 0.9-1.55). Non-inferiority type: OTHER. Outcome: Base Study: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication. Time frame: Up to approximately 60 months of observation. Description: The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.. Parameters: Hazard Ratio (HR) = 1.1 (p = 0.606, CI 0.76-1.59). Non-inferiority type: OTHER. Outcome: Base Study: Yearly Rate of Height Loss. Time frame: Up to approximately 60 months of observation. Description: Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.. Parameters: Difference in Least Squares Means = 0.01 (p = 0.041, CI 0-0.03). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography. Time frame: Baseline, Month 60. Description: Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 8.53 (p = 0.001, CI 5.79-11.28). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA. Time frame: Baseline, Month 60. Description: aBMD was measured at the femoral neck at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 9.98 (p = 0.001, CI 6.91-13.06). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA. Time frame: Baseline, Month 60. Description: aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 60 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 11.08 (p = 0.001, CI 8.41-13.74). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA. Time frame: Baseline, Month 60. Description: aBMD was measured at the total hip at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 10.41 (p = 0.001, CI 8.05-12.78). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA. Time frame: Baseline, Month 60. Description: aBMD was measured at the trochanter at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 14.94 (p = 0.001, CI 11.29-18.59). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography. Time frame: Baseline, Month 60. Description: Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 26.45 (p = 0.001, CI 16.49-36.4). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA. Time frame: Baseline, Month 24. Description: aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 24 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 5.55 (p = 0.001, CI 4.06-7.05). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation. Time frame: Baseline, Month 24. Description: BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -25.02 (p = 0.001, CI -35.92--14.12). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography. Time frame: Baseline, Month 24. Description: Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 24 was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 2.76 (p = 0.001, CI 1.43-4.1). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation. Time frame: Baseline, Month 24. Description: P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction change from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -26.7 (p = 0.001, CI -42.56--10.83). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography. Time frame: Baseline, Month 24. Description: Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 24 (base study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 8.92 (p = 0.001, CI 3.9-13.93). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA. Time frame: Baseline, Month 24. Description: aBMD was measured at the the distal one-third radius at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 1.67 (p = 0.016, CI 0.32-3.01). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA. Time frame: Baseline, Month 24. Description: aBMD was measured at the femoral neck at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 2.79 (p = 0.005, CI 0.86-4.72). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA. Time frame: Baseline, Month 24. Description: aBMD was measured at the total hip at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 3.63 (p = 0.001, CI 2.35-4.9). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA. Time frame: Baseline, Month 24. Description: aBMD was measured at the trochanter at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 5.65 (p = 0.001, CI 3.79-7.5). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation. Time frame: Baseline, Month 24. Description: s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -62.25 (p = 0.001, CI -79.99--44.5). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation. Time frame: Baseline, Month 24. Description: u-NTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. Urine NTx measurements (in BCE) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.. Parameters: Difference in Least Squares Means = -64.43 (p = 0.001, CI -87.8--41.07). Non-inferiority type: OTHER. Outcome: Sarcopenia Substudy PN035: Change From Baseline in Appendicular Lean Body Mass (aLBM). Time frame: Baseline and once yearly up to 4 years. Description: Sarcopenia is the age-related loss of skeletal muscle mass and associated loss of strength. Progression of sarcopenia was assessed using aLBM as measured by total body DXA. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Mean Difference (Final Values) = -0.02 (p = NA, CI -0.14-0.09); Mean Difference (Final Values) = 0 (p = NA, CI -0.12-0.12); Mean Difference (Final Values) = -0.04 (p = NA, CI -0.17-0.09); Mean Difference (Final Values) = -0.21 (p = NA, CI -0.5-0.08). Non-inferiority type: OTHER. Outcome: Sarcopenia Substudy PN035: Change From Baseline in Gait Speed. Time frame: Baseline and once yearly up to 4 years.. Description: Gait speed is a component of the Short Physical Performance Battery (SPPB) Score. Participants are asked to walk a distance of 4 meters at their normal pace. The test is performed 2 times, and the walk done in the shortest time is used for scoring. The activity is timed and then reduced to a categorical 0 to 4 scale based on time achieved. Higher scores indicate an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 0.04 (p = NA, CI -0.08-0.15); Difference in Least Squares Means = 0.08 (p = NA, CI -0.06-0.21); Difference in Least Squares Means = 0.03 (p = NA, CI -0.12-0.17); Difference in Least Squares Means = 0.09 (p = NA, CI -0.09-0.28). Non-inferiority type: OTHER. Outcome: Sarcopenia Substudy PN035: Change From Baseline in Short Physical Performance Battery (SPPB) Score. Time frame: Baseline and once yearly up to 4 years. Description: The Short Physical Performance Battery (SPPB) Score is used to assess physical function in older persons. The SPPB consists of 3 types of physical activities: standing balance, gait speed, and chair rise. Component activities are timed and then reduced to a categorical 0 to 4 scale based on time achieved. A higher composite score (range 0 to 12) indicates an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).. Parameters: Difference in Least Squares Means = 0.11 (p = NA, CI -0.16-0.38); Difference in Least Squares Means = 0.14 (p = NA, CI -0.15-0.44); Difference in Least Squares Means = 0.19 (p = NA, CI -0.15-0.54); Difference in Least Squares Means = 0.19 (p = NA, CI -0.24-0.62). Non-inferiority type: OTHER.
Study: Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Summary: To investigate efficacy and safety of 4 doses of esmirtazapine, compared to placebo, in the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with the menopause. Co-primary efficacy endpoints are the frequency and severity of hot flushes after 4 and 12 weeks as compared to Baseline.

Detailed Description: The most direct treatment of hot flushes may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors (SSRIs) and other similar compounds have been investigated to manage hot flushes, confirming the role of the serotonergic system. In the present trial, the efficacy and safety of four different doses of esmirtazapine compared to placebo were investigated in women with moderate to severe vasomotor symptoms associated with the menopause. The primary objective of this trial was to demonstrate superior efficacy in at least one of the four doses of esmirtazapine as compared to placebo on the four following co-primary endpoints: 1) the mean change from baseline in average daily frequency of moderate and severe vasomotor symptoms at Week 4; 2) the mean change from baseline in average daily frequency of moderate and severe vasomotor symptoms at Week 12; 3) the mean change from baseline in average daily severity of moderate and severe vasomotor symptoms at Week 4; 4) the mean change from baseline in average daily severity of moderate and severe vasomotor symptoms at Week 12. The number and severity of hot flushes was recorded by means of electronic diary by the subjects.

Results: Outcome: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 12. Time frame: Baseline and Week 12. Description: Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency Score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Difference between least squares means = -1 (p = 0.08, CI -2.1-0.1); Difference between least squares means = -1.6 (p = 0.01, CI -2.7--0.5); Difference between least squares means = -1.5 (p = 0.01, CI -2.7--0.4); Difference between least squares means = -2 (p = 0.01, CI -3.1--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4. Time frame: Baseline and Week 4. Description: Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on an electronic diary card (LogPad) on a daily basis during screening and treatment. Frequency Score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Difference between least squares means = -1.2 (p = 0.01, CI -2.2--0.2); Difference between least squares means = -1.7 (p = 0.01, CI -2.7--0.7); Difference between least squares means = -1.4 (p = 0.01, CI -2.4--0.4); Difference between least squares means = -1.9 (p = 0.01, CI -2.9--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 12. Time frame: Baseline and Week 12. Description: Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Difference between least squares means = -0.07 (p = 0.02, CI -0.14--0.01); Difference between least squares means = -0.06 (p = 0.07, CI -0.12-0); Difference between least squares means = -0.05 (p = 0.24, CI -0.11-0.02); Difference between least squares means = -0.04 (p = 0.29, CI -0.11-0.02). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4. Time frame: Baseline and Week 4. Description: Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Difference between least squares means = -0.07 (p = 0.01, CI -0.12--0.01); Difference between least squares means = -0.06 (p = 0.02, CI -0.11--0.01); Difference between least squares means = -0.07 (p = 0.01, CI -0.13--0.02); Difference between least squares means = -0.08 (p = 0.01, CI -0.14--0.03). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Summary: The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Detailed Description: The comparator arms of this risedronate study are 35 mg delayed release given weekly and 5 mg immediate release given daily.

Results: Outcome: Number of Patients With No New Fractured Vertebra, Week 104. Time frame: Week 104. Description: NA. Parameters: Relative Risk = 0.42 (p = 0.4505, CI 0.08-2.14); Relative Risk = 0.82 (p = 1, CI 0.22-3.03). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With No New Fractured Vertebra, Week 104 / Endpoint. Time frame: Week 104 / Endpoint. Description: NA. Parameters: Relative Risk = 0.41 (p = 0.4505, CI 0.08-2.11); Relative Risk = 1.2 (p = 0.7719, CI 0.37-3.9). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With No New Fractured Vertebra, Week 52. Time frame: Week 52. Description: NA. Parameters: Relative Risk = 1 (p = 1, CI 0.14-7.05); Relative Risk = 1.5 (p = 1, CI 0.25-8.9). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With No New Fractured Vertebra, Week 52 / Endpoint. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Relative Risk = 1.03 (p = 1, CI 0.15-7.29); Relative Risk = 1.49 (p = 1, CI 0.25-8.87). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With at Least One New Fractured Vertebra, Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: Relative Risk = 0.41 (p = 0.4505, CI 0.08-2.11); Relative Risk = 1.2 (p = 0.7719, CI 0.37-3.9). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With at Least One New Fractured Vertebra, Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: Relative Risk = 0.42 (p = 0.4505, CI 0.08-2.14); Relative Risk = 0.82 (p = 1, CI 0.22-3.03). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With at Least One New Fractured Vertebra, Week 52. Time frame: Week 52. Description: NA. Parameters: Relative Risk = 1 (p = 1, CI 0.14-7.05); Relative Risk = 1.5 (p = 1, CI 0.25-8.9). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Number of Patients With at Least One New Fractured Vertebra, Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Relative Risk = 1.03 (p = 1, CI 0.15-7.29); Relative Risk = 1.49 (p = 1, CI 0.25-8.87). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Greater Trochanter BMD, Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = -0.249 (p = NA, CI -0.86-0.363); Least Squares Mean Difference = -0.265 (p = NA, CI -0.871-0.342). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine BMD at Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = -1.059 (p = NA, CI -1.762--0.355); LS Mean Difference = -0.922 (p = NA, CI -1.62--0.223). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine BMD at Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = -1.154 (p = NA, CI -1.903--0.405); LS Mean Difference = -1.044 (p = NA, CI -1.789--0.299). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine BMD for Combined 35 mg Delayed-Release Weekly Treatment Group, Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = -0.265 (p = 0.2955, CI -0.763-0.232). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine BMD, Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = -0.131 (p = NA, CI -0.674-0.412); Least Squares Mean Difference = 0.156 (p = NA, CI -0.382-0.695). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine BMD, Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = -0.258 (p = NA, CI -0.836-0.321); Least Squares Mean Difference = -0.322 (p = NA, CI -0.9-0.256). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population. Time frame: 52 weeks / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = -0.233 (p = NA, CI -0.812-0.345); Least Squares Mean Difference = -0.296 (p = NA, CI -0.869-0.277). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 13, ITT Population. Time frame: Week 13. Description: NA. Parameters: Least Squares Mean Difference = 3.723 (p = NA, CI -0.975-8.421); Least Squares Mean Difference = 4.45 (p = NA, CI -0.26-9.16). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = 4.798 (p = NA, CI -0.195-9.79); Least Squares Mean Difference = 4.972 (p = NA, CI 0.02-9.924). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Total Proximal Femur BMD, Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = -0.522 (p = NA, CI -1.03--0.014); LS Mean Difference = -0.468 (p = NA, CI -0.973-0.037). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Total Proximal Femur BMD, Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = -0.587 (p = NA, CI -1.116--0.059); LS Mean Difference = -0.644 (p = NA, CI -1.179--0.11). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Total Proximal Femur BMD, Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = -0.288 (p = NA, CI -0.682-0.106); Least Squares Mean Difference = -0.29 (p = NA, CI -0.681-0.101). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = 4.817 (p = NA, CI -0.693-10.327); LS Mean Difference = 3.192 (p = NA, CI -2.295-8.68). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = 4.739 (p = NA, CI -0.793-10.271); LS Mean Difference = 3.999 (p = NA, CI -1.518-9.515). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = 2.63 (p = NA, CI -2.171-7.431); Least Squares Mean Difference = 4.617 (p = NA, CI -0.152-9.386). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = 6.372 (p = NA, CI 1.329-11.414); Least Squares Mean Difference = 4.403 (p = NA, CI -0.619-9.425). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = 5.04 (p = NA, CI 0.091-9.989); Least Squares Mean Difference = 4.64 (p = NA, CI -0.293-9.574). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline Urine Type-I Collagen N-telopeptide/ Creatinine (NTX/Cr), Week 13, ITT Population. Time frame: Week 13. Description: NA. Parameters: Least Squares Mean Difference = 3.771 (p = NA, CI -0.885-8.427); Least Squares Mean Difference = 2.826 (p = NA, CI -1.819-7.471). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Femoral Neck BMD, Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = -0.555 (p = NA, CI -1.128-0.018); LS Mean Difference = -0.616 (p = NA, CI -1.185--0.046). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Femoral Neck BMD, Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = -0.578 (p = NA, CI -1.189-0.032); LS Mean Difference = -0.799 (p = NA, CI -1.403--0.194). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Femoral Neck BMD, Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = -0.265 (p = NA, CI -0.731-0.201); Least Squares Mean Difference = -0.126 (p = NA, CI -0.588-0.336). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Femoral Neck BMD, Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = -0.327 (p = NA, CI -0.793-0.138); Least Squares Mean Difference = -0.537 (p = NA, CI -1--0.074). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Femoral Neck BMD, Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = -0.563 (p = NA, CI -1.045--0.08); Least Squares Mean Difference = -0.328 (p = NA, CI -0.811-0.156). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Greater Trochanter BMD, Week 104 / Endpoint. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = -0.919 (p = NA, CI -1.655--0.184); LS Mean Difference = -1.056 (p = NA, CI -1.787--0.326). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Greater Trochanter BMD, Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = -1.095 (p = NA, CI -1.861--0.329); LS Mean Difference = -1.19 (p = NA, CI -1.948--0.432). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Greater Trochanter BMD, Week 52 / Endpoint. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = -0.546 (p = NA, CI -1.17-0.078); Least Squares Mean Difference = -0.579 (p = NA, CI -1.199-0.042). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Greater Trochanter BMD, Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = -0.557 (p = NA, CI -1.185-0.071); Least Squares Mean Difference = -0.522 (p = NA, CI -1.149-0.105). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = 2.197 (p = NA, CI -1.318-5.711); LS Mean Difference = 2.251 (p = NA, CI -1.248-5.751). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = 2.749 (p = NA, CI -0.938-6.436); LS Mean Difference = 3.416 (p = NA, CI -0.255-7.087). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 13, ITT Population. Time frame: Week 13. Description: NA. Parameters: Least Squares Mean Difference = 1.755 (p = NA, CI -1.145-4.655); Least Squares Mean Difference = 1.805 (p = NA, CI -1.087-4.698). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = 2.407 (p = NA, CI -0.502-5.316); Least Squares Mean Difference = 1.309 (p = NA, CI -1.576-4.194). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = 1.434 (p = NA, CI -1.652-4.521); Least Squares Mean Difference = 1.462 (p = NA, CI -1.611-4.535). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = 1.555 (p = NA, CI -1.617-4.727); Least Squares Mean Difference = 1.612 (p = NA, CI -1.556-4.779). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104 / Endpoint, ITT Population. Time frame: Week 104 / Endpoint. Description: NA. Parameters: LS Mean Difference = 7.301 (p = NA, CI 0.911-13.69); LS Mean Difference = 7.802 (p = NA, CI 1.385-14.22). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104, ITT Population. Time frame: Week 104. Description: NA. Parameters: LS Mean Difference = 7.83 (p = NA, CI 1.175-14.485); LS Mean Difference = 8.383 (p = NA, CI 1.757-15.01). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: NA. Parameters: Least Squares Mean Difference = 6.552 (p = NA, CI 1.162-11.942); Least Squares Mean Difference = 5.531 (p = NA, CI 0.164-10.897). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = 4.775 (p = NA, CI -0.514-10.065); Least Squares Mean Difference = 5.638 (p = NA, CI 0.356-10.92). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Total Proximal Femur BMD, Week 26, ITT Population. Time frame: Week 26. Description: NA. Parameters: Least Squares Mean Difference = -0.135 (p = NA, CI -0.504-0.234); Least Squares Mean Difference = -0.072 (p = NA, CI -0.437-0.294). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Total Proximal Femur BMD, Week 52, ITT Population. Time frame: Week 52. Description: NA. Parameters: Least Squares Mean Difference = -0.29 (p = NA, CI -0.692-0.112); Least Squares Mean Difference = -0.321 (p = NA, CI -0.724-0.082). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: Responder = a patient showing a positive change (\>0 g/cm2) in lumbar spine BMD from baseline to the timepoint.. Parameters: Relative Risk = 1.08 (p = 0.0547, CI 1-1.16); Relative Risk = 1.1 (p = 0.0066, CI 1.03-1.18). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population. Time frame: Week 52. Description: Responder = a patient showing a positive change (\>0 g/cm2) in lumbar spine BMD from baseline to the timepoint.. Parameters: Relative Risk = 1.12 (p = 0.0014, CI 1.04-1.2); Relative Risk = 1.08 (p = 0.0476, CI 1-1.16). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 52 / Endpoint, ITT Population. Time frame: Week 52 / Endpoint. Description: Responder = a patient showing a positive change (\>0 g/cm2) in lumbar spine BMD from baseline to the timepoint.. Parameters: Relative Risk = 1.06 (p = 0.1639, CI 0.98-1.14); Relative Risk = 1.07 (p = 0.0729, CI 1-1.15). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD), Week 52, ITT Population. Time frame: Week 52. Description: Responder = a patient showing a positive change (\>0 g/cm2) in lumbar spine BMD from baseline to the timepoint.. Parameters: Relative Risk = 1.08 (p = 0.0524, CI 1-1.16); Relative Risk = 1.07 (p = 0.1207, CI 0.99-1.15). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Summary: This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Bone Turnover Markers at Month 1, Month 6 and Month 12. Time frame: Baseline and Months 1, 6 and 12. Description: Serum C-terminal Telopeptide of Type 1 Collagen (sCTX), Serum Procollagen Type 1 N-terminal Propeptide (P1NP) and Serum Bone Tartrate-resistant Acid Phosphatase Isoform 5b (TRACP) are measures of bone resorption and are measured as nanograms per milliliter (ng/mL). Percent change from Baseline to Months 1, 6 and 12 was calculated using analysis of covariance for repeated measurements.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine BMD at Month 6. Time frame: Baseline and Month 6. Description: Lumbar spine BMD was measured at Baseline and Month 6 using DXA. Percent change from Baseline to Month 6 was calculated using analysis of covariance.. Parameters: Mean Difference (Final Values) = 2.22 (p = 0.001, CI 1.22-3.23). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12. Time frame: Baseline and Month 12. Description: Lumbar spine BMD was measured at Baseline, and Months 6 and 12 using dual-energy x-ray absorptiometry (DXA). Percent change from Baseline to Month 12 was calculated using analysis of covariance.. Parameters: Mean Difference (Final Values) = 3.25 (p = 0.001, CI 2.09-4.41). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Total Hip BMD at Month 6 and Month 12. Time frame: Baseline and Months 6 and 12. Description: Left total hip BMD was measured by DXA at Baseline, and Months 6 and 12. If there was prosthesis of left hip, the measurement of right total hip BMD was done by DXA. Percent change from Baseline to Months 6 and 12 was calculated using analysis of (co)variance for repeated measurements.. Parameters: Mean Difference (Final Values) = 0.55 (p = 0.122, CI -0.15-1.25); Mean Difference (Final Values) = 1.81 (p = 0.001, CI 0.96-2.66). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Summary: This 2 arm study will assess the impact of bone marker feedback (BMF), using serum carboxy-terminal collagen crosslinks (CTX) and communication of results at 3 months, on adherence to once monthly ibandronate (150 milligrams \[mg\] per oral \[po\]) in women with post-menopausal osteoporosis supported by patient-relationship program (PRP). Participants will be randomized either to receive BMF or no BMF; both groups will be supported by PRP. The anticipated time on study treatment is 3-12 months.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in CTX Based on Adherence to Ibandronate. Time frame: Baseline, Month 6. Description: Serum CTX, a biochemical marker of bone resorption, was assessed for all participants at baseline and at final visit (Month 6). The sampling was done at the same time of the day each time to overcome the effect of circadian fluctuations. Participants were considered adherent to treatment if they took at least 83% of their assigned medications (5 of the 6 monthly ibandronate tablets) within the -1 to +21 days of their osteoporosis treatment date each month. Participant adherence was assessed by maintaining records of 'drug dispensed' and 'drug returned' on CRF and participant's self-report on Visit 2 (Month 3) and final study visit (Month 6). A drug dispensing log was maintained by the investigator. Participants were instructed at the baseline visit and Visit 2 to save and return unused or partially used medication packages on Visit 2 and final study visit, respectively.. Parameters: NA = NA (p = 0.4917, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Osteoporosis Patient Perception Survey (OPPS) and Osteoporosis Medical Care Satisfaction Questionnaire (OMSQ) Composite Satisfaction High Score. Time frame: At Month 6. Description: OPPS: A standardized 6-item satisfaction questionnaire for osteoporosis medical care and treatment received during the study. Individual item score was transformed and converted to a 0 to 100 scale where higher score indicated greater satisfaction. The composite score was the average of individual item scores (transformed) and ranged from 0 to 100, where higher scores indicated greater satisfaction. OMSQ: A standardized 18-item satisfaction questionnaire for osteoporosis medical care, treatment received and blood test and their results during the study. Individual item score was transformed and converted to a 0 to 100 scale where higher score indicated greater satisfaction. The composite score was the average of individual item scores (transformed) and ranged from 0 to 100, where higher scores indicated greater satisfaction.. Parameters: NA = NA (p = 0.453, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Composite Satisfaction High Scores. Time frame: At Month 6. Description: The OPSAT-Q is a validated questionnaire designed to capture satisfaction with bisphosphonate treatment. It comprises four domains: convenience (questions 1 - 6), quality of life (questions 7 and 8), overall satisfaction (questions 9 and 10), and side effects (questions 11 - 16). Satisfaction with treatment was assessed using the OPSAT-Q composite satisfaction score, which was the average of the scores from the four domains of the OPSAT-Q converted to a 0 - 100-point scale. Higher scores indicated greater treatment satisfaction. A score of 80 or more was considered as high score.. Parameters: NA = NA (p = 0.8989, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

Summary: The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.

Detailed Description: As teriparatide is approved for up to 24 months of treatment in the US, patients will be given the option to continue in a 6-month extension phase upon completion of 18 months of teriparatide treatment. This extension will allow for collection of additional bone quality data. In Canada, the use of teriparatide is currently approved for 18 months. Patients in Canada may be given the opportunity to participate in the 6-month extension phase, contingent upon Health Canada approval of the use of teriparatide treatment for 24 months.

Results: Outcome: Percent Change From Baseline in Areal BMD Responses at Total Hip at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Areal BMD is a measure of the amount of mineral in a given area of bone. Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.7, CI NA-NA); NA = NA (p = 0.092, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at Ultra-Distal Radius at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Areal BMD is a measure of the amount of mineral in a given area of bone. Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.106, CI NA-NA); NA = NA (p = 0.436, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at the Femoral Neck at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Areal BMD is a measure of the amount of mineral in a given area of bone. Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.049, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at the Lumbar Spine at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Areal BMD is a measure of the amount of mineral in a given area of bone. Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at  Distal Radius at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Areal BMD is a measure of the amount of mineral in a given area of bone. Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.013, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Volume (BV)/Total Volume (TV) Ratio in the Distal Radius at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: BV/TV is the estimate of the ratio of detectable bone relative to the total volume of the region of interest. Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.847, CI NA-NA); NA = NA (p = 0.212, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Cortical Thickness (CT) in the Distal Radius at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: Cortical thickness (CT) is the thickness of both cortices in a given volume of bone. Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.816, CI NA-NA); NA = NA (p = 0.934, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 3, 6 and 24 Endpoint. Time frame: Baseline, 3, 6, 24 months. Description: CTX is a measure of bone resorption. Least squares (LS) mean of the percent change from baseline to 3, 6, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.016, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 3, 6 and 24 Endpoint. Time frame: Baseline, 3, 6, 24 months. Description: PINP is a measure of bone formation. Least squares (LS) mean of the percent change from baseline to 3, 6, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Surface-to-Curve Ratio (SCR) at Month 3, 6, 12, 18 and 24 Endpoint. Time frame: Baseline, 3, 6, 12, 18, 24 months. Description: SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network. The higher the value for SCR, the more intact the trabecular network. Least squares (LS) mean of the percent change from baseline to 3, 6, 12, 18, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.335, CI NA-NA); NA = NA (p = 0.916, CI NA-NA); NA = NA (p = 0.61, CI NA-NA); NA = NA (p = 0.363, CI NA-NA); NA = NA (p = 0.837, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 18 Endpoint. Time frame: Baseline, 18 months. Description: SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network. The higher the value for SCR, the more intact the trabecular network. Least squares (LS) mean of the percent change from baseline to 18 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.363, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 24 Endpoint. Time frame: Baseline, 24 months. Description: SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network. The higher the value for SCR, the more intact the trabecular network. Least squares (LS) mean of the percent change from baseline to 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.837, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Topological Erosion Index (TEI) in the Distal Radius at Month 18 and 24 Endpoint. Time frame: Baseline, 18, 24 months. Description: TEI is the ratio of the sum of topological parameters expected to increase with bone erosion compared to the sum of those expected to decrease. The lower the value for TEI, the more intact the trabecular network. Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.. Parameters: NA = NA (p = 0.324, CI NA-NA); NA = NA (p = 0.089, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Hip at Month 18 Endpoint. Time frame: Baseline, 18 months. Description: Volumetric BMD is a measure of the amount of mineral in a given volume of bone. Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.021, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Lumbar Spine at Month 18 Endpoint. Time frame: Baseline, 18 months. Description: Volumetric BMD is a measure of the amount of mineral in a given volume of bone, expressed as milligram per cubic centimeter (mg/cm). Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Estimate of Bone Strength of Hip at Month 18 Endpoint. Time frame: Baseline, 18 months. Description: Finite Element Analysis of computed tomography (CT) data from hip is used to estimate the strength of the proximal femur with a virtual sideways fall. Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.045, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Estimate of Bone Strength of Lumbar Spine at Month 18 Endpoint. Time frame: Baseline, 18 months. Description: Finite Element Analysis of computed tomography (CT) data from spine is used to estimate the strength of a vertebral body using a virtual axial load. Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA). The model included terms for investigator site and prior bisphosphonate use.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

Summary: The most direct treatment of vasomotor symptions (hot flushes) may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors (SSRIs) and other similar compounds have been investigated to manage hot flushes, confirming the role of the serotonergic system. In the present trial, the efficacy and safety of four different doses of esmirtazapine compared to placebo was investigated in women with moderate to severe vasomotor symptoms associated with the menopause. The primary study hypothesis was that esmirtazapine would show superior efficacy to placebo.

Detailed Description: NA

Results: Outcome: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 12. Time frame: Baseline and Week 12. Description: Participants recorded the frequency of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Mean Difference (Final Values) = -1.5 (p = 0.01, CI -2.6--0.5); Mean Difference (Final Values) = -1 (p = 0.06, CI -2-0); Mean Difference (Final Values) = -2 (p = 0.01, CI -3--0.9); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4. Time frame: Baseline and Week 4. Description: Participants recorded the frequency of vasomotor symptoms (hot flushes) on an electronic diary card (LogPad) on a daily basis during screening and treatment. Frequency score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Mean Difference (Final Values) = -1.4 (p = 0.01, CI -2.3--0.4); Mean Difference (Final Values) = -2.2 (p = 0.01, CI -3.1--1.2); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--1); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--1). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 12. Time frame: Baseline and Week 12. Description: Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Mean Difference (Final Values) = 0.01 (p = 1, CI -0.06-0.07); Mean Difference (Final Values) = -0.05 (p = 0.15, CI -0.12-0.01); Mean Difference (Final Values) = -0.03 (p = 0.72, CI -0.09-0.04); Mean Difference (Final Values) = -0.06 (p = 0.13, CI -0.12-0.01). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4. Time frame: Baseline and Week 4. Description: Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward.. Parameters: Mean Difference (Final Values) = -0.06 (p = 0.02, CI -0.12--0.01); Mean Difference (Final Values) = -0.07 (p = 0.01, CI -0.13--0.01); Mean Difference (Final Values) = -0.06 (p = 0.02, CI -0.12--0.01); Mean Difference (Final Values) = -0.03 (p = 0.62, CI -0.09-0.03). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

Summary: To compare the efficacy 50 mg delayed-release risedronate tablet, dosed immediately after breakfast, to a 35 mg immediate-release tablet, administered according to labeling instructions.

Detailed Description: To compare the efficacy, based on the bone turnover marker (BTM) serum Type I collagen C-telopeptide (CTx), of a 50 mg delayed-release risedronate tablet, administered immediately after a typical breakfast, to that of a 35 mg immediate-release tablet, administered according to labeling instructions (ie, at least 30 minutes prior to breakfast) in postmenopausal women after 13 weeks of treatment.

Results: Outcome: Percent Change in Serum BAP (Bone-specific Alkaline Phosphatase), ITT Population. Time frame: Baseline and Week 13. Description: NA. Parameters: Ratio (LS Mean 50 mg DRFB/35 mg DRFB) = 1.668 (p = NA, CI 0.856-4.668); Ratio (LS Mean 50 mg DRFB/50 mgDRBB) = 0.868 (p = NA, CI 0.504-1.488); Ratio (LS Mean 35 mg DRFB/35 mg IRBB) = 0.947 (p = NA, CI 0.316-2.993); Ratio (LS Mean 50 mg DRBB/35 mg IRBB) = 1.82 (p = NA, CI 0.929-5.429); Ratio (LS Mean 50 mg DRFB/35 mg IRBB) = 1.58 (p = NA, CI 0.801-4.718). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Serum CTX (Type I Collagen C-telopeptide), ITT (Intent to Treat) Population. Time frame: Baseline and Week 13. Description: NA. Parameters: Ratio (LS Mean 35 mg DRFB/35 mg IRBB) = 1.437 (p = NA, CI 1.091-1.964); Ratio (LS Mean 50 mg DRBB/35 mg IRBB) = 1.507 (p = NA, CI 1.139-2.066); Ratio (LS Mean 50 mg DRFB/35 mg IRBB) = 1.535 (p = NA, CI 1.177-2.086); Ratio (LS Mean 50 mg DRFB/50 mg DRBB) = 1.068 (p = NA, CI 0.867-1.321); Ratio (LS Mean 50 mg DRFB/50 mg DRBB) = 1.018 (p = NA, CI 0.824-1.267). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Urine NTX/Cr (Urine Type I Collagen Cross-linked N-telopeptide Corrected for Creatinine Clearance), ITT Population. Time frame: Baseline and Week 13. Description: NA. Parameters: Ratio (LS Mean 35 mg DRFB/35 mg IRBB) = 1.208 (p = NA, CI 0.749-2.099); Ratio (LS Mean 50 mg DRBB/35 mg IRBB) = 1.132 (p = NA, CI 0.665-2.003); Ratio (LS Mean 50 mg DRFB/35 mg IRBB) = 1.407 (p = NA, CI 0.913-2.404); Ratio (LS Mean 50 mg DRFB/35 mg DRFB) = 1.165 (p = NA, CI 0.797-1.752); Ratio (LS Mean 50 mg DRFB/50 mg DRBB) = 1.243 (p = NA, CI 0.828-1.99). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

Summary: The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.

Detailed Description: NA

Results: Outcome: Mean Change in Frequency of Vasomotor Symptoms (VMS) From Baseline at Week 12. Time frame: Baseline (Week 0) and Week 12. Description: Individual VMS (hot flash or night sweats) events were recorded by participants in an electronic diary (eDiary) using as Global Change Question. The frequency was assessed using the question 1 as "Since you started the study medication, how has the number of your hot flashes (including night sweats) changed?". the response was rated on a 7-point scale from +3 to -3, where +3=A great deal better, +2=Moderately better, +1=A little better, 0=No change, -1=A little worse, -2=Moderately worse and -3=A great deal worse. The score ranged from +3 to -3, where +3 implied absence of symptoms and lower score implied more severe symptoms. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values. Adjusted mean is presented as least square mean.. Parameters: Adjusted Mean Difference = 0.75 (p = 0.215, CI -0.44-1.93); Adjusted Mean Difference = 1.21 (p = 0.041, CI 0.05-2.37); Adjusted Mean Difference = -2.06 (p = 0.001, CI -3.2--0.92). Non-inferiority type: SUPERIORITY. Outcome: Mean Change in Severity of VMS From Baseline at Week 12. Time frame: Baseline (Week 0) and Week 12. Description: Individual VMS (hot flash or night sweats) events were recorded by participants in an eDiary using global change questions. VMS severity was as follows: mild=score of 1 (brief wave of heat with minimal discomfort, usually without perspiration; able to continue activity \[or sleep\]), moderate=score of 2(heat with some discomfort, usually with perspiration; minimal interruption of activity \[or sleep\]), severe=score of 3(intense heat with considerable discomfort, usually with heavy sweating; may be unable to resume activity \[or sleep\] right away) and extremely severe=score of 4 (unbearable heat with intense discomfort, usually with pouring sweat; may be unable to resume activity \[or sleep\] for quite a while). Total score ranged from 1 to 4 and is the sum of severity scores divided by total number of VMS events. Higher score indicates worst condition. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.. Parameters: Adjusted Mean Difference = 0.15 (p = 0.202, CI -0.08-0.38); Adjusted Mean Difference = 0.31 (p = 0.008, CI 0.08-0.54); Adjusted Mean Difference = -0.52 (p = 0.001, CI -0.75--0.3). Non-inferiority type: SUPERIORITY.
Study: Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Summary: The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with the loss of estrogen because of "oxidative stress," the production of molecules that can damage cells and tissues in the body, and because the arteries lose their ability to expand, or dilate.

Detailed Description: As women get older and go through menopause, estradiol levels decrease. Also with aging, the arteries that are located around the heart get stiffer. Over time this increase in arterial stiffness can lead to a number of health problems such as high blood pressure and heart disease. In this study we want to find out if a short-term drop in estrogen levels in premenopausal and perimenopausal women can cause arteries to become stiffer, and why this happens. Additionally, in postmenopausal women, we want to find out if a short-term increase in estrogen levels causes their arteries to become more flexible (less stiff).

Arterial health (i.e., stiffness) will be examined in premenopausal, perimenopausal and postmenopausal women before and after they are given a drug called Ganirelix (for 7 days), which will markedly lower their reproductive hormones. After the first 4 days of taking Ganirelix, the women will be randomly placed into 1 of 2 treatment groups to take either estrogen (0.075 mg/d skin patch) replacement or placebo for the rest of the Ganirelix treatment. This is to increase estrogen levels back to the normal level. After having the patch on for 4 days, arterial health will be examined again.

Pre-specified Outcome Measures were divided into unit-of-measurement specific Outcome Measure tables for the purposes of results reporting to ClinicalTrials.gov

Results: Outcome: Endothelial Function. Time frame: Baseline, day 4 of GnRHant and Day 7 of GnRHant and estradiol or placebo treatment. Description: Brachial artery flow-mediated dilation (FMD) assessed by ultrasound. This other outcome measure was originally specified as "Secondary" in error and has been updated to "Primary" to be consistent with the protocol.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Estradiol. Time frame: Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment. Description: This other outcome measure was originally specified as "Secondary" in error and has been updated to "Other, Pre-specified" to be consistent with the protocol. Serum estradiol for clinical characteristics and to detect changes in estradiol levels with the interventions.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Progesterone. Time frame: Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back. Description: This other outcome measure was originally specified as "Secondary" in error and has been updated to "Other, Pre-specified" to be consistent with the protocol. Serum progesterone was measured for clinical characteristics and to determine changes in sex hormones.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER.
Study: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Summary: The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo is orally administered once weekly for 52 weeks to Japanese involutional osteoporosis participants. The study will also assess safety and tolerability of odanacatib (10, 25, and 50 mg) in these participants.

The study will enroll approximately 280 participants and randomly assign them to 3 different doses of odanacatib or placebo for 52 weeks, along with supplemental vitamin D3 and calcium carbonate. The primary efficacy hypothesis is that a dose-response relationship on the percent change from baseline in lumbar spine BMD (L1- L4) is seen when odanacatib 10, 25, 50 mg or placebo is orally administered once weekly for 52 weeks to involutional osteoporosis participants. The primary safety hypothesis is that odanacatib will be safe and well tolerated over 52 weeks to involutional osteoporosis participants.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline to Week 52 in Femoral Neck BMD. Time frame: Baseline (Observation visit to Wk 0 treatment visit), Week 52. Description: BMD (g/cm2) data was measured by DXA at the femoral neck subregion of the hip at the Observation visit (up to 5 weeks before Treatment Period), Week 0 (start of Treatment Period) and Week 52 (end of Treatment Period) or at discontinuation. Baseline was defined as the average of the 2 values collected at the Observation visit and Week 0 visit. Percent change from baseline in BMD = (\[BMD at Week 52 visit\] - \[baseline BMD\]  baseline BMD)  100. Measurements were performed using the Hologic QDR Series densitometer, and by same machine and under same scan mode throughout the study period. BMD data was centrally judged.. Parameters: Difference in LS Means = 3.08 (p = 0.001, CI 1.85-4.31); Difference in LS Means = 1.86 (p = 0.003, CI 0.64-3.08); Difference in LS Means = 2.23 (p = 0.001, CI 1.03-3.43). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Lumbar Spine Bone Mineral Density (BMD) at Lumbar Vertebrae 1 to 4 (L1-L4). Time frame: Baseline (Observation visit to Wk 0 treatment visit), Week 52. Description: BMD (g/cm2) data was measured by dual-energy X-ray absorptiometry (DXA) at lumbar spine vertebrae 1 through 4 (L1-L4) from anterior view at the Observation visit (up to 5 weeks before Treatment Period), Week 0 (start of Treatment Period) and Week 52 (end of Treatment Period) or at discontinuation. Baseline was defined as the average of the 2 values collected at the Observation visit and Week 0 visit. Percent change from baseline in BMD = (\[BMD at Week 52 visit\] - \[baseline BMD\]  baseline BMD)  100. Measurements were performed using the Hologic Quantitative Digital Radiography (QDR) Series densitometer, and by same machine and under same scan mode throughout the study period. BMD data was centrally judged.. Parameters: Difference in LS Means = 5.4 (p = 0.001, CI 4.16-6.64); Difference in LS Means = 5.12 (p = 0.001, CI 3.9-6.35); Difference in LS Means = 3.54 (p = 0.001, CI 2.33-4.75). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum Bone Specific Alkaline Phosphatase (s-BSAP) Level. Time frame: Baseline (Wk 0), Week 52. Description: s-BSAP is a biochemical marker index of bone formation. Blood samples were collected in the morning and in fasting state for measurement of s-BSAP. Percent change from baseline in biomarker = (\[biomarker value at Week 52 visit\] - \[baseline biomarker value\]  baseline biomarker value)  100. All measurements of bone biochemical markers were centrally performed.. Parameters: Difference in LS Means = -15.52 (p = 0.001, CI -25.11--5.93); Difference in LS Means = -12.55 (p = 0.009, CI -22.16--2.94); Difference in LS Means = 2.48 (p = 0.598, CI -7.79-12.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum C-Telopeptides of Type 1 Collagen (s-CTx) Level. Time frame: Baseline (Wk 0), Week 52. Description: s-CTx is a biochemical marker index of bone resorption. Blood samples were collected in the morning and in fasting state for measurement of s-CTx. Percent change from baseline in biomarker = (\[biomarker value at Week 52 visit\] - \[baseline biomarker value\]  baseline biomarker value)  100. All measurements of bone biochemical markers were centrally performed.. Parameters: Difference in LS Means = -60.42 (p = 0.001, CI -85.7--35.13); Difference in LS Means = -60.7 (p = 0.001, CI -85.91--35.49); Difference in LS Means = -38.73 (p = 0.001, CI -65.94--11.52). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum N-Terminal Propeptides of Type 1 Collagen (s-P1NP) Level. Time frame: Baseline (Wk 0), Week 52. Description: s-P1NP is a biochemical marker index of bone formation. Blood samples were collected in the morning and in fasting state for measurement of s- P1NP. Percent change from baseline in biomarker = (\[biomarker value at Week 52 visit\] - \[baseline biomarker value\]  baseline biomarker value)  100. All measurements of bone biochemical markers were centrally performed.. Parameters: Difference in LS Means = -28.86 (p = 0.001, CI -44.97--12.75); Difference in LS Means = -5.61 (p = 0.458, CI -23.79-12.56); Difference in LS Means = -26.86 (p = 0.001, CI -43.3--10.42). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Total Hip BMD. Time frame: Baseline (Observation visit to Wk 0 treatment visit), Week 52. Description: BMD (g/cm2) data was measured by DXA for total hip at the Observation visit (up to 5 weeks before Treatment Period), Week 0 (start of Treatment Period) and Week 52 (end of Treatment Period) or at discontinuation. Baseline was defined as the average of the 2 values collected at the Observation visit and Week 0 visit. Percent change from baseline in BMD = (\[BMD at Week 52 visit\] - \[baseline BMD\]  baseline BMD)  100. Measurements were performed using the Hologic QDR Series densitometer, and by same machine and under same scan mode throughout the study period. BMD data was centrally judged.. Parameters: Difference in LS Means = 3.06 (p = 0.001, CI 2.14-3.98); Difference in LS Means = 2.2 (p = 0.001, CI 1.29-3.12); Difference in LS Means = 1.67 (p = 0.001, CI 0.77-2.57). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Trochanter BMD. Time frame: Baseline (Observation visit to Wk 0 treatment visit), Week 52. Description: BMD (g/cm2) data was measured by DXA at the trochanter subregion of the hip (near bony protrusions along outside edge of femur) at the Observation visit (up to 5 weeks before Treatment Period), Week 0 (start of Treatment Period) and Week 52 (end of Treatment Period) or at discontinuation. Baseline was defined as the average of the 2 values collected at the Observation visit and Week 0 visit. Percent change from baseline in BMD = (\[BMD at Week 52 visit\] - \[baseline BMD\]  baseline BMD)  100. Measurements were performed using the Hologic QDR Series densitometer, and by same machine and under same scan mode throughout the study period. BMD data was centrally judged.. Parameters: Difference in LS Means = 4.66 (p = 0.001, CI 3.18-6.14); Difference in LS Means = 3.84 (p = 0.001, CI 2.37-5.3); Difference in LS Means = 2.43 (p = 0.002, CI 0.99-3.88). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Urinary Deoxypyridinoline/Creatinine Ratio (u-DPD/Cre). Time frame: Baseline (Wk 0), Week 52. Description: The u-DPD/Cre ratio is a biochemical marker index of bone resorption. Urine samples were collected from second void morning urine specimens to assess the u-DPD/Cre ratio. Percent change from baseline in biomarker = (\[biomarker value at Week 52 visit\] - \[baseline biomarker value\]  baseline biomarker value)  100. All measurements of bone biochemical markers were centrally performed.. Parameters: Difference in LS Means = -42.91 (p = 0.001, CI -65.55--20.27); Difference in LS Means = -37.45 (p = 0.001, CI -60.32--14.59); Difference in LS Means = -26.77 (p = 0.017, CI -50.37--3.16). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Urinary N-telopeptides/Creatinine (u-NTx/Cre) Ratio. Time frame: Baseline (Wk 0), Week 52. Description: The u-NTx/Cre ratio is a biochemical marker index of bone resorption. Urine samples were collected from second void morning urine specimens to assess the u-NTx/Cre ratio. Percent change from baseline in biomarker = (\[biomarker value at Week 52 visit\] - \[baseline biomarker value\]  baseline biomarker value)  100. All measurements of bone biochemical markers were centrally performed.. Parameters: Difference in LS Means = -44.32 (p = 0.001, CI -60.42--28.21); Difference in LS Means = -35.75 (p = 0.001, CI -52.33--19.16); Difference in LS Means = -50.64 (p = 0.001, CI -66.43--34.84). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)

Summary: To demonstrate the efficacy/safety of Fosamax Plus D

Detailed Description: NA

Results: Outcome: Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of Treatment. Time frame: 16 weeks. Description: NA. Parameters: Odds Ratio (OR) = 0.02 (p = 1e-04, CI 0-0.08). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Less and Greater Than 20 ng/ml at 16 Weeks of Treatment. Time frame: 16 weeks. Description: NA. Parameters: Odds Ratio (OR) = 0.02 (p = 1e-04, CI 0.01-0.04). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Serum PTH (Parathyroid Hormone) Percentage Changes From Baseline to 16 Weeks of Treatment. Time frame: Baseline and 16 weeks. Description: NA. Parameters: NA = NA (p = 0.0091, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.
Study: A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)

Summary: This study will develop a model for the assessment of successful activation/engagement of estrogen receptor beta using salivary biomarkers.

Detailed Description: NA

Results: Outcome: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7. Time frame: Baseline and Day 7. Description: Subset of genes on the log ratio intensity scale from a microarray platform - signature was pre-specified from an internally conducted study in knock-out mice treated with estrogens- quantified as a ratio of up regulated versus down regulated genes. Parameters: NA = NA (p = 0.345, CI NA-NA); NA = NA (p = 0.166, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.. Time frame: Baseline and Day 7. Description: Change from baseline in unstimulated labial gland saliva flow rate at Day 7. Parameters: Mean Difference (Final Values) = 0.38 (p = 0.12, CI -0.16-0.92). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Summary: The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal osteoporosis. Subject participation will last approximately 14.5 months.

Detailed Description: NA

Results: Outcome: Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Month 3: Sleep Sub-Study. Time frame: Baseline, Month 3. Description: Participant-rated questionnaire to assess sleep quality and quantity. Consists of 12-item questionnaires answered on a range of 1 to 6 for questions (Q) 3 to 12, 1 to 5 for Q1 (some questions are reversed so that a high score reflects more of the attributes); and Q2 answered on 0 to 24. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\* 100); total score range: 0 to 100; higher score = greater intensity of attribute. The items contribute to each scale and are averaged to create the 7 scale scores and a sleep quantity scale. Scales with at least one item answered was used to generate a scale score. Scales include; sleep disturbance (SD), snoring, awaken short of breath (ASoB) or with a headache (H), somnolence, sleep adequacy (SA), sleep problem index (SPI) I and II (range: 0-100) and sleep quantity (SQ \[range 0 to 24\]). Except for sleep quantity, higher scores=greater impairment.. Parameters: LS Mean Difference = -2.93 (p = 0.253, CI -7.96-2.1); LS Mean Difference = -3.84 (p = 0.127, CI -8.78-1.1); LS Mean Difference = -3.15 (p = 0.18, CI -7.76-1.46); LS Mean Difference = -2.67 (p = 0.247, CI -7.19-1.85); LS Mean Difference = -0.63 (p = 0.726, CI -4.15-2.9); LS Mean Difference = -2.17 (p = 0.218, CI -5.63-1.29); LS Mean Difference = 0.01 (p = 0.996, CI -3.85-3.87); LS Mean DIfference = 0.83 (p = 0.665, CI -2.94-4.6); LS Mean Difference = 2.76 (p = 0.368, CI -3.26-8.78); LS Mean Difference = 2.84 (p = 0.345, CI -3.07-8.75); LS Mean Difference = -1.35 (p = 0.482, CI -5.12-2.42); LS Mean DIfference = -2.15 (p = 0.254, CI -5.86-1.55); LS Mean Difference = -1.97 (p = 0.308, CI -5.76-1.82); LS Mean Difference = -2.48 (p = 0.19, CI -6.2-1.23); LS Mean Difference = -0.07 (p = 0.55, CI -0.32-0.17); LS Mean Difference = 0.09 (p = 0.477, CI -0.15-0.32). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Menopause-Specific Quality of Life (MENQOL) Score at Month 3: Sleep Sub-Study. Time frame: Baseline, Month 3. Description: MENQOL questionnaire assessed how bothered participants were due to menopause. It consists of 29 items divided into 4 domains: vasomotor function (3 items), psychosocial function (7 items), physical function (16 items), and sexual function (3 items). Each item scores a range from 1 to 8, with 1 indicating that the participant did not experience the symptom or problem, 8 indicating that the participant was extremely bothered by the symptom or problem. The total score for each domain is the average of item scores and ranged from 1 to 8 with higher score indicating worsening of symptoms. The MENQOL total score is the mean of these 4 domain scores and ranged from 1 to 8 with higher score indicating worsening of symptoms.. Parameters: NA = NA (p = 0.055, CI NA-NA); NA = NA (p = 0.428, CI NA-NA); NA = NA (p = 0.071, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.68, CI NA-NA); NA = NA (p = 0.493, CI NA-NA); NA = NA (p = 0.698, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study. Time frame: Baseline, Month 12. Description: BMD measurements of the anteroposterior lumbar spine were acquired by using dual-energy x-ray absorptiometry (DXA) scans, twice at Month 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.. Parameters: Least Squares (LS) Mean Difference = 1.51 (p = 0.001, CI 0.822-2.201); LS Mean Difference = 1.87 (p = 0.001, CI 1.209-2.533). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study. Time frame: Baseline, Month 6. Description: BMD measurements of the anteroposterior lumbar spine were acquired by using DXA scans, twice at Month 6 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.. Parameters: LS Mean Difference = 0.8 (p = 0.017, CI 0.139-1.47); LS Mean Difference = 1.19 (p = 0.001, CI 0.556-1.83). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study. Time frame: Baseline, Month 6, Month 12. Description: BMD measurements of the total hip were acquired by using DXA scans, twice at Month 6 and 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.. Parameters: LS Mean Difference = 1.32 (p = 0.001, CI 0.901-1.742); LS Mean Difference = 1.21 (p = 0.001, CI 0.756-1.671); LS Mean Difference = 1.56 (p = 0.001, CI 1.152-1.962); LS Mean Difference = 1.6 (p = 0.001, CI 1.164-2.044). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Turnover Markers (BTMs) at Month 6 and Month 12: Osteoporosis Sub-Study. Time frame: Baseline, Month 6, 12. Description: Bone turnover is the removal of old bone from the body and its replacement by new bone. Bone turnover markers included serum osteocalcin, C-telopeptide, and procollagen type 1 N-propeptide (P1NP), were measured at Month 6 and Month 12 for a subset of participants who entered the osteoporosis substudy. Blood samples were collected to evaluate bone turnover markers levels.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0012, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0029, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0046, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0043, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0074, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0016, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0016, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.1058, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0024, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Breast Density at Month 12: Breast Density Sub-Study. Time frame: Baseline, Month 12. Description: Breast density was assessed by digitalized mammograms which were centrally read by a single radiologist using specifically-developed software. Breast density was assessed for subset of participants who entered the breast density sub-study. Parameters: LS Mean Difference = -0.06 (p = 0.832, CI -0.632-0.509); LS Mean Difference = -0.13 (p = 0.651, CI -0.696-0.436). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Breast Tenderness. Time frame: Screening, Week 1-4, 5-8, 9-12, 13-16, 17-20, 21-24, 25-28, 29-32, 33-36, 37-40, 41-44, 45-48, 49-52. Description: Percentage of participants who reported at least 1 day of breast tenderness during each 4-week period for 1-year on therapy was calculated.. Parameters: NA = NA (p = 0.058, CI NA-NA); NA = NA (p = 0.546, CI NA-NA); NA = NA (p = 0.23, CI NA-NA); NA = NA (p = 0.821, CI NA-NA); NA = NA (p = 0.36, CI NA-NA); NA = NA (p = 0.698, CI NA-NA); NA = NA (p = 0.892, CI NA-NA); NA = NA (p = 0.446, CI NA-NA); NA = NA (p = 0.912, CI NA-NA); NA = NA (p = 0.892, CI NA-NA); NA = NA (p = 0.791, CI NA-NA); NA = NA (p = 0.81, CI NA-NA); NA = NA (p = 0.473, CI NA-NA); NA = NA (p = 0.03, CI NA-NA); NA = NA (p = 0.453, CI NA-NA); NA = NA (p = 0.391, CI NA-NA); NA = NA (p = 0.407, CI NA-NA); NA = NA (p = 0.644, CI NA-NA); NA = NA (p = 0.666, CI NA-NA); NA = NA (p = 0.641, CI NA-NA); NA = NA (p = 0.361, CI NA-NA); NA = NA (p = 0.1, CI NA-NA); NA = NA (p = 0.142, CI NA-NA); NA = NA (p = 0.906, CI NA-NA); NA = NA (p = 0.798, CI NA-NA); NA = NA (p = 0.258, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Cumulative Amenorrhea: Main Study. Time frame: Day 1 up to Day 364. Description: Cumulative amenorrhea was defined as the absence of any bleeding or spotting for cumulative 4-week periods throughout 1-year study.. Parameters: NA = NA (p = 0.138, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.765, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Uterine Bleeding. Time frame: Week 1-4, 5-8, 9-12, 13-16, 17-20, 21-24, 25-28, 29-32, 33-36, 37-40, 41-44, 45-48, 49-52. Description: Percentage of participants with uterine bleeding were calculated for each 4-week period for 1-year on therapy.. Parameters: NA = NA (p = 0.624, CI NA-NA); NA = NA (p = 0.868, CI NA-NA); NA = NA (p = 0.087, CI NA-NA); NA = NA (p = 0.425, CI NA-NA); NA = NA (p = 0.307, CI NA-NA); NA = NA (p = 0.689, CI NA-NA); NA = NA (p = 0.285, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.769, CI NA-NA); NA = NA (p = 0.065, CI NA-NA); NA = NA (p = 0.014, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.226, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.317, CI NA-NA); NA = NA (p = 0.531, CI NA-NA); NA = NA (p = 0.61, CI NA-NA); NA = NA (p = 0.848, CI NA-NA); NA = NA (p = 0.551, CI NA-NA); NA = NA (p = 0.3, CI NA-NA); NA = NA (p = 0.299, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.66, CI NA-NA); NA = NA (p = 0.199, CI NA-NA); NA = NA (p = 0.77, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women

Summary: The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).

Detailed Description: NA

Results: Outcome: Immunohistochemistry (IHC) Proliferative Effects Measurement. Time frame: 4 weeks. Description: Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.. Parameters: Least Squares Mean = 0.49 (p = 0.001, CI 0.31-1); Least Squares Mean = 0.19 (p = 0.032, CI 0.02-1). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab

Summary: To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT). Participants randomized to either denosumab or placebo in the 20050179 (NCT00293813) study who completed that study (ie, attended an end of study visit) can be included in this study. At least 12 months should have elapsed since the patient's 20050179 end of study visit.

Detailed Description: NA

Results: Outcome: Actual Value of Procollagen Type 1 N-terminal Peptide. Time frame: Day 1. Description: Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).. Parameters: Ratio of Denosumab to Placebo = 1.2 (p = 0.0079, CI 1-1.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Actual Value of Serum Type I C-telopeptide. Time frame: Day 1. Description: Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).. Parameters: Ratio of Denosumab to Placebo = 1.1 (p = 0.0591, CI 1-1.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 0.9 (p = 0.0228, CI 0.1-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 0.4 (p = 0.2897, CI -0.4-1.2). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 3.7 (p = 0.0766, CI -0.4-7.8). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 1.8 (p = 0.0594, CI -0.1-3.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 2.6 (p = 0.0032, CI 0.9-4.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 1.5 (p = 0.1648, CI -0.6-3.5). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 0.7 (p = 0.656, CI -2.5-4). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 3.9 (p = 0.0067, CI 1.1-6.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 2.1 (p = 0.0184, CI 0.4-3.8). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change of Total Radius BMD From the Parent Study Baseline by DXA. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 2.1 (p = 0.0035, CI 0.7-3.5). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA. Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.. Description: Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.. Parameters: Mean Difference (Final Values) = 1.6 (p = 0.0911, CI -0.3-3.5). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Summary: The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.

Detailed Description: The MsFLASH-01 study, Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women is a randomized, double-blind, placebo-controlled, parallel arm clinical trial. The design includes: 3 weeks of daily recording of hot flashes prior to drug treatment; 8 weeks of double-blind treatment with escitalopram or placebo with dose escalation at 4 weeks among non-responders; 1 week of drug taper for those on higher dose, followed by 2 weeks with no treatment; and a telephone follow-up post-treatment. This study is one of five clinical trials to be conducted as part of the Menopause Strategies - Finding Lasting Answers for Symptoms and Health (MsFLASH) study, a network of investigators and clinical trials designed to find new ways to alleviate the most common, bothersome symptoms of the menopausal transition.

Results: Outcome: Change in Daily Frequency of Hot Flashes Between Baseline and Week 8 as Assessed by Prospective Daily Diaries. Time frame: week 8 minus baseline. Description: Change in daily hot flash frequency was calculated as the daily mean difference between baseline and week 8. Baseline was calculated as the daily mean of the frequencies for the first two screening weeks. Week 8 was calculated as the daily mean of the daily frequencies during the week prior to the week 8 visit.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change in Daily Severity of Hot Flashes Between Baseline and Week 8 as Assessed by Prospective Daily Diaries. Time frame: week 8 minus baseline. Description: Change in daily hot flash severity between baseline \& week 8 was calculated as mean difference. Baseline severity ratings were calculated as daily mean ratings for the first two screening weeks pre-baseline. Week 8 severity ratings were calculated as daily mean ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN).. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Outcome: Change in Daily Hot Flash Bother Between Baseline and Week 8 as Recorded on Daily Diaries. Time frame: week 8 minus baseline. Description: Change in daily hot flash bother between baseline \& week 8 was calculated as mean difference. Baseline daily bother was the mean of the highest daily ratings for two screening weeks pre-baseline. Week 8 bother was daily mean of the highest daily bother ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN).. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Summary: The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.

Detailed Description: This study included a 24-month treatment phase followed by rerandomization to a 12-month extension phase with denosumab or placebo, followed by a 12-month retreatment phase with romosozumab, followed by a 24-month follow-on phase with zoledronic acid or no intervention.

* 24-month Romosozumab Treatment Phase (months 1 to 24): Participants were randomized in a 1:1:1:1:1:1:1:1 ratio to receive 1 of 5 double-blind dosing regimens of romosozumab or placebo or open-label alendronate (ALN) or open-label teriparatide (TPTD) for the first 12 months of the study. At month 12, participants in the romosozumab and placebo groups continued their assigned treatment for an additional 12 months, participants in the TPTD group ended study participation, and participants in the ALN group transitioned to receive romosozumab 140 mg subcutaneously (SC) every month (QM) for an additional 12 months (months 12 to 24).
* 12-month Denosumab Extension Phase (months 24 to 36): At the end of the 24-month romosozumab treatment phase, eligible participants were randomized 1:1 within their original treatment group to receive either denosumab or placebo every 6 months (Q6M) for 12 months.
* 12-month Romosozumab Retreatment Phase (months 36 to 48): From months 36 to 48, participants initially randomized to romosozumab or placebo received romosozumab 210 mg SC QM. Participants who initially received ALN ended their participation at month 36 and were not retreated with romosozumab.
* 24-month Follow-on Phase (months 48 to 72): At month 48, participants received 1 dose of zoledronic acid 5 mg intravenously or no intervention for an additional 24 months.

Results: Outcome: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine. Time frame: Baseline to 12 months. Description: Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.. Parameters: LS Mean Difference from Placebo = 8.7 (p = 1e-04, CI 7.5-9.9); LS Mean Difference from placebo = 5.6 (p = 1e-04, CI 4.3-6.9); LS Mean Difference from Placebo = 7.4 (p = 1e-04, CI 6.1-8.7); LS Mean Difference from Placebo = 8.5 (p = 1e-04, CI 7.3-9.8). Non-inferiority type: SUPERIORITY.
Study: Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Summary: Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg & 100 mg DRFB Tablet, Month 2, ITT Population. Time frame: 2 months. Description: NA. Parameters: LS Mean Difference = 4.765 (p = 0.3372, CI -3.421-12.952); LS Mean Difference = -0.218 (p = 0.965, CI -8.427-7.991). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg & 100 mg DRFB Tablet, Month 3, ITT Population. Time frame: 3 months. Description: NA. Parameters: LS Mean Difference = 0.388 (p = 0.9276, CI -6.67-7.447); LS Mean Difference = -10.787 (p = 0.0133, CI -17.917--3.657). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline Urine NTX (Type-1 Collagen Cross-linked N-telopeptide) Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 2, ITT Population. Time frame: 2 months. Description: Urine NTX Bone turnover marker collected after 8 hour fast, 2nd voided urine between 6-9 am assayed by ELISA.. Parameters: LS Mean Difference = 14.528 (p = 0.1192, CI -0.813-29.868); LS Mean Difference = 14.215 (p = 0.1298, CI -1.23-29.659). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 3, ITT Population. Time frame: 3 months. Description: ITT Population. Parameters: LS Mean Difference = 1.119 (p = 0.8546, CI -8.956-11.193); LS Mean Difference = -7.393 (p = 0.2291, CI -17.522-2.737). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline Urine NTX Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 4, ITT Population. Time frame: 4 months. Description: ITT Population. Parameters: LS Mean Difference = 5.505 (p = 0.5436, CI -9.452-20.462); LS Mean Difference = -0.914 (p = 0.9201, CI -15.959-14.132). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg & 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population. Time frame: Month 4. Description: Fasting serum Bone turn-over marker specimen assayed by electochemiluminescence.. Parameters: LS Mean Difference = -3.598 (p = 0.3946, CI -10.568-3.372); LS Mean Difference = -12.197 (p = 0.0045, CI -19.208--5.185). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 3, ITT Population. Time frame: 3 months. Description: ITT Population. Parameters: LS Mean Difference = 4.966 (p = 0.2527, CI -2.189-12.12); LS Mean Difference = 4.926 (p = 0.2613, CI -2.301-12.153). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum BAP Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 4, ITT Population. Time frame: 4 months. Description: ITT Population. Parameters: LS Mean Difference = 1.269 (p = 0.7606, CI -5.609-8.148); LS Mean Difference = -2.825 (p = 0.5006, CI -9.744-4.095). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Bone Specific Alkaline Phosphatase (BAP) Comparing Risedronate 150 mg IRBB Tablet With 75 mg & 100 mg DRFB Tablet, Month 2, ITT Population. Time frame: 2 months. Description: ITT Population. Parameters: LS Mean Difference = 3.108 (p = 0.444, CI -3.59-9.807); LS Mean Difference = 4.842 (p = 0.2349, CI -1.874-11.559). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Summary: The purpose of this study is to investigate how teriparatide or zoledronic acid affects the bone of postmenopausal osteoporotic women after 6 months of treatment as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis). After completing 12 months of treatment all participants are eligible to participate in an additional 12-month open label extension.

Detailed Description: NA

Results: Outcome: Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Ac.f in CC represents the frequency of activation of new remodeling cycles on the bone surface (BFR/BS divided by wall thickness) and is expressed in units of new cycles per unit of time. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Ac.f in CC represents the frequency of activation of new remodeling cycles on BS (bone formation rate \[BFR\]/BS divided by wall thickness) and is expressed in units of new cycles per unit of time. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 micrometer (m)/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Activation Frequency (Ac.f) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Ac.f in EC represents the frequency of activation of new remodeling cycles on the bone surface (BFR/BS divided by wall thickness) and is expressed in units of new cycles per unit of time. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Active Formation Period (a.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: a. FP in CC is the mean time required to rebuild a new bone structural unit, calculated as wall thickness divided by MAR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.159, CI NA-NA); NA = NA (p = 0.906, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Active Formation Period (a.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: a. FP in CC is the mean time required to rebuild a new bone structural unit, calculated as wall thickness divided by MAR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.154, CI NA-NA); NA = NA (p = 0.052, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Active Formation Period (a.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: a. FP in EC is the mean time required to rebuild a new bone structural unit, calculated as wall thickness divided by MAR. Participants were given T for two 3 day-periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.979, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.695, CI NA-NA); NA = NA (p = 0.853, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Aj.AR in CC is MAR averaged over the entire osteoid surface and in a steady state is an estimate of the mean rate of matrix apposition. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.05, CI NA-NA); NA = NA (p = 0.016, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Aj.AR in CC is MAR averaged over the entire osteoid surface and in a steady state is an estimate of the mean rate of matrix apposition. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Aj.AR in EC is MAR averaged over the entire osteoid surface and in a steady state is an estimate of the mean rate of matrix apposition. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Average Length of Tetracycline Double Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: The length of tetracycline double labels is a measure of the extent of bone formation in the cancellous compartment within individual remodeling units and is measured in millimeters (mm). Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.906, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Average Length of Tetracycline Double Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: The length of tetracycline double labels is a measure of the extent of bone formation in the cancellous compartment within individual remodeling units and is measured in millimeters (mm). Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Average Length of Tetracycline Double Labels in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: The length of tetracycline double labels is a measure of the extent of bone formation in the endocortical compartment within individual remodeling units and is measured in millimeters (mm). Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.536, CI NA-NA); NA = NA (p = 0.896, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: BFR in CC is the volume of mineralized bone formed per unit surface bone per unit time (mm/mm/year); calculated as MAR times MS/BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: BFR in CC is the volume of mineralized bone formed per unit surface bone per unit time (cubic millimeter/square millimeter/year \[mm/mm/year\]); calculated as mineral apposition rate (MAR) times MS/BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: BFR in EC is the volume of mineralized bone formed per unit surface bone per unit time (mm/mm/year); calculated as MAR times MS/BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 1, 3 and 6 Endpoint. Time frame: Baseline, 1, 3, 6 months. Description: CTX is a measure of bone resorption.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 12 Endpoint. Time frame: Baseline, 12 months. Description: CTX is a measure of bone resorption.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Osteocalcin (OC) at Month 1, 3, and 6 Endpoint. Time frame: Baseline, 1, 3, 6 months. Description: OC is a measure of osteoblast function.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Osteocalcin (OC) at Month 12 Endpoint. Time frame: Baseline, 12 months. Description: OC is a measure of osteoblast function.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 1, 3 and 6 Endpoint. Time frame: Baseline, 1, 3, 6 months. Description: PINP is a measure of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 12 Endpoint. Time frame: Baseline, 12 months. Description: PINP is a measure of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: MAR in CC is a measure of the linear rate of production of mineralized bone matrix by osteoblasts and is measured by the mean distance between two consecutive labels divided by the time interval. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: MAR in CC is a measure of the linear rate of production of mineralized bone matrix by osteoblasts and is measured by the mean distance between two consecutive T labels divided by the time interval. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: MAR in EC is a measure of the linear rate of production of mineralized bone matrix by osteoblasts and is measured by the mean distance between two consecutive labels divided by the time interval. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.039, CI NA-NA); NA = NA (p = 0.025, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralization Lag Time (Mlt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Mlt in CC is the period between deposition and subsequent mineralization of osteoid. Mlt is calculated as O.Th divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.906, CI NA-NA); NA = NA (p = 0.159, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralization Lag Time (Mlt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Mlt in CC is the period between deposition and subsequent mineralization of osteoid. Mlt is calculated as Osteoid Thickness (O.Th) divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralization Lag Time (Mlt) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Mlt in EC is the period between deposition and subsequent mineralization of osteoid. Mlt is calculated as O.Th divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.049, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.151, CI NA-NA); NA = NA (p = 0.196, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: MS/BS in CC is a measure of the proportion of BS on which new mineralized bone is deposited at the time of tetracycline (T) labeling and is calculated as sum of total extent of double label (DL) plus half the extent of single label (SL) divided by BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in the biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under a microscope. DL indicates active bone formation, SL or no label (NL) suggests suppression of bone formation.. Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: MS/BS in CC is a measure of the proportion of BS on which new mineralized bone is deposited at the time of tetracycline (T) labeling and is calculated as sum of total extent of double label (DL) plus half the extent of single label (SL) divided by BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in the biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under a microscope. DL indicates active bone formation, SL or no label (NL) suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface(MS/BS) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: MS/BS in EC is a measure of the proportion of BS on which new mineralized bone is deposited at the time of tetracycline (T) labeling and is calculated as sum of total extent of double label (DL) plus half the extent of single label (SL) divided by BS. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in the biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under a microscope. DL indicates active bone formation, SL or no label (NL) suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Number of samples with single or double tetracycline labels, both single and double labels, or no labels in the cancellous compartment were compared between teriparatide and zoledronic acid treated participants. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.033, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Number of samples with single or double tetracycline labels, both single and double labels, or no labels in the cancellous compartment were compared between teriparatide and zoledronic acid treated participants. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Number of samples with single or double tetracycline labels, both single and double labels, or no labels in the endocortical compartment were compared between teriparatide and zoledronic acid treated participants. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Maturation Time (Omt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Omt in CC is the period between the onset of deposition and onset of mineralization of a given amount of osteoid. Omt is calculated as O.Th divided by MAR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.358, CI NA-NA); NA = NA (p = 0.077, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Maturation Time (Omt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Omt in CC is the period between the onset of deposition and onset of mineralization of a given amount of osteoid. Omt is calculated as O.Th divided by MAR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.502, CI NA-NA); NA = NA (p = 0.597, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Maturation Time (Omt) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 Months. Description: Omt in EC is the period between the onset of deposition and onset of mineralization of a given amount of osteoid. Omt is calculated as O.Th divided by MAR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.647, CI NA-NA); NA = NA (p = 0.12, CI NA-NA); NA = NA (p = 0.695, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Thickness (OTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Osteoid thickness (OTh.) in the cancellous compartment is a measure of the average thickness of osteoid seams.. Parameters: NA = NA (p = 0.079, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Thickness (OTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Osteoid thickness (OTh.) in the cancellous compartment is a measure of the average thickness of osteoid seams.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Thickness (OTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Osteoid thickness (OTh.) in the endocortical compartment is a measure of the average thickness of osteoid seams.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.039, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: The percent of single or double tetracycline labels per bone surface (sLS/BS, dLS/BS) in the cancellous compartment. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: The percent of single or double tetracycline labels per bone surface (sLS/BS, dLS/BS) in the cancellous compartment. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: The percent of single or double tetracycline labels per bone surface (sLS/BS, dLS/BS) in the endocortical compartment. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.006, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Eroded surface/bone surface (ES/BS) in the cancellous compartment is the fraction of the entire trabecular surface occupied by resorption bays, including both those with and without osteoclasts. It is an indicator of bone resorption.. Parameters: NA = NA (p = 0.025, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Eroded surface/bone surface (ES/BS) in the cancellous compartment is the fraction of the entire trabecular surface occupied by resorption bays, including both those with and without osteoclasts. It is an indicator of bone resorption.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Eroded surface/bone surface (ES/BS) in the endocortical compartment is the fraction of the entire trabecular surface occupied by resorption bays, including both those with and without osteoclasts. It is an indicator of bone resorption.. Parameters: NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.092, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Osteoid surface (OS) in the cancellous compartment is the fraction (%) of the entire trabecular bone surface that is covered by osteoid.. Parameters: NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Osteoid surface (OS) in the cancellous compartment is the fraction (%) of the entire trabecular bone surface that is covered by osteoid.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Osteoid surface (OS) in the endocortical compartment is the fraction (%) of the entire trabecular bone surface that is covered by osteoid.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Osteoid volume (OV) in the cancellous compartment is the percent of a given volume of bone tissue that consists of unmineralized bone (osteoid).. Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Osteoid volume (OV) in the cancellous compartment is the percent of a given volume of bone tissue that consists of unmineralized bone (osteoid).. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Formation Period (Tt.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Tt.FP in CC is a measure of bone formation and is calculated as wall thickness divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.198, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Formation Period (Tt.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Tt.FP in CC is a measure of bone formation and is calculated as wall thickness divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Formation Period (Tt.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Tt.FP in EC is a measure of bone formation and is calculated as wall thickness divided by Aj.AR. Participants were given T for two 3-day periods, 14 days apart. T fluoresces under certain light and temporarily binds to new bone. New bone in biopsy is seen as the amount of bone between 2 fluorescently T labeled lines under microscope. DL indicates active bone formation, SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 m/day or counted as missing.. Parameters: NA = NA (p = 0.022, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.151, CI NA-NA); NA = NA (p = 0.139, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Wall Thickness (WTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months. Time frame: 24 months. Description: Wall thickness (WTh.) in the cancellous compartment is measured as the mean distance from the cement line to the marrow space of completed trabecular bone packets.. Parameters: NA = NA (p = 0.079, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Wall Thickness (WTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months. Time frame: 6 months. Description: Wall thickness (WTh.) in the cancellous compartment is measured as the mean distance from the cement line to the marrow space of completed trabecular bone packets.. Parameters: NA = NA (p = 0.014, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Wall Thickness (WTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months. Time frame: 6 and 24 months. Description: Wall thickness (WTh.) in the endocortical compartment is measured as the mean distance from the cement line to the marrow space of completed trabecular bone packets.. Parameters: NA = NA (p = 0.268, CI NA-NA); NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Summary: This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.

Detailed Description: NA

Results: Outcome: Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12. Time frame: Baseline to Month 12. Description: NA. Parameters: Mean Difference (Net) = 1.2 (p = 1e-04, CI 0.7-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12. Time frame: Baseline to month 12. Description: NA. Parameters: Mean Difference (Net) = 2 (p = 1e-04, CI 1.5-2.5). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1. Time frame: Baseline to month 1. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12. Time frame: Baseline to month 12. Description: NA. Parameters: Mean Difference (Net) = 1.4 (p = 1e-04, CI 1-1.8). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

Summary: RATIONALE: Estrogen can relieve the symptoms of menopause, but can also cause the growth of breast cancer cells. Flaxseed may reduce the number of hot flashes and improve mood and quality of life in postmenopausal women not receiving estrogen therapy.

PURPOSE: This randomized phase III trial is studying flaxseed to see how well it works in treating postmenopausal women with hot flashes who have a history of breast cancer or other cancer or who do not wish to take estrogen therapy.

Detailed Description: OBJECTIVES:

* To evaluate the efficacy of flaxseed on hot flash scores in women with a history of breast cancer or other cancer or in women who do not wish to take estrogen therapy for fear of increased risk of breast cancer as measured by a daily prospective hot flash diary.
* To evaluate the side effect profile of flaxseed in this population.
* To evaluate the effects of flaxseed on mood (per the Profile of Mood States) and broader menopausal symptoms (per the MENQOL), daily interference from hot flashes (per the HFRDIS), and perception of benefit (per Global Impression of Change).

OUTLINE: Patients are stratified according to age (18-49 years vs  50 years); treatment with tamoxifen citrate, selective estrogen receptor modulators, or aromatase inhibitors (yes vs no); duration of hot flashes ( 9 months vs \> 9 months); and daily frequency of hot flashes (4-9 vs  10). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
* Arm II: Patients receive oral placebo bar once daily. In both arms, treatment continues for 6-12 weeks. Patients in arm II may crossover to receive treatment as in arm I after 6 weeks.

Patients complete questionnaires (Hot Flash Diary, Side Effect Experience Questionnaire, Profile of Mood States, Hot Flash Related Daily Interference Scale, and Menopause Specific Quality of Life) at baseline and periodically during treatment. Patients are contacted by telephone at the end of weeks 2, 4, 5, and 7 to assess product tolerability, document compliance, encourage completion of questionnaires, and address problems.

Results: Outcome: Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS). Time frame: Baseline and up to 7 weeks. Description: The change of daily interference as measured by the HFRDIS from baseline to treatment termination between flaxseed versus placebo arms was evaluated with an independent t-test for continuous data. On a 0-10 scale, patients were asked to describe how hot flashes interfered with 10 different aspects of their life (work, social activities, leisure activities, sleep, mood, concentration, relationships with others, sexuality, enjoyment of life and overall quality of life). Scores were converted to a 0-100 scale where 100 is best QOL.The HFRDIS total score was the average of the 10 individual questions. The change in total score from baseline to end of treatment was analyzed between the groups using a Kruskal-Wallace test.. Parameters: NA = NA (p = 0.089, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change of Menopause Specific Quality of Life as Measured by the Menopause Specific Quality of Life (MENQOL). Time frame: Baseline and up to 7 weeks. Description: The change in quality of life as measured by the MENQOL from baseline to treatment termination between flaxseed versus placebo arms was evaluated. On a 0-6 scale, patients were asked to answer questions in in each of 4 domain scores (Vasomotor, Psychosocial, Physical, Sexual) Scores were converted to a 0-100 scale where 100 is best QOL. The change in score from baseline to end of treatment were analyzed separately for each domain. Here we report the mean change in score for each category.. Parameters: NA = NA (p = 0.19, CI NA-NA); NA = NA (p = 0.78, CI NA-NA); NA = NA (p = 0.238, CI NA-NA); NA = NA (p = 0.497, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change of Mood as Measured by the Profile of Mood States (POMS). Time frame: Baseline and up to 7 weeks. Description: Profile of Mood States (POMS) was used to look at total mood disturbance as well as the subscales of tension-anxiety, fatigue-inertia, and vigor-activity. The POMS is a well known, well validated, reliable measure of psychological distress which includes 6 subscales of fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment. The entire scale can be scored to provide a measure of total mood disturbance. The measure contains adjectives related to mood which are scored from 0 (not at all) to 4 (extremely). Individual scores were converted to a 0-100 scale where 100 is best quality of life.

The change of mood as measured by the POMS from baseline to treatment termination between flaxseed versus placebo arms was compared using Kruskal-Wallis test. The mean change in total score for each arm is reported.. Parameters: NA = NA (p = 0.93, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary.. Time frame: Baseline and 7 weeks. Description: The intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. The hot flash activity will be measured by the weekly average hot flash score which is a composite entity of both frequency and severity of hot flashes.

The hot flash severities are graded from 1 to 4, ranging from mild, to moderate, to severe to very severe. The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The average daily hot flash score during the baseline week was compared to the average daily value during week 7.

The primary method of analysis will be the independent sample t-test to examine the change of weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms.. Parameters: NA = NA (p = 0.29, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

Summary: The purpose of this study is to compare the effectiveness and tolerability of two medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal women with osteoporosis. Osteoporosis is the term used to describe a large group of diseases, which are characterized by loss of bone density, which makes the bones weaker. Osteoporosis often occurs in postmenopausal women.

Calcitonin is a hormone found in the human body. Together with other substances, it regulates the concentration of calcium in the blood and inhibits the natural resorption of bone. Both medications in this study contain salmon calcitonin (sCT), because this form of calcitonin is more active than human calcitonin when used as a medicine.

The calcitonin Nasal Spray used in this study is registered and available to doctors in United States for the treatment of osteoporosis. The medication being tested in this study is an oral tablet form of salmon calcitonin.

Detailed Description: This was a randomized, double-blind, double-dummy, multiple dose, placebo-controlled, parallel group, 48- week, Phase III study. Women age 45 and over who were postmenopausal and had a diagnosis of osteoporosis were eligible for the study and were randomly allocated to one of three treatment groups; placebo tablets, oral rsCT tablets or calcitonin nasal spray. Each patient was given a treatment kit, which contained the study medication to which she had been assigned and a placebo of the treatment to which she was not assigned, or placebo nasal and oral preparations, as well as the required dietary supplements (calcium and vitamin D tablets). The study medication and supplements were self-administered at home. It was anticipated that approximately 545 patients would participate in the study.

EFFICACY: Bone Mineral Density (BMD) was recorded at Screening, Week 24, and Week 48. CTx-1 and N-telopeptide of collagen 1 (NTx-1), biochemical markers of bone resorption and total Procollagen type 1 N-terminal propeptide (P1NP),a marker of bone formation, were assessed at Week 0, Week 24, and Week 48. SAFETY: Adverse events were assessed at the clinic at Weeks 0, 12, 24, 36 and 48, and by interim phone calls at Weeks 4, 8, 16, 20, 28, 32, 40, 44, and 52. At Screening, Week 12, and Week 48, a physical examination, including nasal exam, was performed and specimens for safety laboratory analysis (clinical chemistry, hematology, and urinalysis) were collected. Sera for immunogenicity evaluations were collected at Baseline, Week 12, and Week 48.

EFFICACY: The primary comparison of interest was the percent change from baseline to 48 weeks in axial lumbar spine (L1 to L4) corrected BMD comparing the rsCT oral tablet group and the calcitonin nasal spray group. The model included the factors of the covariate (baseline BMD), treatment group, and center. The hypothesis to be tested was performed to examine the non-inferiority of the oral tablet group to the nasal spray group with respect to the percent change in axial lumbar L1-L4 spine corrected BMD. Specifically, the null hypothesis to be tested was: \[Mean(oral) - Mean(placebo)\] - 0.5 x \[Mean(nasal) - Mean(placebo)\] \< 0 The alternative hypothesis was that the above expression was \> 0, which implied that the oral tablet group was non-inferior to nasal spray group. The primary analysis of interest employed the modified intent-to-treat population.

SAFETY: Adverse events were summarized descriptively. Mean vital signs and clinical laboratory test results in each treatment group were compared using a one-way analysis of variance. Additionally, shift tables were prepared for each laboratory variable.

Results: Outcome: Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1). Time frame: 24 weeks. Description: Change from baseline in plasma CTx-1 at 24 and 48 weeks. CTx-1 is an accepted plasma biomarker as evidence of an effect on bone resorption and the effect of oral calcitonin was compared to that of intranasal calcitonin, both vs placebo.. Parameters: Mean Difference (Net) = -21.84 (p = 6e-04, CI NA-NA). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Change in Plasma CTx-1 From Baseline. Time frame: 48 weeks. Description: Percent change from baseline of plasma CTx-1 at end of study=48 weeks. Parameters: Mean Difference (Net) = -18.09 (p = 0.0012, CI NA-NA). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine. Time frame: 48 weeks. Description: Bone Mineral Density is measured by Dual-Energy X-ray Absorptiometry (DXA) body scans. Two scans were taken for each timepoint(baseline, week 24 and week 48) and the mean of the two values was entered. The primary outcome timepoint was 48 weeks, but if a patient did not complete the full study, then the 24 week BMD value was used as Last Observation Carried Forward. The percentage change from the baseline value, set as 0%, was recorded as the primary outcome measure.. Parameters: Mean Difference (Net) = 0.77 (p = 0.002, CI 0.08-1.45). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Summary: The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.

Detailed Description: The study is a randomized, double blind, multicenter, placebo controlled, parallel group, proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an evaluation of the dose response of 3 dose levels of AUS-131 (S-equol) and placebo with respect to reducing the mean number of moderate to severe vasomotor symptoms after 4 weeks of treatment. The safety of S-equol will be evaluated during the study.

Results: Outcome: Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4. Time frame: 2 and 4 weeks from Baseline (Day 0). Description: The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. The pH scale is logarithmic and as a result, each whole pH value below 7 is ten times more acidic than the next higher value.

Normal vaginal pH is 3.8 to 4.5, slightly acidic.

The LSMeans refer to overall adjusted mean pH.. Parameters: NA = NA (p = 0.2211, CI NA-NA); LS means difference = -0.21 (p = 0.05, CI -0.53-0.12); LS means difference = -0.23 (p = 0.05, CI -0.55-0.09); LS means difference = 0.03 (p = 0.05, CI -0.28-0.35); LS means difference = -0.26 (p = 0.05, CI -0.54-0.02); LS means difference = -0.13 (p = 0.05, CI -0.4-0.14); LS means difference = -0.24 (p = 0.05, CI -0.51-0.03). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2. Time frame: 1 and 2 weeks from Baseline (Day 0). Description: The frequency of MSVS per week, at each of the protocol visits, was calculated as follows, for each patient: \[# of Moderate+Severe hot flushes)/(Current protocol visit date-Previous protocol visit date (days)\] \* 7.

The ANCOVA procedure tested the following hypotheses:

H0: 1 = p versus HA: 1  p, where 1 and p denote the mean frequency of MSVS, adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.

LSMeans refer to the overall adjusted mean frequecy of MSVS.. Parameters: LS means difference = 9.69 (p = 0.05, CI 0.79-18.6); LS means difference = 1.31 (p = 0.05, CI -7.73-10.36); LS means difference = -6.7 (p = 0.05, CI -18.36-4.96); LS means difference = 3.56 (p = 0.05, CI -8.01-15.14); NA = NA (p = 0.1217, CI NA-NA); LS means difference = -3.77 (p = 0.05, CI -12.69-5.16); LS means difference = 0.91 (p = 0.05, CI -10.77-12.58). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4. Time frame: 1, 2, and 4 weeks from Baseline (Day 0). Description: The severity of vasomotor symptoms per week at each of the protocol visits was calculated for each patient as follows: \[(Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date - Previous protocol visit date (days)\] \* 7, where severity of vasomotor symptoms were scored as: 1 = mild, 2 = moderate and 3 = severe. Higher values represented worse severity.

LSMeans refer to the overall adjusted mean severity of VMS.

Hot Flush Classification: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.

Patients recorded the number of hot flushes (day and night) in their diaries related to the severity (mild/moderate/severe).. Parameters: NA = NA (p = 0.1609, CI NA-NA); LS means difference = -6.34 (p = 0.05, CI -26.41-13.73); LS means difference = 25.67 (p = 0.05, CI 5.64-45.69); LS means difference = 2.09 (p = 0.05, CI -18.21-22.39); LS means difference = -16.14 (p = 0.05, CI -43.29-11.01); LS means difference = 8.73 (p = 0.05, CI -18.19-35.65); LS means difference = -0.65 (p = 0.05, CI -27.8-26.5); LS means difference = -1.69 (p = 0.05, CI -28.68-25.3); LS means difference = 16.15 (p = 0.05, CI -10.4-42.71); LS means difference = -1.29 (p = 0.05, CI -28.18-25.6). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Estradiol Concentration at Weeks 2 and 4. Time frame: 2 and 4 weeks from Baseline (Day 0). Description: The LSMeans refer to overall adjusted mean estradiol concentration.. Parameters: NA = NA (p = 0.0681, CI NA-NA); LS means difference = 35.32 (p = 0.05, CI 1.75-68.9); LS means difference = 3.61 (p = 0.05, CI -29.12-36.34); LS means difference = -4.58 (p = 0.05, CI -37.39-28.23); LS means difference = 22.12 (p = 0.05, CI -23.56-67.8); LS means difference = 7.8 (p = 0.05, CI -36.7-52.29); LS means difference = -22.74 (p = 0.05, CI -67.44-21.96). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Menopause Rating Scale (MRS) - Dryness of Vagina- S-equol Groups Combined. Time frame: 4 weeks from Baseline (Day 0). Description: The following analysis pre-specified the combining of all S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) into a single treatment group. The results from the Wilcoxon-Mann-Whitney test (pair-wise test), based on the change from Baseline at Week 4, are presented.

Note: Dryness of Vagina was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'. Parameters: NA = NA (p = 0.0381, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort) - S-equol Groups Combined. Time frame: 4 weeks from Baseline (Day 0). Description: The following analysis shows the results when the S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) are combined and regarded as a single treatment group.

Note: Each MRS symptoms was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'. Parameters: NA = NA (p = 0.0097, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4. Time frame: 2 and 4 weeks from Baseline (Day 0). Description: The Vaginal Maturation Index was calculated by examining the maturation of the vaginal epithelium as adjudged by the cell types exfoliated. Parabasal cells are the least mature cells, intermediate cells display mild maturation, and superficial cells display the most maturity. The cell count is expressed as a percentage. The Vaginal Maturation Index was calculated as: 0.2\*(parabasal cells, %)+0.6\*(intermediate cells, %)+1.0\*(superficial cells, %). This method is described in Menopause 2005;12(6):708-15.

The index serves as an objective means of evaluating hormonal secretion or response; lower values indicate more immature cells on the surface (atrophy), while higher values indicate more mature epithelium.

The LSMeans refer to overall adjusted mean percent of cells counted.. Parameters: LS means difference = -0.31 (p = 0.05, CI -6.73-6.11); LS means difference = -6.14 (p = 0.05, CI -12.36-0.07); LS means difference = -2.88 (p = 0.05, CI -9.05-3.28); NA = NA (p = 0.6375, CI NA-NA); LS means difference = -1.58 (p = 0.05, CI -9.57-6.42); LS means difference = -1.58 (p = 0.05, CI -9.63-6.46); LS means difference = -1.59 (p = 0.05, CI -9.66-6.47). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period). Time frame: 4 weeks from Baseline (period following first 7 days of 2-week run-in period). Description: Change from Baseline in the frequency of MSVS (difference between Baseline \[period following first 7 days of 2-week run-in period\] and period following first 7 days of 2-week Week 4 period), where the Baseline MSVS frequency was captured at visit 3 (Day 0), in the period following the first 7 days, as per CRF. Note: this endpoint is identical to the primary endpoint, however, instead of a 14  2 day period, the period following the first 7 days was used, at Baseline and visit 3.

Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.. Parameters: NA = NA (p = 0.7364, CI NA-NA); LS means difference = -0.19 (p = 0.05, CI -12.38-12.01); LS means difference = 4.77 (p = 0.05, CI -6.94-16.48); LS means difference = -1.63 (p = 0.05, CI -13.41-10.15). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period). Time frame: 4 weeks from Baseline (2-week run-in period). Description: The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline \[2-week run-in period\] and Week 4), where the baseline MSVS frequency was captured over 14  2 day period. Moderate is defined as "sensation of heat with sweating, able to continue activity"; severe is defined as "sensation of heat with sweating, causing cessation of activity". Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified.

Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.. Parameters: NA = NA (p = 0.573, CI NA-NA); LS means difference = 1.13 (p = 0.05, CI -10.06-12.32); LS means difference = 6.98 (p = 0.05, CI -3.87-17.84); LS means difference = 0.94 (p = 0.05, CI -10.16-12.04). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4. Time frame: 4 weeks from Baseline (Day 0). Description: Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: MRS consists of 11 symptoms, where each symptom is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').. Parameters: NA = NA (p = 0.4352, CI NA-NA); NA = NA (p = 0.26, CI NA-NA); NA = NA (p = 0.7037, CI NA-NA); NA = NA (p = 0.7155, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort). Time frame: 4 weeks from Baseline (Day 0). Description: Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: Each MRS symptoms is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').. Parameters: NA = NA (p = 0.0475, CI NA-NA); NA = NA (p = 0.0258, CI NA-NA); NA = NA (p = 0.0281, CI NA-NA); NA = NA (p = 0.0645, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Summary: This study seeks to demonstrate that additional gain in bone mineral density (BMD) can be achieved by switching to MK-5442 from an oral bisphosphonate in participants who have been receiving oral bisphosphonate therapy for at least 3 years.

Detailed Description: The study was originally planned for a duration of 2 years and included efficacy analysis of a 15 mg MK-5442 treatment arm. Amendment 1 of the protocol eliminated the 2nd year of the study as well the 15-mg arm. Enrollment into the 15-mg MK-5442 arm was stopped as a result of the amendment and all participants who had been randomly assigned to the MK-5442 15-mg treatment arm were discontinued from the study.

Results: Outcome: Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD). Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -1.96 (p = 0.012, CI -3.58--0.35); Difference in Least Squares Means = -1.81 (p = 0.019, CI -3.37--0.25); Difference in Least Squares Means = -1.82 (p = 0.019, CI -3.23--0.41). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in 1/3 Distal Forearm Areal BMD. Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -0.47 (p = 0.68, CI -1.88-0.94); Difference in Least Squares Means = -0.01 (p = 0.993, CI -1.3-1.28); Difference in Least Squares Means = -1.1 (p = 0.23, CI -2.67-0.46); Difference in Least Squares Means = -0.84 (p = 0.333, CI -2.29-0.61); Difference in Least Squares Means = -0.37 (p = 0.577, CI -1.69-0.94); Difference in Least Squares Means = -1.47 (p = 0.078, CI -3.07-0.12). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip. Time frame: Baseline and Month 12. Description: vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm\^3.. Parameters: Difference in Least Squares Means = -1.48 (p = 0.01, CI -2.66--0.29); Difference in Least Squares Means = -1.14 (p = 0.053, CI -2.29-0.01); Difference in Least Squares Means = -1.15 (p = 0.053, CI -2.19--0.11); Difference in Least Squares Means = -0.58 (p = 0.509, CI -1.77-0.6); Difference in Least Squares Means = -0.25 (p = 0.843, CI -1.27-0.77); Difference in Least Squares Means = -0.26 (p = 0.843, CI -1.43-0.92). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Lumbar Spine. Time frame: Baseline and Month 12. Description: vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm\^3.. Parameters: Difference in Least Squares Means = -16.22 (p = 0.227, CI -39.15-6.72); Difference in Least Squares Means = 1.85 (p = 0.853, CI -17.9-21.61); Difference in Least Squares Means = -13.14 (p = 0.327, CI -35.67-9.39); Difference in Least Squares Means = -2.74 (p = 0.94, CI -23.91-18.43); Difference in Least Squares Means = 15.33 (p = 0.273, CI -7.86-38.52); Difference in Least Squares Means = 0.33 (p = 0.973, CI -19.23-19.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD. Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -2.04 (p = 0.002, CI -3.43--0.64); Difference in Least Squares Means = -1.29 (p = 0.035, CI -2.48--0.09); Difference in Least Squares Means = -1.76 (p = 0.009, CI -3.14--0.38); Difference in Least Squares Means = -0.86 (p = 0.335, CI -2.26-0.54); Difference in Least Squares Means = -0.11 (p = 0.857, CI -1.3-1.08); Difference in Least Squares Means = -0.59 (p = 0.542, CI -1.96-0.79). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP). Time frame: Baseline and Month 12. Description: Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of g/L.. Parameters: Difference in Least Mean Squares = 20.47 (p = 0.009, CI 5.96-35.03); Difference in Least Squares Means = 22.13 (p = 0.009, CI 4.47-39.89); Difference in Least Squares Means = 53.86 (p = 0.001, CI 39.31-68.6); Difference in Least Squares Means = 53.81 (p = 0.001, CI 41.37-66.38); Difference in Least Squares Means = 55.47 (p = 0.001, CI 41.19-69.94); Difference in Least Squares Means = 20.53 (p = 0.009, CI 5.96-35.03). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx). Time frame: Baseline and Month 12. Description: C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis and in measured in units of nanograms (n)/milliliter (ml).. Parameters: Difference in Least Squares Means = 187.31 (p = 0.001, CI 154.44-221.25); Difference in Least Squares Means = 200.29 (p = 0.001, CI 161.21-240.91); Difference in Least Squares Means = 224.3 (p = 0.001, CI 180.19-270.39); Difference in Least Squares Means = 48.29 (p = 0.034, CI 3.75-93.11); Difference in Least Squares Means = 61.27 (p = 0.019, CI 8.8-114.22); Difference in Least Squares Means = 85.28 (p = 0.002, CI 26.7-144.63). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP). Time frame: Baseline and Month 12. Description: s-P1NP is a sensitive marker of bone formation rate in the assessment of osteoporosis and is measured in units of ng/ml.. Parameters: Difference in Least Squares Means = 133.03 (p = 0.001, CI 110.01-156.75); Difference in Least Squares Means = 133.03 (p = 0.001, CI 110.01-156.75); Difference in Least Squares Means = 131.53 (p = 0.001, CI 110.7-152.94); Difference in Least Squares Means = 169.8 (p = 0.001, CI 141.59-199.11); Difference in Least Squares Means = 58.57 (p = 0.001, CI 29.42-88.04); Difference in Least Squares Means = 57.07 (p = 0.001, CI 30.76-83.64); Difference in Least Squares Means = 95.34 (p = 0.001, CI 60.4-130.91). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD. Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -1.36 (p = 0.001, CI -2.18--0.54); Difference in Least Squares Means = -1.51 (p = 0.001, CI -2.46--0.55); Difference in Least Squares Means = -1.92 (p = 0.001, CI -2.93--0.91); Difference in Least Squares Means = -0.37 (p = 0.383, CI -1.21-0.46); Difference in Least Squares Means = -0.52 (p = 0.383, CI -1.49-0.45); Difference in Least Squares Means = -0.94 (p = 0.084, CI -1.96-0.09). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD. Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -2.64 (p = 0.001, CI -3.9--1.38); Difference in Least Squares Means = -2.62 (p = 0.001, CI -3.83--1.4); Difference in Least Squares Means = -2.12 (p = 0.001, CI -3.22--1.02); Difference in Least Square Means = -0.74 (p = 0.376, CI -1.99-0.52); Difference in Least Squares Means = -0.71 (p = 0.376, CI -1.93-0.5); Difference in Least Squares Means = -0.22 (p = 0.699, CI -1.32-0.88). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD (vBMD) of the Lumbar Spine. Time frame: Baseline and Month 12. Description: vBMD was measured using quantitative computed tomography (QCT) in order to assess bone strength. Quantitative computed tomography is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm\^3.. Parameters: Difference in Least Squares Means = -1.99 (p = 0.094, CI -4.22-0.25); Difference in Least Squares Means = -1.66 (p = 0.157, CI -3.82-0.5); Difference in Least Squares Means = -1.57 (p = 0.157, CI -3.53-0.38); Difference in Least Squares Means = -0.43 (p = 0.937, CI -2.61-1.76); Difference in Least Squares Means = -0.1 (p = 0.992, CI -2.21-2.01); Difference in Least Squares Means = -0.01 (p = 0.992, CI -1.93-1.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD of the Hip. Time frame: Baseline and Month 12. Description: vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm\^3.. Parameters: Difference in Least Squares Means = -0.47 (p = 0.824, CI -2.5-1.56); Difference in Least Squares Means = -0.42 (p = 0.824, CI -2.28-1.43); Difference in Least Squares Means = -0.96 (p = 0.624, CI -3.23-1.31); Difference in Least Squares Means = 0.78 (p = 0.7, CI -1.25-2.82); Difference in Least Squares Means = 0.83 (p = 0.7, CI -1.39-3.06); Difference in Least Squares Means = 0.3 (p = 0.759, CI -1.6-2.19). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD. Time frame: Baseline and Month 12. Description: Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.

BMD = BMC / W, where BMD = bone mineral density in g/cm\^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm. Parameters: Difference in Least Squares Means = -3.24 (p = 0.001, CI -4.91--1.57); Difference in Least Square Means = -3.18 (p = 0.001, CI -4.78--1.57); Difference in Least Squares Means = -3.2 (p = 0.001, CI -4.66--1.74); Difference in Least Squares Means = -1.27 (p = 0.18, CI -2.93-0.4); Difference in Least Squares Means = -1.2 (p = 0.18, CI -2.81-0.4); Difference in Least Squares Means = -1.22 (p = 0.18, CI -2.68-0.23). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx). Time frame: Baseline and Month 12. Description: Urinary, type I collagen, crosslinked N-telopeptide (uNTx) is a biomarker used to measure the rate of bone turnover found in urine.

uNTx was expressed in units of nanomoles (nM) per bone collagen equivalents (BCE) per millimoles of creatinine (Cr) or nM/BCE/mM Cr. Parameters: Difference in Least Squares Means = 86.33 (p = 0.001, CI 64.87-108.29); Difference in Least Squares Means = 82.14 (p = 0.001, CI 63-101.66); Difference in Least Squares Means = 107.26 (p = 0.001, CI 82.03-133.23); Difference in Least Squares Means = 22.87 (p = 0.104, CI -3.8-49.68); Difference in Least Squares Means = 18.68 (p = 0.123, CI -5.11-42.56); Difference in Least Squares Means = 43.8 (p = 0.003, CI 12.85-75.06). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Research Investigation of Soy and Estrogen

Summary: The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.

Detailed Description: Anxiety is a common, but understudied complaint in midlife women, and increases during the menopausal transition. Changes in estrogen are dramatic during the menopausal transition, and indirect data suggest a potential role for estrogen, particularly estrogen receptor beta, in mediating anxiety. Two subtypes of the estrogen receptor, alpha and beta (ER-alpha and ER-beta), appear to be critically involved in the expression of anxiety in females. Compounds that preferentially target ER-beta, including plant-derived estrogens (phytoestrogens), lower both anxiety behaviors and responsivity to discrete stressors, including social stress, in laboratory animals. The primary aim of this proposal is to carry out the first study to translate these preclinical studies to humans by comparing and contrasting of the effects of phytoestrogens, estradiol, and placebo on daily anxiety and responses to moderate psychosocial stress in the laboratory. As second focus is emotional and non-emotional cognition. This focus stems from evidence that estrogen can protect against the negative impact of glucocorticoids on memory. These aims will be accomplished in a 12-week randomized placebo-controlled, clinical trial comparing three treatments: 1) a phytoestrogen supplement (Novasoy 400, 55 mg tablet twice daily); 2) oral estradiol (1 mg/daily; plus 10 mg medroxyprogesterone acetate at study end 10 for 10 days); and 3) placebo (identical appearing tablets twice daily). The enrollment target is 120 healthy women in the menopausal transition (40 per group). To measure anxiety, women will complete the State-Trait Anxiety Inventory (STAI). To measure responsivity to psychosocial stress, parallel forms of the Trier Social Stress Test, a widely used laboratory induction that involves unanticipated public speaking and social evaluative fear, will be used to induce moderate psychosocial stress before and after treatment. At both laboratory sessions, measures of subjective stress (STAI), cortisol, and emotional memory performance will be obtained at multiple points during a control condition and during the psychosocial stress condition. Lastly, we will measure treatment effects on measures of verbal memory.

Results: Outcome: Change in STAI-6 Score. Time frame: Week 0, 10, 12, and 16-18. Description: STAI-6; State-Trait Anxiety Inventory- Short Form is a measure of anxiety where higher scores indicate higher/elevated anxiety. Minimum value 6 is and maximum value is 24.. Parameters: NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: OTHER. Outcome: Change in Verbal Memory, Delayed Recall. Time frame: Baseline and 12 weeks. Description: Delayed recall on the Logical Memory subset of the Wechsler Memory Scale-Revised, in which higher scores indicate a better recall and outcome. The minimum value is 0 and maximum value is 25.. Parameters: NA = NA (p = 0.86, CI NA-NA). Non-inferiority type: OTHER. Outcome: Change in Verbal Memory, Immediate Recall. Time frame: Baseline and 12 weeks. Description: Immediate recall on the Logical Memory subset of the Wechsler Memory Scale-Revised, in which higher scores indicate a better recall and outcome. The minimum value is 0 and maximum value is 25.. Parameters: NA = NA (p = 0.11, CI NA-NA). Non-inferiority type: OTHER. Outcome: Changes in STAI-6 Scores Before and After Psychosocial Stressor Over Time. Time frame: Baseline (Week 0) and Treatment (Week 12). Description: STAI-6; State-Trait Anxiety Inventory- Short Form is a measure of anxiety where higher scores indicate higher/elevated anxiety. Minimum value 6 is and maximum value is 24.. Parameters: NA = NA (p = 0.98, CI NA-NA). Non-inferiority type: OTHER. Outcome: Memory for Emotionally Valent Words and Neutral Words. Time frame: Baseline (Week 0) and Treatment (Week 12). Description: Proportion correct out of 18 word pairs (6 positive, 6 negative and 6 neutral) after laboratory-induced stress using Trier Social Stress Test (TSST). Maximum score is 18 and minimum score is 0; higher scores indicate a better score.. Parameters: NA = NA (p = 0.68, CI NA-NA). Non-inferiority type: OTHER.
Study: A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

Summary: This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women. The primary study hypothesis is that one or more doses of MK-6913 will result in a significantly greater reduction from baseline, compared to placebo, in the number of moderate to very severe hot flashes after 4 weeks of treatment.

Detailed Description: NA

Results: Outcome: Change From Baseline in Follicle-stimulating Hormone (FSH) Level at Week 4. Time frame: Baseline and Week 4. Description: FSH was measured to assess estrogen receptor (ER) selectivity (a biomarker for ER activity and a pharmacodynamic endpoint).. Parameters: Difference in LS means = 0.94 (p = 0.827, CI -6.19-8.07); Difference in the LS means = -14.52 (p = 0.001, CI -21.73--7.32). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Number of Weekly Moderate to Very Severe Hot Flashes (Excluding Outliers) at Week 4. Time frame: Baseline and Week 4. Description: Hot flashes were recorded in real time and hot flashes recorded retrospectively in the morning and evening reports in a diary day via the Hot Flash e-diary were summed to determine the total number of hot flashes over a diary day. The total number of weekly moderate or worse hot flashes were calculated as the sum of the total number of hot flashes that occur over a diary week (non-missing diary day), divided by the number of days of diary completion, and multiplied by 7 (standardized week). At least 4 non-missing diary days were required to define the total number of weekly moderate or worse hot flashes. Hot flash data was excluded for participants whose number of moderate to severe hot flashes per week were in the top 1% of number of hot flashes reported to exclude any outlier effect.. Parameters: Differrence in the least squares means = -6.28 (p = 0.488, CI -24.2-11.64); Difference in the least squares means = -17.45 (p = 0.069, CI -36.28-1.38). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Weekly Hot Flash Severity Score (Combining Severe and Very Severe Score) at Week 4. Time frame: Baseline and Week 4. Description: Hot flash severity score is calculated by the sum of: the number of mild hot flashes, 2 times number of moderate hot flashes, 3 times the number of severe hot flashes, and 4 times the number of very severe hot flashes. This sum was standardized to a 7-day week if there were any missing days in the e-diary. The severity of each hot flash was recorded by the Hot Flash e-diary.. Parameters: Differrence in the least squares means = -6.05 (p = 0.529, CI -25.06-12.96); Difference in the least squares means = -11.22 (p = 0.264, CI -31.03-8.59). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Early Menopause Hormone Treatment and Cognition

Summary: The objective of this study is to evaluate the neurobiological effects of hormone therapy (HT) in healthy early postmenopausal women. The studies proposed in this project seek to define the association between different hormone forms (estradiol only and progesterone only) versus placebo on brain functional measures. The functional measures will include the performance of the volunteers on a comprehensive neuropsychological testing battery, and the brain functional responses to episodic memory (verbal and non-verbal) challenges as well as emotional processing determined with functional magnetic resonance imaging (fMRI).

Detailed Description: Specific Aims

Aim 1. To examine the effects of estradiol alone on brain functioning in early post-menopausal women during verbal and non-verbal cognitive tasks.

Hypothesis: It is expected that with estradiol treatment brain activation will be more prominent in the hippocampus and prefrontal cortical areas compared to placebo. The magnitude of activation in these regions will be positively correlated with task performance in the scanner and with the results of neuropsychological tests assessing verbal and non-verbal delayed recall.

Aim 2. To determine the effects of progesterone alone on brain functioning in early postmenopausal women during verbal and non-verbal cognitive tasks.

Hypothesis: It is expected that with progesterone treatment brain activation in the hippocampus and prefrontal cortical areas will be decreased compared to both the placebo condition (within subjects) and the estradiol condition (between subjects). Interindividual variations in the magnitude of activation in these regions will be positively correlated with task performance in the scanner and with the results of neuropsychological tests assessing verbal and non-verbal delayed recall.

Aim 3. To determine the individual effects of estradiol and progesterone on brain functioning in early postmenopausal women during emotional processing stimuli.

Hypothesis: During negative stimuli estradiol-treated women compared to placebo group, are expected to have increased activity in the amygdala, posterior cingulate, and orbitofrontal cortex, while in progesterone-treated women compared to placebo, decreased activity is expected in these brain regions.

Results: Outcome: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans. Time frame: August 2010 - March 2012. Description: Measure the changes in brain activity in verbal tasks with hormone use (either estradiol or progesterone) versus placebo.

The test is a deep and shallow verbal processing task, where the subjects are presented lists of words, one word at a time, and are asked to make one of 2 decisions about each list. One decision is whether each word is written in upper or lower case letters (shallow processing), and the other decision is whether each word denotes an abstract or concrete concept (deep processing).

The test was administered 3 months after baseline and 38 weeks after baseline.. Parameters: NA = NA (p = 0.222, CI NA-NA); NA = NA (p = 0.107, CI NA-NA); NA = NA (p = 0.127, CI NA-NA); NA = NA (p = 0.954, CI NA-NA); NA = NA (p = 0.385, CI NA-NA); NA = NA (p = 0.31, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Changes in Brain Activation Patterns in Visual Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans. Time frame: August 2010 - March 2012. Description: Measure the changes in brain activity in visual tasks with hormone use (either estradiol or progesterone) versus placebo.

The test is a visual working memory task, where the women are presented with 3 geometric grids on the screen. The target grid is on top, and 2 test grids are on the bottom. The women must decide if the right or left test grid matches the grid on top. There are 3 conditions: a match condition where all 3 grids are shown simultaneously, and 2 delay conditions, where the target grid is shown first, disappears, and the test grids appear after a 1 or a 4 second delay.

The test was administered 3 months after baseline and 38 weeks after baseline.. Parameters: NA = NA (p = 0.452, CI NA-NA); NA = NA (p = 0.868, CI NA-NA); NA = NA (p = 0.549, CI NA-NA); NA = NA (p = 0.124, CI NA-NA); NA = NA (p = 0.158, CI NA-NA); NA = NA (p = 0.055, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Neuropsychological Testing Scores - Verbal Learning Retention. Time frame: August 2010 - March 2012. Description: Changes in neuropsychological testing measures (verbal learning retention) with hormone use (either estradiol or progesterone) versus placebo.

Subjects are given tests that present them with a series of words. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the Benton Visual Memory Test, Revised.

The tests were administered 3 months after baseline and 38 weeks after baseline.. Parameters: NA = NA (p = 0.594, CI NA-NA); NA = NA (p = 0.653, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Neuropsychological Testing Scores - Visual Learning Retention. Time frame: August 2010 - March 2012. Description: Changes in neuropsychological testing measures (visual learning retention) with hormone use (either estradiol or progesterone) versus placebo.

Subjects are given tests that present them with a series of pictures. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the California Verbal Learning Test - 2nd edition.

The tests were administered 3 months after baseline and 38 weeks after baseline.. Parameters: NA = NA (p = 0.561, CI NA-NA); NA = NA (p = 0.726, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Impact of Hot Flashes on Sleep and Mood Disturbance

Summary: We plan to enroll premenopausal women in a trial investigating the impact of hot flashes developed in response to an injection of a gonadotropin-releasing hormone agonist (GnRHa), leuprolide (brand name: Lupron), on sleep disruption and mood. This study is designed to mimic the menopause transition. We will collect data on sleep disruption and mood changes to assess their relationship to the development of hot flashes.

Detailed Description: NA

Results: Outcome: Change in Montgomery-Asperg Depression Rating Scale (MADRS). Time frame: baseline and 4 weeks. Description: The Montgomery-sberg Depression Rating Scale is a widely used 10-item clinician-rated scale that describes the severity of depressive symptoms. It has a range of 0-60 with higher scores indicating greater symptom burden. Participants were assessed at baseline and four weeks after the GnRHa injection in order to calculate the change in MADRS score.. Parameters: NA = NA (p = 0.01, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Wake After Sleep Onset (WASO). Time frame: baseline and 4 weeks. Description: Wake after sleep onset (WASO) is calculated by averaging the number of minutes spent awake after initiating sleep each night from the two ambulatory polysomnography studies conducted at baseline and the two ambulatory polysomnography studies conducted four weeks after the GnRHa injection.. Parameters: NA = NA (p = 0.007, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Measuring Quality of Decisions About Treatment of Menopausal Symptoms

Summary: The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of menopause. In particular, we will examine whether the decision aid increases knowledge about menopause/managing menopause symptoms and concordance between goals and treatment choices.

Detailed Description: NA

Results: Outcome: Menopause Knowledge. Time frame: 2 weeks, on average. Description: Total knowledge score from factual questions about menopause and methods for managing menopause symptoms. Score is the percent of knowledge questions answered correctly (0 - 100%). Parameters: Mean Difference (Net) = 4.6 (p = 0.01, CI 1.02-7.96). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Nave Women With Post-Menopausal Osteoporosis

Summary: This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-nave patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Lumbar Spine T-score at Month 12 and 24. Time frame: Baseline, Month 12, Month 24. Description: Percent change was calculated as \[(measure at time "t" - measure at baseline)/measure at baseline\]\*100, where t=12 and 24 months. The baseline value is used as a reference to calculate the relative change from baseline. T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis. A T-score below -2.5 in combination with a prevalent fracture indicates serious osteoporosis.. Parameters: NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Hip BMD at Month 24. Time frame: Baseline, Month 24. Description: Percent change was calculated as \[(measure at time "t" - measure at baseline)/measure at baseline\]\*100, where t=24 months. The baseline value is used as a reference to calculate the relative change from baseline.. Parameters: NA = NA (p = 0.056, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Hip Bone BMD at Month 12. Time frame: Baseline, Month 12. Description: Percent change was calculated as \[(measure at time "t" - measure at baseline)/measure at baseline\]\*100, where t=12 months. The baseline value is used as a reference to calculate the relative change from baseline.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine BMD at Month 24. Time frame: Baseline, Month 24. Description: Percent change was calculated as \[(measure at time "t" - measure at baseline)/measure at baseline\]\*100, where t=24 months. The baseline value is used as a reference to calculate the relative change from baseline.. Parameters: NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12. Time frame: Baseline, Month 12. Description: Percent change was calculated as \[(measure at time "t" minus \[-\] measure at baseline) divided by (/) measure at baseline\] multiplied by (\*) 100, where t=12 months. The baseline value is used as a reference to calculate the relative change from baseline.. Parameters: NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Total Hip T-score at Month 12 and 24. Time frame: Baseline, Month 12, Month 24. Description: Percent change was calculated as \[(measure at time "t" - measure at baseline)/measure at baseline\]\*100, where t=12 and 24 months. The baseline value is used as a reference to calculate the relative change from baseline. T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis. A T-score below -2.5 in combination with a prevalent fracture indicates serious osteoporosis.. Parameters: NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Effects of Denosumab on the Pharmacokinetics of Etanercept

Summary: The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis based on area under the serum concentration-time curve (AUC) and maximum observed serum concentration (Cmax).

Detailed Description: NA

Results: Outcome: Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept. Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.. Description: The AUC0-168 of etanercept was measured when administered alone (assessed from day 1) and after administration with denosumab (assessed from day 22, 14 days after denosumab dosing, close to the time of the maximum observed denosumab serum concentration and corresponding to a time approximately 1 week after maximal pharmacodynamic (PD) effects of denosumab are attained).. Parameters: Least Squares Mean Ratio of Day 22/Day 1 = 0.96 (p = NA, CI 0.85-1.08). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Maximum Observed Serum Concentration (Cmax) of Etanercept. Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.. Description: NA. Parameters: Least Squares Mean Ratio of Day 22/Day 1 = 0.92 (p = NA, CI 0.81-1.05). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Summary: The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.

Detailed Description: This is a randomized, double-blind, placebo-controlled, comparative Phase 3, multicenter international study to evaluate the efficacy and safety of BA058 (abaloparatide) 80 g in the prevention of fracture in otherwise healthy ambulatory postmenopausal women with severe osteoporosis.

Results: Outcome: Number of Participants With New Vertebral Fractures at 18 Months. Time frame: 18 months. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Non-vertebral Fractures at 18 Months. Time frame: 18 months. Description: NA. Parameters: NA = NA (p = 0.0318, CI NA-NA); NA = NA (p = 0.2304, CI NA-NA); NA = NA (p = 0.3361, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18. Time frame: Baseline and 18 months. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 4e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months. Time frame: Basline and 18 months. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 0.8155, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18. Time frame: Baseline and 18 months. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)

Summary: For the contraceptive application a film-coated tablet has been developed which combines nomegestrol acetate (NOMAC) with estradiol (E2). This was an open-label, randomized, single-dose, four-way, replicate, cross-over study design conducted in 2 parallel parts at two sites, one site per study part. The primary objective of Part 1 was to assess the bioequivalence of NOMAC and E2 of the drug product manufactured using the commercial process ("commercial batch") versus the Phase 3 drug product ("Batch A"). The primary objective of Part 2 was to assess bioequivalence of NOMAC and E2 of the drug product manufactured using the commercial process ("commercial batch") versus the Phase 3 drug product ("Batch B").

Detailed Description: NA

Results: Outcome: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measurable Sample (AUC Last) and Area Under the Concentration-time Curve From Time 0 to Infinity (AUC Infinity) for NOMAC. Time frame: 0 hours to time of the last measurable sample (blood samples were collected for NOMAC evaluation up to 144 hours postdose). Description: Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2.

AUClast is the AUC from time 0 to the time of the final quantifiable sample.

AUC infinity is the AUC from time 0 to infinity.

Blood samples for PK evaluation of NOMAC were collected at predose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours postdose Day 1.. Parameters: Ratio (Test/Ref %) = 110 (p = NA, CI 106.4-113.7); Ratio (Test/Ref %) = 103.3 (p = NA, CI 100.9-105.7); Ratio (Test/Ref %) = 108.1 (p = NA, CI 104.7-111.6); Ratio (Test/Ref %) = 103.1 (p = NA, CI 100.5-105.8). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Baseline Corrected Area Under the Concentration-time Curve From Time 0 to 72 Hours (AUC72) for E2. Time frame: 0 hours to 72 hours. Description: Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2.

AUC72 is the AUC from time 0 to 72 hours.

Blood samples for PK evaluation of E2 were collected predose (-1, -0.5, and 0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose Day 1; multiple predose samples were needed to correct for endogenous levels.. Parameters: Ratio (Test/Ref %) = 101.3 (p = NA, CI 98.1-104.7); Ratio (Test/Ref %) = 101.5 (p = NA, CI 96.7-106.4). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Baseline Corrected Maximum Observed Serum Concentration of E2 (Cmax of E2). Time frame: 0 hours to time of maximum observed serum concentration of E2 (tmax of E2) (blood samples were collected for E2 evaluation up to 96 hours postdose). Description: Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2.

Blood samples for PK evaluation of E2 were collected predose (-1, -0.5, and 0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose Day 1; multiple predose samples were needed to correct for endogenous levels.. Parameters: Ratio (Test/Ref %) = 107.3 (p = NA, CI 99-116.4); Ratio (Test/Ref %) = 103.6 (p = NA, CI 99.2-108.2). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Maximum Observed Plasma Concentration of NOMAC (Cmax of NOMAC). Time frame: 0 hours to time of maximum observed plasma concentration of NOMAC (tmax of NOMAC) (blood samples were collected for NOMAC evaluation up to 144 hours postdose). Description: Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2.

Blood samples for pharmacokinetic (PK) evaluation of NOMAC were collected at predose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours postdose Day 1.. Parameters: Ratio (Test/Ref %) = 137.5 (p = NA, CI 131-144.4); Ratio (Test/Ref %) = 111.8 (p = NA, CI 107.5-116.4). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY.
Study: A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)

Summary: This study will evaluate whether the once weekly administration of the combination tablet alendronate/vitamin D3 (FOSAMAX PLUS) will increase lumbar spine bone mineral density (BMD) more than the daily use of calcitriol.

Detailed Description: This was a 6-month, randomized, open-label, active-comparator controlled, parallel-group study with a 6-month extension to evaluate the safety and efficacy of alendronate sodium 70 mg plus vitamin D3 5600 IU combination tablets versus calcitriol in the treatment of osteoporosis in postmenopausal women in China. Participants were randomly assigned to receive alendronate 70 mg plus vitamin D3 5600 IU combination tablet once weekly orally or calcitriol 0.25 g daily orally.

Results: Outcome: Base Study: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6. Time frame: Baseline and Month 6. Description: BMD at the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) at baseline and Month 6.. Parameters: Estimated Difference = 1.95 (p = 0.001, CI 0.8-3.1). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Base Study: Percentage Change From Baseline in Serum C-Telopeptides of Type 1 Collagen (s-CTx) at Month 6. Time frame: Baseline and Month 6. Description: s-CTx is a biochemical marker for bone turnover that has been shown to detect increased bone resorption, a process by which bone is broken down within the body. s-CTx was measured at baseline and Month 6.. Parameters: LS mean difference = -52.03 (p = 0.001, CI -59.04--45.3). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Base Study: Percentage Change From Baseline in Serum Procollagen Type 1 N-Terminal Propeptide (s-P1NP) at Month 6. Time frame: Baseline and Month 6. Description: s-P1NP is a biochemical marker of bone turnover that is particularly useful in monitoring bone resorption, a process by which bone is broken down within the body. s-P1NP was measured at baseline and Month 6.. Parameters: LS mean difference = -42.37 (p = 0.001, CI -48.16--36.67). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in Lumbar Spine BMD at Month 12. Time frame: Baseline and Month 12. Description: BMD at the lumbar spine was assessed by DXA at baseline and Month 12.. Parameters: Estimated Difference = 2.92 (p = 0.001, CI 1.8-4.1). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in s-CTx at Month 12. Time frame: Baseline and Month 12. Description: s-CTx is a biochemical marker for bone turnover that has been shown to detect increased bone resorption, a process by which bone is broken down within the body. s-CTx was measured at baseline and Month 12.. Parameters: LS mean difference = -51.96 (p = 0.001, CI -58.77--45.39). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in s-P1NP at Month 12. Time frame: Baseline and Month 12. Description: s-P1NP is a biochemical marker of bone turnover that is particularly useful in monitoring bone resorption, a process by which bone is broken down within the body. s-P1NP was measured at baseline and Month 12.. Parameters: LS mean difference = -51.07 (p = 0.001, CI -57.29--44.99). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage of Participants With Serum 25-Hydroxyvitamin (OH) D <20 ng/mL at Month 12. Time frame: Baseline and Month 12. Description: The term "vitamin D insufficiency" is used to describe vitamin D levels that are low enough to cause secondary hyperparathyroidism, bone loss, and increased risk of skeletal fracture. In this study, a threshold for vitamin D insufficiency was a level of serum 25(OH) D \<20 ng/mL.. Parameters: Odds Ratio (OR) = 0.0279 (p = 0.001, CI 0.0074-0.1048). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.
Study: Efficacy/Safety Study of Brisdelle (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Summary: The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.

Detailed Description: This is 12-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg and placebo capsules in subjects with moderate to severe postmenopausal VMS, defined as follows:

* Moderate VMS: Sensation of heat with sweating, able to continue activity
* Severe VMS: Sensation of heat with sweating, causing cessation of activity

The study is comprised of a screening period, a run-in period, a baseline visit, and a double-blind treatment period.

Results: Outcome: Clinical Meaningfulness Anchored to Patient Global Improvement (PGI-I) (%). Time frame: Week 4 and Week 12. Description: A patient improvement scale questionnaire was used during participant visits.

The clinical meaningfulness of the observed treatment effect was demonstrated by performing the following analysis:

Subjects were categorized in to 2 groups (satisfied and unsatisfied). Based on a 7 point patient global impression (PGI) questionnaire which assesses the subject improvement in VMS. Subjects were considered satisfied with their treatment if their response to the question "Compared to before starting the study medication, how would you describe your hot flushes now?" is 'Very much better' (1) or 'Much better' (2) or 'A little better' (3) and will be considered unsatisfied if their response to the same question is 'No change' (4) or 'A little worse' (5) or 'Much worse' (6) or 'Very much worse' (7). Receiver Operator Curve (ROC) analysis was performed on the combined data.

Subjects who were satisfied with their treatment were considered to have a treatment effect with clinical meaningfulness. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.055, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12. Time frame: Week 4 and Week 12. Description: Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.

Weekly Severity Score = (2Fm +3FS)/(Fm + FS) Daily Severity Score = {(2F) m +3FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.. Parameters: NA = NA (p = 0.0017, CI NA-NA); NA = NA (p = 0.1658, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.. Time frame: Week 4 and Week 12. Description: Subjects recorded the number of hot flashes per week using an electronic diary. The results reported are not hot flashes per week.

The results reported are:

* Mean Baseline frequency of moderate to severe VMS
* Mean change in frequency of moderate to severe VMS from baseline to Week 4
* Mean change in frequency of moderate to severe VMS from baseline to Week 12.. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Summary: The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.

Detailed Description: This is a randomized (study drug assigned by chance), open-label (all participants will know the identity of the assigned study drug) study divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. The treatment phase will comprise a series of 28-day cycles with continuous study treatment until breast cancer progression, when an end-of-treatment visit will be completed before the follow-up phase begins. The duration of participation in the study for an individual patient may be up to approximately 7 years, including follow-up evaluations. Patients will be evaluated for the safety and effectiveness of study treatments. During the treatment phase, patients will take the following study drugs by mouth once daily: abiraterone acetate, 1 g/day, as four 250-mg tablets, on an empty stomach, and patients must not eat for at least 1 hour after abiraterone acetate; prednisone (prednisolone when prednisone is not available), 5 mg/day; and exemestane, 25 mg/day, as a single tablet. The treatment phase will consist of a series of 28-day cycles with continuous study treatment until breast cancer progression. At the planned interim analysis, the Data Review Committee has recommended that further randomization to the abiraterone acetate alone group be stopped and that the study is to be continued otherwise.

Results: Outcome: Clinical Benefit Rate. Time frame: Approximately 2 years. Description: Clinical benefit rate was defined as the percentage of participants with measurable disease achieving a best overall response of a CR, PR, or stable disease (SD) for at least 6 months based on RECIST. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.. Parameters: Risk Ratio (RR) = 0.757 (p = 0.603, CI 0.264-2.175); Risk Ratio (RR) = 1.79 (p = 0.137, CI 0.816-3.926). Non-inferiority type: SUPERIORITY. Outcome: Overall Response Rate (ORR). Time frame: Approximately 2 years. Description: Overall response rate was defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target lesions and non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.. Parameters: Risk Ratio (RR) = 0.909 (p = 1, CI 0.213-3.878); Risk Ratio (RR) = 1.909 (p = 0.366, CI 0.605-6.026). Non-inferiority type: SUPERIORITY. Outcome: Overall Survival (OS). Time frame: Approximately 3 years. Description: OS was calculated as the time from randomization to death from any cause.. Parameters: Hazard Ratio (HR) = 1.074 (p = 0.807, CI 0.608-1.896); Hazard Ratio (HR) = 1.183 (p = 0.542, CI 0.688-2.036). Non-inferiority type: SUPERIORITY. Outcome: Progression-Free Survival (PFS). Time frame: Approximately 2 years. Description: Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.. Parameters: Hazard Ratio (HR) = 1.143 (p = 0.437, CI 0.816-1.603); Hazard Ratio (HR) = 0.958 (p = 0.794, CI 0.695-1.32). Non-inferiority type: SUPERIORITY.
Study: Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Summary: This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.

Detailed Description: All women in the database meeting the inclusion criteria will be included in the study without any statistical sampling.

Results: Outcome: Cumulative Incidence of All Malignancies. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: All malignancies included and not limited only to thyroid, breast, renal, genital / urogenital, lung cancer, gastrointestinal tract and respiratory tract. Cumulative incidence was calculated as total participants with malignancies events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.5 (p = 0.01, CI 0.3-0.7); Hazard Ratio (HR) = 0.8 (p = 0.38, CI 0.5-1.4). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Atrial Fibrillation. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Atrial fibrillation is an irregular heartbeat that increases the risk of stroke and heart disease. Cumulative incidence was calculated as total participants with atrial fibrillation events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.7 (p = 0.19, CI 0.4-1.2); Hazard Ratio (HR) = 0.7 (p = 0.1, CI 0.5-1.1). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Biliary Events. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Biliary events included cholecystitis and cholelithiasis. Cumulative incidence was calculated as total participants with biliary events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.7); Hazard Ratio (HR) = 1 (p = 0.9, CI 0.4-2.1). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Cardiac Disorders. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Cardiac disorders included myocardial infarction, myocardial ischemia, and coronary occlusion. Cumulative incidence was calculated as total participants with cardiac disorders events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.6 (p = 0.01, CI 0.3-0.9); Hazard Ratio (HR) = 0.7 (p = 0.37, CI 0.4-1.5). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Clinical Fractures. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: A fracture is a break in a bone. Cumulative incidence was calculated as total participants with clinical fractures events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.6); Hazard Ratio (HR) = 0.6 (p = 0.01, CI 0.4-0.9). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Depression. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Cumulative incidence was calculated as total participants with depression events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 1.2 (p = 0.24, CI 0.9-1.5); Hazard Ratio (HR) = 1.1 (p = 0.59, CI 0.8-1.6). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Hypertriglyceridemia. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Hypertriglyceridemia refers to high blood levels of triglycerides. Cumulative incidence was calculated as total participants with hypertriglyceridemia events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 1.9 (p = 0.01, CI 1.4-2.5); Hazard Ratio (HR) = 0.9 (p = 0.74, CI 0.7-1.3). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Ischemic Stroke. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Ischemic stroke is caused by a blockage in an artery that supplies blood to the brain. Cumulative incidence was calculated as total participants with ischemic stroke events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.5 (p = 0.01, CI 0.3-0.7); Hazard Ratio (HR) = 1.1 (p = 0.76, CI 0.5-2.4). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Renal Failure. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Cumulative incidence was calculated as total participants with renal failure events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.3 (p = 0.01, CI 0.1-0.5); Hazard Ratio (HR) = 0.4 (p = 0.06, CI 0.2-1.1). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Selected Ocular Events. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Selected ocular events included retinal vascular occlusions, disorders of the globe, iris, ciliary body, retina, eye adnexa and cornea. Cumulative incidence was calculated as total participants with selected ocular events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.8 (p = 0.03, CI 0.6-1); Hazard Ratio (HR) = 0.8 (p = 0.19, CI 0.6-1.1). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Thyroid Disorders- Goitre. Time frame: Up to a maximum of follow-up period of 92.1 months. Description: Goitre is a swelling in the neck resulting from an enlarged thyroid gland. Cumulative incidence was calculated as total participants with thyroid disorders-goitre events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.3 (p = 0.01, CI 0.2-0.5); Hazard Ratio (HR) = 0.6 (p = 0.24, CI 0.3-1.3). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Venous Thromboembolism (VTE). Time frame: Up to a maximum of follow-up period of 92.1 months. Description: VTE is defined as deep vein thrombosis (DVT), pulmonary embolism (PE), retinal vein thrombosis, and sinus thrombosis. DVT: occurs when a blood clot forms in a vein located deep inside the body. PE: a blockage of an artery in the lungs by a substance that has moved from elsewhere in the body through the bloodstream (embolism). Sinus thrombosis: presence of a blood clot in the dural venous sinuses, which drain blood from the brain. Retinal vein thrombosis: blockage of the small veins that carry blood away from the retina. Cumulative incidence was calculated as total participants with VTE events during follow-up period divided by total persons at risk during follow-up period\*100 and hence cumulative incidence was expressed as percentage of participants.. Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.7); Hazard Ratio (HR) = 1 (p = 0.91, CI 0.4-2.2). Non-inferiority type: SUPERIORITY.
Study: MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Summary: The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17--estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR to estradiol therapy, to provide evidence of the relative efficacy of venlafaxine to what is currently considered the most established but also a controversial therapy. 17--estradiol is a type of estrogen. Venlafaxine XR is the extended release (XR) version of venlafaxine. Venlafaxine XR is an serotonin-norepinephrine reuptake inhibitor (SNRI). A placebo is a substance containing no medication.

Detailed Description: The MsFLASH-03 study (Menopausal Strategies: Finding Lasting Answers for Symptoms and Health - 03), Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms, is a randomized, double-blind, placebo-controlled, three arm clinical trial. The design includes: 3 weeks of daily recording of hot flashes prior to drug treatment; 8 weeks of double-blind treatment with oral estradiol, venlafaxine, or placebo; followed by 14 days of drug taper for those on venlafaxine and 14 days of progesterone treatment for those on estradiol; followed by 2 weeks with no treatment for all groups; and a telephone follow-up post-treatment.

Results: Outcome: Bothersomeness of Hot Flashes -- Week 8. Time frame: Week 8. Description: Measured by self-report diary twice daily (day and night) for 7 days. Bothersomeness ratings ranged from 0 to 3 with lower numbers being less bothersome and higher numbers being more bothersome. Data from the day and night bothersomeness ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS bothersomeness for week 8.. Parameters: NA = NA (p = 0.01, CI NA-NA); NA = NA (p = 0.07, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Frequency of Hot Flashes (Daily Vasomotor Symptom [VMS] Frequency) -- Week 8. Time frame: Week 8. Description: Measured by self-report diary twice daily (day and night). The day and night frequencies were summed to produce a single number of hot flashes per day. The single number of hot flashes per day were summed and averaged for one week prior to the week 8 study assessment to produce a mean daily frequency for week 8.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 8. Time frame: Week 8. Description: The perceived hot flash related daily interference scale (HFRDIS) is a tool for assessing the impact of hot flashes on quality of life. There are 10 questions with each having a score ranging from 0 to 10. The scores from each question are summed for a total score ranging from 0 to 100. Lower numbers indicate less interference and higher numbers indicate more interference.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Severity of Hot Flashes -- Week 8. Time frame: Week 8. Description: Measured by self-report diary twice daily (day and night) for 7 days. Severity ratings ranged from 0 to 3 with lower numbers being less severe and higher numbers being more severe. Data from the day and night severity ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS severity for week 8.. Parameters: NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Summary: The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.

Detailed Description: NA

Results: Outcome: Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6. Time frame: Baseline and Month 6. Description: Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.. Parameters: Mean Difference (Final Values) = 3.21 (p = 1e-04, CI 2.06-4.36). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Summary: The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.

Detailed Description: NA

Results: Outcome: Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6. Time frame: Baseline and Month 6. Description: Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).. Parameters: Mean Difference (Final Values) = 3.05 (p = 1e-04, CI 1.91-4.19). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Summary: The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs. a placebo liquid in reducing pain.

The investigators hypothesize that the pain arises in the vulvar vestibule. The investigators predict that the localized use of lidocaine will be more efficacious than use of placebo liquid.

Detailed Description: For this study there will be three visits over a 3 month period. Subjects will undergo a gynecological exam at the screening visit to determine the severity of pain associated with uncomfortable intercourse. A touch test using Q-tips will be used during screening exam so subjects can report pain during application of both study drug and placebo. Subjects will also report pain during tampon test. A sample of vaginal cells and liquid will be obtained at screening visit so that PI can rule out possible infection, disease, or disorders. PI will also show subject the area of the vestibule in a mirror so that subject can apply study drug at home properly. Subjects will fill out 4 questionnaires about medical and health history, cancer history, pain, and distress and sexual activity. Subject will be given a supply of either study drug or placebo to take home. The first visit will last approximately 2 hours.

Subjects will return for a second visit after 4 weeks and a third visit after 8 weeks for diary review, questionnaires, and examination. The second and third visit examinations will be repeats of the examination done at the first visit, but there will be no comparison with placebo, the PI will use only study drug during the touch test. The second and third visits will last approximately 1 hour.

Subjects will fill out questionnaires throughout study participation. Topics include; medical and health history, cancer history, pain, distress and sexual activity. Subjects will also fill out a diary that charts tampon test completed from home, sexual activity performed, pain levels and study drug application days.

Results: Outcome: Improvement of Quality of Sexual Life - Visit 1. Time frame: Visit 1 (Enrollment). Description: To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; 23 considered normal function), Arousal-sensation (score range 4-20; 14 considered normal function), Arousal-lubrication (score ranges 2-10; 8 considered normal function), Arousal-cognitive (score range 2-10; 8 considered normal function), Orgasm (score range 1-15; 12 considered normal function), Pain (2-15; 12 considered normal function), Enjoyment (score range 6-30; 23 considered normal function) and Partner (score range 2-10; 8 considered normal function).. Parameters: NA = NA (p = 0.66, CI NA-NA); NA = NA (p = 0.11, CI NA-NA); NA = NA (p = 0.15, CI NA-NA); NA = NA (p = 0.28, CI NA-NA); NA = NA (p = 0.07, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.54, CI NA-NA); NA = NA (p = 0.92, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Location of Pain in Postmenopausal Dyspareunia. Time frame: Enrollment visit. Description: To determine the specific site of vulvovaginal tenderness in menopausal breast cancer survivors who have entry dyspareunia. Examine the vulvar vestibule with a swab test to determine locations and severity of touch tenderness. Eight sites were evaluated around the vaginal opening and there location was in reference to a clock face. Measured using the Numerical Rating Scale, a scale which measures pain from 0 to 10 with 0="no pain" and 10="the worst pain you have ever felt".. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Prevention of Entry Dyspareunia With Non-hormonal Therapy. Time frame: During Phase II (0-4 weeks) and during Phase III (5-12 weeks). Description: Mean intercourse pain reported by subjects using the Numerical Rating Scale pain ratings (range 0-10, 0 being "no pain" and 10 being "worst possible pain"). Testing was during weeks 0-4 (Phase II) (with blinded randomization for placebo vs active intervention medication) and testing was during weeks 5-12 (Phase III) (with open-label active medication for 8 weeks after completing the blinded 4 weeks). Subjects agreed to try penetration twice per week and score their pain using the Numerical Rating Scale pain ratings.The scores were averaged during each phase.. Parameters: NA = NA (p = 0.0149, CI NA-NA); NA = NA (p = 0.412, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Summary: The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis

Detailed Description: NA

Results: Outcome: Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24. Time frame: Baseline and Month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 11.1 (p = 0.001, CI 10.8-11.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12. Time frame: Baseline and Month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 12.7 (p = 0.001, CI 12.4-12.9). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12. Time frame: Baseline and Month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 5.2 (p = 0.001, CI 4.9-5.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24. Time frame: Baseline and Month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 4.9 (p = 0.001, CI 4.7-5.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12. Time frame: Baseline and Month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 5.8 (p = 0.001, CI 5.6-6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24. Time frame: Baseline and Month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 5.3 (p = 0.001, CI 5.1-5.5). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12. Time frame: 12 Months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were  2 vertebrae from T4 to L4 with  1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.. Parameters: Odds Ratio (OR) = 0.11 (p = 0.011, CI 0.01-0.87). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24. Time frame: 24 Months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were  2 vertebrae from T4 to L4 with  1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.. Parameters: Odds Ratio (OR) = 0.06 (p = 0.001, CI 0.01-0.44). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fracture Through Month 12. Time frame: 12 Months. Description: New vertebral fractures occurred when there was  1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.

The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:

* Grade 0 (Normal) = no fracture;
* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.. Parameters: Odds Ratio (OR) = 0.27 (p = 0.001, CI 0.15-0.47). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fracture Through Month 24. Time frame: 24 months. Description: New vertebral fractures occurred when there was  1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.

The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:

* Grade 0 (Normal) = no fracture;
* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.. Parameters: Odds Ratio (OR) = 0.24 (p = 0.001, CI 0.15-0.39). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 12. Time frame: 12 Months. Description: Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.64 (p = 0.008, CI 0.46-0.89). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 24. Time frame: 24 Months. Description: Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.67 (p = 0.096, CI 0.52-0.87). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture Through Month 12. Time frame: 12 Months. Description: Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.. Parameters: Hazard Ratio (HR) = 0.54 (p = 0.18, CI 0.22-1.35). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture Through Month 24. Time frame: 24 Months. Description: Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.. Parameters: Hazard Ratio (HR) = 0.5 (p = 0.12, CI 0.24-1.04). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Nonvertebral Fracture Through Month 12. Time frame: 12 Months. Description: A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.. Parameters: Hazard Ratio (HR) = 0.67 (p = 0.096, CI 0.44-1.02). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Nonvertebral Fracture Through Month 24. Time frame: 24 Months. Description: A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.. Parameters: Hazard Ratio (HR) = 0.67 (p = 0.096, CI 0.49-0.91). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Osteoporotic Fracture Through Month 12. Time frame: 12 Months. Description: Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.6 (p = 0.012, CI 0.4-0.9). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Osteoporotic Fracture Through Month 24. Time frame: 24 Months. Description: Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.62 (p = 0.002, CI 0.46-0.84). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12. Time frame: 12 Months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4.. Parameters: Odds Ratio (OR) = 0.28 (p = 0.096, CI 0.17-0.49). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24. Time frame: 24 Months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4.. Parameters: Odds Ratio (OR) = 0.26 (p = 0.096, CI 0.16-0.41). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture Through Month 12. Time frame: 12 Months. Description: A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.75 (p = 0.096, CI 0.53-1.05). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture Through Month 24. Time frame: 24 Months. Description: A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.75 (p = 0.057, CI 0.57-0.97). Non-inferiority type: SUPERIORITY.
Study: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Summary: The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.

Detailed Description: In this trial, women were randomly assigned in a 1:1 ratio to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months. Randomization was stratified according to age (\<75 vs. 75 years). After completion of the double-blind treatment period, all the participants were to receive open-label weekly oral alendronate until the end of the trial, with blinding to the initial treatment assignment maintained.

The primary analysis was performed when clinical fracture events had been confirmed in at least 330 participants and all the participants had completed the month 24 visit. The study was to continue in an event-driven manner until at least 440 participants experienced a nonvertebral fracture or if the superiority of romosozumab was proven for nonvertebral fractures at the primary analysis.

Results: Outcome: Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.2 (p = 0.001, CI 2.9-3.54). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 8.7 (p = 0.001, CI 8.31-9.09). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24. Time frame: Baseline and month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 8.1 (p = 0.001, CI 7.58-8.57). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.3 (p = 0.001, CI 3.03-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36. Time frame: Baseline and month 36. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.6 (p = 0.001, CI 3.18-3.97). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24. Time frame: Baseline and month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.8 (p = 0.001, CI 3.4-4.14). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36. Time frame: Baseline and month 36. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 7.4 (p = 0.001, CI 6.84-7.89). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24. Time frame: Baseline and month 24. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.8 (p = 0.001, CI 3.42-4.1). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36. Time frame: Baseline and month 36. Description: Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: LS Mean Difference = 3.7 (p = 0.001, CI 3.29-4.02). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Any Fracture Through Month 12. Time frame: 12 months. Description: All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.. Parameters: Hazard Ratio (HR) = 0.71 (p = 0.002, CI 0.57-0.88). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Any Fracture at the Primary Analysis. Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).. Description: All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.. Parameters: Hazard Ratio (HR) = 0.65 (p = 0.001, CI 0.56-0.76). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24. Time frame: 24 months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were  2 vertebrae from T4 to L4 with  1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.. Parameters: Odds Ratio (OR) = 0.51 (p = 0.008, CI 0.31-0.85); Risk Ratio (RR) = 0.52 (p = NA, CI 0.32-0.85); Absolute risk reduction = 1.21 (p = NA, CI 0.33-2.1). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fractures Through Month 12. Time frame: 12 months. Description: New vertebral fractures occurred when there was  1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:

* Grade 0 (Normal) = no fracture;
* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

Incident vertebral fractures were confirmed by a second independent reader.. Parameters: Odds Ratio (OR) = 0.63 (p = 0.008, CI 0.44-0.89); Risk Ratio (RR) = 0.64 (p = NA, CI 0.46-0.89); Absolute risk reduction = 1.84 (p = NA, CI 0.51-3.17). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fractures Through Month 24. Time frame: 24 months. Description: All fracture assessments were performed by blinded central imaging readers.

New vertebral fractures occurred when there was  1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:

* Grade 0 (Normal) = no fracture;
* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.. Parameters: Risk Ratio (RR) = 0.5 (p = NA, CI 0.38-0.66); Absolute risk reduction = 4.03 (p = NA, CI 2.5-5.57); Odds Ratio (OR) = 0.48 (p = 0.001, CI 0.36-0.64). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 12. Time frame: 12 months. Description: Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.72 (p = 0.027, CI 0.54-0.96). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 24. Time frame: 24 months. Description: Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.74 (p = 0.005, CI 0.59-0.91). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture at the Primary Analysis. Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).. Description: All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.73 (p = 0.001, CI 0.61-0.88). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Vertebral Fracture Through Month 12. Time frame: 12 months. Description: A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.. Parameters: Hazard Ratio (HR) = 0.56 (p = 0.14, CI 0.26-1.22). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Vertebral Fracture Through Month 24. Time frame: 24 months. Description: A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.. Parameters: Hazard Ratio (HR) = 0.41 (p = 0.001, CI 0.24-0.71). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture Through Month 12. Time frame: 12 months. Description: Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.. Parameters: Hazard Ratio (HR) = 0.64 (p = 0.19, CI 0.33-1.26). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture Through Month 24. Time frame: 24 months. Description: Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.. Parameters: Hazard Ratio (HR) = 0.72 (p = 0.17, CI 0.46-1.15). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture at the Primary Analysis. Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).. Description: Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.. Parameters: Hazard Ratio (HR) = 0.62 (p = 0.015, CI 0.42-0.92). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis. Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).. Description: Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.. Parameters: Hazard Ratio (HR) = 0.73 (p = 0.004, CI 0.59-0.9). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Osteoporotic Fracture Through Month 12. Time frame: 12 months. Description: Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.72 (p = 0.053, CI 0.52-1.01). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24. Time frame: 24 months. Description: A new or worsening vertebral fracture was identified when there was a  1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:

* Grade 0 (Normal) = no fracture;
* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.. Parameters: Odds Ratio (OR) = 0.49 (p = 0.001, CI 0.37-0.64); Risk Ratio (RR) = 0.52 (p = NA, CI 0.4-0.66); Absolute risk reduction = 4.44 (p = NA, CI 2.8-6.08). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture Through Month 12. Time frame: 12 months. Description: A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.74 (p = 0.057, CI 0.54-1.01). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture Through Month 24. Time frame: 24 months. Description: A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.81 (p = 0.074, CI 0.64-1.02). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis. Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).. Description: A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.. Parameters: Hazard Ratio (HR) = 0.81 (p = 0.04, CI 0.66-0.99). Non-inferiority type: SUPERIORITY.
Study: Homeopathic Treatment for Depression in Peri- and Postmenopausal Women

Summary: The aim of this study was to determine whether individualized homeopathic treatment and fluoxetine are more efficient than placebo for moderate to severe depression in peri- and postmenopausal women.

Detailed Description: Perimenopausal period is characterized by an increased risk of depressive symptoms. Major depression is one of the most disabling medical conditions worldwide. At present, it is becoming more difficult to prove that antidepressants actually work better than placebo in clinical trials.Use of homeopathy to treat depression is widespread, but there is a lack of clinical trails about its efficacy in depression in peri- and postmenopausal women. Previous trials suggest that individualized homeopathic treatments improve depression in general population. The purpose of this study was to determine whether individualized homeopathic treatment and fluoxetine are more efficient than placebo for moderate depression in peri- and postmenopausal women.

Results: Outcome: Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.. Time frame: Baseline and 6 weeks. Description: 17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score \< or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), \> 24 (severe depression).. Parameters: Mean Difference (Final Values) = 5 (p = 0.05, CI 3.1-7); Mean Difference (Final Values) = 3.2 (p = 0.05, CI 1.31-5.25). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Beck Depression Inventory at 6 Weeks.. Time frame: Baseline and 6 weeks. Description: Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), \> 29 (severe depression).. Parameters: Mean Difference (Final Values) = 3.4 (p = 0.14, CI -0.73-7.61); Mean Difference (Final Values) = 1.28 (p = 0.99, CI -2.93-5.5). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Greenes Scale at 6 Weeks.. Time frame: Baseline and 6 weeks. Description: Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and \> 50 (severe symptoms).. Parameters: Mean Difference (Final Values) = 8.6 (p = 0.002, CI 2.72-14.52); Mean Difference (Final Values) = 3.6 (p = 0.424, CI -2.33-9.6). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Remission Rates at 6 Weeks. Time frame: 6 weeks. Description: 17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score \< or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), \> 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score \< 7 points after 6 weeks of treatment.. Parameters: Odds Ratio (OR) = 0.26 (p = 0.1, CI 0.05-1.32); Odds Ratio (OR) = 0.27 (p = 0.11, CI 0.05-1.39). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Responder Rates at 6 Weeks.. Time frame: 6 weeks. Description: 17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score \< or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), \> 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment.. Parameters: Odds Ratio (OR) = 0.11 (p = 0.05, CI 0.03-0.34); Odds Ratio (OR) = 0.19 (p = 0.05, CI 0.06-0.56). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Summary: To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in BMD of Forearm at 6 Months. Time frame: Baseline, 6 Months. Description: Percent change in BMD as specified by DXA scans of the forearm.. Parameters: NA = NA (p = 0.9493, CI NA-NA); NA = NA (p = 0.9806, CI NA-NA); NA = NA (p = 0.5191, CI NA-NA); Mean Difference (Final Values) = -0.564 (p = NA, CI -2.168-1.04); Mean Difference (Final Values) = -0.483 (p = NA, CI -2.115-1.15); Mean Difference (Final Values) = 0.517 (p = NA, CI -1.106-2.139). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in BMD of Total Hip at 6 Months. Time frame: Baseline, 6 Months. Description: Percent change in BMD as specified by DXA scans of the total hip.. Parameters: NA = NA (p = 0.0547, CI NA-NA); NA = NA (p = 0.0056, CI NA-NA); NA = NA (p = 0.0018, CI NA-NA); Mean Difference (Final Values) = -1.768 (p = NA, CI -2.864--0.672); Mean Difference (Final Values) = -1.42 (p = NA, CI -2.522--0.318); Mean Difference (Final Values) = -1.247 (p = NA, CI -2.368--0.126). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months. Time frame: Baseline, 6 Months. Description: Percent change in BMD as specified by dual energy x-ray absorptiometry (DXA) scans of the lumbar spine.. Parameters: NA = NA (p = 0.0066, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); Mean Difference (Final Values) = -3.93 (p = NA, CI -5.555--2.305); Mean Difference (Final Values) = -3.47 (p = NA, CI -5.104--1.837); Mean Difference (Final Values) = -2.856 (p = NA, CI -4.519--1.193). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months. Time frame: Baseline, 6 Months. Description: NA. Parameters: NA = NA (p = 0.239, CI NA-NA); Mean Difference (Final Values) = -22.146 (p = NA, CI -40.501--3.79); Mean Difference (Final Values) = -12.086 (p = NA, CI -30.543-6.372); Mean Difference (Final Values) = -22.828 (p = NA, CI -41.614--4.041); NA = NA (p = 0.2549, CI NA-NA); NA = NA (p = 0.9115, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months. Time frame: Baseline, 6 Months. Description: NA. Parameters: NA = NA (p = 0.3483, CI NA-NA); NA = NA (p = 0.6839, CI NA-NA); NA = NA (p = 0.1067, CI NA-NA); Mean Difference (Final Values) = -43.721 (p = NA, CI -75.748--11.694); Mean Difference (Final Values) = -39.461 (p = NA, CI -71.665--7.257); Mean Difference (Final Values) = -49.334 (p = NA, CI -82.113--16.555). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Serum Osteocalcin at 6 Months. Time frame: Baseline, 6 Months. Description: NA. Parameters: NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.12, CI NA-NA); NA = NA (p = 0.9998, CI NA-NA); Mean Difference (Final Values) = -73.906 (p = NA, CI -96.926--50.886); Mean Difference (Final Values) = -62.872 (p = NA, CI -86.019--39.725); Mean Difference (Final Values) = -73.367 (p = NA, CI -96.927--49.807). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months. Time frame: Baseline, 6 Months. Description: NA. Parameters: NA = NA (p = 0.1632, CI NA-NA); NA = NA (p = 0.9834, CI NA-NA); NA = NA (p = 0.2179, CI NA-NA); Mean Difference (Final Values) = -27.541 (p = NA, CI -48.557--6.525); Mean Difference (Final Values) = -18.702 (p = NA, CI -39.835-2.43); Mean Difference (Final Values) = -26.914 (p = NA, CI -48.424--5.405). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months. Time frame: Baseline, 6 Months. Description: NA. Parameters: NA = NA (p = 0.6091, CI NA-NA); NA = NA (p = 0.9999, CI NA-NA); Mean Difference (Final Values) = -110.398 (p = NA, CI -156.966--63.831); Mean Difference (Final Values) = -96.115 (p = NA, CI -142.94--49.29); Mean Difference (Final Values) = -104.418 (p = NA, CI -152.079--56.758); NA = NA (p = 0.8569, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.
Study: VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Summary: The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.

Detailed Description: NA

Results: Outcome: Change From Baseline to 24 Months Endpoint in Back Pain Using an 11-point Numerical Pain Rating Scale. Time frame: Baseline, 24 Months. Description: Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used.. Parameters: Least Squares Mean = -0.09 (p = 0.585, CI -0.42-0.24). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline to 24 Months Endpoint in Height. Time frame: Baseline, 24 Months. Description: NA. Parameters: Least Squares Mean = -0.13 (p = 0.093, CI -0.28-0.02). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (UK). Time frame: Baseline, 24 Months. Description: The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state.. Parameters: Least Squares Mean = 0 (p = 0.757, CI -0.03-0.02). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (US). Time frame: Baseline, 24 Months. Description: The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state.. Parameters: Least Squares Mean = 0 (p = 0.694, CI -0.02-0.01). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Major Non-Vertebral Fragility Fractures. Time frame: Baseline through 24 Months. Description: A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving.. Parameters: Stratified Hazard Ratio (HR) = 0.5786 (p = 0.062432, CI 0.318-1.052). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With New Moderate and/or Severe Vertebral Fractures. Time frame: Baseline through 24 Months. Description: Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on \~25 to 40% (moderate) or \~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4).. Parameters: Odds Ratio (OR) = 0.3812 (p = 0.001, CI 0.237-0.614); Risk Ratio (RR) = 0.4173 (p = 0.001, CI 0.27-0.646). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With New Multiple (2 or More) Vertebral Fractures. Time frame: Baseline through 24 Months. Description: NA. Parameters: Odds Ratio (OR) = 0.1593 (p = 0.007, CI 0.035-0.728); Risk Ratio (RR) = 0.1643 (p = 0.007, CI 0.036-0.744). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With New Vertebral Fractures. Time frame: Baseline through 24 Months. Description: The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation.

A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture.. Parameters: Odds Ratio (OR) = 0.4071 (p = 9.4e-05, CI 0.256-0.647); Risk Ratio (RR) = 0.4431 (p = 9.4e-05, CI 0.29-0.677). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Non-Vertebral Fragility Fractures. Time frame: Baseline through 24 Months. Description: A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures.. Parameters: Stratified Hazard Ratio (HR) = 0.6553 (p = 0.099023, CI 0.39-1.101). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures. Time frame: Baseline through 24 Months. Description: A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture.

All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader.. Parameters: Stratified Hazard Ratio (HR) = 0.4831 (p = 0.000869, CI 0.316-0.739). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Pooled Fragility and Traumatic Non-Vertebral Fractures. Time frame: Baseline through 24 Months. Description: Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object.. Parameters: Stratified Hazard Ratio (HR) = 0.696 (p = 0.078, CI 0.461-1.05). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Pooled New and Worsening Vertebral Fractures. Time frame: Baseline through 24 Months. Description: Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as \~20 to 25% (mild), \~25 to 40% (moderate) or \~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4).. Parameters: Odds Ratio (OR) = 0.4187 (p = 7.5e-05, CI 0.269-0.652); Risk Ratio (RR) = 0.4561 (p = 7.5e-05, CI 0.305-0.682). Non-inferiority type: SUPERIORITY.
Study: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Summary: This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12 - Superiority Analysis. Time frame: Baseline and Month 12. Description: NA. Parameters: Treatment Difference = 2.1 (p = 1e-04, CI 1.6-2.6). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority Analysis. Time frame: Baseline and Month 12. Description: Bone mineral density (BMD) of the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging facility.. Parameters: Treatment Difference = 2.1 (p = 1e-04, CI 1.6-2.6). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12 - Non-inferiority Analysis. Time frame: Baseline and Month 12. Description: BMD of the hip was measured by DXA. DXA scans were analyzed by a central imaging facility.. Parameters: Treatment Difference = 1.4 (p = 1e-04, CI 1-1.7). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12 - Superiority Analysis. Time frame: Baseline and Month 12. Description: NA. Parameters: Treatment Difference = 1.4 (p = 1e-04, CI 1-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.
Study: Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

Summary: This is a study to determine how vaginal estrogen cream given for several weeks before pelvic reconstructive therapy will effect elastic fiber assembly in the muscularis layer of the vaginal wall. Postmenopausal women with at least Stage 2 pelvic organ prolapse will receive either estrogen vaginal cream or placebo cream 6-8 weeks prior to reconstructive surgery. At time of surgery, full thickness biopsies will be obtained from a standardized location at the top of vagina. The investigators will measure the thickness of the vaginal muscularis, elastic fiber number and morphology, and analyze if elastic fiber synthesis or degradation is affected by estrogen therapy. The results will provide important data to support a larger clinical trial to determine if preoperative and maintenance estrogen therapy alter long-term success rates of pelvic reconstructive surgery for pelvic organ prolapse.

Detailed Description: NA

Results: Outcome: Estimated Blood Loss. Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Intraoperative estimated blood loss. Parameters: NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: LOXL1 (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.82, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Lysyl Oxidase (LOX) (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.15, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Estradiol Levels, Baseline. Time frame: Baseline. Description: NA. Parameters: NA = NA (p = 0.51, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Estradiol Levels, Surgery. Time frame: Time of surgery. Description: NA. Parameters: NA = NA (p = 0.24, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Estrone Levels, Baseline. Time frame: Baseline. Description: NA. Parameters: NA = NA (p = 0.91, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Estrone Levels, Surgery. Time frame: Time of surgery. Description: NA. Parameters: NA = NA (p = 0.78, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: TGFB1 (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.25, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Collagen Content in Vaginal Muscularis, (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess hydroxy-proline assays as index of amount of collagen. Parameters: NA = NA (p = 0.1, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Tropoelastin (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.7, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Epithelium (Intention to Treat). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thicknesses of epithelium. Parameters: NA = NA (p = 0.21, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Epithelium (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thicknesses of epithelium. Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Lamina Propria (Intention to Treat). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thickness of lamina propria.. Parameters: NA = NA (p = 0.53, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Lamina Propria (Per-Protocol). Time frame: Time of surgery, i.e. 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thickness of lamina propria. Parameters: NA = NA (p = 0.33, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Muscularis (Intention to Treat). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thicknesses of muscularis. Parameters: NA = NA (p = 0.22, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Composition: Muscularis (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess vaginal wall histology - thicknesses of muscularis. Parameters: NA = NA (p = 0.088, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Degradative Activity, Mucosa, MMP-9. Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess zymograms for total matrix metalloprotease (MMP) 9 activity. Parameters: NA = NA (p = 0.06, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Degradative Activity, Muscularis, MMP-9. Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Will assess zymograms for total matrix metalloprotease (MMP) 9 activity. Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: hCOL1A1, Per-Protocol. Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: hCOL3, (Per-Protocol). Time frame: Time of surgery, i.e. after 6-8 weeks of intervention. Description: Data represent ratio of total mRNA relative to postmenopausal external control.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Summary: The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD). Time frame: Baseline, month 6 and month 12. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.. Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.7-3.8). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12. Time frame: Baseline and month 12. Description: Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.. Parameters: Treatment difference = 4.6 (p = 1e-04, CI 3.9-5.3). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6. Time frame: Baseline and month 6. Description: Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.. Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.8-4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12. Time frame: Baseline and month 12. Description: Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.. Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.1-4.3). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6. Time frame: Baseline and month 6. Description: Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.. Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.4-3.8). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Femoral Neck BMD at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.6-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Femoral Neck BMD at Month 6. Time frame: Baseline and month 6. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.5-3.9). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12. Time frame: Baseline and month 12. Description: Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.. Parameters: Treatment difference = 3.6 (p = 1e-04, CI 2.9-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6. Time frame: Baseline and month 6. Description: Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.. Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.5-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 4.4 (p = 1e-04, CI 3.4-5.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 6. Time frame: Baseline and month 6. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 3.8 (p = 1e-04, CI 2.9-4.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12. Time frame: Baseline and month 12. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.8-4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 6. Time frame: Baseline and month 6. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.5-3.7). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12. Time frame: Baseline and month 12. Description: Total hip integral BMC was measured using quantitative computed tomography (QCT).. Parameters: Treatment difference = 3.6 (p = 1e-04, CI 2.9-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6. Time frame: Baseline and month 6. Description: Total hip integral BMC was measured using quantitative computed tomography (QCT).. Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.6-3.6). Non-inferiority type: SUPERIORITY.
Study: Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition

Summary: The primary object is to evaluate the efficacy and safety of electroacupuncture for symptoms of women during menopausal transition .

Detailed Description: Menopause transition is called perimenopause in the past time. 40-80% women aged 40 to 65 have symptoms during this period. Hormone therapy is the recommended therapy for menopause and there is not enough evidence in favor of alternative medicine's effect.

Our pilot trial showed that electroacupuncture had better effect for menopause transition symptoms than sham electroacupuncture. We are going to conduct a phase  clinical trial to further evaluate the safety and effect of electroacupuncture for menopause transition symptoms.

Results: Outcome: Change From Baseline in Menopause Rating Scale Total Score. Time frame: at baseline and week 8. Description: The change in menopause rating scale (MRS) total score compared with baseline at week 8 equals MRS total score at week 8 minus MRS total score at baseline.

MRS is a self-report questionnaire for evaluating the severity of menopausal symptoms in women, which contains 11 items. Each of the 11 symptoms contained a scoring scale from "0" (no complaints) to "4" (very severe symptoms). The total score will be calculated as the all items ranging from 0 to 44, with higher scores indicating worse symptoms. The MRS including 3 dimensions: psychological, somatic-vegetative, and urogenital.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

Summary: This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.

Detailed Description: Postmenopausal subjects with an intact uterus who meet the study entry criteria will be randomized to one of five treatment arms (four active and one placebo) and followed for 12 months. During the Screening period all subjects will be provided with a diary to self-assess the frequency and severity of their vasomotor symptoms. Subjects experiencing a minimum daily frequency of 7 (or 50 per week) moderate to severe hot flushes will participate in a VMS Substudy during the first 12 weeks of treatment. The Substudy subjects will be stratified by treatment arm within the sites, and only Substudy subjects have the possibility of being randomized to placebo. Subjects who qualify for the study except for experiencing a minimum daily frequency of 7 (or 50 per week) moderate to severe hot flushes will be stratified within sites to one of the four active treatment arms and followed for 12 months, but will not participate in the VMS Substudy. (However, VMS information will be collected from all subjects during the first 12 weeks of treatment.) All Study Subjects: Postmenopausal women with an intact uterus who seek relief from hot flushes and meet all other inclusion/exclusion criteria are eligible for 12 months of study treatment.

VMS Substudy Subjects: A subset of All Study Subjects who have 7 per day or 50 per week moderate to severe hot flushes (as determined during Screening) are eligible for the 12-week VMS Substudy and for a total of 12 months of study treatment.

Clinical evaluations will be performed at the following time points:

* Screening Period (Week: - 8.5) (up to -60 Days)
* Visit 1 Randomization (Week 0) (Day 1)
* Visit 2 Interim (Week 4)
* Visit 3 Interim (Week 8)
* Visit 4 Interim (Week 12)
* Visit 5 Interim (Month 6)
* Visit 6 Interim (Month 9)
* Visit 7 End of Treatment (Month 12)

Results: Outcome: Clinical Global Impression (CGI) - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: The number and percentage of subjects for each possible response to the CGI at Week 12. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Clinical Global Impression (CGI) - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: The number and percentage of subjects for each possible response to the CGI at Week 4. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.005, CI NA-NA); NA = NA (p = 0.007, CI NA-NA); NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Clinical Global Impression (CGI) - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: The number and percentage of subjects for each possible response to the CGI at Week 8. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -16.58 (p = 0.001, CI -23.33--9.82); Mean Difference (Final Values) = -15.07 (p = 0.001, CI -21.72--8.42); Mean Difference (Final Values) = -10.79 (p = 0.002, CI -17.48--4.1); Mean Difference (Final Values) = -11.71 (p = 0.001, CI -18.31--5.11). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -12.81 (p = 0.001, CI -19.29--6.32); Mean Difference (Final Values) = -8.07 (p = 0.013, CI -14.46--1.68); Mean Difference (Final Values) = -4.81 (p = 0.141, CI -11.21-1.59); Mean Difference (Final Values) = -10.4 (p = 0.001, CI -16.73--4.08). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.38); Mean Difference (Final Values) = -0.39 (p = 0.001, CI -0.59--0.2); Mean Difference (Final Values) = -0.24 (p = 0.018, CI -0.43--0.04); Mean Difference (Final Values) = -0.16 (p = 0.096, CI -0.36-0.03). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.13 (p = 0.031, CI -0.25--0.01); Mean Difference (Final Values) = -0.17 (p = 0.005, CI -0.28--0.05); Mean Difference (Final Values) = -0.05 (p = 0.401, CI -0.17-0.07); Mean Difference (Final Values) = -0.1 (p = 0.1, CI -0.21-0.02). Non-inferiority type: SUPERIORITY. Outcome: Endometrial Protection - Hyperplasia. Time frame: Baseline and Month 12. Description: Endometrial biopsies centrally evaluated by 3 primary pathologists using criteria described in Blaustein's Pathology text. Pathologists classified biopsy into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus was reached when the 2 of 3 pathologist readers agreed on any of the above categories; if all three reads were disparate, the final diagnosis was based on the most severe diagnosis. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects with biopsies following M11 meeting the criteria specified plus all subjects with biopsies positive for endometrial hyperplasia by any of the pathologists before M11.. Parameters: incidence rate = 0 (p = NA, CI NA-1.06); incidence rate = 0 (p = NA, CI NA-0.98); incidence rate = 0 (p = NA, CI NA-0.97); incidence rate = 0 (p = NA, CI NA-1.09); incidence rate = 0 (p = NA, CI NA-3.2). Non-inferiority type: OTHER. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS). Time frame: Baseline and Week 1. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = 0.49 (p = 0.865, CI -5.16-6.14); Mean Difference (Final Values) = 0.55 (p = 0.847, CI -5.01-6.1); Mean Difference (Final Values) = 2.09 (p = 0.463, CI -3.5-7.68); Mean Difference (Final Values) = -3.55 (p = 0.207, CI -9.07-1.97). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS). Time frame: Baseline and Week 10. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -21.01 (p = 0.001, CI -28.72--13.29); Mean Difference (Final Values) = -18.37 (p = 0.001, CI -25.96--10.78); Mean Difference (Final Values) = -13.03 (p = 0.001, CI -20.66--5.39); Mean Difference (Final Values) = -14.65 (p = 0.001, CI -22.19--7.12). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS). Time frame: Baseline and Week 11. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -21.83 (p = 0.001, CI -29.57--14.08); Mean Difference (Final Values) = -19.4 (p = 0.001, CI -27.02--11.77); Mean Difference (Final Values) = -13.98 (p = 0.001, CI -21.65--6.32); Mean Difference (Final Values) = -15.66 (p = 0.001, CI -23.23--8.1). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -20.61 (p = 0.001, CI -28.32--12.89); Mean Difference (Final Values) = -18.24 (p = 0.001, CI -25.84--10.65); Mean Difference (Final Values) = -12.62 (p = 0.001, CI -20.26--4.98); Mean Difference (Final Values) = -13.97 (p = 0.001, CI -21.51--6.43). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS). Time frame: Baseline and Week 2. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -5.07 (p = 0.14, CI -11.8-1.67); Mean Difference (Final Values) = -0.08 (p = 0.982, CI -6.7-6.55); Mean Difference (Final Values) = 2.33 (p = 0.492, CI -4.32-8.98); Mean Difference (Final Values) = -4.14 (p = 0.216, CI -10.72-2.43). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS). Time frame: Baseline and Week 3. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -10.38 (p = 0.003, CI -17.26--3.5); Mean Difference (Final Values) = -3.75 (p = 0.277, CI -10.53-3.02); Mean Difference (Final Values) = -2.95 (p = 0.394, CI -9.75-3.84); Mean Difference (Final Values) = -7.86 (p = 0.022, CI -14.58--1.15). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -15.32 (p = 0.001, CI -22.75--7.89); Mean Difference (Final Values) = -8.92 (p = 0.017, CI -16.24--1.6); Mean Difference (Final Values) = -4.56 (p = 0.223, CI -11.9-2.78); Mean Difference (Final Values) = -11.32 (p = 0.002, CI -18.57--4.07). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS). Time frame: Baseline and Week 5. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -17.47 (p = 0.001, CI -24.65--10.28); Mean Difference (Final Values) = -10.26 (p = 0.005, CI -17.33--3.18); Mean Difference (Final Values) = -6.21 (p = 0.087, CI -13.31-0.89); Mean Difference (Final Values) = -12.66 (p = 0.001, CI -19.68--5.65). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS). Time frame: Baseline and Week 6. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -20.32 (p = 0.001, CI -27.77--12.87); Mean Difference (Final Values) = -12.61 (p = 0.001, CI -19.95--5.28); Mean Difference (Final Values) = -8.33 (p = 0.027, CI -15.7--0.96); Mean Difference (Final Values) = -13.85 (p = 0.001, CI -21.13--6.58). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS). Time frame: Baseline and Week 7. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -21.45 (p = 0.001, CI -28.87--14.04); Mean Difference (Final Values) = -16.1 (p = 0.001, CI -23.39--8.8); Mean Difference (Final Values) = -12.01 (p = 0.001, CI -19.34--4.68); Mean Difference (Final Values) = -15.73 (p = 0.001, CI -22.97--8.49). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -20.52 (p = 0.001, CI -28.06--12.97); Mean Difference (Final Values) = -15.37 (p = 0.001, CI -22.8--7.95); Mean Difference (Final Values) = -11.49 (p = 0.003, CI -18.95--4.03); Mean Difference (Final Values) = -13.82 (p = 0.001, CI -21.19--6.46). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS). Time frame: Baseline and Week 9. Description: Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -20.34 (p = 0.001, CI -27.93--12.74); Mean Difference (Final Values) = -17.92 (p = 0.001, CI -25.39--10.45); Mean Difference (Final Values) = -12.97 (p = 0.001, CI -20.49--5.46); Mean Difference (Final Values) = -14.28 (p = 0.001, CI -21.7--6.87). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS). Time frame: Baseline and Week 1. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = 1.36 (p = 0.588, CI -3.57-6.3); Mean Difference (Final Values) = 1.29 (p = 0.601, CI -3.56-6.15); Mean Difference (Final Values) = 3.17 (p = 0.202, CI -1.71-8.06); Mean Difference (Final Values) = -1.93 (p = 0.431, CI -6.76-2.89). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS). Time frame: Baseline and Week 10. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -16.8 (p = 0.001, CI -23.58--10.03); Mean Difference (Final Values) = -15.66 (p = 0.001, CI -22.32--8.99); Mean Difference (Final Values) = -11.2 (p = 0.001, CI -17.9--4.49); Mean Difference (Final Values) = -12.16 (p = 0.001, CI -18.78--5.55). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS). Time frame: Baseline and Week 11. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -18.11 (p = 0.001, CI -24.92--11.29); Mean Difference (Final Values) = -16.45 (p = 0.001, CI -23.17--9.74); Mean Difference (Final Values) = -12.41 (p = 0.001, CI -19.15--5.66); Mean Difference (Final Values) = -13.6 (p = 0.001, CI -20.26--6.93). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -10.79 (p = 0.002, CI -17.48--4.1); Mean Difference (Final Values) = -11.71 (p = 0.001, CI -18.31--5.11); Mean Difference (Final Values) = -16.58 (p = 0.001, CI -23.33--9.82); Mean Difference (Final Values) = -15.07 (p = 0.001, CI -21.72--8.42). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS). Time frame: Baseline and Week 2. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -4.35 (p = 0.154, CI -10.34-1.64); Mean Difference (Final Values) = -0.17 (p = 0.956, CI -6.06-5.73); Mean Difference (Final Values) = 3.54 (p = 0.24, CI -2.37-9.46); Mean Difference (Final Values) = -2.77 (p = 0.353, CI -8.62-3.08). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS). Time frame: Baseline and Week 3. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -8.56 (p = 0.007, CI -14.75--2.36); Mean Difference (Final Values) = -3.76 (p = 0.227, CI -9.86-2.35); Mean Difference (Final Values) = -1.65 (p = 0.597, CI -7.77-4.47); Mean Difference (Final Values) = -7.24 (p = 0.019, CI -13.28--1.19). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -12.81 (p = 0.001, CI -19.29--6.32); Mean Difference (Final Values) = -8.07 (p = 0.013, CI -14.46--1.68); Mean Difference (Final Values) = -4.81 (p = 0.141, CI -11.21-1.59); Mean Difference (Final Values) = -10.4 (p = 0.001, CI -16.73--4.08). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS). Time frame: Baseline and Week 5. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -9.88 (p = 0.003, CI -16.34--3.41); Mean Difference (Final Values) = -5.9 (p = 0.075, CI -12.4-0.59); Mean Difference (Final Values) = -12.05 (p = 0.001, CI -18.47--5.64); Mean Difference (Final Values) = -15.59 (p = 0.001, CI -22.16--9.02). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS). Time frame: Baseline and Week 6. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -17.87 (p = 0.001, CI -24.57--11.05); Mean Difference (Final Values) = -11.35 (p = 0.001, CI -18--4.7); Mean Difference (Final Values) = -7.82 (p = 0.022, CI -14.5--1.14); Mean Difference (Final Values) = -12.51 (p = 0.001, CI -19.11--5.91). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS). Time frame: Baseline and Week 7. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -17.75 (p = 0.001, CI -24.45--11.06); Mean Difference (Final Values) = -13.29 (p = 0.001, CI -19.88--6.7); Mean Difference (Final Values) = -10.22 (p = 0.003, CI -16.83--3.6); Mean Difference (Final Values) = -13.61 (p = 0.001, CI -20.15--7.07). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -16.63 (p = 0.001, CI -23.35--9.91); Mean Difference (Final Values) = -12.97 (p = 0.001, CI -19.58--6.36); Mean Difference (Final Values) = -9.63 (p = 0.005, CI -16.27--2.99); Mean Difference (Final Values) = -11.97 (p = 0.001, CI -18.53--5.41). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS). Time frame: Baseline and Week 9. Description: Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.. Parameters: Mean Difference (Final Values) = -17.12 (p = 0.001, CI -23.79--10.44); Mean Difference (Final Values) = -15.58 (p = 0.001, CI -22.15--9.01); Mean Difference (Final Values) = -11.05 (p = 0.001, CI -17.65--4.44); Mean Difference (Final Values) = -13.02 (p = 0.001, CI -19.54--6.5). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 5.02 (p = 0.089, CI -0.76-10.8); Mean Difference (Final Values) = 7.56 (p = 0.01, CI 1.83-13.29); Mean Difference (Final Values) = 7.65 (p = 0.009, CI 1.94-13.36); Mean Difference (Final Values) = 7.89 (p = 0.007, CI 2.11-13.67). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 0.96 (p = 0.796, CI -6.34-8.27); Mean Difference (Final Values) = 5.14 (p = 0.15, CI -1.87-12.15); Mean Difference (Final Values) = 8.58 (p = 0.019, CI 1.39-15.77); Mean Difference (Final Values) = 7.51 (p = 0.041, CI 0.3-14.71). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 5.11 (p = 0.054, CI -0.08-10.31); Mean Difference (Final Values) = 7.1 (p = 0.007, CI 1.93-12.26); Mean Difference (Final Values) = 5.9 (p = 0.025, CI 0.75-11.04); Mean Difference (Final Values) = 8.38 (p = 0.002, CI 3.2-13.55). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 4.07 (p = 0.205, CI -2.23-10.37); Mean Difference (Final Values) = 9.58 (p = 0.002, CI 3.43-15.74); Mean Difference (Final Values) = 5.04 (p = 0.115, CI -1.23-11.32); Mean Difference (Final Values) = 8.94 (p = 0.005, CI 2.75-15.13). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 4.35 (p = 0.084, CI -0.58-9.28); Mean Difference (Final Values) = 2.61 (p = 0.298, CI -2.3-7.53); Mean Difference (Final Values) = 3.72 (p = 0.136, CI -1.17-8.62); Mean Difference (Final Values) = 3.48 (p = 0.163, CI -1.41-8.37). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS\_4\_new = (6-MOS\_4\_old) x 20; MOS\_12\_new = (6-MOS\_12\_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.. Parameters: Mean Difference (Final Values) = 1.81 (p = 0.558, CI -4.24-7.86); Mean Difference (Final Values) = 3.61 (p = 0.233, CI -2.34-9.57); Mean Difference (Final Values) = 6.16 (p = 0.043, CI 0.2-12.13); Mean Difference (Final Values) = 2.07 (p = 0.488, CI -3.8-7.95). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -8.97 (p = 0.001, CI -13.76--4.19); Mean Difference (Final Values) = -9.6 (p = 0.001, CI -14.34--4.85); Mean Difference (Final Values) = -9.3 (p = 0.001, CI -14.03--4.56); Mean Difference (Final Values) = -7.72 (p = 0.002, CI -12.51--2.93). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -6.56 (p = 0.04, CI -12.8--0.31); Mean Difference (Final Values) = -10.02 (p = 0.001, CI -15.99--4.04); Mean Difference (Final Values) = -9.96 (p = 0.002, CI -16.11--3.81); Mean Difference (Final Values) = -6.85 (p = 0.029, CI -12.99--0.7). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -8.38 (p = 0.001, CI -12.72--4.04); Mean Difference (Final Values) = -7.52 (p = 0.001, CI -11.83--3.2); Mean Difference (Final Values) = -7.32 (p = 0.001, CI -11.63--3.02); Mean Difference (Final Values) = -5.6 (p = 0.011, CI -9.93--1.27). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -7.54 (p = 0.008, CI -13.14--1.93); Mean Difference (Final Values) = -6.72 (p = 0.016, CI -12.18--1.26); Mean Difference (Final Values) = -8.69 (p = 0.002, CI -14.28--3.1); Mean Difference (Final Values) = -6.18 (p = 0.028, CI -11.68--0.68). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -6.48 (p = 0.02, CI -11.92--1.04); Mean Difference (Final Values) = -3.36 (p = 0.216, CI -8.69-1.97); Mean Difference (Final Values) = -5.85 (p = 0.033, CI -11.22--0.48); Mean Difference (Final Values) = -2.99 (p = 0.265, CI -8.27-2.28). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -7.34 (p = 0.001, CI -11.55--3.13); Mean Difference (Final Values) = -5.6 (p = 0.009, CI -9.8--1.4); Mean Difference (Final Values) = -5.13 (p = 0.016, CI -9.31--0.95); Mean Difference (Final Values) = -3.04 (p = 0.154, CI -7.22-1.14). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -6.01 (p = 0.001, CI -9.71--2.32); Mean Difference (Final Values) = -7.22 (p = 0.001, CI -10.89--3.55); Mean Difference (Final Values) = -6.92 (p = 0.001, CI -10.58--3.27); Mean Difference (Final Values) = -6.42 (p = 0.001, CI -10.12--2.72). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -3.39 (p = 0.171, CI -8.24-1.47); Mean Difference (Final Values) = -6.49 (p = 0.006, CI -11.14--1.85); Mean Difference (Final Values) = -7.39 (p = 0.003, CI -12.17--2.61); Mean Difference (Final Values) = -6.69 (p = 0.006, CI -11.46--1.92). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -5.69 (p = 0.001, CI -9.05--2.33); Mean Difference (Final Values) = -5.58 (p = 0.001, CI -8.93--2.24); Mean Difference (Final Values) = -5.12 (p = 0.003, CI -8.45--1.79); Mean Difference (Final Values) = -5.11 (p = 0.003, CI -8.46--1.76). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -5.32 (p = 0.013, CI -9.52--1.13); Mean Difference (Final Values) = -5.76 (p = 0.006, CI -9.85--1.68); Mean Difference (Final Values) = -5.59 (p = 0.009, CI -9.77--1.4); Mean Difference (Final Values) = -5.68 (p = 0.007, CI -9.79--1.57). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -4.92 (p = 0.003, CI -8.18--1.65); Mean Difference (Final Values) = -3.79 (p = 0.023, CI -7.05--0.53); Mean Difference (Final Values) = -3.28 (p = 0.047, CI -6.52--0.04); Mean Difference (Final Values) = -3.41 (p = 0.039, CI -6.65--0.17). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -3.99 (p = 0.059, CI -8.13-0.16); Mean Difference (Final Values) = -2.57 (p = 0.215, CI -6.63-1.49); Mean Difference (Final Values) = -5.1 (p = 0.015, CI -9.19--1); Mean Difference (Final Values) = -3.16 (p = 0.122, CI -7.17-0.85). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -6.28 (p = 0.001, CI -9.91--2.65); Mean Difference (Final Values) = -7.58 (p = 0.001, CI -11.18--3.98); Mean Difference (Final Values) = -7.43 (p = 0.001, CI -11.02--3.84); Mean Difference (Final Values) = -6.54 (p = 0.001, CI -10.17--2.91). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -4.21 (p = 0.083, CI -8.96-0.55); Mean Difference (Final Values) = -7.36 (p = 0.002, CI -11.91--2.81); Mean Difference (Final Values) = -7.92 (p = 0.001, CI -12.6--3.23); Mean Difference (Final Values) = -6.78 (p = 0.005, CI -11.46--2.1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -5.41 (p = 0.011, CI -9.57--1.25); Mean Difference (Final Values) = -5.54 (p = 0.008, CI -9.6--1.48); Mean Difference (Final Values) = -5.74 (p = 0.007, CI -9.9--1.59); Mean Difference (Final Values) = -5.32 (p = 0.011, CI -9.4--1.24). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -4.6 (p = 0.004, CI -7.75--1.44); Mean Difference (Final Values) = -3.49 (p = 0.03, CI -6.64--0.34); Mean Difference (Final Values) = -3.15 (p = 0.049, CI -6.29--0.02); Mean Difference (Final Values) = -2.48 (p = 0.121, CI -5.61-0.65). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -4.21 (p = 0.039, CI -8.21--0.21); Mean Difference (Final Values) = -2.39 (p = 0.232, CI -6.31-1.53); Mean Difference (Final Values) = -4.37 (p = 0.03, CI -8.32--0.42); Mean Difference (Final Values) = -2.22 (p = 0.262, CI -6.09-1.66). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -1.96 (p = 0.389, CI -6.42-2.5); Mean Difference (Final Values) = -2.43 (p = 0.281, CI -6.85-1.99); Mean Difference (Final Values) = -1.51 (p = 0.504, CI -5.92-2.91); Mean Difference (Final Values) = -1.68 (p = 0.46, CI -6.15-2.78). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -2.61 (p = 0.379, CI -8.44-3.22); Mean Difference (Final Values) = -3.07 (p = 0.279, CI -8.64-2.49); Mean Difference (Final Values) = -0.39 (p = 0.894, CI -6.19-5.4); Mean Difference (Final Values) = -2.98 (p = 0.308, CI -8.72-2.76). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -2.46 (p = 0.255, CI -6.71-1.78); Mean Difference (Final Values) = -2.27 (p = 0.293, CI -6.49-1.96); Mean Difference (Final Values) = -1.44 (p = 0.502, CI -5.66-2.77); Mean Difference (Final Values) = -1.47 (p = 0.495, CI -5.71-2.76). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -5 (p = 0.074, CI -10.48-0.48); Mean Difference (Final Values) = -0.87 (p = 0.748, CI -6.22-4.47); Mean Difference (Final Values) = 0.05 (p = 0.987, CI -5.46-5.56); Mean Difference (Final Values) = -1.02 (p = 0.709, CI -6.41-4.36). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -0.44 (p = 0.83, CI -4.48-3.59); Mean Difference (Final Values) = -0.64 (p = 0.755, CI -4.66-3.38); Mean Difference (Final Values) = 0.51 (p = 0.802, CI -3.5-4.53); Mean Difference (Final Values) = -0.46 (p = 0.823, CI -4.46-3.55). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -1.25 (p = 0.631, CI -6.34-3.84); Mean Difference (Final Values) = 1.15 (p = 0.651, CI -3.84-6.14); Mean Difference (Final Values) = -0.61 (p = 0.813, CI -5.67-4.45); Mean Difference (Final Values) = -0.42 (p = 0.869, CI -5.35-4.52). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -3.36 (p = 0.097, CI -7.34-0.61); Mean Difference (Final Values) = -5.34 (p = 0.008, CI -9.28--1.4); Mean Difference (Final Values) = -4.94 (p = 0.014, CI -8.87--1.01); Mean Difference (Final Values) = -3.88 (p = 0.056, CI -7.86-0.1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -2.19 (p = 0.415, CI -7.46-3.08); Mean Difference (Final Values) = -6.01 (p = 0.019, CI -11.04--0.97); Mean Difference (Final Values) = -4.72 (p = 0.074, CI -9.9-0.46); Mean Difference (Final Values) = -5.75 (p = 0.03, CI -10.94--0.57). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -1.09 (p = 0.572, CI -4.86-2.69); Mean Difference (Final Values) = -1.14 (p = 0.553, CI -4.89-2.62); Mean Difference (Final Values) = -1.42 (p = 0.456, CI -5.16-2.32); Mean Difference (Final Values) = -0.12 (p = 0.949, CI -3.89-3.64). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -1 (p = 0.687, CI -5.86-3.86); Mean Difference (Final Values) = -2.15 (p = 0.373, CI -6.88-2.58); Mean Difference (Final Values) = -0.91 (p = 0.714, CI -5.75-3.94); Mean Difference (Final Values) = -0.9 (p = 0.711, CI -5.67-3.87). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -1.64 (p = 0.349, CI -5.07-1.79); Mean Difference (Final Values) = -1.18 (p = 0.499, CI -4.6-2.24); Mean Difference (Final Values) = 0.14 (p = 0.936, CI -3.27-3.55); Mean Difference (Final Values) = -0.68 (p = 0.696, CI -4.08-2.72). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -2.69 (p = 0.221, CI -7-1.62); Mean Difference (Final Values) = -1.42 (p = 0.511, CI -5.65-2.81); Mean Difference (Final Values) = 0.66 (p = 0.761, CI -3.6-4.92); Mean Difference (Final Values) = -2.07 (p = 0.332, CI -6.25-2.11). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 1.25 (p = 0.662, CI -4.36-6.87); Mean Difference (Final Values) = -1.35 (p = 0.635, CI -6.91-4.21); Mean Difference (Final Values) = -0.44 (p = 0.877, CI -5.98-5.11); Mean Difference (Final Values) = -0.39 (p = 0.893, CI -6.01-5.24). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 1.91 (p = 0.579, CI -4.85-8.67); Mean Difference (Final Values) = -3.99 (p = 0.223, CI -10.43-2.44); Mean Difference (Final Values) = -2.05 (p = 0.542, CI -8.67-4.56); Mean Difference (Final Values) = -2.41 (p = 0.476, CI -9.04-4.23). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 0.25 (p = 0.927, CI -5.08-5.58); Mean Difference (Final Values) = -1.65 (p = 0.541, CI -6.95-3.64); Mean Difference (Final Values) = -3.68 (p = 0.171, CI -8.96-1.6); Mean Difference (Final Values) = -1.17 (p = 0.667, CI -6.48-4.15). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 1.82 (p = 0.573, CI -4.51-8.14); Mean Difference (Final Values) = -0.91 (p = 0.769, CI -7.01-5.19); Mean Difference (Final Values) = -6.33 (p = 0.047, CI -12.56--0.09); Mean Difference (Final Values) = -2.59 (p = 0.409, CI -8.74-3.56). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 2.02 (p = 0.434, CI -3.03-7.07); Mean Difference (Final Values) = 1.97 (p = 0.442, CI -3.06-7); Mean Difference (Final Values) = 1.5 (p = 0.558, CI -3.52-6.51); Mean Difference (Final Values) = 1.59 (p = 0.534, CI -3.42-6.6). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS\_n\_new \<- (6-MOS\_n\_old) x 20. Score range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = 3.15 (p = 0.294, CI -2.75-9.05); Mean Difference (Final Values) = 2.86 (p = 0.327, CI -2.87-8.6); Mean Difference (Final Values) = -1.39 (p = 0.637, CI -7.18-4.39); Mean Difference (Final Values) = 0.17 (p = 0.952, CI -5.51-5.86). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = 0 (p = 0.992, CI -0.11-0.11); Mean Difference (Final Values) = 0.04 (p = 0.45, CI -0.07-0.15); Mean Difference (Final Values) = -0.02 (p = 0.663, CI -0.13-0.08); Mean Difference (Final Values) = -0.06 (p = 0.309, CI -0.16-0.05). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = -0.05 (p = 0.452, CI -0.18-0.08); Mean Difference (Final Values) = 0.07 (p = 0.244, CI -0.05-0.2); Mean Difference (Final Values) = -0.06 (p = 0.354, CI -0.19-0.07); Mean Difference (Final Values) = -0.04 (p = 0.527, CI -0.17-0.09). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = 0.11 (p = 0.045, CI 0-0.21); Mean Difference (Final Values) = 0.09 (p = 0.069, CI -0.01-0.2); Mean Difference (Final Values) = 0.08 (p = 0.126, CI -0.02-0.18); Mean Difference (Final Values) = 0.01 (p = 0.907, CI -0.1-0.11). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = 0.11 (p = 0.075, CI -0.01-0.24); Mean Difference (Final Values) = 0.11 (p = 0.074, CI -0.01-0.23); Mean Difference (Final Values) = 0.06 (p = 0.37, CI -0.07-0.18); Mean Difference (Final Values) = 0.01 (p = 0.851, CI -0.11-0.13). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline (BL) to Wk 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = 0.06 (p = 0.225, CI -0.04-0.16); Mean Difference (Final Values) = 0.02 (p = 0.741, CI -0.08-0.11); Mean Difference (Final Values) = 0.04 (p = 0.414, CI -0.06-0.14); Mean Difference (Final Values) = -0.02 (p = 0.69, CI -0.11-0.08). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline (BL) to Week 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.. Parameters: Mean Difference (Final Values) = 0 (p = 0.938, CI -0.12-0.11); Mean Difference (Final Values) = 0.02 (p = 0.779, CI -0.1-0.13); Mean Difference (Final Values) = -0.03 (p = 0.646, CI -0.14-0.09); Mean Difference (Final Values) = 0.05 (p = 0.421, CI -0.07-0.16). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.. Parameters: Mean Difference (Final Values) = -5.44 (p = 0.001, CI -8.74--2.14); Mean Difference (Final Values) = -5.53 (p = 0.001, CI -8.81--2.25); Mean Difference (Final Values) = -5.12 (p = 0.002, CI -8.39--1.85); Mean Difference (Final Values) = -4.64 (p = 0.006, CI -7.93--1.35). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -6.54 (p = 0.001, CI -10.18--2.9); Mean Difference (Final Values) = -7.61 (p = 0.001, CI -11.23--4); Mean Difference (Final Values) = -7.44 (p = 0.001, CI -11.04--3.84); Mean Difference (Final Values) = -6.76 (p = 0.001, CI -10.41--3.1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -4.61 (p = 0.058, CI -9.38-0.16); Mean Difference (Final Values) = -7.48 (p = 0.001, CI -12.04--2.92); Mean Difference (Final Values) = -7.96 (p = 0.001, CI -12.67--3.25); Mean Difference (Final Values) = -6.78 (p = 0.005, CI -11.5--2.06). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -5.39 (p = 0.002, CI -8.73--2.05); Mean Difference (Final Values) = -5.39 (p = 0.002, CI -8.72--2.06); Mean Difference (Final Values) = -4.88 (p = 0.004, CI -8.19--1.58); Mean Difference (Final Values) = -4.42 (p = 0.009, CI -7.75--1.09). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -5.48 (p = 0.011, CI -9.68--1.28); Mean Difference (Final Values) = -5.25 (p = 0.012, CI -9.36--1.14); Mean Difference (Final Values) = -5.58 (p = 0.009, CI -9.75--1.41); Mean Difference (Final Values) = -4.99 (p = 0.018, CI -9.11--0.87). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -4.88 (p = 0.003, CI -8.08--1.69); Mean Difference (Final Values) = -3.61 (p = 0.027, CI -6.8--0.42); Mean Difference (Final Values) = -3.44 (p = 0.034, CI -6.61--0.26); Mean Difference (Final Values) = -2.53 (p = 0.119, CI -5.71-0.65). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS\_n\_new = (6-MOS\_n\_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS\_1\_new =(MOS\_1\_old - 1) x 25; MOS\_4\_new =(MOS\_4\_old - 1) x 20; MOS\_12\_new=(MOS\_12\_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.. Parameters: Mean Difference (Final Values) = -4.39 (p = 0.033, CI -8.44--0.35); Mean Difference (Final Values) = -2.54 (p = 0.207, CI -6.5-1.41); Mean Difference (Final Values) = -4.6 (p = 0.024, CI -8.58--0.61); Mean Difference (Final Values) = -2.53 (p = 0.207, CI -6.47-1.41). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Change in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.89--0.36); Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.88--0.36); Mean Difference (Final Values) = -0.47 (p = 0.001, CI -0.73--0.21); Mean Difference (Final Values) = -0.37 (p = 0.006, CI -0.63--0.1). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Changes in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.43 (p = 0.012, CI -0.76--0.1); Mean Difference (Final Values) = -0.73 (p = 0.001, CI -1.05--0.41); Mean Difference (Final Values) = -0.49 (p = 0.004, CI -0.81--0.16); Mean Difference (Final Values) = -0.3 (p = 0.07, CI -0.63-0.03). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Change in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.61 (p = 0.001, CI -0.85--0.38); Mean Difference (Final Values) = -0.45 (p = 0.001, CI -0.69--0.22); Mean Difference (Final Values) = -0.36 (p = 0.003, CI -0.59--0.12); Mean Difference (Final Values) = -0.26 (p = 0.03, CI -0.5--0.03). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Changes in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.55 (p = 0.001, CI -0.84--0.25); Mean Difference (Final Values) = -0.42 (p = 0.004, CI -0.71--0.13); Mean Difference (Final Values) = -0.44 (p = 0.003, CI -0.73--0.14); Mean Difference (Final Values) = -0.2 (p = 0.179, CI -0.49-0.09). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Change in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.85--0.4); Mean Difference (Final Values) = -0.49 (p = 0.001, CI -0.71--0.26); Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.75--0.3); Mean Difference (Final Values) = -0.42 (p = 0.001, CI -0.64--0.2). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Changes in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.58 (p = 0.001, CI -0.87--0.29); Mean Difference (Final Values) = -0.34 (p = 0.016, CI -0.62--0.06); Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.76--0.2); Mean Difference (Final Values) = -0.32 (p = 0.023, CI -0.6--0.05). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.26 (p = 0.06, CI -0.53-0.01); Mean Difference (Final Values) = -0.3 (p = 0.026, CI -0.57--0.04); Mean Difference (Final Values) = -0.23 (p = 0.097, CI -0.49-0.04); Mean Difference (Final Values) = -0.17 (p = 0.23, CI -0.44-0.1). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.08 (p = 0.635, CI -0.42-0.26); Mean Difference (Final Values) = -0.43 (p = 0.01, CI -0.75--0.1); Mean Difference (Final Values) = -0.28 (p = 0.092, CI -0.62-0.05); Mean Difference (Final Values) = -0.2 (p = 0.243, CI -0.53-0.13). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.24 (p = 0.056, CI -0.48-0.01); Mean Difference (Final Values) = -0.13 (p = 0.279, CI -0.38-0.11); Mean Difference (Final Values) = -0.1 (p = 0.435, CI -0.34-0.15); Mean Difference (Final Values) = -0.06 (p = 0.607, CI -0.31-0.18). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.2 (p = 0.197, CI -0.49-0.1); Mean Difference (Final Values) = -0.15 (p = 0.308, CI -0.44-0.14); Mean Difference (Final Values) = -0.24 (p = 0.117, CI -0.54-0.06); Mean Difference (Final Values) = -0.05 (p = 0.739, CI -0.34-0.24). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.16 (p = 0.181, CI -0.38-0.07); Mean Difference (Final Values) = -0.19 (p = 0.108, CI -0.41-0.04); Mean Difference (Final Values) = -0.28 (p = 0.014, CI -0.51--0.06); Mean Difference (Final Values) = -0.11 (p = 0.323, CI -0.34-0.11). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.1 (p = 0.474, CI -0.38-0.18); Mean Difference (Final Values) = -0.12 (p = 0.378, CI -0.4-0.15); Mean Difference (Final Values) = -0.33 (p = 0.018, CI -0.61--0.06); Mean Difference (Final Values) = -0.05 (p = 0.73, CI -0.32-0.22). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.22 (p = 0.153, CI -0.52-0.08); Mean Difference (Final Values) = -0.29 (p = 0.058, CI -0.58-0.01); Mean Difference (Final Values) = -0.09 (p = 0.55, CI -0.39-0.21); Mean Difference (Final Values) = -0.03 (p = 0.854, CI -0.33-0.27). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.21 (p = 0.25, CI -0.57-0.15); Mean Difference (Final Values) = -0.54 (p = 0.002, CI -0.88--0.2); Mean Difference (Final Values) = -0.05 (p = 0.796, CI -0.4-0.31); Mean Difference (Final Values) = -0.01 (p = 0.955, CI -0.36-0.34). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.31 (p = 0.023, CI -0.59--0.04); Mean Difference (Final Values) = -0.28 (p = 0.045, CI -0.55--0.01); Mean Difference (Final Values) = -0.12 (p = 0.384, CI -0.39-0.15); Mean Difference (Final Values) = -0.11 (p = 0.424, CI -0.38-0.16). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.35 (p = 0.04, CI -0.68--0.02); Mean Difference (Final Values) = -0.3 (p = 0.066, CI -0.63-0.02); Mean Difference (Final Values) = -0.12 (p = 0.469, CI -0.45-0.21); Mean Difference (Final Values) = -0.08 (p = 0.616, CI -0.41-0.24). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.2 (p = 0.126, CI -0.46-0.06); Mean Difference (Final Values) = -0.17 (p = 0.2, CI -0.42-0.09); Mean Difference (Final Values) = -0.16 (p = 0.222, CI -0.41-0.1); Mean Difference (Final Values) = -0.12 (p = 0.358, CI -0.37-0.14). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.17 (p = 0.284, CI -0.49-0.14); Mean Difference (Final Values) = -0.05 (p = 0.732, CI -0.36-0.26); Mean Difference (Final Values) = -0.12 (p = 0.437, CI -0.44-0.19); Mean Difference (Final Values) = -0.12 (p = 0.439, CI -0.43-0.19). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.44 (p = 0.029, CI -0.84--0.05); Mean Difference (Final Values) = -0.45 (p = 0.026, CI -0.84--0.05); Mean Difference (Final Values) = -0.33 (p = 0.093, CI -0.72-0.06); Mean Difference (Final Values) = -0.25 (p = 0.223, CI -0.64-0.15). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.21 (p = 0.421, CI -0.71-0.3); Mean Difference (Final Values) = -0.49 (p = 0.044, CI -0.97--0.01); Mean Difference (Final Values) = -0.42 (p = 0.093, CI -0.92-0.07); Mean Difference (Final Values) = -0.29 (p = 0.247, CI -0.79-0.2). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.31 (p = 0.081, CI -0.65-0.04); Mean Difference (Final Values) = -0.22 (p = 0.212, CI -0.56-0.12); Mean Difference (Final Values) = -0.17 (p = 0.345, CI -0.51-0.18); Mean Difference (Final Values) = -0.04 (p = 0.829, CI -0.38-0.31). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.27 (p = 0.221, CI -0.7-0.16); Mean Difference (Final Values) = 0 (p = 0.992, CI -0.42-0.42); Mean Difference (Final Values) = -0.29 (p = 0.181, CI -0.72-0.14); Mean Difference (Final Values) = -0.04 (p = 0.846, CI -0.47-0.38). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.27 (p = 0.107, CI -0.61-0.06); Mean Difference (Final Values) = -0.17 (p = 0.302, CI -0.51-0.16); Mean Difference (Final Values) = -0.27 (p = 0.106, CI -0.6-0.06); Mean Difference (Final Values) = -0.24 (p = 0.156, CI -0.57-0.09). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -0.41 (p = 0.049, CI -0.83-0); Mean Difference (Final Values) = 0.06 (p = 0.773, CI -0.34-0.46); Mean Difference (Final Values) = -0.36 (p = 0.081, CI -0.77-0.05); Mean Difference (Final Values) = -0.1 (p = 0.625, CI -0.5-0.3). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT). Time frame: Baseline and Month 12. Description: Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.65 (p = 0.001, CI -2.06--1.25); Mean Difference (Final Values) = -1.47 (p = 0.001, CI -1.87--1.07); Mean Difference (Final Values) = -1.3 (p = 0.001, CI -1.7--0.9); Mean Difference (Final Values) = -1.08 (p = 0.001, CI -1.48--0.67). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS). Time frame: Baseline and Month 12. Description: Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.2 (p = 0.001, CI -1.75--0.66); Mean Difference (Final Values) = -1.46 (p = 0.001, CI -1.98--0.94); Mean Difference (Final Values) = -1.23 (p = 0.001, CI -1.76--0.69); Mean Difference (Final Values) = -0.72 (p = 0.008, CI -1.26--0.19). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT). Time frame: Baseline and Month 6. Description: Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.73 (p = 0.001, CI -2.12--1.34); Mean Difference (Final Values) = -1.29 (p = 0.001, CI -1.68--0.91); Mean Difference (Final Values) = -1.2 (p = 0.001, CI -1.58--0.81); Mean Difference (Final Values) = -0.96 (p = 0.001, CI -1.34--0.57). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS). Time frame: Baseline and Month 6. Description: Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.4 (p = 0.001, CI -1.91--0.89); Mean Difference (Final Values) = -1.32 (p = 0.001, CI -1.81--0.82); Mean Difference (Final Values) = -1.12 (p = 0.001, CI -1.63--0.62); Mean Difference (Final Values) = -0.69 (p = 0.007, CI -1.19--0.19). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT). Time frame: Baseline and Week 12. Description: Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.92 (p = 0.001, CI -2.29--1.55); Mean Difference (Final Values) = -1.44 (p = 0.001, CI -1.81--1.07); Mean Difference (Final Values) = -1.44 (p = 0.001, CI -1.81--1.07); Mean Difference (Final Values) = -1.25 (p = 0.001, CI -1.62--0.88). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".. Parameters: Mean Difference (Final Values) = -1.65 (p = 0.001, CI -2.13--1.17); Mean Difference (Final Values) = -1.31 (p = 0.001, CI -1.79--0.84); Mean Difference (Final Values) = -1.17 (p = 0.001, CI -1.64--0.69); Mean Difference (Final Values) = -1.04 (p = 0.001, CI -1.51--0.58). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13. Time frame: Cycle 1 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 1 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.049, CI NA-NA); NA = NA (p = 0.328, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13. Time frame: Cycle 10 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 10 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.387, CI NA-NA); NA = NA (p = 0.215, CI NA-NA); NA = NA (p = 0.639, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13. Time frame: Cycle 11 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 11 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.008, CI NA-NA); NA = NA (p = 0.643, CI NA-NA); NA = NA (p = 0.501, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13. Time frame: Cycle 12 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 12 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.013, CI NA-NA); NA = NA (p = 0.616, CI NA-NA); NA = NA (p = 0.352, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13. Time frame: Cycle 2 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 2 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.123, CI NA-NA); NA = NA (p = 0.03, CI NA-NA); NA = NA (p = 0.649, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13. Time frame: Cycle 3 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 3 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.059, CI NA-NA); NA = NA (p = 0.023, CI NA-NA); NA = NA (p = 0.426, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13. Time frame: Cycle 4 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 4 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.044, CI NA-NA); NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.481, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13. Time frame: Cycle 5 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 5 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.11, CI NA-NA); NA = NA (p = 0.045, CI NA-NA); NA = NA (p = 0.853, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13. Time frame: Cycle 6 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 6 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.245, CI NA-NA); NA = NA (p = 0.145, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13. Time frame: Cycle 7 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 7 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.163, CI NA-NA); NA = NA (p = 0.091, CI NA-NA); NA = NA (p = 0.693, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13. Time frame: Cycle 8 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 8 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.178, CI NA-NA); NA = NA (p = 0.097, CI NA-NA); NA = NA (p = 0.522, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13. Time frame: Cycle 9 to 13. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 9 to 13 was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.315, CI NA-NA); NA = NA (p = 0.181, CI NA-NA); NA = NA (p = 0.821, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From the 13th Cycle. Time frame: The 13th Cycle. Description: Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from the 13th Cycle was calculated and compared between active and placebo treatments.. Parameters: NA = NA (p = 0.023, CI NA-NA); NA = NA (p = 0.535, CI NA-NA); NA = NA (p = 0.183, CI NA-NA); NA = NA (p = 0.738, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 1 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.122, CI NA-NA); NA = NA (p = 0.28, CI NA-NA); NA = NA (p = 0.692, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 10 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.183, CI NA-NA); NA = NA (p = 0.745, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 11 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.035, CI NA-NA); NA = NA (p = 0.536, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 12 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.261, CI NA-NA); NA = NA (p = 0.536, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 2 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.069, CI NA-NA); NA = NA (p = 0.131, CI NA-NA); NA = NA (p = 0.661, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 3 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.04, CI NA-NA); NA = NA (p = 0.082, CI NA-NA); NA = NA (p = 0.495, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 4 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.032, CI NA-NA); NA = NA (p = 0.137, CI NA-NA); NA = NA (p = 0.792, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 5 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.067, CI NA-NA); NA = NA (p = 0.26, CI NA-NA); NA = NA (p = 0.792, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 6 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.095, CI NA-NA); NA = NA (p = 0.352, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 7 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.075, CI NA-NA); NA = NA (p = 0.225, CI NA-NA); NA = NA (p = 0.769, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 8 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.084, CI NA-NA); NA = NA (p = 0.183, CI NA-NA); NA = NA (p = 0.738, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: Cycle 9 to 13. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.125, CI NA-NA); NA = NA (p = 0.386, CI NA-NA); NA = NA (p = 0.737, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles. Time frame: The 13th Cycle. Description: No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.. Parameters: NA = NA (p = 0.463, CI NA-NA); NA = NA (p = 0.687, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Primary Safety Endpoint: Endometrial Protection - Hyperplasia. Time frame: Baseline and Month 12. Description: Endometrial biopsies centrally evaluated by 2 primary pathologists using criteria from Blaustein's Pathology text. Pathologists classified bx into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus reached when 2 primary pathologist agreed on any of above categories; if primary pathologists disagreed on presence of hyperplasia, result of 3rd pathologist was utilized and final decision regarding presence of hyperplasia was based on diagnosis of majority. If all 3 reads disparate, final diagnosis based on most severe dx. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects w/biopsies following M11 meeting criteria specified plus all subjects w/biopsies positive for endometrial hyperplasia by any pathologists before M11.. Parameters: incidence rate = 0 (p = NA, CI NA-1.09); incidence rate = 0 (p = NA, CI NA-3.2); incidence rate = 0 (p = NA, CI NA-1.06); incidence rate = 0 (p = NA, CI NA-0.98); incidence rate = 0 (p = NA, CI NA-0.97). Non-inferiority type: OTHER. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS). Time frame: Baseline and Week 1. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1.. Parameters: NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.828, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.239, CI NA-NA); NA = NA (p = 0.377, CI NA-NA); NA = NA (p = 0.523, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.821, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS). Time frame: Baseline and Week 10. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS). Time frame: Baseline and Week 11. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS). Time frame: Baseline and Week 12. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.056, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.017, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS). Time frame: Baseline and Week 2. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2.. Parameters: NA = NA (p = 0.036, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.546, CI NA-NA); NA = NA (p = 0.352, CI NA-NA); NA = NA (p = 0.261, CI NA-NA); NA = NA (p = 0.058, CI NA-NA); NA = NA (p = 0.011, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS). Time frame: Baseline and Week 3. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.115, CI NA-NA); NA = NA (p = 0.11, CI NA-NA); NA = NA (p = 0.089, CI NA-NA); NA = NA (p = 0.074, CI NA-NA); NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS). Time frame: Baseline and Week 4. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS). Time frame: Baseline and Week 5. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5.. Parameters: NA = NA (p = 0.058, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.063, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS). Time frame: Baseline and Week 6. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.05, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS). Time frame: Baseline and Week 7. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS). Time frame: Baseline and Week 8. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8.. Parameters: NA = NA (p = 0.013, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS). Time frame: Baseline and Week 9. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS). Time frame: Baseline and Week 1. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe VMS from Baseline to Week 1.. Parameters: NA = NA (p = 0.85, CI NA-NA); NA = NA (p = 0.622, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 0.374, CI NA-NA); NA = NA (p = 0.706, CI NA-NA); NA = NA (p = 0.372, CI NA-NA); NA = NA (p = 0.316, CI NA-NA); NA = NA (p = 0.221, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS). Time frame: Baseline and Week 10. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10.. Parameters: NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.018, CI NA-NA); NA = NA (p = 0.021, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS). Time frame: Baseline and Week 11. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS). Time frame: Baseline and Week 2. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2.. Parameters: NA = NA (p = 0.283, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.68, CI NA-NA); NA = NA (p = 0.232, CI NA-NA); NA = NA (p = 0.677, CI NA-NA); NA = NA (p = 0.073, CI NA-NA); NA = NA (p = 0.301, CI NA-NA); NA = NA (p = 0.013, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS). Time frame: Baseline and Week 3. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3.. Parameters: NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.135, CI NA-NA); NA = NA (p = 0.231, CI NA-NA); NA = NA (p = 0.377, CI NA-NA); NA = NA (p = 0.478, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 0.1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.017, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.025, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS). Time frame: Baseline and Week 5. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.066, CI NA-NA); NA = NA (p = 0.055, CI NA-NA); NA = NA (p = 0.174, CI NA-NA); NA = NA (p = 0.319, CI NA-NA); NA = NA (p = 0.007, CI NA-NA); NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS). Time frame: Baseline and Week 6. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.019, CI NA-NA); NA = NA (p = 0.061, CI NA-NA); NA = NA (p = 0.026, CI NA-NA); NA = NA (p = 0.104, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.018, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS). Time frame: Baseline and Week 7. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.017, CI NA-NA); NA = NA (p = 0.025, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.037, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.016, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.053, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.074, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS). Time frame: Baseline and Week 9. Description: Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS). Time frame: Baseline and Week 1. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = 0.01 (p = 0.676, CI -0.04-0.07); Mean Difference (Final Values) = 0.02 (p = 0.436, CI -0.03-0.07); Mean Difference (Final Values) = 0.04 (p = 0.106, CI -0.01-0.1); Mean Difference (Final Values) = -0.01 (p = 0.752, CI -0.06-0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS). Time frame: Baseline and Week 10. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.71--0.33); Mean Difference (Final Values) = -0.26 (p = 0.007, CI -0.44--0.07); Mean Difference (Final Values) = -0.2 (p = 0.038, CI -0.39--0.01); Mean Difference (Final Values) = -0.1 (p = 0.283, CI -0.29-0.08). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS). Time frame: Baseline and Week 11. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.53 (p = 0.001, CI -0.72--0.34); Mean Difference (Final Values) = -0.35 (p = 0.001, CI -0.54--0.16); Mean Difference (Final Values) = -0.22 (p = 0.027, CI -0.41--0.02); Mean Difference (Final Values) = -0.17 (p = 0.071, CI -0.36-0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.37); Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.57--0.18); Mean Difference (Final Values) = -0.21 (p = 0.039, CI -0.4--0.01); Mean Difference (Final Values) = -0.17 (p = 0.088, CI -0.36-0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS). Time frame: Baseline and Week 2. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.05 (p = 0.193, CI -0.12-0.02); Mean Difference (Final Values) = -0.04 (p = 0.319, CI -0.11-0.04); Mean Difference (Final Values) = 0.04 (p = 0.239, CI -0.03-0.12); Mean Difference (Final Values) = -0.01 (p = 0.72, CI -0.09-0.06). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS). Time frame: Baseline and Week 3. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.11 (p = 0.03, CI -0.2--0.01); Mean Difference (Final Values) = -0.09 (p = 0.06, CI -0.19-0); Mean Difference (Final Values) = 0.03 (p = 0.506, CI -0.06-0.13); Mean Difference (Final Values) = -0.06 (p = 0.232, CI -0.15-0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.13 (p = 0.027, CI -0.24--0.01); Mean Difference (Final Values) = -0.15 (p = 0.011, CI -0.26--0.03); Mean Difference (Final Values) = -0.02 (p = 0.71, CI -0.13-0.09); Mean Difference (Final Values) = -0.1 (p = 0.072, CI -0.21-0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS). Time frame: Baseline and Week 5. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.23 (p = 0.001, CI -0.36--0.09); Mean Difference (Final Values) = -0.13 (p = 0.062, CI -0.26-0.01); Mean Difference (Final Values) = 0.01 (p = 0.886, CI -0.12-0.14); Mean Difference (Final Values) = -0.12 (p = 0.067, CI -0.26-0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS). Time frame: Baseline and Week 6. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.36 (p = 0.001, CI -0.53--0.2); Mean Difference (Final Values) = -0.16 (p = 0.053, CI -0.32-0); Mean Difference (Final Values) = -0.07 (p = 0.413, CI -0.23-0.09); Mean Difference (Final Values) = -0.19 (p = 0.018, CI -0.35--0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS). Time frame: Baseline and Week 7. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.54--0.2); Mean Difference (Final Values) = -0.23 (p = 0.006, CI -0.4--0.07); Mean Difference (Final Values) = -0.15 (p = 0.072, CI -0.32-0.01); Mean Difference (Final Values) = -0.2 (p = 0.014, CI -0.37--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.38 (p = 0.001, CI -0.55--0.21); Mean Difference (Final Values) = -0.21 (p = 0.016, CI -0.37--0.04); Mean Difference (Final Values) = -0.12 (p = 0.169, CI -0.29-0.05); Mean Difference (Final Values) = -0.15 (p = 0.081, CI -0.31-0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS). Time frame: Baseline and Week 9. Description: Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.66--0.3); Mean Difference (Final Values) = -0.27 (p = 0.003, CI -0.45--0.1); Mean Difference (Final Values) = -0.21 (p = 0.022, CI -0.39--0.03); Mean Difference (Final Values) = -0.25 (p = 0.006, CI -0.43--0.07). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS). Time frame: Baseline and Week 1. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = 0.01 (p = 0.801, CI -0.06-0.08); Mean Difference (Final Values) = 0 (p = 0.991, CI -0.07-0.07); Mean Difference (Final Values) = 0.02 (p = 0.642, CI -0.05-0.08); Mean Difference (Final Values) = 0 (p = 0.928, CI -0.07-0.06). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS). Time frame: Baseline and Week 10. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.71--0.33); Mean Difference (Final Values) = -0.28 (p = 0.003, CI -0.46--0.09); Mean Difference (Final Values) = -0.23 (p = 0.016, CI -0.41--0.04); Mean Difference (Final Values) = -0.1 (p = 0.31, CI -0.28-0.09). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS). Time frame: Baseline and Week 11. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.53 (p = 0.001, CI -0.72--0.34); Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.56--0.19); Mean Difference (Final Values) = -0.25 (p = 0.011, CI -0.44--0.06); Mean Difference (Final Values) = -0.17 (p = 0.076, CI -0.36-0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS). Time frame: Baseline and Week 12. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.16 (p = 0.096, CI -0.36-0.03); Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.38); Mean Difference (Final Values) = -0.39 (p = 0.001, CI -0.59--0.2); Mean Difference (Final Values) = -0.24 (p = 0.018, CI -0.43--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS). Time frame: Baseline and Week 2. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.05 (p = 0.231, CI -0.14-0.03); Mean Difference (Final Values) = -0.06 (p = 0.173, CI -0.14-0.03); Mean Difference (Final Values) = 0.02 (p = 0.717, CI -0.07-0.1); Mean Difference (Final Values) = -0.01 (p = 0.849, CI -0.09-0.07). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS). Time frame: Baseline and Week 3. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.11 (p = 0.039, CI -0.21--0.01); Mean Difference (Final Values) = -0.11 (p = 0.03, CI -0.21--0.01); Mean Difference (Final Values) = 0 (p = 0.946, CI -0.1-0.1); Mean Difference (Final Values) = -0.05 (p = 0.309, CI -0.15-0.05). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS). Time frame: Baseline and Week 4. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.13 (p = 0.031, CI -0.25--0.01); Mean Difference (Final Values) = -0.17 (p = 0.005, CI -0.28--0.05); Mean Difference (Final Values) = -0.05 (p = 0.401, CI -0.17-0.07); Mean Difference (Final Values) = -0.1 (p = 0.1, CI -0.21-0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS). Time frame: Baseline and Week 5. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.23 (p = 0.001, CI -0.37--0.09); Mean Difference (Final Values) = -0.15 (p = 0.034, CI -0.28--0.01); Mean Difference (Final Values) = -0.02 (p = 0.79, CI -0.16-0.12); Mean Difference (Final Values) = -0.12 (p = 0.086, CI -0.25-0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS). Time frame: Baseline and Week 6. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.36 (p = 0.001, CI -0.53--0.2); Mean Difference (Final Values) = -0.18 (p = 0.03, CI -0.34--0.02); Mean Difference (Final Values) = -0.1 (p = 0.247, CI -0.26-0.07); Mean Difference (Final Values) = -0.19 (p = 0.022, CI -0.35--0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS). Time frame: Baseline and Week 7. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.25 (p = 0.002, CI -0.42--0.09); Mean Difference (Final Values) = -0.18 (p = 0.031, CI -0.34--0.02); Mean Difference (Final Values) = -0.2 (p = 0.016, CI -0.36--0.04); Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.54--0.2). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS). Time frame: Baseline and Week 8. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.38 (p = 0.001, CI -0.55--0.21); Mean Difference (Final Values) = -0.23 (p = 0.008, CI -0.4--0.06); Mean Difference (Final Values) = -0.15 (p = 0.087, CI -0.32-0.02); Mean Difference (Final Values) = -0.14 (p = 0.092, CI -0.31-0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS). Time frame: Baseline and Week 9. Description: Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).. Parameters: Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.66--0.3); Mean Difference (Final Values) = -0.29 (p = 0.001, CI -0.47--0.12); Mean Difference (Final Values) = -0.24 (p = 0.009, CI -0.42--0.06); Mean Difference (Final Values) = -0.24 (p = 0.007, CI -0.42--0.07). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 1 (Safety Pop.). Time frame: Trimester 1. Description: Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.135, CI NA-NA); NA = NA (p = 0.26, CI NA-NA); NA = NA (p = 0.257, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 2 (Safety Pop.). Time frame: Trimester 2. Description: Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.085, CI NA-NA); NA = NA (p = 0.184, CI NA-NA); NA = NA (p = 0.681, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 3 (Safety Pop.). Time frame: Trimester 3. Description: Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.008, CI NA-NA); NA = NA (p = 0.036, CI NA-NA); NA = NA (p = 0.138, CI NA-NA); NA = NA (p = 0.685, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 4 (Safety Pop.). Time frame: Trimester 4. Description: Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.023, CI NA-NA); NA = NA (p = 0.265, CI NA-NA); NA = NA (p = 1, CI NA-NA); NA = NA (p = 1, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 1 (Safety Pop.). Time frame: Trimester 1. Description: Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.032, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 2 (Safety Pop.). Time frame: Trimester 2. Description: Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.022, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.256, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 3 (Safety Pop.). Time frame: Trimester 3. Description: Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.025, CI NA-NA); NA = NA (p = 0.182, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 4 (Safety Pop.). Time frame: Trimester 4. Description: Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.. Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.469, CI NA-NA); NA = NA (p = 0.188, CI NA-NA); NA = NA (p = 0.613, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Summary: The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.

Detailed Description: NA

Results: Outcome: Area Under the Curve Through Month 12 of P1NP. Time frame: Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.. Description: NA. Parameters: Treatment Difference = -15.3 (p = 0.5084, CI -60.8-30.2); Treatment Difference = 84.1 (p = 2e-04, CI 40.1-128); Treatment Difference = 153.8 (p = 1e-04, CI 109.2-198.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine. Time frame: Baseline and 6 months. Description: Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 5.3 (p = 1e-04, CI 4.4-NA); Treatment Difference = 11.9 (p = 1e-04, CI 10.6-NA); Treatment Difference = 9 (p = 1e-04, CI 8-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip. Time frame: Baseline and 6 months. Description: Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 1.7 (p = 2e-04, CI 0.9-NA); Treatment Difference = 0.6 (p = 0.125, CI -0.3-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.7-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck. Time frame: Baseline and 12 months. Description: Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 1.6 (p = 0.0067, CI 0.5-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.6-NA); Treatment Difference = 3.5 (p = 1e-04, CI 2.3-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine. Time frame: Baseline and 12 months. Description: Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 7.5 (p = 1e-04, CI 6.5-NA); Treatment Difference = 12.4 (p = 1e-04, CI 11.1-NA); Treatment Difference = 16 (p = 1e-04, CI 14.6-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip. Time frame: Baseline and 12 months. Description: Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 1.5 (p = 0.0012, CI 0.7-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.8-NA); Treatment Difference = 4.1 (p = 1e-04, CI 3.3-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck. Time frame: Baseline and 6 months. Description: Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.. Parameters: Treatment Difference = 0.3 (p = 0.2846, CI -0.6-NA); Treatment Difference = 1.3 (p = 0.0151, CI 0.3-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.5-NA). Non-inferiority type: SUPERIORITY.
Study: Denosumab China Phase III Study

Summary: This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.

Detailed Description: The aim of this Phase III, randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of denosumab (DMAb) in Chinese postmenopausal women with osteoporosis at increased risk of fracture. The study design consists of two phases: Screening and 12-month Double-Blind treatment phase. Following the Screening phase, all eligible subjects will be randomized to receive Double-Blind DMAb (60 mg) or Placebo study medication in a 3:1 ratio. DMAb 60 mg and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the Double-Blind phase and at 6 months following the initial dose. All subjects will receive daily supplementation of oral elemental calcium (at least 600 mg) and vitamin D (at least 400 International Units \[IU\]). The primary objective is to determine the effects of DMAb compared to placebo with respect to mean percent change in BMD at the lumbar spine, as measured by dual-energy x-ray absorptiometry (DXA), from Baseline to Month 12. Secondary objectives include the evaluation between the DMAb and placebo treatment groups: change in BMD: at the lumbar spine (Month 6), total hip (Months 6 and 12), femoral neck (Months 6 and 12) and trochanter (Months 6 and 12); and serum biomarkers of bone formation and resorption (Months 6 and 12). Clinical safety of denosumab will also be assessed in this population.

Results: Outcome: Percent Change From Baseline in BMD at the Femoral Neck at Month 12. Time frame: Baseline and Month 12. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 2.62 (p = 1e-04, CI 1.96-3.27); NA = NA (p = 0.541, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Femoral Neck at Month 6. Time frame: Baseline and Month 6. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: NA = NA (p = 0.4369, CI NA-NA); Mean Difference (Net) = 1.59 (p = 1e-04, CI 0.98-2.2). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Lumbar Spine at Month 6. Time frame: Baseline and Month 6. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: NA = NA (p = 0.9029, CI NA-NA); Mean Difference (Net) = 3.21 (p = 1e-04, CI 2.45-3.96). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Total Hip at Month 12. Time frame: Baseline and Month 12. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 3.31 (p = 1e-04, CI 2.74-3.88); NA = NA (p = 0.3513, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Total Hip at Month 6. Time frame: Baseline and Month 6. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 2.26 (p = 1e-04, CI 1.72-2.8); NA = NA (p = 0.107, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Trochanter at Month 12. Time frame: Baseline and Month 12. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 4.72 (p = 1e-04, CI 3.71-5.72); NA = NA (p = 0.3957, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Trochanter at Month 6. Time frame: Baseline and Month 6. Description: BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 3.36 (p = 1e-04, CI 2.39-4.32); NA = NA (p = 0.6082, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12. Time frame: Baseline and Month 12. Description: Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.. Parameters: Mean Difference (Net) = 4.42 (p = 1e-04, CI 3.67-5.18); NA = NA (p = 0.7495, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12. Time frame: Baseline, Month 6 and Month 12. Description: s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in s-CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.. Parameters: Hodges Lehmann Estimate of Difference = -56.92 (p = 1e-04, CI -61.38--52.65); Hodges Lehmann Estimate of Difference = -52.56 (p = 1e-04, CI -59.38--46.17). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12. Time frame: Baseline, Month 6, Month 12. Description: s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in serum CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.. Parameters: Hodges Lehmann Estimate of Difference = -56.94 (p = 1e-04, CI -61.6--52.7); Hodges Lehmann Estimate of Difference = -51.21 (p = 1e-04, CI -56.26--45.91). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Summary: The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.

Detailed Description: Upon confirmation of eligibility, participants were randomized in a 22:5:22:5 ratio to the following treatment groups:

* Romosozumab 90 mg/mL
* Placebo 90 mg/mL
* Romosozumab 70 mg/mL
* Placebo 70 mg/mL

After completing a 6-month treatment period, participants entered a 3-month follow-up period with an end of study (EOS) at month 9.

For the analysis of efficacy endpoints, the 2 placebo groups were combined into a single placebo group. For safety analyses, the data for placebo were presented separately for each group.

Results: Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine. Time frame: Baseline and month 6. Description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).. Parameters: Least Squares Mean Difference = -0.4 (p = NA, CI -1.5-0.7). Non-inferiority type: NON_INFERIORITY.
Study: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Summary: This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Lumbar Spine BMD. Time frame: Baseline and Month 12. Description: Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.. Parameters: Difference from CP2 = -0.07 (p = 0.001, CI -0.72-0.57); Difference from CP2 = -0.07 (p = 0.001, CI -0.72-0.57). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.
Study: Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

Summary: This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

Detailed Description: NA

Results: Outcome: Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia). Time frame: Baseline and Week 12. Description:  Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 12. Parameters: NA = NA (p = 0.0149, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells. Time frame: Baseline and 12 Weeks. Description:  Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells. Time frame: Baseline and 12 Weeks. Description:  Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal pH. Time frame: Baseline and 12 Weeks. Description:  Change from Baseline to Week 12 in vaginal pH as compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Total Score as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.9075, CI NA-NA); NA = NA (p = 0.0492, CI NA-NA); NA = NA (p = 0.0019, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.9719, CI NA-NA); NA = NA (p = 0.0614, CI NA-NA); NA = NA (p = 0.0085, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.9999, CI NA-NA); NA = NA (p = 0.2855, CI NA-NA); NA = NA (p = 0.1189, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.4162, CI NA-NA); NA = NA (p = 0.0013, CI NA-NA); NA = NA (p = 3e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.9929, CI NA-NA); NA = NA (p = 0.9634, CI NA-NA); NA = NA (p = 0.0898, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.5146, CI NA-NA); NA = NA (p = 0.0099, CI NA-NA); NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction. Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo

The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.. Parameters: NA = NA (p = 0.9039, CI NA-NA); NA = NA (p = 0.3751, CI NA-NA); NA = NA (p = 0.0073, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 12. Parameters: NA = NA (p = 0.0503, CI NA-NA); NA = NA (p = 0.0055, CI NA-NA); NA = NA (p = 0.0263, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 2. Parameters: NA = NA (p = 0.9616, CI NA-NA); NA = NA (p = 0.2439, CI NA-NA); NA = NA (p = 0.6518, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 6. Parameters: NA = NA (p = 0.7829, CI NA-NA); NA = NA (p = 0.2328, CI NA-NA); NA = NA (p = 0.4118, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 8. Parameters: NA = NA (p = 0.0639, CI NA-NA); NA = NA (p = 0.0356, CI NA-NA); NA = NA (p = 0.0914, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 2. Parameters: NA = NA (p = 0.026, CI NA-NA); NA = NA (p = 0.0019, CI NA-NA); NA = NA (p = 0.0105, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 6. Parameters: NA = NA (p = 0.0069, CI NA-NA); NA = NA (p = 9e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 8. Parameters: NA = NA (p = 3e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 12. Parameters: NA = NA (p = 0.0014, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 2. Parameters: NA = NA (p = 0.1269, CI NA-NA); NA = NA (p = 0.0019, CI NA-NA); NA = NA (p = 0.0082, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 6. Parameters: NA = NA (p = 0.0094, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo

VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

Subjects assessed severity at Baseline and Week 8. Parameters: NA = NA (p = 0.0128, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 8e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in Vaginal Color as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in Vaginal Color as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color). Time frame: Baseline to Week 6. Description: Change from Baseline to Week 6 in Vaginal Color as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color). Time frame: Baseline to Week 8. Description: Change from Baseline to Week 8 in Vaginal Color as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

Severity was assessed by the Investigator at Baseline and Week 12. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

Severity was assessed by the Investigator at Baseline and Week 2. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

Severity was assessed by the Investigator at Baseline and Week 6. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

Severity was assessed by the Investigator at Baseline and Week 8. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3

Severity was assessed by the Investigator at Baseline and Week 12. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3

Severity was assessed by the Investigator at Baseline and Week 2. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3

Severity was assessed by the Investigator at Baseline and Week 6. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3

Severity was assessed by the Investigator at Baseline and Week 8. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions). Time frame: Baseline and Week 12. Description: Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3

Severity was assessed by the Investigator at Baseline and Week 12. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions). Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3

Severity was assessed by the Investigator at Baseline and Week 2. Parameters: NA = NA (p = 4e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions). Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3

Severity was assessed by the Investigator at Baseline and Week 6. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions). Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo

Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3

Severity was assessed by the Investigator at Baseline and Week 8. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Parabasal Cells. Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Parabasal Cells. Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Parabasal Cells. Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Superficial Cells. Time frame: Baseline and Week 2. Description:  Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Superficial Cells. Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal pH. Time frame: Baseline and Week 2. Description: Change from Baseline to Week 2 in vaginal pH as compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal pH. Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in vaginal pH as compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal pH. Time frame: Baseline and Week 8. Description: Change from Baseline to Week 8 in vaginal pH as compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints- Vaginal Superficial Cells. Time frame: Baseline and Week 6. Description: Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo. Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Perimenopausal Effects of Estradiol on Reward Responsiveness

Summary: Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.

Detailed Description: Despite decades of research, affective disorders are prevalent and associated with significant morbidity and mortality. Unraveling the pathophysiology of affective disorders has been uniquely challenging because depressive syndromes are heterogeneous and have diverse etiologies. Thus, past studies aimed at identifying neural and genetic biomarkers that would improve the prediction of susceptibility, course of illness, and treatment response have yielded inconsistent results. The investigator proposes to address this problem by studying perimenopausal major depressive disorder (MDD), a depression subtype with a specific endocrine trigger (i.e., ovarian hormone withdrawal). Evidence supporting ovarian hormone withdrawal as a trigger for affective dysfunction in perimenopausal MDD includes the following: perimenopausal women show a temporal association between ovarian hormone withdrawal and the onset of mood symptoms; treatment with estrogen reduces mood symptoms; and blinded estradiol withdrawal re-precipitates depression in women with a history of perimenopausal MDD (manuscript in preparation). Focusing on perimenopausal MDD, a more homogeneous subtype with a specific endocrine trigger, will increase the likelihood of identifying meaningful neurobiological markers.One of the most powerful tools for understanding the neural mediators of MDD is brain imaging. Prior research suggests that the frontostriatal reward system is regulated by estradiol and implicated in MDD. However, neural mechanisms of perimenopausal MDD have never been studied. We will assess the neural reward system in perimenopausal women with and without MDD using functional magnetic resonance imaging (fMRI) at baseline and following estradiol treatment. The central hypothesis is that the neural reward system is hypoactive in perimenopausal MDD, and the antidepressant effects of a three-week transdermal estradiol intervention will be mediated by increased activity in the neural reward system, assessed using fMRI. The investigator will test the hypothesis by executing the following aims:

Aim 1: To measure the frontostriatal response to reward in perimenopausal MDD and test the effects of estradiol on neural activation in perimenopausal women. The investigator will use fMRI at baseline and following estradiol treatment in women with and without MDD to probe frontostriatal reward circuitry.

Aim 2: To quantify motivated behavior at baseline and following estradiol administration in perimenopausal women with and without MDD. Motivated behavior will be operationally defined as the response latency to reward versus non-reward during the fMRI reward task.

Aim 3: To measure the psychological correlates of the frontostriatal response to reward in women with perimenopausal MDD at baseline and following estradiol administration. Depressive symptoms will be assessed at baseline and following estradiol administration.

The results will provide critical information about the neuroendocrine pathophysiology of perimenopausal depression and may subsequently contribute to the development of novel pharmacologic interventions.

Results: Outcome: Caudate Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.. Time frame: Post-treatment (visit 6). Description: Caudate reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups following treatment.. Parameters: NA = NA (p = 0.518, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment. Time frame: Pre-treatment (visit 3). Description: Caudate reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups at pre-treatment.. Parameters: NA = NA (p = 0.62, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Scores. Time frame: Assessed at pre- and post-treatment (visits 3 and 6). Description: The Dysphoria Scale of the Inventory of Depression and Anxiety Symptoms (IDAS) will be used to assess the change in depressive symptom severity. The IDAS Dysphoria Scale consists of 10 items and uses a 5-point Likert-type scale, ranging from 1 to 5 with 1 indicating "not at all" and 5 indicating "extremely". As such, the range of possible scores is 10 to 50. The Dysphoria scale includes items assessing feelings of depression, inadequacy, psychomotor agitation, guilt, discouragement, anhedonia, poor concentration, difficulty with decision-making, psychomotor retardation, and worry. Higher scores indicate worse depression symptoms.. Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.. Time frame: Post-treatment (visit 6). Description: Nucleus accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups following treatment.. Parameters: NA = NA (p = 0.645, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment. Time frame: Pre-treatment (visit 3). Description: Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups at pre-treatment.. Parameters: NA = NA (p = 0.855, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Putamen Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.. Time frame: Post-treatment (visit 6). Description: Putamen reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups following treatment.. Parameters: NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Putamen Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment. Time frame: Pre-treatment (visit 3). Description: Putamen reactivity to reward during the Monetary Incentive Delay (MID) task was measured between the two groups. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared between the two groups at pre-treatment.. Parameters: NA = NA (p = 0.758, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Response Latency to Reward During the MID fMRI Task Following Estradiol Treatment. Time frame: Post-treatment (visit 6). Description: Time (ms) between stimulus and response will be measured during reward trials of the Monetary Incentive Delay (MID) task. During MID the task, participants need to select the correct response during "win" and "lose" conditions by pressing a button on a button box in the MRI.. Parameters: NA = NA (p = 0.831, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Response Latency to Reward During the MID fMRI Task at Pre-treatment. Time frame: Pre-treatment (visit 3). Description: Time (ms) between stimulus and response will be measured during the Monetary Incentive Delay (MID) task during the win trials. During MID the task, participants need to select the correct response during "win" and "lose" conditions by pressing a button on a button box in the MRI.. Parameters: NA = NA (p = 0.486, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Summary: The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 g in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints. In addition, the systemic exposure to estradiol from single and multiple doses of TX-12-004-HR was to be investigated.

Detailed Description: This study was a randomized, double-blind, placebo-controlled trial to evaluate safety and efficacy of the TX-12-004-HR formulation in reducing moderate to severe symptoms of vaginal atrophy associated with menopause and to investigate the systemic exposure to estradiol following once daily intravaginal administrations of TX-12-004-HR for 14 days.

Postmenopausal subjects who met the study entry criteria were randomized to one of two treatment groups (TX-12-004-HR or Placebo). During the Screening period subjects were asked to self-assess the symptoms of vulvar and/or vaginal atrophy, including vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity and vaginal bleeding associated with sexual activity. Subjects with at least one self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy identified by the subject as being most bothersome to her were eligible to participate in the study.

Results: Outcome: Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color). Time frame: Baseline to 15 days post-treatment. Description: Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).. Parameters: NA = NA (p = 0.1945, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity). Time frame: Baseline to 15 days post-treatment. Description: Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions). Time frame: Baseline to 15 days post-treatment. Description: Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).. Parameters: NA = NA (p = 0.0401, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells). Time frame: Baseline to 15 days post-treatment. Description: NA. Parameters: NA = NA (p = 0.0017, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells). Time frame: Baseline to 15 days post-treatment. Description: NA. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells). Time frame: Baseline to 15 days post-treatment. Description: NA. Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom. Time frame: Baseline to 15 days post-treatment. Description: The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.. Parameters: NA = NA (p = 0.9951, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity. Time frame: Baseline to 15 days post-treatment. Description: Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.. Parameters: NA = NA (p = 0.1429, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Vaginal pH. Time frame: Baseline to 15 days post-treatment. Description: NA. Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness). Time frame: Baseline to 15 days post-treatment. Description: Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).. Parameters: NA = NA (p = 0.182, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: The Vaginal Health Trial

Summary: This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. Here we propose to conduct a large multicenter trial comparing two common treatments, a vaginal hormone tablet and an over-the-counter gel, with placebo to evaluate their effects on bothersome vaginal symptoms and sexual function, and to create a biorepository of specimens for future translational, mechanistic research on the etiology of vaginal symptoms.

Detailed Description: The Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network was established in 2009. By the end of 2014, the network completed 4 clinical trials testing 7 interventions in approximately 1000 women ages 40-62 with vasomotor (VMS) and other menopause symptoms.

The current trial will evaluate a relatively understudied area of menopause - vaginal health and sexual function. This is a 3-arm, randomized, controlled, double-blind, clinical trial among postmenopausal women ages 45-70.

Our primary aim is to evaluate the effectiveness of ultra-low dose vaginal estradiol (Vagifem 10 mcg), non-hormonal hydrophilic non-prescriptive vaginal gel (Replens) and placebo in reducing the Most Bothersome Symptom (MBS) severity. Choices for MBS include vulvovaginal itching, pain, dryness, irritation, or pain with penetration.

Secondary aims include an evaluation of a composite score of vaginal symptoms, sexual function, treatment satisfaction, menopause quality of life, and objective measures of genitourinary atrophy. We will also create a biorepository of vaginal and blood specimens. In a subset of women, we will examine whether treatment response is related to: a) the post-menopausal vaginal microbiome; b) vaginal mucosal inflammation; and c) reproductive hormone profiles. The in-depth focus on the mechanisms associated with postmenopausal vaginal symptoms will use state of the art microbiologic techniques on longitudinally collected biologic specimens and will guide future translational studies.

Results: Outcome: Female Sexual Function Index. Time frame: Baseline, Week 4, Week 12. Description: Female Sexual Function Index (FSFI); Evaluate dyspareunia, sexual function and distress. A composite score from 2 (not sexually active and no desire) to 36 and 6 domains.. Parameters: NA = NA (p = 0.64, CI NA-NA); NA = NA (p = 0.17, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Most Bothersome Symptom (MBS) Severity. Time frame: Baseline, Week 4, Week 12. Description: Mean change from baseline to 12 weeks in the severity of the MBS on a scale of 0-3, better to worse.. Parameters: NA = NA (p = 0.25, CI NA-NA); NA = NA (p = 0.31, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Patient Benefit Evaluation. Time frame: Week 12. Description: Patient Benefit Evaluation: Overall, do you believe that you experienced a meaningful benefit from the study medication? (Yes/No).. Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Vaginal Maturation Index. Time frame: Week 12. Description: Objective Measures of Genitourinary Atrophy: Vaginal Maturation Index (VMI) described by % parabasal, intermediate, and superficial cells ( 5% or \>5% superficial cells) at week 12. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.95, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Vaginal Symptoms Index. Time frame: Baseline, Week 4, Week 12. Description: Mean change from baseline to 12 weeks in composite Vaginal Symptoms Index (VSI).

The VSI is a Modified Bachman scale measuring vulvovaginal itching, dryness, irritation, soreness, and pain with sexual activity among sexually active women, each rated 0=none to 3=severe, and then averaged for a total score of 0-3.. Parameters: NA = NA (p = 0.99, CI NA-NA); NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: pH. Time frame: Week 12. Description: Objective measures of genitourinary atrophy: pH (\<5 or \>5) at week 12. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.6, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

Summary: The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.

Detailed Description: Although close to 85% of frail women in long-term care (LTC) facilities have osteoporosis and the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few are treated and studies are scarce. It is postulated that in frail, LTC women an annual infusion of zoledronic acid, an antiresorptive therapy for osteoporosis, will:

1. be effective demonstrated by fracture reduction;
2. be safe.

To address these hypotheses, up to 1000 female LTC residents age 65 and older will be screened in order to enroll 310 eligible for randomization in a 3 year, randomized, double-blind, calcium and vitamin D controlled trial with the antiresorptive agent zoledronic acid. Use of an intravenous, once yearly agent avoids concerns of oral bisphosphonate side effects, poor absorption and burden on staff. Participants will reside in the long-term care settings associated with the Division of Geriatric Medicine, University of Pittsburgh and will include women with multiple comorbid conditions, functional and cognitive impairment, and limited mobility.

Results: Outcome: Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year). Time frame: 3 years. Description: Number of fractures divided by number of person-years. Effectiveness of fracture reduction will be demonstrated by total non-traumatic incidental fractures (vertebral and nonvertebral \[identified by x-ray, CT, MRI, VFA imaging) except those viewed as severe trauma (fall from a height higher than a stool or chair or severe trauma other than a fall), cancer-related or fractures of the toes, finger or facial bones.. Parameters: Incident Rate Ratio = 1.05 (p = 0.7251, CI 0.9-1.22). Non-inferiority type: SUPERIORITY.
Study: A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Summary: This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.

Detailed Description: NA

Results: Outcome: Percentage of Participants Who Were "Very Confident" or "Confident" to Items on the Boniva Confidence Scale (BCS) at Month 6. Time frame: Month 6. Description: The BCS is designed to measure the participant's confidence level that Boniva (ibandronate) therapy is effective in treating osteoporosis and reducing the risk of fracture. Response options ranged on a 5-point scale from 'Not At All Confident' to 'Very Confident.' A Boniva confidence responder was defined as a participant who reported a response of 'confident' or 'very confident' on the 2 items in BCS. (1) ibandronate was effective in treating osteoporosis and (2) ibandronate reduces the risk of breaking a bone.. Parameters: Difference in percentage of participants = 16.9 (p = 0.002, CI 6.1-27.7); Difference in percentage of participants = 14.9 (p = 0.009, CI 4-25.8); Difference in percentage of participants = 16.9 (p = 0.001, CI 6.3-27.5); Difference in percentage of participants = 14.9 (p = 0.01, CI 3.9-25.9). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Summary: This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a period of improvement. Ribociclib may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Cancer cells that are estrogen receptor positive may need estrogen to grow. Letrozole lowers the amount of estrogen made by the body and this may stop the growth of tumor cells that need estrogen to grow. Giving ribociclib together with letrozole may be an effective treatment in patients with ovarian, fallopian tube, primary peritoneal, or endometrial cancer.

Detailed Description: PRIMARY OBJECTIVES:

I. Demonstrate if the combination of letrozole and ribociclib (LEE011) leads to a higher percentage of patients who are progression free at 12 weeks (PFS 12) as compared with that observed in prior studies with single agent letrozole.

SECONDARY OBJECTIVES:

I. Demonstrate if the combination of letrozole and ribociclib (LEE011) leads to a higher cancer antigen 125 (CA-125) response rate in patients with relapsed ER positive ovarian cancers and endometrial cancers as compared to that observed in previously reported single agent letrozole studies.

II. Median progression-free survival (PFS), overall survival (OS), the confirmed response rate, and adverse events.

TERTIARY OBJECTIVES:

I. Identify molecular biomarkers associated with a response to treatment with letrozole and ribociclib (LEE011) (in patients with relapsed ovarian carcinomas and endometrial cancers).

II. Develop patient derived xenograft (PDX) avatars on tumors from participants for possible future translational study evaluating a potential correlation between responses in the PDX model to patients' responses.

OUTLINE:

Patients receive ribociclib orally (PO) daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3-6 months for 2 years.

Results: Outcome: Overall Survival. Time frame: From registration to death from any cause, assessed up to 2 years. Description: Overall survival time is defined as the time from registration to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.. Parameters: NA = NA (p = 0.9127, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Progression-free Survival. Time frame: From registration to the first of either disease progression or death from any cause, assessed up to 2 years. Description: Progression free survival (PFS) is defined as the time from the date of registration to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.. Parameters: NA = NA (p = 0.5004, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Neuropeptide Treatment for Hot Flushes During the Menopause

Summary: Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product

Detailed Description: Double-blinded, placebo-controlled, 2-way crossover study in 30 menopausal women with untreated hot flushes treated with a neurokinin 3 receptor (NK3R) antagonist

Aims:

To investigate whether an NK3R antagonist can reduce menopausal flushing

Treatment:

4 weeks administration of active drug and placebo in random order

Results: Outcome: Hot Flush Bother. Time frame: twice daily (day/night) for 14 weeks. Description: Score on a scale - HF bother (rated as 1-none, 2-a little, 3-moderate, 4-a lot, as per Joffe 2014) will be recorded twice daily (day/night as described above for HF frequency). The data will be analysed as detailed above for the HF frequency. Scores are summed.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Hot Flush Interference. Time frame: Daily at bedtime for 14 weeks. Description: Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain. Overall score is a mean of the means. Highr scor = higher interference.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Hot Flush Severity. Time frame: Twice daily, morning and night for 14 weeks. Description: Score on a scale - HF severity (rated as 1-nil, 2-mild, 3-moderate, 4-severe, as per Joffe 2014) recorded twice daily (day/night as described above for HF frequency). Scores are summed.. Parameters: Mean Difference (Net) = 50 (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Skin Conductance Monitor Data.. Time frame: Once per week for 48 hours over 14 weeks. Description: Mean number of flushes detected during the 48 hours by the skin conductance monitoring will be compared each week when the patients receive AZD4901 versus placebo. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period. Time frame: Final week of each 4 week treatment period. Description: To ensure accurate records, participants recorded their flushes in real time using either a tally chart on a piece of paper (n=34) or an application on their smartphone such as Tally Counter (Pixel Research Labs, Minneapolis-Saint Paul, MN, USA; n=3), and then collated their total number of flushes twice daily on waking to record previous overnight symptoms and before bed to record daytime symptoms.. Parameters: Mean Difference (Net) = 29.66 (p = 1e-04, CI 17.39-42.87). Non-inferiority type: SUPERIORITY.
Study: Flushing Reduction Associated With Nitrates

Summary: A randomized, double-blinded, placebo-controlled trial of uninterrupted transdermal nitrate therapy in 140 peri- or postmenopausal women who have frequent hot flashes. Women will be randomly assigned to uninterrupted use of transdermal nitrate therapy (participant directed dose-escalation of 0.2 to 0.6 mg/hr) or identical-appearing placebo patches for 12 weeks.

Detailed Description: NA

Results: Outcome: Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-60, a higher score indicates a lower quality of life.. Parameters: Model generated Least Square Mean Differ = 0.4 (p = 0.68, CI -1.52-2.32). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life. Parameters: Model generated Least Square Mean Differ = 0.43 (p = 0.3, CI -0.38-1.23). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline Hot Flash Frequency. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.. Parameters: Model generated Least Square Mean = -0.54 (p = 0.34, CI -1.66-0.58). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.

Range 0-100, Higher score indicates lower quality of life. Parameters: Model generated Least Square Mean = 0.51 (p = 0.88, CI -6.15-7.18). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.

Range 1-8, Higher score indicates lower quality of life. Parameters: Model generated Least Square Mean = -0.2 (p = 0.57, CI -0.88-0.48). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life. Parameters: Model generated Least Square Mean Differ = -0.09 (p = 0.81, CI -0.8-0.63). Non-inferiority type: SUPERIORITY. Outcome: Change in Baseline Frequency of Moderate-to-severe Hot Flashes. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. Parameters: Model generated Least Square Mean Differ = -0.83 (p = 0.12, CI -1.89-0.23). Non-inferiority type: SUPERIORITY. Outcome: Change in Baseline Total Hot Flash Severity Score. Time frame: Repeated change from baseline to 5 and 12 weeks. Description: Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. The hot flash severity score is calculated as the sum of severity ratings for all hot flashes recorded on the symptom over a 7-day period (mild=1, moderate=2, severe=3), and then divided by 7 for the daily average score.

Range 12-60, higher score indicates lower quality of life.. Parameters: Model generated Least Square Mean Differ = -1.41 (p = 0.25, CI -3.81-0.99). Non-inferiority type: SUPERIORITY.
Study: Preventing Osteoporosis Using Denosumab

Summary: The purpose of this research study is to find out if denosumab (Prolia), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.

Detailed Description: Objective:

The long term goal is to improve health, well-being and quality of life in the frail long-term care (LTC) elderly population by reducing fractures. The short term goal is to demonstrate efficacy of the non-bisphosphonate denosumab to improve bone mineral density (BMD), a necessary (but not sufficient) pre-condition of a large fracture reduction trial. The investigators propose to conduct a 2-year, randomized, double-blind, calcium-vitamin D controlled trial to test the efficacy and predictability of the antiresorptive RANK ligand inhibitor, denosumab (60 mg), among a cohort of 212 institutionalized, under-served, frail men and women 65 years old in LTC.

Specific Aims:

Aim 1: To evaluate efficacy of denosumab in improving/maintaining bone mineral density. The investigators will measure conventional hip and spine bone mineral density (BMD).

Primary Hypothesis: After 2 years, women and men on denosumab will have greater hip and spine BMD increases.

Results: Outcome: Bone Density of the Spine. Time frame: 24 months. Description: Bone Mineral Density (BMD) of the spine percent change over 24 months as assessed by dual-energy x-ray absorptiometry (DXA). Parameters: Mean Difference (Final Values) = 3.99 (p = 0.014, CI NA-NA); Mean Difference (Final Values) = 5.16 (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Bone Density of the Total Hip. Time frame: 24 months. Description: Bone Mineral Density (BMD) of the total hip percent change over 24 months as assessed by dual-energy x-ray absorptiometry (DXA). Parameters: Mean Difference (Final Values) = 4.8 (p = 0.007, CI NA-NA); Mean Difference (Final Values) = 2.7 (p = 0.018, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: CTX. Time frame: 12 Months. Description: Bone Turnover Marker change from Baseline. Parameters: Mean Difference (Final Values) = -0.16 (p = 0.001, CI NA-NA); Mean Difference (Final Values) = -0.09 (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Distal Radius BMD. Time frame: 24 Months. Description: Percent change over 24 months. Parameters: Mean Difference (Final Values) = 2.54 (p = 0.06, CI NA-NA); Mean Difference (Final Values) = 2.45 (p = 0.055, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Femoral Neck BMD. Time frame: 24 Months. Description: Percent change over 24 months. Parameters: Mean Difference (Final Values) = 2.21 (p = 0.112, CI NA-NA); Mean Difference (Final Values) = 2.46 (p = 0.07, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: P1NP. Time frame: 12 Months. Description: Bone Turnover Marker Change from Baseline. Parameters: Mean Difference (Final Values) = -26.2 (p = 0.001, CI NA-NA); Mean Difference (Final Values) = -8.2 (p = 0.038, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: TBS. Time frame: 24 Months. Description: Trabecular Bone Score (TBS) Percent change over 24 months. This not a scale. Higher values are better.. Parameters: Mean Difference (Final Values) = -0.17 (p = 0.904, CI NA-NA); Mean Difference (Final Values) = -1.17 (p = 0.616, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Summary: The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.

Detailed Description: NA

Results: Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck. Time frame: Baseline and month 6. Description: Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.. Parameters: LS Mean Difference = 2.2 (p = 0.004, CI 0.7-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine. Time frame: Baseline and month 6. Description: Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.. Parameters: LS Mean Difference = 9.6 (p = 0.001, CI 7.6-11.5). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip. Time frame: Baseline and month 6. Description: Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.. Parameters: LS Mean Difference = 2.6 (p = 0.001, CI 1.4-3.7). Non-inferiority type: SUPERIORITY.
Study: A Food Effect Study of TAK-385 Final Formulation

Summary: The purpose of this study is to evaluate food effects on the pharmacokinetics of a single oral dose of TAK-385 in Japanese premenopausal healthy adult women.

Detailed Description: This is a phase 1 clinical pharmacological study of TAK-385 in Japanese premenopausal healthy adult women.

Using an open-label crossover design, food effects on the pharmacokinetics and safety of TAK-385 will be evaluated in participants receiving a single oral dose of TAK-385 40 mg in fasted condition without breakfast, before breakfast, or after breakfast.

Participants determined to be eligible will be randomly assigned to one of Groups A to F prior to study medication administration in Period 1; subsequently, participants will receive one TAK-385 40 mg tablet in fasted condition without breakfast (following a minimum 10-hour overnight fast), before breakfast (30 minutes before starting breakfast), or after breakfast (30 minutes after starting breakfast) in Periods 1, 2, and 3.

Results: Outcome: AUC(0-120): Area Under the Plasma Concentration-time Curve From Time 0 to 120 Hours Postdose for TAK-385. Time frame: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, and 120hrs; up to 120 hrs) post-dose. Description: NA. Parameters: Least Square Mean Ratio (%) = 84.68 (p = 0.256, CI 66.23-108.27); Least Square Mean Ratio (%) = 52.56 (p = 0.001, CI 40.78-67.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-385. Time frame: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, and 120hrs; up to 120 hrs) post-dose. Description: NA. Parameters: Least Square Mean Ratio (%) = 84.68 (p = 0.256, CI 66.23-108.27); Least Square Mean Ratio (%) = 52.56 (p = 0.001, CI 40.78-67.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: AUC: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385. Time frame: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, and 120hrs; up to 120 hrs) post-dose. Description: NA. Parameters: Least Square Mean Ratio (%) = 84.28 (p = 0.238, CI 66.09-107.47); Least Square Mean Ratio (%) = 53.2 (p = 0.001, CI 41.39-68.37). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Cmax: Maximum Observed Plasma Concentration for TAK-385. Time frame: Day 1: Pre-dose and at multiple time points (up to 120 hrs) post-dose. Description: NA. Parameters: Least Square Mean Ratio (%) = 113.06 (p = 0.659, CI 70.37-181.67); Least Square Mean Ratio (%) = 45.43 (p = 0.012, CI 27.86-74.07). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Uterine Artery and Spiral Artery Doppler Parameters in Patients With Postmenopausal Bleeding

Summary: This study was to investigate the diagnostic value of ultrasonography and blood flow measurements in uterine arteries and spiral arteries by transvaginal color Doppler ultrasonography in the detection of the endometrial pathology in women with postmenopausal bleeding.

Detailed Description: This prospective Cross-sectional Observational study will be conducted at the Department of Obstetrics and Gynecology, Banha University, Egypt during the period starting from January 2014. The study protocol will be approved by the Local Ethics Committee and written informed consent will be obtained from each patient before the study commenced.

Seventy patients with postmenopausal bleeding will be included in the study after verbal consent. They will be recruited from patients attending gynecologic clinic in Banha University hospital.

All patients will be subjected to the following:

For all included women the following will be done:

1. Full history taking.
2. Complete general, abdominal, and local examination.
3. Ultrasonographic assessment of the uterus

All data were performed for all patients in the lithotomy position after they had emptied their bladder using a 7.5 megahertz transducer by a single operator.

1. Using colour Doppler in the 2D mode, flow velocity waveforms were obtained from the ascending main branch of the uterine artery on the right and left side of the cervix in a longitudinal plane before they entered the uterus.
2. The gate of the Doppler was positioned when the vessel with good colour signals was identified on the screen. Pulsatility index of the uterine arteries were calculated electronically when similar consecutive waveforms of good quality were obtained and the averaged uterine PI.

   Pulsatility index (PI):

   This index, also known as the mean pulsatility index, to distinguish it from the peak to peak pulsatility index, is expressed by: PI= (S-D) / Mean Where S is the peak systolic velocity, D is the end diastolic velocity and velocity is the time averaged maximum velocity over the cardiac cycle (1).
3. Blood flow velocity waveforms were evaluated in the spiral arteries at the sub endometrial region that is within 1 mm of the originally defined myometrial-endometrial contour (2).

Histopathological diagnosis of endometrium obtained by biopsy is the gold standard for diagnosis.

Results: Outcome: Endometrial Thickness According to Histological Diagnosis. Time frame: 2 weeks. Description: Endometrial Thickness was assessed by measuring the trilaminar halo of the Endometrial Thickness by trans vaginal sonography. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Pulsatility Indices (PI) of Spiral Artery According to Histological Diagnosis. Time frame: two weeks. Description: Pulsatility index is a measure of the variability of blood velocity in a vessel, and was calculated as the difference between the peak systolic and end diastolic velocities divided by the mean velocity during the cardiac cycle. Higher values are indicative of increased vascular resistance. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Resistive Indices (PI) of Spiral Artery According to Histological Diagnosis. Time frame: two weeks. Description: The primary outcome measure is spiral artery resistive index (RI) .In ultrasonography,it can be calculated from the peak systolic velocity and end diastolic velocity of blood flow and is calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity.lower values are better than higher values.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Uterine Artery Pulsatility Index According to Histological Diagnosis. Time frame: 2 weeks. Description: Pulsatility index is a measure of the variability of blood velocity in a vessel, and was calculated as the difference between the peak systolic and end diastolic velocities divided by the mean velocity during the cardiac cycle. Higher values are indicative of increased vascular resistance. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Uterine Artery Resistive Index According to Histological Diagnosis. Time frame: two weeks. Description: The primary outcome measures is uterine artery resistive index (RI) .In ultrasonography,it can be calculated from the peak systolic velocity and end diastolic velocity of blood flow and is calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity.lower values are better than higher values.. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.
Study: Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Summary: This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.

Detailed Description: NA

Results: Outcome: Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8). Time frame: baseline (day-1) to day 1 and day 7, pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours). Description: Change in Luteinizing Hormone(LH) AUC from time zero to 8 hours. Pre-dose samples for LH were taken within 30 minutes prior to dose administration.. Parameters: LS means difference = -9.7 (p = 0.3768, CI -27.8-8.5); LS means difference = -25 (p = 0.0248, CI -43.1--6.8); LS means difference = -43.9 (p = 1e-04, CI -62.1--25.8); LS means difference = -42.9 (p = 4e-04, CI -61.9--23.8); LS means difference = 10.4 (p = 0.4819, CI -14.2-35.1); LS means difference = -2.4 (p = 0.8694, CI -27.1-22.2); LS means difference = -23.9 (p = 0.1105, CI -48.6-0.7); LS means difference = -18.4 (p = 0.239, CI -44.2-7.4). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.. Time frame: Baseline (week -1) and week 1 , 2. Description: The hot flushes severity score was a composite of the frequency and severity of hot flushes, and was calculated as follows: number of mild hot flushes recorded on Day Y + number of moderate hot flushes recorded on Day Y  2 + number of severe hot flushes recorded on Day Y  3. Higher scores mean more severe hot flushes.. Parameters: LS means difference = -10.18 (p = 0.0012, CI -15.2--5.15); LS means difference = -6.14 (p = 0.0548, CI -11.37--0.9); LS means difference = 6.59 (p = 0.0522, CI 1.03-12.15); LS means difference = -5.07 (p = 0.1326, CI -10.61-0.48); LS means difference = -12.28 (p = 4e-04, CI -17.73--6.83); LS means difference = -7.79 (p = 0.0253, CI -13.47--2.11); LS means difference = 5.29 (p = 0.09, CI 0.16-10.42); LS means difference = -4.46 (p = 0.1487, CI -9.55-0.63). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary. Time frame: Baseline (week -1) and weeks 1, Week 2. Description: Participants documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.. Parameters: LS means difference = 0.09 (p = 0.4641, CI -0.12-0.3); Linear mixed-effects model = 0 (p = 0.9894, CI -0.21-0.21); LS means difference = -0.31 (p = 0.0199, CI -0.52--0.09); LS means difference = -0.12 (p = 0.3907, CI -0.34-0.11); LS means difference = 0.1 (p = 0.5393, CI -0.17-0.38); LS means difference = -0.04 (p = 0.7931, CI -0.33-0.24); LS means difference = -0.63 (p = 4e-04, CI -0.92--0.35); LS means difference = -0.16 (p = 0.3739, CI -0.45-0.13). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary. Time frame: Baseline (week-1) and weeks 1 , 2. Description: The number of NTAs secondary to hot flushes was the sum of the number of moderate and severe night-time hot flushes recorded the following morning (twice-daily hot flush diary) or recorded contemporaneously on the continuous diary.. Parameters: LS means difference = 0.84 (p = 0.1482, CI -0.12-1.8); LS means difference = -1.04 (p = 0.0734, CI -1.99--0.09); LS means difference = -1.8 (p = 0.0022, CI -2.74--0.86); LS means difference = -1.1 (p = 0.066, CI -2.08--0.12); LS means difference = 1.18 (p = 0.0593, CI 0.15-2.2); LS means difference = -0.93 (p = 0.1354, CI -1.95-0.1); LS means difference = -2.2 (p = 5e-04, CI -3.21--1.2); LS means difference = -1.38 (p = 0.0309, CI -2.43--0.34). Non-inferiority type: OTHER. Outcome: Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.. Time frame: Baseline(day -1) and Day 7, 14. Description: Subjects recorded each hot flush and its severity on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3) in the hot flush paper diary as they occurred during the day and night.. Parameters: LS means difference = 1.4 (p = 0.3796, CI -1.2-4); LS means difference = -2.3 (p = 0.1413, CI -4.9-0.3); LS means difference = -5.5 (p = 7e-04, CI -8.1--2.9); LS means difference = -3.1 (p = 0.0624, CI -5.8--0.4); LS means difference = 1.3 (p = 0.293, CI -0.7-3.3); LS means difference = -2.4 (p = 0.0512, CI -4.4--0.4); LS means difference = -5 (p = 1e-04, CI -7--3); LS means difference = -3.4 (p = 0.008, CI -5.5--1.3). Non-inferiority type: OTHER.
Study: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women

Summary: The physiological relevance of brown adipose tissue (BAT) in humans is largely unknown. The investigators have shown that suppressing ovarian function in premenopausal women reduces resting energy expenditure (REE), and this is prevented by adding back estradiol (E2). The investigators preliminary data suggest that this may be due, in part, to reduced brown adipose tissue (BAT) activity. The overarching hypothesis is that BAT activity in humans is modulated by E2. To determine if natural declines in endogenous E2 contribute to changes in BAT activity, we will compare BAT activity in pre-and post-menopausal women. The investigators will also explore whether suppression of ovarian hormones in pre-menopausal women impairs BAT activity. BAT activity will be quantified using dynamic positron emission topography/computed tomography (PET/CT) imaging combined with 11C-acetate tracers. We will assess the thermogenic response of BAT by measuring cold-induced changes in REE, shivering, and skin and core temperature.

Detailed Description: Participants will be asked to perform studies to measure resting metabolic rate and activity of brown adipose tissue or brown fat. Brown fat is different from regular "white fat" in that it produces heat and burns calories. The investigators will measure how active brown fat is at normal room temperature and after participants have been exposed to cold.

The study will last 5-6 hours. It will consist of measurements made in warm temperatures and then after a period of cold exposure. For the cold exposure part of the study, participants will be asked to wear a cooling suit for 3 hrs. Skin temperature is normally about 90 Fahrenheit. The cooling suit will adjust the water temperature until your skin temperature is about 82 Fahrenheit. The suit will cover the entire body except for the face, hands, and feet. Participants may feel cold while wearing the suit and you may shiver some, but based on past studies, any shivering should be minor.

Before and after the cooling suit is turned on, body scans will be performed using a procedure called positron emission tomography (PET). These scans do not use radiation. Before the PET scans, the investigators will infuse radioactive tracer into an arm. These tracers have a low dose of radiation and will show us where the brown fat is and how active it is. One PET scan will be performed at room temperature, and the second scan will be performed after the cooling suit has been worn for 3 hours. Two additional scans using computed tomography (CT) will be performed at end of the study. CT scans are like an x-ray, and use radiation. The radiation dose in the CT scan is much higher than the tracers. When the CT scans are combined with the PET scans, we can separate brown fat from white fat.

15 pre-menopausal women will be asked to volunteer for a follow up study. For 5 months, pre-menopausal women in this study will receive monthly injections that contain a study drug (leuprolide) that reduces estrogen to postmenopausal levels. This drug is approved by the FDA to reduce estrogen for the treatment of uterine fibroids and endometriosis, but is not approved for use in healthy women. In this study, the drug is being used to decrease hormones to determine if this reduces brown fat activity. 6 months after the first injection, these women will be asked to repeat the PET/CT studies.

Results: Outcome: Brown Adipose Tissue Activity -Warm Exposure. Time frame: 5-6 hrs. Description: Brown adipose tissue activity in warm temperatures will be measured using the radioactive tracer 11C-acetate. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: OTHER.
Study: Study Assessing Injection Pain of Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Summary: To demonstrate that Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena

Detailed Description: NA

Results: Outcome: Clinician Assessment of Ease of Drug Preparation. Time frame: 4 weeks. Description: Investigate the clinician's assessment of the ease of drug preparation associated with the administration of Makena via subcutaneous auto-injector versus intramuscular injection as measured by a categorical scale.

Scores were as follows: completely dissatisfied = -3; mostly dissatisfied = -2, somewhat dissatisfied = -1, neither satisfied nor unsatisfied = 0, somewhat satisfied = 1, mostly satisfied = 2, completely satisfied = 3. Parameters: Mean Difference (Final Values) = 0.3 (p = 0.234, CI -0.2-0.7). Non-inferiority type: SUPERIORITY. Outcome: Clinician Assessment of Ease of Injection Technique. Time frame: 4 weeks. Description: Investigate the clinician's assessment of the ease of injection technique associated with the administration of Makena via subcutaneous auto-injector versus intramuscular injection as measured by a categorical scale.

Scores were as follows: completely dissatisfied = -3; mostly dissatisfied = -2, somewhat dissatisfied = -1, neither satisfied nor unsatisfied = 0, somewhat satisfied = 1, mostly satisfied = 2, completely satisfied = 3. Parameters: Mean Difference (Final Values) = 0.4 (p = 0.093, CI -0.1-0.9). Non-inferiority type: SUPERIORITY.
Study: Comparing Bioavailability When Preservative-free Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Summary: To demonstrate that a single dose of Makena delivered SQ via auto-injector has comparable bioavailability to a single IM injection of Makena.

Detailed Description: NA

Results: Outcome: Comparison of AUC (0-168). Time frame: 9 weeks. Description: Comparison of PK Parameter AUC (0-168) for the Primary PK Population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER. Outcome: Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration  LLOQ [AUC0-t] and to Infinity [AUCinf]. Time frame: 9 weeks. Description: Comparison of areas under the curve (AUC) to the last time with a concentration  LLOQ \[AUC0-t\] and to infinity \[AUCinf\] for the Primary PK Population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER. Outcome: Comparison of Elimination Rate Constant. Time frame: 9 weeks. Description: Comparison of the elimination rate constant for the Primary PK Population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER. Outcome: Comparison of Tmax. Time frame: 9 weeks. Description: Comparison of PK parameter Tmax for the Primary PK population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER. Outcome: Comparison of t1/2. Time frame: 9 weeks. Description: Comparison of PK parameter t1/2 for the Primary PK Population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER. Outcome: Comparison of the Maximum Plasma Concentration (Cmax). Time frame: 9 weeks. Description: Comparison of the maximum plasma concentration (Cmax) for the Primary PK Population. Parameters: NA = NA (p = NA, CI NA-NA). Non-inferiority type: OTHER.
Study: Menopausal Sleep Fragmentation and Body Fat Gain

Summary: This study aims to investigate the impact of menopause-related sleep fragmentation on metabolic biomarkers of body fat gain. The investigators hypothesize that experimental sleep fragmentation will result in an adverse leptin response as a metabolic biomarker for body fat gain.

Detailed Description: While obesity is highly prevalent in midlife and older women, with rates increasing markedly after age 40 and body fat increasing in half of women during and after the menopause transition, factors causing these changes are not well understood. Reduced total sleep time has been shown to adversely impact biomarkers of obesity, but the effect of the highly prevalent menopause-related sleep fragmentation secondary to hot flashes on metabolism and eating behaviors in humans is not known. We will use experimental paradigms to isolate the impact of menopause-related sleep disruption, as well as that of hot flashes and estrogen withdrawal, metabolic biomarkers of body fat gain and on eating behaviors, results of which will inform strategies to prevent body fat gain and improve cardio-metabolic health outcomes in women.

Results: Outcome: Normalized Satiety Scores. Time frame: pre/post sleep fragmentation (3 days); pre/post estradiol withdrawal (~5 weeks). Description: 12-hr overnight fasted AM satiety scores were collected on study days 2-6 under both estrogenized and estradiol-withdrawal conditions \[total: 10 scores\]. For each individual, satiety scores were normalized relative to the mean baseline satiety score. Baseline was defined as the unfragmented estrogenized condition (avg. of study days 2-3 in the estrogenized condition).. Parameters: NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.58, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Normalized Serum Leptin Levels. Time frame: pre/post sleep fragmentation (3 days); pre/post estradiol withdrawal (~5 weeks). Description: 12-hr overnight fasted AM (morning) blood samples were assayed for leptin levels on study days 2-6 under both estrogenized and estradiol-withdrawal conditions \[total: 10 samples\]. For each individual, leptin values were normalized relative to the mean baseline leptin value. Baseline was defined as the unfragmented estrogenized condition (avg. of study days 2-3 in the estrogenized condition).. Parameters: NA = NA (p = 0.22, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Summary: This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.

Detailed Description: PRIMARY OBJECTIVES:

I. Measure the ability of two dose levels of bupropion hydrochloride (bupropion), 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 weeks (8 weeks on the target dose) as measured by the desire subscale of the female sexual function index (FSFI).

SECONDARY OBJECTIVES:

I. Evaluate the side effects of 150 and 300 mg bupropion extended release and differentiate these side effects from those observed in the placebo arm.

II. Evaluate the effect of 150 and 300 mg of bupropion extended release on the Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale, PROMIS sexual desire and satisfaction measure, patient health questionnaire (PHQ)-4, and the FSFI total score, at 5 and 9 weeks, as well as the desire subscale score of the FSFI at 5 weeks.

III. Evaluate the effect of 150 and 300 mg of bupropion extended release on the global impression of change scale and the patient's perception of risk versus (vs.) benefit at 5 weeks (4 weeks at target dose) and 9 weeks (8 weeks at target dose).

Patients are randomized to 1 of 3 arms.

Results: Outcome: Change From Baseline at 5 Weeks in Desire Subscore of the FSFI ("Sexual Desire"). Time frame: Baseline (prior to randomization) and 5 weeks from start of study treatment (within 21 days of randomization). Description: The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as "sexual desire" in the protocol.. Parameters: NA = NA (p = 0.24, CI NA-NA); NA = NA (p = 0.74, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire"). Time frame: Baseline (prior to randomization) and 9 weeks from start of study treatment (within 21 days of randomization). Description: The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as "sexual desire" in the protocol.. Parameters: NA = NA (p = 0.46, CI NA-NA); NA = NA (p = 0.54, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in FSFI Total Score ("Sexual Functioning"). Time frame: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization). Description: The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as "sexual functioning" in the protocol.. Parameters: NA = NA (p = 0.41, CI NA-NA); NA = NA (p = 0.35, CI NA-NA); NA = NA (p = 0.83, CI NA-NA); NA = NA (p = 0.79, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure ("Sexual Desire and Satisfaction"). Time frame: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization). Description: The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the "PROMIS sexual desire and satisfaction measure" in the protocol.. Parameters: NA = NA (p = 0.6, CI NA-NA); NA = NA (p = 0.9, CI NA-NA); NA = NA (p = 0.79, CI NA-NA); NA = NA (p = 0.41, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Patient Health Questionnaire (PHQ)-4 Score ("Depressive Mood"). Time frame: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization). Description: The PHQ-4 is a brief screening questionnaire for depression. Possible scores range from 0 to 12, with higher scores indicating more severe depression. Change score is calculated by subtracting baseline from later score, with a negative change score indicating decreased severity of depression. This measure is referred to as "depressive mood" in the protocol.. Parameters: NA = NA (p = 0.78, CI NA-NA); NA = NA (p = 0.51, CI NA-NA); NA = NA (p = 0.49, CI NA-NA); NA = NA (p = 0.5, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score. Time frame: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization). Description: The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible scores range from 33.1 to 77.8, with higher scores indicating more fatigue. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased fatigue.. Parameters: NA = NA (p = 0.95, CI NA-NA); NA = NA (p = 0.73, CI NA-NA); NA = NA (p = 0.46, CI NA-NA); NA = NA (p = 0.42, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Global Impression of Change at 9 Weeks ("Perception of Change"). Time frame: 9 weeks from start of study treatment (within 21 days of randomization). Description: Participants are asked, "Since beginning the study agent, my desire of sexual intimacy is:" with seven possible answers of "very much better," "moderately better," "a little better," "about the same," "a little worse," "moderately worse," and "very much worse." The first three answers have been categorized as "Better' and the last three answers as "Not Better". This measure is referred to as "perception of change" in the protocol.. Parameters: NA = NA (p = 0.71, CI NA-NA); NA = NA (p = 0.34, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Perception of Risk vs. Benefit at 9 Weeks. Time frame: 9 weeks from start of study treatment (within 21 days of randomization). Description: Participants are asked, "Were the benefits of this treatment greater than any side effects?". Parameters: NA = NA (p = 0.23, CI NA-NA); NA = NA (p = 0.25, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

Summary: This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.

Detailed Description: This was a 12-week randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multi-center study to assess the efficacy of ESN364 in postmenopausal women suffering from vasomotor symptoms (hot flashes).

This study consisted of a screening period (Days -35 to -1, including the screening visit \[Visit 1\] and a minimum 7-day collection of baseline vasomotor symptom frequency and severity assessments), a 12 week treatment period (Day 1 \[Visit 2\] to Week 12 \[Visit 5\]), and a follow up visit (Week 15 \[Visit 6\]) 3 weeks after the last dose of study drug.

The study was performed on an ambulatory basis. The screening visit (Visit 1) occurred up to 35 days prior to randomization. Eligibility was assessed via physical examination, clinical laboratory testing, vital signs, ECG, Pap smear, mammography, and endometrial biopsy. Subjects received an electronic diary to record daily vasomotor symptoms during the duration of the screening period. Subjects who had 7 consecutive days of vasomotor symptom recordings participated in the study. Subjects are encouraged to continue recording for the duration of the whole screening period. The electronic diary was reviewed by study site staff on Day 1 (Visit 2) to confirm study eligibility. Subjects were rescreened 1 time upon approval of the medical monitor.

During the treatment period, subjects returned to the study site every 4 weeks for assessments.

The follow-up visit occurred approximately 3 weeks following the last dose of study drug.

Results: Outcome: Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15. Time frame: Baseline and weeks 4, 8, 12, and 15. Description: The GCS is a 21-item scale that provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item is rated by the participant according to its severity using a 4-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into 3 main independent symptom measures by summing up the individual item scores: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and VMS (items 19 to 20; score 0 to 6). Item 21 is a probe for sexual dysfunction. The total score can range from 0 to 63. Higher scores indicate worse symptoms.. Parameters: LSMean difference = -1.1 (p = 0.2159, CI -2.93-0.67); LSMean difference = -1.9 (p = 0.0405, CI -3.7--0.08); LSMean difference = -2.4 (p = 0.0115, CI -4.18--0.53); LSMean difference = -1 (p = 0.2753, CI -2.82-0.8); LSMean difference = 0.6 (p = 0.514, CI -1.2-2.4); LSMean difference = -2.2 (p = 0.0178, CI -4.03--0.38); LSMean difference = -1.8 (p = 0.0553, CI -3.62-0.04); LSMean difference = -0.8 (p = 0.1111, CI -1.82-0.19); LSMean difference = -0.5 (p = 0.1764, CI -1.16-0.21); LSMean difference = -1 (p = 0.0037, CI -1.73--0.34); LSMean difference = -1.6 (p = 1e-04, CI -2.3--0.92); LSMean difference = -1.5 (p = 1e-04, CI -2.21--0.81); LSMean difference = -0.5 (p = 0.1444, CI -1.21-0.18); LSMean difference = -0.9 (p = 0.0088, CI -1.6--0.23); LSMean difference = -1.2 (p = 5e-04, CI -1.93--0.54); LSMean difference = -0.4 (p = 0.0416, CI -0.69--0.01); LSMean difference = -0.4 (p = 0.0353, CI -0.71--0.03); LSMean difference = -0.5 (p = 0.004, CI -0.84--0.16); LSMean difference = -3.6 (p = 0.0225, CI -6.6--0.5); LSMean differencce = -4.3 (p = 0.0058, CI -7.38--1.26); LSMean difference = -3.4 (p = 0.0301, CI -6.48--0.33); LSMean difference = 0 (p = 0.9675, CI -1.02-0.98); LSMean difference = -0.5 (p = 0.3122, CI -1.52-0.49); LSMean difference = 0 (p = 0.9977, CI -1-1); LSMean Difference = 0 (p = 0.9312, CI -1.05-0.97); LSMean difference = -0.3 (p = 0.6005, CI -1.27-0.74); LSMean difference = 0.3 (p = 0.5284, CI -0.68-1.32); LSMean difference = -0.3 (p = 0.0495, CI -0.69-0); LSMean difference = 0 (p = 0.8665, CI -0.31-0.37); LSMean difference = 0 (p = 0.9303, CI -0.35-0.32); LSMean difference = -0.3 (p = 0.1039, CI -0.62-0.06); LSMean difference = -1.8 (p = 0.2547, CI -4.78-1.27); LSMean difference = -1.5 (p = 0.322, CI -4.59-1.51); LSMean difference = 0.2 (p = 0.8782, CI -2.8-3.27); LSMean difference = -4.2 (p = 0.0069, CI -7.27--1.17); LSMean difference = -1.6 (p = 0.089, CI -3.49-0.25); LSMean difference = -1.4 (p = 0.1444, CI -3.25-0.48); LSMean difference = -1.6 (p = 0.1022, CI -3.51-0.32); LSMean difference = -1.2 (p = 0.2342, CI -3.07-0.75); LSMean difference = 0 (p = 0.9906, CI -1.89-1.87); LSMean difference = 0.5 (p = 0.577, CI -1.34-2.4); LSMean difference = -1.3 (p = 0.1865, CI -3.14-0.61); LSMean difference = -0.4 (p = 0.4575, CI -1.45-0.65); LSMean difference = -0.3 (p = 0.6016, CI -1.33-0.77); LSMean difference = 0.2 (p = 0.7026, CI -0.86-1.28); LSMean difference = -0.6 (p = 0.2971, CI -1.64-0.5); LSMean difference = -0.3 (p = 0.5491, CI -1.38-0.74); LSMean difference = -0.8 (p = 0.1157, CI -1.89-0.21); LSMean difference = -0.6 (p = 0.1114, CI -1.3-0.14); LSMean difference = -1.1 (p = 0.0025, CI -1.83--0.4); LSMean difference = -1.5 (p = 1e-04, CI -2.2--0.74); LSMean difference = -0.2 (p = 0.5093, CI -0.96-0.48); LSMean difference = 0.2 (p = 0.7142, CI -0.86-1.25); LSMean difference = -0.3 (p = 0.1274, CI -0.65-0.08); LSMean difference = -0.2 (p = 0.1865, CI -0.61-0.12); LSMean difference = -0.2 (p = 0.1857, CI -0.61-0.12); LSMean difference = 0 (p = 0.8631, CI -0.33-0.39); LSMean difference = -0.4 (p = 0.0304, CI -0.75--0.04); LSMean difference = -2.5 (p = 0.1246, CI -5.71-0.7); LSMean difference = -3 (p = 0.068, CI -6.19-0.22); LSMean difference = -3 (p = 0.0729, CI -6.28-0.28); LSMean difference = -1.6 (p = 1e-04, CI -2.33--0.86); LSMean difference = -1 (p = 0.009, CI -1.67--0.24); LSMean difference = -1.1 (p = 0.0024, CI -1.84--0.4); LSMean difference = -0.1 (p = 0.5497, CI -0.47-0.25); LSMean difference = -0.4 (p = 0.0276, CI -0.76--0.04); LSMean difference = -0.6 (p = 0.696, CI -3.87-2.59); LSMean difference = -3.2 (p = 0.0541, CI -6.49-0.06); LSMean difference = -0.6 (p = 0.2582, CI -1.57-0.42); LSMean difference = 0.5 (p = 0.3448, CI -0.53-1.52); LSMean difference = 0.2 (p = 0.6587, CI -0.81-1.28); LSMean difference = -0.1 (p = 0.8299, CI -1.16-0.93); LSMean difference = -0.1 (p = 0.8129, CI -1.17-0.92); LSMean difference = -0.1 (p = 0.9725, CI -3.27-3.15); LSMean difference = -3.3 (p = 0.0419, CI -6.53--0.12); LSMean difference = -1.7 (p = 0.0794, CI -3.57-0.2); LSMean difference = -1.5 (p = 0.1153, CI -3.47-0.38); -1.5 = -1.5 (p = 0.1334, CI -3.47-0.46); LSMean difference = -0.9 (p = 0.3457, CI -2.93-1.03); LSMean difference = -1.1 (p = 0.2607, CI -3.07-0.83); LSMean difference = -0.3 (p = 0.7816, CI -2.18-1.64); LSMean difference = -1.6 (p = 0.0955, CI -3.54-0.29); LSMean Difference = 0.6 (p = 0.213, CI -0.37-1.66); LSMean difference = -0.4 (p = 0.4131, CI -1.42-0.59); LSMean difference = -0.5 (p = 0.1273, CI -1.2-0.15); LSMean difference = -1 (p = 0.0046, CI -1.69--0.31); LSMean difference = -1.5 (p = 1e-04, CI -2.19--0.8); LSMean difference = -1.5 (p = 1e-04, CI -2.19--0.78); LSMean difference = -0.8 (p = 0.0208, CI -1.49--0.12); LSMean difference = -2.5 (p = 0.1305, CI -5.74-0.74); LSMean difference = -0.8 (p = 0.0333, CI -1.45--0.06); LSMean difference = -0.7 (p = 0.0423, CI -1.39--0.02); LSMean difference = -0.2 (p = 0.3435, CI -0.55-0.19); LSMean difference = -0.6 (p = 0.0021, CI -0.98--0.22); LSMean difference = -0.4 (p = 0.0408, CI -0.79--0.02); LSMean difference = -3 (p = 0.0707, CI -6.34-0.26); LSMean difference = -2.6 (p = 0.1232, CI -5.92-0.71); LSMean difference = -1.9 (p = 0.253, CI -5.18-1.37); LSMean difference = -0.2 (p = 0.9133, CI -3.4-3.04); LSMean difference = -2.6 (p = 0.1078, CI -5.85-0.58); LSMean differencce = -0.3 (p = 0.0911, CI -0.73-0.05); LSMean difference = -0.1 (p = 0.7891, CI -0.44-0.33); LSMean difference = 0 (p = 0.9973, CI -0.38-0.38); -0.1 = -0.1 (p = 0.6377, CI -0.47-0.29); LSMean difference = -2.8 (p = 0.0862, CI -5.95-0.4); LSMean differencce = -1.9 (p = 0.0719, CI -4.07-0.18); LSMean difference = -1.7 (p = 0.1298, CI -3.8-0.49); LSMean difference = -0.1 (p = 0.9532, CI -2.26-2.13); LSMean difference = 0.4 (p = 0.751, CI -1.84-2.55); LSMean difference = -1.8 (p = 0.112, CI -3.95-0.42); LSMean difference = -1.4 (p = 0.206, CI -3.57-0.77); LSMean difference = -0.4 (p = 0.5332, CI -1.46-0.76); LSMean difference = -0.4 (p = 0.4599, CI -1.54-0.7); LSMean difference = 0.4 (p = 0.4752, CI -0.72-1.55); LSMean difference = 0 (p = 0.9781, CI -2.13-2.19); LSMean difference = -0.1 (p = 0.9051, CI -1.21-1.07); LSMean difference = -0.4 (p = 0.3632, CI -1.36-0.5); LSMean difference = -0.5 (p = 0.2828, CI -1.43-0.42); LSMean difference = -0.3 (p = 0.4702, CI -1.24-0.58); LSMean difference = 0 (p = 0.9937, CI -1.14-1.15); LSMean difference = 0.2 (p = 0.6956, CI -0.91-1.35); LSMean difference = -0.7 (p = 0.2302, CI -1.81-0.44); LSMean difference = -0.7 (p = 0.1544, CI -1.55-0.25); LSMean difference = -0.1 (p = 0.8262, CI -1.02-0.81); LSMean difference = -0.2 (p = 0.3152, CI -0.6-0.19); LSMean difference = -0.2 (p = 0.4399, CI -0.56-0.24); LSMean difference = -0.3 (p = 0.1898, CI -0.67-0.13); LSMean difference = -0.2 (p = 0.6847, CI -1.1-0.72); LSMean difference = -0.3 (p = 0.552, CI -1.2-0.64); LSMean difference = 0 (p = 0.9791, CI -0.4-0.41); LSMean difference = -0.2 (p = 0.3178, CI -0.61-0.2); LSMean difference = -2.9 (p = 0.1233, CI -6.57-0.79); LSMean difference = -2 (p = 0.2858, CI -5.76-1.7); LSMean difference = -0.2 (p = 0.4174, CI -0.57-0.24); LSMean difference = -0.2 (p = 0.249, CI -0.63-0.16); LSMean difference = -0.1 (p = 0.9716, CI -3.87-3.73); LSMean difference = 0.2 (p = 0.9072, CI -3.58-4.03); LSMean difference = -2.3 (p = 0.2334, CI -6.07-1.49); LSMean difference = -2 (p = 0.287, CI -5.77-1.72); LSMean difference = 0 (p = 0.9859, CI -3.79-3.72). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15. Time frame: Baseline and weeks 4, 8, 12, and 15. Description: The HFRDIS is a 10-item scale that measures a woman's perceptions of the degree to which VMS interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, and enjoying life); the tenth item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory, which assess the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which VMS had interfered with each item during the previous 2-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score is the average of individual item scores (sum of items/10).. Parameters: LSMean difference = -1.1 (p = 0.0179, CI -1.95--0.18); LSMean difference = -1.4 (p = 0.0027, CI -2.25--0.47); LSMean difference = -1.6 (p = 4e-04, CI -2.5--0.73); LSMean difference = -1.5 (p = 9e-04, CI -2.43--0.64); LSMean difference = -0.3 (p = 0.5806, CI -1.14-0.64); LSMean difference = -1.2 (p = 0.0105, CI -2.03--0.27); LSMean difference = -1.3 (p = 0.0048, CI -2.16--0.39); LSMean difference = -0.6 (p = 0.1801, CI -1.52-0.29); LSMean difference = -0.9 (p = 0.0609, CI -1.76-0.04); LSMean difference = -1.4 (p = 0.0028, CI -2.33--0.49); LSMean difference = -1.5 (p = 0.0018, CI -2.4--0.55); LSMean difference = -0.1 (p = 0.883, CI -1.13-0.97); LSMean difference = -0.3 (p = 0.5519, CI -1.19-0.64); LSMean difference = -0.6 (p = 0.1922, CI -1.51-0.31); LSMean difference = -0.9 (p = 0.0463, CI -1.82--0.02); LSMean difference = -0.7 (p = 0.1288, CI -1.53-0.19); LSMean difference = -0.8 (p = 0.0577, CI -1.72-0.03); LSMean difference = -1.4 (p = 0.0027, CI -2.26--0.48); -1.3 = -1.3 (p = 0.0043, CI -2.2--0.41); LSMean difference = -0.4 (p = 0.4089, CI -1.27-0.52); LSMean difference = -0.6 (p = 0.205, CI -1.44-0.31); LSMean difference = -1 (p = 0.0265, CI -1.84--0.11); LSMean difference = -0.2 (p = 0.7617, CI -1.2-0.88); LSMean difference = 0.3 (p = 0.6061, CI -0.77-1.32); LSMean difference = 0.1 (p = 0.7997, CI -0.93-1.21); LSMean difference = 0.5 (p = 0.3391, CI -0.55-1.6); LSMean difference = -0.5 (p = 0.3934, CI -1.55-0.61); LSMean difference = 0 (p = 0.975, CI -1.08-1.04). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15. Time frame: Baseline and weeks 4, 8, 12, and 15. Description: The MENQoL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of 1 of 4 domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1 to 3), psychosocial (items 4 to 10), physical (items 11 to 26), and sexual (items 27 to 29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a 0 (not bothersome) to 6 (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a "1" and endorsement a "2," plus the number of the particular rating, so that the possible score on any item ranges from 1 to 8. Higher scores indicate that menopause symptoms are more bothersome.. Parameters: LSMean difference = -0.6 (p = 0.1632, CI -1.41-0.24); LSMean difference = -1.2 (p = 0.0045, CI -2.03--0.38); LSMean difference = -1.6 (p = 2e-04, CI -2.43--0.77); LSMean difference = -1.9 (p = 1e-04, CI -2.7--1.02); LSMean difference = -0.1 (p = 0.8569, CI -0.91-0.76); LSMean difference = -0.7 (p = 0.111, CI -1.49-0.15); LSMean difference = 0.4 (p = 0.1671, CI -0.16-0.92); LSMean difference = 0 (p = 0.9462, CI -0.57-0.53); LSMean difference = -0.5 (p = 0.0265, CI -1.02--0.06); LSMean difference = -0.4 (p = 0.1119, CI -0.86-0.09); LSMean difference = -0.1 (p = 0.7607, CI -0.54-0.4); LSMean difference = -0.6 (p = 0.0124, CI -1.06--0.13); LSMean difference = -0.2 (p = 0.4367, CI -0.65-0.28); LSMean difference = 0 (p = 0.9318, CI -0.48-0.44); LSMean difference = -1 (p = 0.0187, CI -1.83--0.17); LSMean difference = -0.2 (p = 0.4972, CI -0.73-0.36); LSMean difference = -0.3 (p = 0.2568, CI -0.86-0.23); LSMean difference = -0.3 (p = 0.2609, CI -0.86-0.23); LSMean difference = -0.2 (p = 0.4148, CI -0.78-0.32); LSMean difference = 0.2 (p = 0.5575, CI -0.38-0.71); LSMean difference = -0.4 (p = 0.0699, CI -0.91-0.04); LSMean difference = -0.7 (p = 0.0056, CI -1.15--0.2); LSMean difference = -0.4 (p = 0.1117, CI -0.86-0.09); LSMean difference = -0.5 (p = 0.0437, CI -0.97--0.01); LSMean difference = -0.8 (p = 0.0211, CI -1.51--0.12); LSMean difference = -1.1 (p = 0.0017, CI -1.82--0.42); LSMean difference = -0.7 (p = 0.0598, CI -1.37-0.03); LSMean differencce = -0.5 (p = 0.1573, CI -1.21-0.2); LSMean difference = -0.1 (p = 0.7257, CI -0.83-0.58); LSMean difference = 0 (p = 0.9324, CI -0.72-0.66); LSMean difference = -0.4 (p = 0.2172, CI -1.14-0.26); LSMean difference = -0.4 (p = 0.0742, CI -0.88-0.04); LSMean difference = -0.7 (p = 0.0035, CI -1.16--0.23); LSMean difference = -0.5 (p = 0.0266, CI -0.99--0.06); LSMean difference = -1 (p = 0.0211, CI -1.78--0.15); LSMean difference = -1.3 (p = 0.0021, CI -2.1--0.47); LSMean difference = 0 (p = 0.889, CI -0.55-0.48); LSMean difference = 0.2 (p = 0.4409, CI -0.31-0.72); LSMean difference = 0.1 (p = 0.8062, CI -0.45-0.58); LSMean difference = -0.4 (p = 0.0714, CI -0.89-0.04); LSMean difference = -0.5 (p = 0.2027, CI -1.35-0.29); LSMean difference = -1.3 (p = 0.0013, CI -2.16--0.53); LSMean difference = -1.7 (p = 1e-04, CI -2.53--0.87); LSMean difference = -2 (p = 1e-04, CI -2.83--1.16); LSMean difference = -0.4 (p = 0.3791, CI -1.19-0.45); LSMean difference = -0.2 (p = 0.5568, CI -0.67-0.36); LSMean difference = -0.2 (p = 0.3989, CI -0.75-0.3); LSMean difference = -0.1 (p = 0.6094, CI -0.66-0.39); LSMean difference = 0.2 (p = 0.5229, CI -0.35-0.69); LSMean differnce = -0.3 (p = 0.2162, CI -0.8-0.18); LSMean difference = 0 (p = 0.9833, CI -0.49-0.48); LSMean difference = -0.3 (p = 0.2034, CI -0.81-0.17); LSMean difference = 0 (p = 0.9576, CI -0.7-0.67); LSMean difference = -0.7 (p = 0.041, CI -1.4--0.03); LSMean difference = -0.3 (p = 0.3961, CI -1-0.4); LSMean difference = -0.2 (p = 0.5012, CI -0.94-0.46); LSMean difference = -0.4 (p = 0.2592, CI -1.1-0.3); LSMean difference = 0.2 (p = 0.6141, CI -0.51-0.86); LSMean difference = -0.2 (p = 0.3663, CI -0.71-0.26); LSMean difference = -0.5 (p = 0.0424, CI -0.99--0.02); LSMean difference = -0.4 (p = 0.1597, CI -0.85-0.14); LSMean difference = -0.5 (p = 0.0595, CI -0.97-0.02); LSMean difference = -0.3 (p = 0.439, CI -0.95-0.41); LSMean difference = -0.2 (p = 0.4521, CI -0.64-0.29); LSMean difference = -0.5 (p = 0.0257, CI -0.99--0.06); LSMean difference = -0.5 (p = 0.0564, CI -0.93-0.01); LSMean difference = -0.5 (p = 0.0293, CI -0.99--0.05); LSMean difference = -0.2 (p = 0.3742, CI -0.68-0.26); LSMean difference = 0 (p = 0.9106, CI -0.49-0.44); LSMean difference = -0.3 (p = 0.1844, CI -0.78-0.15); LSMean difference = -0.9 (p = 0.0287, CI -1.69--0.09); LSMean difference = -1.2 (p = 0.0028, CI -2.05--0.43); LSMean difference = -1.5 (p = 4e-04, CI -2.32--0.67); LSMean difference = -2 (p = 1e-04, CI -2.87--1.22); LSMean difference = -0.6 (p = 0.1826, CI -1.38-0.26); LSMean difference = -1 (p = 0.0178, CI -1.79--0.17); LSMean differnce = -1.2 (p = 0.0025, CI -2.06--0.44); LSMean difference = -0.2 (p = 0.5401, CI -0.72-0.38); LSMean difference = 0.2 (p = 0.3788, CI -0.3-0.79); 0.28 = 0.2 (p = 0.4541, CI -0.33-0.74); LSMean difference = 0 (p = 0.9233, CI -0.51-0.56); LSMean difference = -0.1 (p = 0.6043, CI -0.61-0.35); LSMean difference = -0.3 (p = 0.1781, CI -0.82-0.15); LSMean difference = -0.6 (p = 0.1212, CI -1.38-0.16); LSMean difference = -0.1 (p = 0.7709, CI -0.89-0.66); LSMean difference = -0.5 (p = 0.1667, CI -1.33-0.23); LSMean difference = 0 (p = 0.9213, CI -0.72-0.79); LSMean difference = -0.5 (p = 0.2315, CI -1.21-0.29); LSMean difference = -0.2 (p = 0.4731, CI -0.63-0.29); LSMean difference = 0 (p = 0.9163, CI -0.55-0.5); LSMean difference = -0.4 (p = 0.1597, CI -0.92-0.15); LSMean difference = -0.2 (p = 0.4871, CI -0.74-0.35); LSMean difference = -0.2 (p = 0.5221, CI -0.66-0.34); LSMean difference = -0.2 (p = 0.4744, CI -0.68-0.32); LSMean difference = -0.2 (p = 0.5167, CI -0.66-0.33); LSMean difference = 0.2 (p = 0.3441, CI -0.25-0.72); LSMean difference = -0.2 (p = 0.5362, CI -0.64-0.33); LSMean difference = 0 (p = 0.9349, CI -0.78-0.71); LSMean differencce = -1 (p = 0.0084, CI -1.78--0.26); LSMean difference = 0.4 (p = 0.3965, CI -0.56-1.4); LSMean difference = 0.1 (p = 0.8189, CI -0.87-1.1); LSMean difference = -0.3 (p = 0.5693, CI -1.27-0.7); LSMean difference = -0.3 (p = 0.5217, CI -1.29-0.65); LSMean difference = 0.5 (p = 0.2988, CI -0.46-1.48); LSMean difference = -0.1 (p = 0.7957, CI -0.69-0.53); LSMean difference = -0.4 (p = 0.254, CI -0.97-0.26); LSMean difference = -0.1 (p = 0.6956, CI -0.75-0.5); LSMean difference = 0.1 (p = 0.8694, CI -0.57-0.68); LSMean difference = -0.2 (p = 0.5047, CI -0.84-0.41); LSMean difference = -0.5 (p = 0.031, CI -0.98--0.05); LSMean difference = -0.4 (p = 0.132, CI -0.84-0.11); LSMean difference = -0.4 (p = 0.1212, CI -0.85-0.1); LSMean difference = -0.1 (p = 0.5689, CI -0.62-0.34); 0.1 = 0.1 (p = 0.734, CI -0.39-0.55); LSMean difference = -0.3 (p = 0.2704, CI -0.73-0.2); LSMean difference = -0.3 (p = 0.561, CI -1.24-0.67); LSMean difference = 0.1 (p = 0.7966, CI -0.83-1.09); LSMean difference = 0.1 (p = 0.7515, CI -0.52-0.71); LSMean difference = -0.1 (p = 0.7818, CI -0.7-0.53); LSMean difference = -0.1 (p = 0.577, CI -0.65-0.36); LSMean difference = -0.3 (p = 0.1893, CI -0.85-0.17); LSMean difference = 0.3 (p = 0.2997, CI -0.25-0.79); LSMean difference = -0.1 (p = 0.7529, CI -0.6-0.44); LSMean difference = -0.2 (p = 0.4173, CI -0.73-0.31); LSMean difference = 0.2 (p = 0.4944, CI -0.34-0.69); LSMean differencce = 0 (p = 0.9231, CI -0.54-0.49); LSMean differencce = -0.3 (p = 0.5112, CI -1.04-0.52); LSMean difference = -0.9 (p = 0.03, CI -1.66--0.09); LSMean difference = -0.8 (p = 0.0634, CI -1.57-0.04); LSMean difference = 0 (p = 0.9406, CI -0.78-0.84); LSMean difference = -0.6 (p = 0.1168, CI -1.46-0.16); LSMean difference = 0 (p = 0.9937, CI -0.79-0.8); LSMean difference = -0.5 (p = 0.1858, CI -1.32-0.26); LSMean difference = -0.1 (p = 0.5765, CI -0.65-0.36); LSMean difference = -0.3 (p = 0.1848, CI -0.86-0.17); LSMean difference = 0.1 (p = 0.7299, CI -0.43-0.61); LSMean difference = 0 (p = 0.9415, CI -0.54-0.5); LSMean difference = -0.3 (p = 0.2742, CI -0.82-0.23); LSMean difference = 0.1 (p = 0.6946, CI -0.41-0.62); LSMean difference = 0 (p = 0.9442, CI -0.53-0.5). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The hot flash score per 24h (or 12 h day time or 12 h night time) of VMS (mild, moderate, and severe) is calculated as follows:

(number of mild VMS x 1) + (number of moderate VMS x 2) + (number of severe VMS x 3).

Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing.

Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Higher score indicates greater severity.. Parameters: LSMean difference = -4.8 (p = 0.0142, CI -8.62--0.97); LSMean difference = -7.9 (p = 1e-04, CI -11.73--4.05); LSMean difference = -9.1 (p = 1e-04, CI -12.98--5.31); LSMean difference = -10.5 (p = 1e-04, CI -14.39--6.61); LSMean difference = -5.5 (p = 0.0075, CI -9.46--1.47); LSMean difference = -8.4 (p = 1e-04, CI -12.44--4.42); LSMean difference = -8.2 (p = 1e-04, CI -12.15--4.16); LSMean difference = -10.2 (p = 1e-04, CI -14.3--6.16); LSMean difference = -6.4 (p = 0.0021, CI -10.46--2.34); LSMean difference = -8.3 (p = 1e-04, CI -12.25--4.25); LSMean difference = -7.6 (p = 2e-04, CI -11.58--3.62); LSMean difference = -4.8 (p = 0.0123, CI -8.6--1.05); LSMean difference = -7.8 (p = 1e-04, CI -11.63--4.07); LSMean difference = -8 (p = 1e-04, CI -11.8--4.23); LSMean difference = -9.9 (p = 1e-04, CI -13.73--6.03); LSMean difference = -6.3 (p = 0.0013, CI -10.13--2.47); LSMean difference = -7.2 (p = 2e-04, CI -10.97--3.41); LSMean difference = -6.7 (p = 6e-04, CI -10.41--2.89); LSMean difference = -4.8 (p = 0.0119, CI -8.54--1.07); LSMean difference = -6.8 (p = 4e-04, CI -10.58--3.09); LSMean difference = -7.8 (p = 1e-04, CI -11.57--4.06); LSMean difference = -9.1 (p = 1e-04, CI -12.89--5.27); LSMean difference = -5.4 (p = 0.0057, CI -9.18--1.58); LSMean difference = -6.7 (p = 6e-04, CI -10.4--2.9); LSMean difference = -6.5 (p = 6e-04, CI -10.27--2.81); LSMean difference = -4.5 (p = 0.021, CI -8.27--0.68); LSMean difference = -7.2 (p = 2e-04, CI -10.98--3.38); LSMean difference = -7.3 (p = 2e-04, CI -11.12--3.49); LSMean difference = -9.1 (p = 1e-04, CI -12.99--5.25); LSMean difference = -5.6 (p = 0.0047, CI -9.45--1.73); LSMean difference = -6 (p = 0.0017, CI -9.77--2.29); LSMean difference = -4.7 (p = 0.0119, CI -8.37--1.05); LSMean difference = -6 (p = 0.0015, CI -9.61--2.29); LSMean difference = -7.7 (p = 1e-04, CI -11.38--3.99); LSMean difference = -7.6 (p = 1e-04, CI -11.33--3.87); LSMean difference = -5.3 (p = 0.0051, CI -9.07--1.62); LSMean difference = -6.6 (p = 4e-04, CI -10.33--2.96); LSMean difference = -6 (p = 0.0014, CI -9.64--2.34); LSMean difference = -5.1 (p = 0.0054, CI -8.67--1.51); LSMean difference = -6.1 (p = 8e-04, CI -9.71--2.55); LSMean difference = -7.6 (p = 1e-04, CI -11.2--3.97); LSMean difference = -8.2 (p = 1e-04, CI -11.88--4.59); LSMean difference = -5.6 (p = 0.0026, CI -9.27--1.99); LSMean difference = -6.8 (p = 3e-04, CI -10.35--3.16); LSMean difference = -6.3 (p = 6e-04, CI -9.88--2.75); LSMean difference = -5.3 (p = 0.0126, CI -9.48--1.15); LSMean difference = -2.9 (p = 0.1724, CI -7.06-1.27); LSMean difference = -2 (p = 0.3548, CI -6.31-2.27); LSMean difference = -3.8 (p = 0.086, CI -8.04-0.53); LSMean difference = -5.6 (p = 0.0111, CI -9.89--1.28); LSMean difference = -4.6 (p = 0.0349, CI -8.94--0.33); LSMean difference = -2.6 (p = 0.2205, CI -6.77-1.57); LSMean differencce = -4 (p = 0.0645, CI -8.29-0.24); LSMean difference = -1.4 (p = 0.5031, CI -5.69-2.8); LSMean difference = -1.4 (p = 0.5263, CI -5.84-2.99); LSMean differencce = -2.4 (p = 0.2782, CI -6.83-1.97); LSMean difference = -5.3 (p = 0.0198, CI -9.67--0.84); LSMean difference = -4.6 (p = 0.0417, CI -9.05--0.18); LSMean difference = -2.3 (p = 0.2963, CI -6.52-2); LSMean difference = -1.3 (p = 0.5408, CI -5.39-2.83); LSMean difference = -0.7 (p = 0.7473, CI -4.74-3.41); LSMean difference = 0.2 (p = 0.9214, CI -4.07-4.5); LSMean difference = 0 (p = 0.9876, CI -4.19-4.26); LSMean difference = -2.6 (p = 0.2379, CI -6.86-1.71); LSMean difference = -3.2 (p = 0.1491, CI -7.45-1.14); LSMean difference = 0.1 (p = 0.956, CI -3.96-4.19); LSMean difference = -3.5 (p = 0.0819, CI -7.36-0.44); LSMean difference = -6.9 (p = 4e-04, CI -10.78--3.09); LSMean difference = -6.9 (p = 5e-04, CI -10.69--3.05); LSMean difference = -4.1 (p = 0.038, CI -8.01--0.23); LSMean difference = -7.6 (p = 2e-04, CI -11.46--3.64); LSMean differencce = -8.1 (p = 1e-04, CI -11.96--4.17); LSMean difference = -9.2 (p = 1e-04, CI -13.17--5.25); LSMean difference = -4.6 (p = 0.0245, CI -8.52--0.59); LSMean difference = -5.9 (p = 0.0031, CI -9.83--2.01); LSMean difference = -5.6 (p = 0.0046, CI -9.53--1.75); LSMean difference = -5.6 (p = 0.0064, CI -9.61--1.59); LSMean difference = -8.7 (p = 1e-04, CI -12.72--4.65); LSMean difference = -8.8 (p = 1e-04, CI -12.78--4.75); LSMean difference = -10.2 (p = 1e-04, CI -14.27--6.09); LSMean difference = -6.4 (p = 0.0021, CI -10.54--2.36); LSMean difference = -7.7 (p = 2e-04, CI -11.71--3.66); LSMean difference = -7 (p = 7e-04, CI -10.96--2.95); LSMean difference = -6.5 (p = 9e-04, CI -10.29--2.67); LSMean difference = -6.5 (p = 8e-04, CI -10.28--2.71); LSMean difference = -3.3 (p = 0.0889, CI -7.1-0.51); LSMean difference = -5.9 (p = 0.0023, CI -9.76--2.13); LSMean difference = -6.5 (p = 9e-04, CI -10.36--2.71); LSMean difference = -7.5 (p = 2e-04, CI -11.36--3.58); LSMean difference = -4.4 (p = 0.0255, CI -8.3--0.55); LSMean difference = -5.8 (p = 0.0031, CI -9.63--1.98); LSMean difference = -5.7 (p = 0.0037, CI -9.45--1.85); LSMean difference = -4 (p = 0.0316, CI -7.59--0.35); LSMean difference = -5.4 (p = 0.0036, CI -9.02--1.78); LSMean difference = -6.6 (p = 4e-04, CI -10.23--2.94); LSMean difference = -7.2 (p = 1e-04, CI -10.93--3.54); LSMean difference = -3.7 (p = 0.0502, CI -7.37-0); LSMean difference = -5.6 (p = 0.0025, CI -9.28--1.99); LSMean difference = -5.1 (p = 0.0063, CI -8.67--1.44); LSMean difference = -4.8 (p = 0.0117, CI -8.58--1.08); LSMean difference = -5.4 (p = 0.0047, CI -9.17--1.67); LSMean difference = -7 (p = 3e-04, CI -10.8--3.23); LSMean difference = -7.7 (p = 1e-04, CI -11.51--3.86); LSMean difference = -5.2 (p = 0.0083, CI -8.97--1.34); LSMean difference = -6.3 (p = 0.0011, CI -10.1--2.56). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The hot flash score per 24h of moderate and severe VMS is calculated as follows:

(number of moderate VMS x 2) + (number of severe VMS x 3).

Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). VMS. Baseline is the average frequency of 24h vasomotor symptom from 7 non-missing days prior to Day 1. Higher score indicates greater severity.. Parameters: LSMean difference = -5.2 (p = 0.0089, CI -9.01--1.3); LSMean difference = -8.4 (p = 1e-04, CI -12.22--4.48); LSMean difference = -9.2 (p = 1e-04, CI -13.06--5.34); LSMean difference = -10.7 (p = 1e-04, CI -14.58--6.75); LSMean difference = -3.7 (p = 0.063, CI -7.65-0.2); LSMean difference = -7.2 (p = 3e-04, CI -11.04--3.3); LSMean difference = -6.7 (p = 7e-04, CI -10.53--2.84); LSMean difference = -4.5 (p = 0.0231, CI -8.43--0.63); LSMean difference = -8 (p = 1e-04, CI -11.94--4.09); LSMean differencce = -8 (p = 1e-04, CI -11.87--4.05); LSMean difference = -9.2 (p = 1e-04, CI -13.21--5.26); LSMean difference = -4.8 (p = 0.0177, CI -8.8--0.84); LSMean difference = -6.5 (p = 0.0012, CI -10.45--2.6); LSMean difference = -6.6 (p = 0.0072, CI -9.26--2.64); LSMean difference = -5.9 (p = 0.0044, CI -9.86--1.84); LSMean difference = -9.2 (p = 1e-04, CI -13.27--5.21); LSMean difference = -8.6 (p = 1e-04, CI -12.57--4.55); LSMean difference = -10.2 (p = 1e-04, CI -14.29--6.11); LSMean difference = -7 (p = 9e-04, CI -11.04--2.87); LSMean difference = -8.4 (p = 1e-04, CI -12.44--4.39); LSMean difference = -6.6 (p = 0.0012, CI -10.65--2.64); LSMean difference = -5.7 (p = 0.0053, CI -9.72--1.71); LSMean difference = -8.8 (p = 1e-04, CI -12.77--4.73); LSMean difference = -7.8 (p = 1e-04, CI -11.84--3.84); LSMean difference = -10 (p = 1e-04, CI -14.12--5.96); LSMean difference = -6.9 (p = 0.001, CI -10.92--2.78); LSMean difference = -8.5 (p = 1e-04, CI -12.49--4.46); LSMean difference = -7.1 (p = 5e-04, CI -11.12--3.13); LSMean difference = -5.4 (p = 0.0057, CI -9.15--1.58); LSMean difference = -8.4 (p = 1e-04, CI -12.15--4.56); LSMean difference = -7.9 (p = 1e-04, CI -11.68--4.08); LSMean difference = -9.8 (p = 1e-04, CI -13.66--5.93); LSMean difference = -6.7 (p = 7e-04, CI -10.54--2.85); LSMean difference = -7.7 (p = 1e-04, CI -11.55--3.95); LSMean difference = -6.4 (p = 0.001, CI -10.16--2.6); LSMean difference = -5.2 (p = 0.0064, CI -8.99--1.48); LSMean difference = -7.2 (p = 2e-04, CI -10.94--3.42); LSMean difference = -7.5 (p = 1e-04, CI -11.29--3.75); LSMean difference = -8.9 (p = 1e-04, CI -12.69--5.03); LSMean difference = -5.8 (p = 0.003, CI -9.62--1.99); LSMean difference = -7.1 (p = 2e-04, CI -10.92--3.37); LSMean difference = -6.2 (p = 0.0013, CI -9.91--2.42); LSMean difference = -4.8 (p = 0.0137, CI -8.61--0.99); LSMean difference = -7.4 (p = 2e-04, CI -11.24--3.6); LSMean difference = -7 (p = 4e-04, CI -10.79--3.13); LSMean difference = -8.9 (p = 1e-04, CI -12.74--4.97); LSMean difference = -5.9 (p = 0.0028, CI -9.82--2.07); LSMean difference = -6.8 (p = 6e-04, CI -10.6--2.94); LSMean difference = -6 (p = 0.002, CI -9.82--2.21); LSMean difference = -3.7 (p = 0.0588, CI -7.46-0.14); LSMean difference = -3.7 (p = 0.0018, CI -9.9-0.14); LSMean difference = -6.2 (p = 0.0017, CI -9.98--2.34); LSMean difference = -7.2 (p = 3e-04, CI -11.09--3.32); LSMean difference = -4.7 (p = 0.081, CI -8.55--0.81); LSMean difference = -6.1 (p = 0.002, CI -9.88--2.23); LSMean difference = -5.2 (p = 0.0076, CI -8.98--1.39); LSMean difference = -4.4 (p = 0.0182, CI -8.01--0.75); LSMean difference = -5.8 (p = 0.0019, CI -9.42--2.16); LSMean difference = -6.4 (p = 7e-04, CI -10.02--2.71); LSMean difference = -7.1 (p = 2e-04, CI -10.76--3.35); LSMean difference = -4.2 (p = 0.0263, CI -7.89--0.5); LSMean difference = -6 (p = 0.0015, CI -9.61--2.29); LSMean difference = -4.7 (p = 0.0113, CI -8.32--1.07); LSMean difference = -5.3 (p = 0.0059, CI -9.04--1.54); LSMean difference = -6 (p = 0.0018, CI -9.76--2.25); LSMean difference = -6.8 (p = 4e-04, CI -10.62--3.05); LSMean difference = -7.6 (p = 1e-04, CI -11.39--3.73); LSMean difference = -5.6 (p = 0.0044, CI -9.4--1.75); LSMean difference = -6.6 (p = 6e-04, CI -10.4--2.84); LSMean difference = -5.8 (p = 0.0025, CI -9.57--2.07); LSMean difference = -5.2 (p = 0.0059, CI -8.81--1.49); LSMean difference = -6.4 (p = 7e-04, CI -10.06--2.74); LSMean difference = -7.5 (p = 1e-04, CI -11.18--3.79); LSMean difference = -7.5 (p = 1e-04, CI -11.18--3.72); LSMean difference = -5.8 (p = 0.0022, CI -9.56--2.11); LSMean difference = -6.9 (p = 3e-04, CI -10.56--3.19); LSMean difference = -5.8 (p = 0.002, CI -9.44--2.13); LSMean difference = -5.6 (p = 0.0023, CI -9.18--2.01); LSMean difference = -6.5 (p = 4e-04, CI -10.06--2.89); LSMean difference = -7.4 (p = 1e-04, CI -11.05--3.81); LSMean difference = -8.1 (p = 1e-04, CI -11.8--4.49); LSMean difference = -6.1 (p = 0.0011, CI -9.77--2.47); LSMean difference = -6.9 (p = 2e-04, CI -10.54--3.32); LSMean difference = -6.1 (p = 8e-04, CI -9.71--2.56); LSMean difference = -6 (p = 0.0054, CI -10.26--1.8); LSMean difference = -3.4 (p = 0.1145, CI -7.63-0.83); LSMean difference = -2.8 (p = 0.2106, CI -7.13-1.58); LSMean difference = -4 (p = 0.0685, CI -8.39-0.31); LSMean difference = -6.7 (p = 0.0029, CI -11.02--2.29); LSMean difference = -5 (p = 0.0239, CI -9.42--0.67); LSMean difference = -2.6 (p = 0.2224, CI -6.86-1.6); LSMean differencce = -4.8 (p = 0.0308, CI -9.17--0.45); LSMean difference = -1.8 (p = 0.4194, CI -6.13-2.56); LSMean difference = -2 (p = 0.3759, CI -6.55-2.48); LSMean differencce = -2.8 (p = 0.2285, CI -7.26-1.74); LSMean difference = -6.2 (p = 0.0072, CI -10.71--1.7); LSMean difference = -4.9 (p = 0.0338, CI -9.46--0.38); LSMean difference = -2.3 (p = 0.3026, CI -6.64-2.07); LSMean difference = -2.2 (p = 0.312, CI -6.45-2.07); LSMean difference = -0.9 (p = 0.6816, CI -5.11-3.34); LSMean difference = -0.4 (p = 0.8599, CI -4.85-4.05); LSMean difference = -0.3 (p = 0.9093, CI -4.64-4.13); LSMean difference = -4 (p = 0.0788, CI -8.43-0.46); LSMean difference = -3.5 (p = 0.1278, CI -7.92-1); LSMean difference = 0 (p = 0.9848, CI -4.19-4.27). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = -2.7 (p = 0.0014, CI -4.3--1.04); LSMean differencce = -3.2 (p = 1e-04, CI -4.82--1.58); LSMean difference = -3.6 (p = 1e-04, CI -5.3--2); LSMean difference = -1.5 (p = 0.0752, CI -3.15-0.15); LSMean difference = -1.8 (p = 0.0343, CI -3.38--0.13); LSMean difference = -2.3 (p = 0.0049, CI -3.95--0.71); LSMean difference = -1.8 (p = 0.0285, CI -3.5--0.2); LSMean difference = -3 (p = 4e-04, CI -4.69--1.37); LSMean difference = -3.5 (p = 1e-04, CI -5.14--1.84); LSMean difference = -4 (p = 1e-04, CI -5.65--2.28); LSMean difference = -2.1 (p = 0.0169, CI -3.74--0.37); LSMean difference = -2.4 (p = 0.0049, CI -4.04--0.73); LSMean difference = -2.8 (p = 8e-04, CI -4.48--1.18); LSMean difference = -1.7 (p = 0.0428, CI -3.36--0.06); LSMean difference = -3 (p = 4e-04, CI -4.65--1.34); LSMean difference = -3.2 (p = 1e-05, CI -4.88--1.58); LSMean difference = -3.9 (p = 1e-04, CI -5.44--2.28); LSMean difference = -2 (p = 0.0134, CI -3.58--0.42); LSMean difference = -2.2 (p = 0.0057, CI -3.76--0.65); LSMean difference = -2.5 (p = 0.0016, CI -4.06--0.96); LSMean difference = -1.4 (p = 0.0843, CI -2.94-0.19); LSMean difference = -2.3 (p = 0.0035, CI -3.9--0.77); LSMean difference = -3.1 (p = 1e-04, CI -4.66--1.52); LSMean difference = -3.7 (p = 1e-04, CI -5.28--2.1); LSMean difference = -1.7 (p = 0.0315, CI -3.33--0.16); LSMean difference = -2.2 (p = 0.0063, CI -3.75--0.62); LSMean difference = -2.7 (p = 7e-04, CI -4.25--1.14); LSMean difference = -1.3 (p = 0.109, CI -2.89-0.29); LSMean difference = -2.5 (p = 0.0018, CI -4.14--0.95); LSMean difference = -2.9 (p = 4e-04, CI -4.54--1.34); LSMean difference = -3.8 (p = 1e-04, CI -5.4--2.15); LSMean difference = -1.9 (p = 0.0231, CI -3.5--0.26); LSMean difference = -2.3 (p = 0.0056, CI -3.86--0.67); LSMean difference = -2.8 (p = 7e-04, CI -4.35--1.17); LSMean difference = -0.8 (p = 0.3568, CI -2.35-0.85); LSMean difference = -2 (p = 0.0129, CI -3.65--0.43); LSMean difference = -2.6 (p = 0.0018, CI -4.19--0.97); LSMean difference = -3.1 (p = 3e-04, CI -4.7--1.42); LSMean difference = -1.4 (p = 0.1004, CI -3-0.27); LSMean difference = -2.7 (p = 9e-04, CI -4.3--1.12); LSMean difference = -3.1 (p = 2e-04, CI -4.68--1.46); LSMean difference = -1.6 (p = 0.0456, CI -3.25--0.03); LSMean difference = -2.2 (p = 0.0073, CI -3.76--0.59); LSMean difference = -2.4 (p = 0.0026, CI -4.01--0.86); LSMean difference = -1.3 (p = 0.0878, CI -2.87-0.2); LSMean difference = -1.9 (p = 0.0182, CI -3.39--0.32); LSMean difference = -3 (p = 2e-04, CI -4.55--1.44); LSMean difference = -3 (p = 2e-04, CI -4.53--1.4); LSMean difference = -1.7 (p = 0.0387, CI -3.22--0.09); LSMean difference = -2.3 (p = 0.0031, CI -3.89--0.8); LSMean difference = -2.3 (p = 0.0029, CI -3.88--0.81); LSMean difference = -1.4 (p = 0.0653, CI -2.9-0.09); LSMean difference = -2 (p = 0.0102, CI -3.46--0.47); LSMean difference = -2.9 (p = 2e-04, CI -4.38--1.36); LSMean difference = -3.2 (p = 1e-04, CI -4.72--1.67); LSMean difference = -1.8 (p = 0.0231, CI -3.3--0.25); LSMean difference = 0.2 (p = 0.8248, CI -1.4-1.75); LSMean difference = 0.7 (p = 0.4226, CI -0.98-2.33); LSMean difference = 0.4 (p = 0.6469, CI -1.25-2.01); LSMean difference = 0.3 (p = 0.7642, CI -1.41-1.91); LSMean difference = -0.7 (p = 0.4068, CI -2.36-0.966); LSMean difference = 0.2 (p = 0.7974, CI -1.37-1.78); LSMean difference = -1.4 (p = 0.0865, CI -2.92-0.2); LSMean difference = -2.7 (p = 9e-04, CI -4.22--1.1); LSMean difference = -3.5 (p = 1e-05, CI -5.06--1.94); LSMean difference = -4 (p = 1e-05, CI -5.63--2.47); LSMean difference = -1 (p = 0.236, CI -2.55-0.63); LSMean difference = -2.4 (p = 0.0032, CI -3.92--0.8); LSMean difference = -2.7 (p = 6e-04, CI -4.29--1.19); LSMean difference = -1.2 (p = 0.1318, CI -2.86-0.38); LSMean difference = -4.1 (p = 1e-04, CI -5.73--2.37); LSMean difference = -2 (p = 0.0225, CI -3.64--0.28); LSMean difference = -2.8 (p = 8e-04, CI -4.49--1.19); LSMean difference = -3.1 (p = 3e-04, CI -4.7--1.42); LSMean difference = -1.2 (p = 0.1168, CI -2.8-0.31); LSMean difference = -2.6 (p = 0.0012, CI -4.15--1.03); LSMean difference = -3 (p = 2e-04, CI -4.54--1.42); LSMean difference = -2 (p = 0.0173, CI -3.57--0.35); LSMean difference = -2.4 (p = 0.0038, CI -3.97--0.77); LSMean difference = -1 (p = 0.1767, CI -2.57-0.48); LSMean difference = -1.7 (p = 0.0308, CI -3.2--0.16); LSMean difference = -2.5 (p = 0.0013, CI -4.07--1); LSMean difference = -2.9 (p = 3e-04, CI -4.47--1.36); LSMean difference = -1 (p = 0.2109, CI -2.55-0.56); LSMean difference = -1.9 (p = 0.0152, CI -3.44--0.37); LSMean difference = -2.1 (p = 0.0075, CI -3.61--0.56); LSMean difference = -1.4 (p = 0.0869, CI -2.96-0.2); LSMean difference = -1.6 (p = 0.052, CI -3.14-0.01); LSMean difference = -2.4 (p = 0.0021, CI -3.88--0.87); LSMean difference = -2.4 (p = 0.0021, CI -3.88--0.87); LSMean difference = -2.5 (p = 0.0013, CI -3.96--0.97); LSMean difference = -1.2 (p = 0.146, CI -2.89-0.43); LSMean difference = -0.4 (p = 0.6066, CI -2.1-1.23); LSMean difference = -0.2 (p = 0.8422, CI -1.88-1.54); LSMean difference = -1 (p = 0.2346, CI -2.74-0.67); LSMean difference = -1.4 (p = 0.1128, CI -3.11-0.33); LSMean difference = -1.2 (p = 0.1811, CI -2.89-0.55); LSMean difference = -0.8 (p = 0.3521, CI -2.45-0.87); LSMean difference = -0.8 (p = 0.357, CI -2.44-0.88); LSMean differencce = -0.1 (p = 0.9227, CI -1.73-1.57); LSMean difference = -0.1 (p = 0.8894, CI -1.84-1.6); LSMean difference = -0.6 (p = 0.5074, CI -2.29-1.13); LSMean differencce = -1.2 (p = 0.1753, CI -2.91-0.53); LSMean difference = -1.4 (p = 0.1212, CI -3.09-0.36); LSMean difference = -0.8 (p = 0.3702, CI -2.41-0.9); LSMean difference = 0.4 (p = 0.6459, CI -1.22-1.96). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = -1.7 (p = 0.0297, CI -3.23--0.17); LSMean difference = -3.1 (p = 1e-04, CI -4.66--1.58); LSMean difference = -3.6 (p = 1e-05, CI -5.1--2.02); LSMean difference = -4.2 (p = 1e-04, CI -5.78--2.66); LSMean difference = -2.6 (p = 0.0021, CI -4.17--0.93); LSMean difference = -3.1 (p = 1e-04, CI -4.71--1.52); LSMean difference = -2.5 (p = 0.002, CI -4.11--0.93); LSMean difference = -1.8 (p = 0.021, CI -3.27--0.27); LSMean difference = -3.1 (p = 1e-04, CI -4.59--1.58); LSMean difference = -2.88 (p = 3e-04, CI -4.34--1.33); LSMean difference = -3.8 (p = 1e-04, CI -5.29--2.23); LSMean difference = -2.4 (p = 0.0023, CI -3.91--0.86); LSMean difference = -2.7 (p = 4e-04, CI -4.25--1.24); LSMean difference = -2.2 (p = 0.0036, CI -3.73--0.74); LSMean difference = -1.8 (p = 0.0195, CI -3.33--0.29); LSMean difference = -2.7 (p = 6e-04, CI -4.21--1.17); LSMean difference = -2.8 (p = 4e-04, CI -4.32--1.27); LSMean difference = -3.5 (p = 1e-04, CI -5.01--1.92); LSMean difference = -2.2 (p = 0.0061, CI -3.71--0.62); LSMean difference = -2.7 (p = 6e-04, CI -4.19--1.14); LSMean difference = -2.3 (p = 0.003, CI -3.81--0.78); LSMean difference = -1.6 (p = 0.0383, CI -3.17--0.09); LSMean difference = -2.8 (p = 4e-04, CI -4.33--1.24); LSMean difference = -2.6 (p = 0.0011, CI -4.14--1.04); LSMean difference = -3.5 (p = 1e-04, CI -5.07--1.93); LSMean difference = -2.2 (p = 0.0055, CI -3.8--0.66); LSMean difference = -2.5 (p = 0.0014, CI -4.09--0.99); LSMean difference = -2.3 (p = 0.004, CI -3.8--0.73); LSMean difference = -1.1 (p = 0.1502, CI -2.68-0.41); LSMean difference = -2.2 (p = 0.0057, CI -3.74--0.64); LSMean difference = -2.2 (p = 0.0054, CI -3.76--0.66); LSMean difference = -2.8 (p = 6e-04, CI -4.38--1.22); LSMean difference = -1.6 (p = 0.0412, CI -3.21--0.07); LSMean difference = -1.2 (p = 0.1318, CI -2.76-0.36); LSMean difference = -2.6 (p = 0.001, CI -4.13--1.05); LSMean difference = -2.6 (p = 0.0011, CI -4.1--1.04); LSMean difference = -1.6 (p = 0.0405, CI -3.2--0.07); LSMean difference = -3.1 (p = 1e-04, CI -4.7--1.55); LSMean differencce = -3.1 (p = 1e-04, CI -4.66--1.52); LSMean difference = -3.7 (p = 1e-04, CI -5.26--2.07); LSMean difference = -1.7 (p = 0.0325, CI -3.34--0.15); LSMean difference = -2.4 (p = 0.0035, CI -3.92--0.78); LSMean difference = -2.1 (p = 0.0102, CI -3.61--0.49); LSMean difference = -2.1 (p = 0.0098, CI -3.69--0.51); LSMean difference = -3.6 (p = 1e-04, CI -5.18--1.98); LSMean difference = -3.3 (p = 1e-04, CI -4.89--1.7); LSMean difference = -4 (p = 1e-04, CI -5.61--2.37); LSMean difference = -2.2 (p = 0.0054, CI -3.76--0.66); LSMean difference = -1.9 (p = 0.0167, CI -3.43--0.34); LSMean difference = -1.5 (p = 0.0533, CI -2.94-0.02); LSMean difference = -2.1 (p = 0.0065, CI -3.54--0.58); LSMean difference = -2.3 (p = 0.0025, CI -3.8--0.82); LSMean difference = -2.7 (p = 5e-04, CI -4.22--1.2); LSMean difference = -1.5 (p = 0.0541, CI -2.99-0.03); LSMean difference = -2.2 (p = 0.0039, CI -3.69--0.71); LSMean difference = -1.7 (p = 0.0245, CI -3.18--0.22); LSMean difference = -1.8 (p = 0.0187, CI -3.36--0.31); LSMean difference = -2.1 (p = 0.006, CI -3.68--0.62); LSMean difference = -2.5 (p = 0.0014, CI -4.06--0.98); LSMean difference = -2.9 (p = 3e-04, CI -4.49--1.37); LSMean difference = -2.1 (p = 0.01, CI -3.61--0.49); LSMean difference = -2.4 (p = 0.0019, CI -3.98--0.91); LSMean difference = -2.2 (p = 0.0049, CI -3.73--0.67); LSMean difference = -1.8 (p = 0.0186, CI -3.25--0.3); LSMean difference = -2.3 (p = 0.0024, CI -3.77--0.82); LSMean difference = -2.8 (p = 3e-04, CI -4.28--1.3); LSMean difference = -2.8 (p = 3e-04, CI -4.3--1.29); LSMean difference = -2.1 (p = 0.0058, CI -3.63--0.62); LSMean difference = -2.6 (p = 8e-04, CI -4.04--1.7); LSMean difference = -2.1 (p = 0.005, CI -3.59--0.64); LSMean difference = -2 (p = 0.0205, CI -3.63--0.31); LSMean difference = -0.9 (p = 0.2818, CI -2.58-0.75); LSMean difference = -0.9 (p = 0.3102, CI -2.6-0.83); LSMean difference = -1.3 (p = 0.1422, CI -2.99-0.43); LSMean difference = -2.4 (p = 0.0064, CI -4.12--0.68); LSMean difference = -1.6 (p = 0.0752, CI -3.28-0.16); LSMean difference = -0.8 (p = 0.3632, CI -2.43-0.89); LSMean differencce = -1.6 (p = 0.0625, CI -3.32-0.09); LSMean difference = -0.4 (p = 0.6613, CI -2.07-1.32); LSMean difference = -0.7 (p = 0.4209, CI -2.48-1.04); LSMean differencce = -0.9 (p = 0.3288, CI -2.63-0.88); LSMean difference = -2.1 (p = 0.0202, CI -3.86--0.33); LSMean difference = -1.6 (p = 0.0682, CI -3.42-0.12); LSMean difference = -0.7 (p = 0.3912, CI -2.44-0.96); LSMean difference = -0.6 (p = 0.4964, CI -2.25-1.09); LSMean difference = 0 (p = 0.983, CI -1.64-1.68); LSMean difference = 0 (p = 0.9715, CI -1.71-1.78); LSMean difference = 0.1 (p = 0.8715, CI -1.58-1.86); LSMean difference = -1.1 (p = 0.2233, CI -2.83-0.66); LSMean difference = -0.9 (p = 0.2882, CI -2.69-0.8); LSMean difference = 0.1 (p = 0.8643, CI -1.52-1.8). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: Severity of mild, moderate \& severe VMS per day was calculated as follows

\[(number of mild VMS  1) + (number of moderate VMS  2) + (number of severe VMS  3)\]/number of daily mild/moderate/severe VMS

Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot \& was sweating \& needed to take action Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.. Parameters: LSMean difference = -0.5 (p = 1e-04, CI -0.71--0.24); LSMean difference = -0.6 (p = 1e-04, CI -0.85--0.38); LSMean difference = 0 (p = 0.6977, CI -0.28-0.19); LSMean difference = -0.3 (p = 0.0121, CI -0.53--0.07); LSMean difference = -0.3 (p = 0.0086, CI -0.54--0.08); LSMean difference = -0.4 (p = 0.0138, CI -0.66--0.08); LSMean difference = -0.5 (p = 0.0014, CI -0.78--0.19); LSMean differencce = -0.7 (p = 1e-04, CI -1.02--0.43); LSMean difference = -0.9 (p = 1e-04, CI -1.19--0.59); LSMean difference = -0.2 (p = 0.2831, CI -0.46-0.14); LSMean difference = -0.4 (p = 0.0051, CI -0.72--0.13); LSMean difference = -0.5 (p = 6e-04, CI -0.81--0.22); LSMean difference = -0.5 (p = 0.0058, CI -0.83--0.14); LSMean difference = -0.6 (p = 4e-04, CI -0.97--0.28); LSMean difference = -0.8 (p = 1e-04, CI -1.14--0.46); LSMean difference = -0.9 (p = 1e-04, CI -1.27--0.57); LSMean difference = -0.3 (p = 0.0915, CI -0.69-0.05); LSMean difference = -0.4 (p = 0.0378, CI -0.75--0.02); LSMean difference = -0.5 (p = 0.0053, CI -0.89--0.16); LSMean difference = -0.5 (p = 0.0614, CI -0.83--0.08); LSMean difference = -0.5 (p = 0.004, CI -0.92--0.18); LSMean difference = -1 (p = 1e-04, CI -1.33--0.58); LSMean difference = -1.1 (p = 1e-04, CI -1.47--0.71); LSMean difference = -0.3 (p = 0.0967, CI -0.7-0.06); LSMean difference = -0.4 (p = 0.0315, CI -0.84--0.04); LSMean difference = -0.8 (p = 2e-04, CI -1.18--0.38); LSMean difference = -0.8 (p = 1e-04, CI -1.26--0.43); LSMean difference = -0.2 (p = 0.4494, CI -0.56-0.25); LSMean difference = -0.4 (p = 0.0595, CI -0.79-0.02); LSMean difference = -0.6 (p = 0.0065, CI -0.96--0.16); LSMean difference = -0.4 (p = 0.0745, CI -0.77-0.04); LSMean difference = -0.4 (p = 0.054, CI -0.8-0.01); LSMean difference = -0.8 (p = 1e-04, CI -1.22--0.41); LSMean difference = -0.8 (p = 1e-04, CI -1.26--0.43); LSMean difference = -0.1 (p = 0.5317, CI -0.54-0.28); LSMean difference = -0.4 (p = 0.0424, CI -0.83--0.01); LSMean difference = -0.5 (p = 0.0134, CI -0.91--0.11); LSMean difference = -0.4 (p = 0.03, CI -0.84--0.04); LSMean difference = -0.4 (p = 0.0605, CI -0.78-0.02); LSMean difference = -0.8 (p = 1e-04, CI -1.2--0.4); LSMean difference = -1 (p = 1e-04, CI -1.38--0.56); LSMean difference = -0.3 (p = 0.1848, CI -0.68-0.13); LSMean difference = -0.4 (p = 0.0321, CI -0.84--0.04); LSMean difference = -0.6 (p = 0.0025, CI -1.01--0.22); LSMean difference = -0.4 (p = 0.0441, CI -0.81--0.01); LSMean difference = -0.4 (p = 0.0422, CI -0.82--0.01); LSMean difference = -0.9 (p = 1e-04, CI -1.27--0.45); LSMean difference = -1 (p = 1e-04, CI -1.44--0.62); LSMean difference = -0.3 (p = 0.1464, CI -0.71-0.11); LSMean difference = -0.5 (p = 0.0144, CI -0.91--0.1); LSMean difference = -0.7 (p = 0.0013, CI -1.06--0.26); LSMean difference = -0.4 (p = 0.0596, CI -0.8-0.02); LSMean difference = -0.4 (p = 0.036, CI -0.85--0.03); LSMean difference = -0.7 (p = 6e-04, CI -1.15--0.32); LSMean difference = -0.8 (p = 2e-04, CI -1.23--0.39); LSMean difference = -0.2 (p = 0.3227, CI -0.62-0.21); LSMean difference = -0.5 (p = 0.022, CI -0.89--0.07); LSMean difference = -0.4 (p = 0.038, CI -0.84--0.02); LSMean difference = -0.3 (p = 0.0067, CI -0.6--0.1); LSMean difference = -0.2 (p = 0.1227, CI -0.45-0.05); LSMean difference = -0.3 (p = 0.0208, CI -0.57--0.05); LSMean difference = -0.2 (p = 0.2396, CI -0.41-0.1); LSMean difference = -0.4 (p = 0.0022, CI -0.67--0.15); LSMean difference = -0.3 (p = 0.0479, CI -0.53-0); LSMean difference = -0.1 (p = 0.4152, CI -0.35-0.15); LSMean differencce = -0.3 (p = 0.0262, CI -0.52--0.03); LSMean difference = -0.2 (p = 0.121, CI -0.43-0.05); LSMean difference = -0.3 (p = 0.0369, CI -0.52--0.02); LSMean differencce = -0.1 (p = 0.5855, CI -0.32-0.18); LSMean difference = -0.4 (p = 0.0041, CI -0.62--0.12); LSMean difference = -0.2 (p = 0.0614, CI -0.5-0.01); LSMean difference = -0.1 (p = 0.3391, CI -0.36-0.12); LSMean difference = -0.2 (p = 0.0515, CI -0.49-0); LSMean difference = -0.2 (p = 0.0667, CI -0.47-0.02); LSMean difference = -0.4 (p = 0.0047, CI -0.63--0.12); LSMean difference = -0.1 (p = 0.513, CI -0.34-0.17); LSMean difference = -0.5 (p = 2e-04, CI -0.75--0.23); LSMean difference = -0.3 (p = 0.0126, CI -0.6--0.07); LSMean difference = -0.1 (p = 0.3507, CI -0.36-0.13); LSMean difference = -0.3 (p = 0.0104, CI -0.53--0.07); LSMean difference = -0.3 (p = 0.006, CI -0.56--0.09); LSMean difference = -0.3 (p = 0.0807, CI -0.66-0.04); LSMean difference = -0.6 (p = 0.0014, CI -0.91--0.22); LSMean difference = -0.7 (p = 1e-04, CI -1.02--0.34); LSMean difference = -0.5 (p = 0.0046, CI -0.85--0.16); LSMean difference = -0.6 (p = 3e-04, CI -0.99--0.29); LSMean difference = -0.8 (p = 1e-04, CI -1.14--0.45); LSMean difference = -1.1 (p = 1e-04, CI -1.14--0.7); LSMean difference = -0.4 (p = 0.0209, CI -0.77--0.06); LSMean difference = -0.6 (p = 0.0011, CI -0.93--0.24); LSMean difference = -0.7 (p = 1e-04, CI -1.07--0.38); LSMean difference = -0.3 (p = 0.0956, CI -0.67-0.05); LSMean difference = -0.5 (p = 0.005, CI -0.89--0.16); LSMean difference = -0.8 (p = 1e-04, CI -1.18--0.45); LSMean difference = -1 (p = 1e-04, CI -1.4--0.65); LSMean difference = -0.5 (p = 0.0063, CI -0.9--0.15); LSMean difference = -0.8 (p = 1e-04, CI -1.13--0.38); LSMean difference = -0.4 (p = 0.0632, CI -0.75-0.02); LSMean difference = -0.6 (p = 0.002, CI -1--0.23); LSMean difference = -0.9 (p = 1e-04, CI -1.29--0.51); LSMean difference = -1.1 (p = 1e-04, CI -1.48--0.69); LSMean difference = -0.4 (p = 0.0308, CI -0.82--0.04); LSMean difference = -0.5 (p = 0.0105, CI -0.89--0.12); LSMean difference = -0.6 (p = 0.001, CI -1.03--0.26); LSMean difference = -0.3 (p = 0.1469, CI -0.69-0.11). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15. Description: Severity of moderate to severe VMS per day was calculated as follows:

\[(number of moderate VMS  2) + (number of severe VMS  3)\]/number of daily moderate/severe VMS.

Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for patients that had no moderate or severe VMS. Higher score indicates greater severity.. Parameters: LSMean difference = -0.3 (p = 0.0098, CI -0.6--0.08); LSMean difference = -0.4 (p = 0.0048, CI -0.63--0.11); LSMean difference = -0.5 (p = 1e-04, CI -0.8--0.28); LSMean difference = -0.7 (p = 1e-04, CI -1--0.47); LSMean difference = -0.1 (p = 0.6761, CI -0.32-0.21); LSMean difference = -0.3 (p = 0.0188, CI -0.57--0.05); LSMean difference = -0.4 (p = 0.0067, CI -0.61--0.1); LSMean difference = -0.4 (p = 0.0335, CI -0.68--0.03); LSMean difference = -0.6 (p = 7e-04, CI -0.91--0.25); LSMean differencce = -0.8 (p = 1e-04, CI -1.14--0.48); LSMean difference = -1.1 (p = 1e-04, CI -1.41--0.74); LSMean difference = -0.2 (p = 0.3227, CI -0.5-0.17); LSMean difference = -0.4 (p = 0.0085, CI -0.77--0.11); LSMean difference = -0.6 (p = 2e-04, CI -0.95--0.3); LSMean difference = -0.5 (p = 0.0102, CI -0.87--0.12); LSMean difference = -0.8 (p = 1e-04, CI -1.15--0.39); LSMean difference = -0.9 (p = 1e-04, CI -1.29--0.54); LSMean difference = -1.1 (p = 1e-04, CI -1.46--0.68); LSMean difference = -0.4 (p = 0.074, CI -0.73-0.03); LSMean difference = -0.6 (p = 0.0024, CI -0.97--0.21); LSMean difference = -0.8 (p = 1e-04, CI -1.17--0.41); LSMean difference = -0.3 (p = 0.1197, CI -0.72-0.08); LSMean difference = -0.6 (p = 0.0046, CI -0.98--0.18); LSMean difference = -0.9 (p = 1e-04, CI -1.28--0.47); LSMean difference = -1.1 (p = 1e-04, CI -1.51--0.69); LSMean difference = -0.4 (p = 0.0553, CI -0.8-0.01); LSMean difference = -0.4 (p = 0.0823, CI -0.76-0.05); LSMean difference = -0.6 (p = 0.006, CI -0.96--0.16); LSMean difference = -0.4 (p = 0.0374, CI -0.83--0.03); LSMean difference = -0.6 (p = 0.0042, CI -1--0.19); LSMean difference = -1 (p = 1e-04, CI -1.38--0.56); LSMean difference = -1.1 (p = 1e-04, CI -1.54--0.71); LSMean difference = -0.5 (p = 0.0371, CI -0.88--0.03); LSMean difference = -0.5 (p = 0.0121, CI -0.97--0.12); LSMean difference = -0.5 (p = 0.0281, CI -0.89--0.05); LSMean difference = -0.4 (p = 0.0436, CI -0.86--0.01); LSMean difference = -0.9 (p = 1e-04, CI -1.34--0.49); LSMean difference = -1 (p = 1e-04, CI -1.47--0.6); LSMean difference = -0.3 (p = 0.1488, CI -0.75-0.11); LSMean difference = -0.5 (p = 0.0251, CI -0.91--0.06); LSMean difference = -0.7 (p = 0.0027, CI -1.08--0.23); LSMean difference = -0.3 (p = 0.1053, CI -0.77-0.07); LSMean difference = -0.1 (p = 0.4291, CI -0.49-0.21); LSMean difference = -0.5 (p = 0.0076, CI -0.83--0.13); LSMean difference = -0.3 (p = 0.1506, CI -0.62-0.1); LSMean difference = -0.1 (p = 0.5479, CI -0.44-0.24); LSMean differencce = -0.2 (p = 0.1427, CI -0.57-0.08); LSMean difference = -0.2 (p = 0.1498, CI -0.56-0.09); LSMean difference = -0.4 (p = 0.0103, CI -0.79--0.11); LSMean differencce = 0 (p = 0.8984, CI -0.36-0.32); LSMean difference = -0.4 (p = 0.0095, CI -0.79--0.11); LSMean difference = -0.3 (p = 0.137, CI -0.6-0.08); LSMean difference = -0.1 (p = 0.4223, CI -0.46-0.19); LSMean difference = -0.2 (p = 0.3265, CI -0.5-0.17); LSMean difference = -0.3 (p = 0.0852, CI -0.62-0.04); LSMean difference = -0.6 (p = 0.0021, CI -0.91--0.21); LSMean difference = -0.1 (p = 0.5717, CI -0.45-0.25); LSMean difference = -0.5 (p = 0.0084, CI -0.82--0.12); LSMean difference = -0.4 (p = 0.0277, CI -0.75--0.04); LSMean difference = -0.1 (p = 0.4627, CI -0.46-0.21); LSMean difference = -0.4 (p = 0.071, CI -0.79-0.03); LSMean difference = -0.5 (p = 0.016, CI -0.91--0.09); LSMean difference = -0.7 (p = 3e-04, CI -1.15--0.34); LSMean difference = -0.3 (p = 0.1013, CI -0.76-0.07); LSMean difference = -0.7 (p = 0.0011, CI -1.11--0.28); LSMean difference = -0.9 (p = 1e-04, CI -1.36--0.53); LSMean difference = -1.1 (p = 1e-04, CI -1.57--0.72); LSMean difference = -0.4 (p = 0.0476, CI -0.85-0); LSMean difference = -0.5 (p = 0.022, CI -0.9--0.07); LSMean difference = -0.7 (p = 0.0019, CI -1.07--0.24); LSMean difference = -0.3 (p = 0.1457, CI -0.74-0.11); LSMean difference = -0.5 (p = 0.0284, CI -0.91--0.05); LSMean difference = -0.8 (p = 2e-04, CI -1.26--0.39); LSMean difference = -0.9 (p = 1e-04, CI -1.36--0.48); LSMean difference = -0.2 (p = 0.4223, CI -0.61-0.26); LSMean difference = -0.4 (p = 0.0442, CI -0.87--0.01); LSMean difference = -0.6 (p = 0.0071, CI -1.02--0.16); LSMean difference = -0.4 (p = 0.0823, CI -0.8-0.05); LSMean difference = -0.5 (p = 0.0336, CI -0.89--0.04); LSMean difference = -0.9 (p = 1e-04, CI -1.32--0.46); LSMean difference = -0.9 (p = 1e-04, CI -1.34--0.47); LSMean difference = -0.2 (p = 0.4819, CI -0.59-0.28); LSMean difference = -0.5 (p = 0.0304, CI -0.9--0.04); LSMean difference = -0.9 (p = 1e-04, CI -1.33--0.43); LSMean difference = -1.1 (p = 1e-04, CI -1.49--0.61); LSMean difference = -0.4 (p = 0.0873, CI -0.81-0.06); LSMean difference = -0.5 (p = 0.0124, CI -0.97--0.12); LSMean difference = -0.7 (p = 0.0014, CI -1.12--0.27); LSMean difference = -0.3 (p = 0.0479, CI -0.68-0); LSMean difference = -0.2 (p = 0.2342, CI -0.54-0.13); LSMean difference = -0.5 (p = 0.007, CI -0.84--0.13). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4. Time frame: Baseline and week 4. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = -1.9 (p = 0.024, CI -3.56--0.25); LSMean difference = -3 (p = 4e-04, CI -4.68--1.38); LSMean difference = -2.8 (p = 0.001, CI -4.44--1.14); LSMean difference = -3.5 (p = 1e-04, CI -5.2--1.89); LSMean difference = -2.3 (p = 0.0058, CI -4--0.68); LSMean difference = -3 (p = 3e-04, CI -4.65--1.41); LSMean difference = -2.4 (p = 0.0042, CI -4.06-0.76). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12. Time frame: Baseline and week 12. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = -1.8 (p = 0.0154, CI -3.3--0.35); LSMean difference = -2.1 (p = 0.0043, CI -3.6--0.67); LSMean difference = -2.3 (p = 0.0023, CI -3.76--0.83); LSMean difference = -2.6 (p = 5e-04, CI -4.09--1.16); LSMean difference = -2.1 (p = 0.0064, CI -3.52--0.58); -2.6 = -2.6 (p = 5e-04, CI -4.04--1.15); LSMean difference = -2.1 (p = 0.0063, CI -3.52--0.59). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12. Time frame: Baseline and week 12. Description: Severity of moderate to severe VMS per day was calculated as follows:

\[(number of moderate VMS  2) + (number of severe VMS  3)\]/number of daily moderate/severe VMS.

Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Severity was zero for participants that had no moderate or severe VMS. Higher scores indicates greater severity.. Parameters: LSMean difference = -0.3 (p = 0.2324, CI -0.67--0.16); LSMean difference = -0.4 (p = 0.0736, CI -0.8-0.04); LSMean difference = -0.6 (p = 0.008, CI -0.98--0.15); LSMean difference = -0.6 (p = 0.0028, CI -1.07--0.22); LSMean differnce = -0.2 (p = 0.4647, CI -0.58-0.26); LSMean difference = -0.5 (p = 0.016, CI -0.92--0.1); LSMean difference = -0.4 (p = 0.0901, CI -0.78-0.06). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4. Time frame: Baseline and week 4. Description: Severity of moderate to severe VMS per day was calculated as follows:

\[(number of moderate VMS  2) + (number of severe VMS  3)\]/number of daily moderate/severe VMS.

Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.. Parameters: LSMean difference = -0.5 (p = 0.0215, CI -0.84--0.07); LSMean difference = -0.6 (p = 0.0017, CI -1.01--0.24); LSMean difference = -0.8 (p = 1e-04, CI -1.21--0.44); LSMean difference = -1 (p = 1e-04, CI -1.37--0.59); LSMean difference = -0.4 (p = 0.0322, CI -0.81--0.04); LSMean difference = -0.6 (p = 0.0017, CI -0.99--0.23); LSMean differencce = -0.7 (p = 4e-04, CI -1.08--0.31). Non-inferiority type: SUPERIORITY. Outcome: Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15. Time frame: Weeks 4, 8, 12, and 15. Description: The LSEQ is a 10-item self-rated questionnaire that assesses a participants aspects of sleep and early morning behavior. The questions are grouped into 4 chronological areas: ease of getting to sleep, perceived quality of sleep, ease of awaking from sleep, and integrity of early morning behavior following wakefulness. The LSEQ is a visual analog scale that requires respondents to place marks on a group of 10 cm lines. Lines extend between extremes like "more difficult than usual" and "easier than usual." Responses are measured using a 100 mm scale and are averaged to a score for each domain. Higher scores indicates better sleep and better early morning behavior.. Parameters: LSMean difference = 2.3 (p = 0.5872, CI -6.09-10.73); LSMean difference = 3.8 (p = 0.3779, CI -4.7-12.35); LSMean difference = -4.1 (p = 0.3506, CI -12.61-4.49); LSMean difference = 1 (p = 0.8236, CI -7.66-9.62); LSMean difference = 2.3 (p = 0.5949, CI -6.24-10.87); LSMean difference = -0.4 (p = 0.9237, CI -8.65-7.85); LSMean difference = 4 (p = 0.3599, CI -4.54-12.46); LSMean difference = 1.7 (p = 0.7422, CI -8.33-11.68); LSMean difference = -2.6 (p = 0.603, CI -12.67-7.37); LSMean difference = -6 (p = 0.2478, CI -16.07-4.17); LSMean difference = -0.4 (p = 0.9371, CI -9.18-8.47); LSMean difference = 0.8 (p = 0.8521, CI -8.07-9.77); LSMean difference = 0.4 (p = 0.9367, CI -8.62-9.35); LSMean difference = -8.8 (p = 0.0551, CI -17.82-0.19); LSMean differencce = -3.2 (p = 0.4936, CI -12.32-5.96); LSMean difference = 2.1 (p = 0.6404, CI -6.89-11.17); LSMean difference = 0.6 (p = 0.8955, CI -8.17-9.34); LSMean difference = 0.1 (p = 0.9776, CI -8.91-9.17); LSMean difference = -1.1 (p = 0.7852, CI -9.27-7.01); LSMean difference = 1.2 (p = 0.7812, CI -7.02-9.33); LSMean difference = -4.7 (p = 0.2648, CI -13.07-3.61); LSMean difference = -2 (p = 0.6312, CI -10.41-6.32); LSMean difference = 1.4 (p = 0.7416, CI -6.89-9.67); LSMean difference = 3.3 (p = 0.5295, CI -6.94-13.47); LSMean difference = -2 (p = 0.6938, CI -12.2-8.13); LSMean difference = -0.1 (p = 0.9765, CI -9.93-9.63); LSMean difference = 3.7 (p = 0.4771, CI -6.45-13.76); LSMean difference = 3.5 (p = 0.4256, CI -5.19-12.27); LSMean difference = 0.2 (p = 0.9559, CI -8.52-9.01); LSMean difference = -5.8 (p = 0.2003, CI -14.6-3.07); LSMean difference = -1.9 (p = 0.6692, CI -10.86-6.98); LSMean difference = -1.8 (p = 0.6894, CI -10.68-7.08); LSMean difference = -6.1 (p = 0.1627, CI -14.66-2.48); LSMean difference = -3.4 (p = 0.4904, CI -12.97-6.23); LSMean difference = -2.9 (p = 0.5521, CI -12.48-6.69); LSMean difference = -1.5 (p = 0.737, CI -10.38-7.35); LSMean difference = -2.8 (p = 0.5269, CI -11.62-5.96); LSMean difference = -3.9 (p = 0.3937, CI -12.93-5.11); LSMean difference = 0.9 (p = 0.846, CI -8.15-9.94); LSMean difference = -2.6 (p = 0.5673, CI -11.62-6.38); LSMean difference = 4 (p = 0.3791, CI -4.88-12.79); LSMean difference = 0.9 (p = 0.834, CI -7.86-9.73); LSMean difference = -0.3 (p = 0.9457, CI -9.51-8.88); LSMean difference = -2.1 (p = 0.657, CI -11.22-7.09); LSMean difference = -5.7 (p = 0.231, CI -15-3.64); LSMean difference = 0.6 (p = 0.9066, CI -8.84-9.96); LSMean differnce = -5 (p = 0.2914, CI -14.26-4.3); LSMean difference = 7.4 (p = 0.1219, CI -1.99-16.75); LSMean difference = 9.6 (p = 0.0316, CI 0.85-18.36); LSMean difference = 6.4 (p = 0.1557, CI -2.44-15.16); LSMean difference = 0.9 (p = 0.8592, CI -8.91-10.67); LSMean difference = 2.1 (p = 0.6891, CI -8.08-12.2); LSMean difference = -0.3 (p = 0.9481, CI -10.59-9.92); LSMean difference = -1.9 (p = 0.7246, CI -12.46-8.68); LSMean difference = 0.8 (p = 0.8842, CI -9.94-11.53); LSMean difference = 3.3 (p = 0.4254, CI -4.83-11.41); LSMean difference = 3.4 (p = 0.4038, CI -4.66-11.54); LSMean difference = -4.8 (p = 0.327, CI -14.49-4.85); LSMean difference = -1.7 (p = 0.7333, CI -11.21-7.9); LSMean difference = -7.5 (p = 0.1319, CI -17.36-2.28); LSMean difference = -2.5 (p = 0.6132, CI -12.38-7.32); LSMean difference = -4.2 (p = 0.4024, CI -13.98-5.63); LSMean difference = 0.4 (p = 0.9277, CI -8.73-9.57); LSMean difference = -0.4 (p = 0.9367, CI -9.51-8.77); LSMean difference = 5.1 (p = 0.2407, CI -3.46-13.69); LSMean difference = 6.9 (p = 0.1305, CI -2.06-15.89); LSMean difference = 5.7 (p = 0.2152, CI -3.34-14.75); LSMean difference = 7.6 (p = 0.1099, CI -1.73-16.89); LSMean difference = 1.2 (p = 0.8103, CI -8.74-11.17); LSMean difference = 0.2 (p = 0.9631, CI -9.81-10.28); LSMean difference = -0.1 (p = 0.9788, CI -9.73-9.47); LSMean difference = -1.4 (p = 0.7875, CI -11.26-8.54); LSMean difference = 0.2 (p = 0.9746, CI -9.85-10.17); LSMean difference = 0.6 (p = 0.9092, CI -9.67-10.86); LSMean difference = -0.2 (p = 0.9745, CI -10.55-10.21); LSMean difference = 4.7 (p = 0.3458, CI -5.08-14.44); LSMean differnce = 3.6 (p = 0.4657, CI -6.17-13.45); LSMean difference = 2.8 (p = 0.5838, CI -7.2-12.76); LSMean difference = 1.1 (p = 0.8322, CI -9.18-11.39); LSMean difference = -1 (p = 0.8475, CI -10.9-8.96); LSMean difference = 5 (p = 0.3044, CI -4.57-14.59); LSMean difference = 4.2 (p = 0.3895, CI -5.42-13.86); LSMean difference = -4.5 (p = 0.4551, CI -16.5-7.42); LSMean difference = 1.8 (p = 0.7366, CI -8.59-12.13); LSMean difference = 5.6 (p = 0.2971, CI -4.99-16.28); LSMean difference = -0.3 (p = 0.9562, CI -10.96-10.37); 0.28 = 8.7 (p = 0.0926, CI -1.44-18.76); LSMean difference = 3.5 (p = 0.4996, CI -6.7-13.7); LSMean difference = -0.6 (p = 0.896, CI -9.99-8.75); LSMean difference = 2.9 (p = 0.5471, CI -6.68-12.58); LSMean difference = 1.7 (p = 0.738, CI -8.06-11.36); LSMean difference = 9.6 (p = 0.0644, CI -0.58-19.69); LSMean difference = 1.6 (p = 0.783, CI -10.04-13.31); 0.1 = 15.4 (p = 0.0074, CI 4.19-26.67); LSMean difference = 11 (p = 0.0551, CI -0.24-22.32); LSMean difference = -5.8 (p = 0.2959, CI -16.63-5.08); LSMean difference = 5.8 (p = 0.2976, CI -5.14-16.74); LSMean difference = 2 (p = 0.7236, CI -9.07-13.05); LSMean difference = 10.1 (p = 0.0884, CI -1.52-21.63); LSMean difference = -5 (p = 0.3887, CI -16.35-6.38); LSMean difference = 6.2 (p = 0.2671, CI -4.8-17.24); LSMean difference = 2.9 (p = 0.6076, CI -8.2-13.99); LSMean differencce = -2.2 (p = 0.7182, CI -14.21-9.81); LSMean difference = -3 (p = 0.6259, CI -15.26-9.2); LSMean difference = 6.6 (p = 0.312, CI -6.22-19.4); LSMean difference = -6.3 (p = 0.3297, CI -18.89-6.37); LSMean difference = 3.1 (p = 0.613, CI -9.02-15.26); LSMean difference = 2.2 (p = 0.7292, CI -10.09-14.4); LSMean difference = 0.9 (p = 0.8695, CI -1.11-11.96); LSMean difference = 3.1 (p = 0.58, CI -7.99-14.25); LSMean difference = 2.2 (p = 0.7024, CI -9.11-13.5); LSMean difference = 11.4 (p = 0.0572, CI -0.35-23.23). Non-inferiority type: SUPERIORITY. Outcome: Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = 14.6 (p = 0.0388, CI 0.76-28.49); LSMean difference = 23.1 (p = 0.0012, CI 9.17-37.02); LSMean difference = 37.3 (p = 1e-04, CI 23.41-51.22); LSMean difference = 41 (p = 1e-04, CI 26.88-55.05); LSMean difference = 8.2 (p = 0.2569, CI -5.98-22.32); LSMean difference = 25.6 (p = 3e-04, CI 11.65-39.47); LSMean difference = 30.2 (p = 1e-04, CI 16.39-44.06); LSMean difference = 15.9 (p = 0.024, CI 2.11-29.71); LSMean difference = 24.5 (p = 6e-04, CI 10.62-38.37); LSMean differencce = 33.7 (p = 1e-04, CI 19.87-47.52); LSMean difference = 38 (p = 1e-04, CI 23.93-52.04); LSMean difference = 14.5 (p = 0.0441, CI 0.38-28.53); LSMean difference = 19.4 (p = 0.0061, CI 5.58-33.28); LSMean difference = 25.7 (p = 3e-04, CI 11.96-39.53); LSMean difference = 20.2 (p = 0.0078, CI 5.36-35.07); LSMean difference = 28.3 (p = 2e-04, CI 13.36-43.22); LSMean difference = 36.9 (p = 1e-04, CI 22.07-51.77); LSMean difference = 40.5 (p = 1e-04, CI 25.41-55.67); LSMean difference = 19.7 (p = 0.0108, CI 4.59-34.88); LSMean difference = 25 (p = 0.0011, CI 10.09-39.84); LSMean difference = 30.9 (p = 1e-04, CI 16.03-45.67); LSMean difference = 20.5 (p = 0.0063, CI 5.84-35.23); LSMean difference = 28.7 (p = 2e-04, CI 13.98-43.46); LSMean difference = 33.3 (p = 1e-04, CI 18.66-48); LSMean difference = 41.5 (p = 1e-04, CI 26.52-56.41); LSMean difference = 19.7 (p = 0.0098, CI 4.78-34.66); LSMean difference = 29.9 (p = 1e-04, CI 15.26-44.61); LSMean difference = 33.1 (p = 1e-04, CI 18.5-47.73); LSMean difference = 15.4 (p = 0.0303, CI 1.48-29.4); LSMean difference = 24.8 (p = 6e-04, CI 10.77-38.74); LSMean difference = 30.8 (p = 1e-04, CI 16.77-44.75); LSMean difference = 38.8 (p = 1e-04, CI 24.55-53); LSMean difference = 19.1 (p = 0.0086, CI 4.88-33.23); LSMean difference = 22.3 (p = 0.0018, CI 8.33-36.24); LSMean difference = 25.1 (p = 4e-04, CI 11.24-39.05); LSMean difference = 14.6 (p = 0.0282, CI 1.56-27.6); LSMean difference = 19.9 (p = 0.0029, CI 6.85-32.92); LSMean difference = 29.7 (p = 1e-04, CI 16.58-42.73); LSMean difference = 35.7 (p = 1e-04, CI 22.42-48.99); LSMean difference = 14.6 (p = 0.0304, CI 1.4-27.9); LSMean difference = 20.4 (p = 0.0022, CI 7.38-33.5); LSMean difference = 26.5 (p = 1e-04, CI 13.56-39.5); LSMean difference = 14.4 (p = 0.0362, CI 0.93-27.95); LSMean difference = 22.9 (p = 9e-04, CI 9.41-36.47); LSMean difference = 28.9 (p = 1e-04, CI 15.27-42.46); LSMean difference = 36.8 (p = 1e-04, CI 22.99-50.57); LSMean difference = 15.6 (p = 0.0265, CI 1.83-29.34); LSMean difference = 21.2 (p = 0.0023, CI 7.6-34.71); LSMean difference = 27.1 (p = 1e-04, CI 13.64-40.59); LSMean difference = 9.6 (p = 0.158, CI -3.75-22.99); LSMean difference = 18.1 (p = 0.0082, CI 4.72-31.5); LSMean difference = 25.2 (p = 3e-04, CI 11.77-38.71); LSMean difference = 30.6 (p = 1e-04, CI 16.93-44.31); LSMean difference = 11.2 (p = 0.1074, CI -2.45-24.84); LSMean difference = 18.3 (p = 0.0077, CI 4.87-31.76); LSMean difference = 23.6 (p = 6e-04, CI 10.29-37.01); LSMean difference = 11.8 (p = 0.0689, CI -0.92-24.53); LSMean difference = 14.6 (p = 0.025, CI 1.84-27.27); LSMean difference = 24.4 (p = 2e-04, CI 11.54-37.17); LSMean difference = 29.6 (p = 1e-04, CI 16.6-42.57); LSMean difference = 8.4 (p = 0.2041, CI -4.58-21.36); LSMean difference = 18.4 (p = 0.0049, CI 5.62-31.2); LSMean difference = 20.7 (p = 0.0015, CI 8-33.37); LSMean difference = 15.8 (p = 0.0184, CI 2.68-28.89); LSMean difference = 12.8 (p = 0.0551, CI -0.28-25.93); LSMean difference = 25.8 (p = 2e-04, CI 12.51-39); LSMean difference = 31.6 (p = 1e-04, CI 18.17-44.93); LSMean difference = 14.3 (p = 0.0367, CI 0.89-27.62); LSMean difference = 21.2 (p = 0.0017, CI 7.99-34.34); LSMean difference = 24.4 (p = 3e-04, CI 11.29-37.44); LSMean difference = 14.5 (p = 0.0255, CI 1.78-27.15); LSMean difference = 15.3 (p = 0.0186, CI 2.57-27.94); LSMean difference = 26.5 (p = 1e-04, CI 13.71-39.36); LSMean difference = 29.9 (p = 1e-04, CI 16.94-42.81); LSMean difference = 13.9 (p = 0.0347, CI 1.01-26.85); LSMean difference = 21.9 (p = 8e-04, CI 9.16-34.65); LSMean difference = 23.4 (p = 3e-04, CI 10.75-36.04); LSMean difference = 14.8 (p = 0.0221, CI 2.13-27.43); LSMean difference = 17 (p = 0.0087, CI 4.32-29.62); LSMean difference = 26.4 (p = 1e-04, CI 13.65-39.23); LSMean difference = 31 (p = 1e-04, CI 18.13-43.94); LSMean difference = 14.8 (p = 0.0244, CI 1.92-27.7); LSMean difference = 21.9 (p = 8e-04, CI 9.21-34.62); LSMean difference = 23.2 (p = 3e-04, CI 10.63-35.83); LSMean difference = 9.8 (p = 0.1871, CI -4.77-24.3); LSMean difference = 2.3 (p = 0.7552, CI -12.23-16.83); LSMean difference = 1.5 (p = 0.8407, CI -13.44-16.5); LSMean difference = 7.2 (p = 0.345, CI -7.77-22.14); LSMean difference = 5.7 (p = 0.455, CI -9.34-20.8); LSMean difference = 10.4 (p = 0.1747, CI -4.64-25.44); LSMean difference = 4.4 (p = 0.5476, CI -10.08-18.97); LSMean difference = 2.1 (p = 0.7954, CI -13.69-17.84); LSMean differencce = 1.3 (p = 0.8731, CI -14.41-16.95); LSMean difference = -0.3 (p = 0.9689, CI -16.68-16.03); LSMean difference = 3.9 (p = 0.6378, CI -12.4-20.21); LSMean differencce = 1.6 (p = 0.8503, CI -14.82-17.97); LSMean difference = 13 (p = 0.1224, CI -3.51-29.44); LSMean difference = 7.1 (p = 0.3743, CI -8.62-22.85); LSMean difference = -7.9 (p = 0.3173, CI -23.44-7.63); LSMean difference = -2.1 (p = 0.7905, CI -17.48-13.32); LSMean difference = -7.2 (p = 0.3804, CI -23.46-8.98); LSMean difference = -5.6 (p = 0.4905, CI -21.58-10.38); LSMean difference = -12.6 (p = 0.1289, CI -28.83-3.68); LSMean difference = 6.4 (p = 0.4398, CI -9.86-22.61); LSMean difference = -2.1 (p = 0.7921, CI -17.45-13.33). Non-inferiority type: SUPERIORITY. Outcome: Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: LSMean difference = 19.1 (p = 0.009, CI 4.82-33.46); LSMean difference = 27 (p = 3e-04, CI 12.61-41.39); LSMean difference = 39.5 (p = 1e-04, CI 25.14-53.9); LSMean difference = 44.8 (p = 1e-04, CI 30.27-59.39); LSMean difference = 24.4 (p = 3e-04, CI 11.2-37.6); LSMean difference = 32.1 (p = 1e-04, CI 18.77-45.42); LSMean difference = 19.1 (p = 0.005, CI 5.79-32.38); LSMean difference = 23.1 (p = 6e-04, CI 9.95-36.22); LSMean difference = 22.8 (p = 6e-04, CI 9.79-35.85); LSMean difference = 18.5 (p = 0.0036, CI 6.11-30.98); LSMean difference = 31.9 (p = 1e-04, CI 19.11-44.67); LSMean difference = 20.1 (p = 0.0021, CI 7.32-32.81); LSMean difference = 22.7 (p = 4e-04, CI 10.1-35.29); LSMean difference = 21.9 (p = 6e-04, CI 9.42-34.38); LSMean difference = 17 (p = 0.0304, CI 1.62-32.4); LSMean difference = 6.8 (p = 0.3857, CI -8.6-22.19); LSMean difference = 7.5 (p = 0.3497, CI -8.31-23.4); LSMean difference = 10.9 (p = 0.1771, CI -4.95-26.75); LSMean difference = 16.3 (p = 0.0444, CI 0.41-32.29); LSMean difference = 11.7 (p = 0.15, CI -4.25-27.63); LSMean difference = 3.9 (p = 0.6196, CI -11.51-19.29); LSMean difference = 9.4 (p = 0.2664, CI -7.25-26.15); LSMean differencce = 4 (p = 0.6388, CI -12.66-20.59); LSMean difference = 12.2 (p = 0.1019, CI -2.43-26.79); LSMean difference = 27.8 (p = 2e-04, CI 13.45-42.22); LSMean difference = 29.5 (p = 1e-04, CI 15.21-43.82); LSMean difference = 19.9 (p = 0.0049, CI 6.1-33.76); LSMean difference = 28.6 (p = 1e-04, CI 14.64-42.46); LSMean differencce = 33.8 (p = 1e-04, CI 19.96-47.69); LSMean difference = 39.5 (p = 1e-04, CI 25.4-53.58); LSMean difference = 17.6 (p = 0.0146, CI 3.5-31.7); LSMean difference = 24.1 (p = 7e-04, CI 10.21-38); LSMean difference = 23.9 (p = 8e-04, CI 10.05-37.7); LSMean difference = 23.2 (p = 0.002, CI 8.56-37.9); LSMean difference = 34.4 (p = 1e-04, CI 19.6-49.11); LSMean difference = 35.6 (p = 1e-04, CI 20.96-50.32); LSMean difference = 43 (p = 1e-04, CI 28.03-57.93); LSMean difference = 25.4 (p = 9e-04, CI 10.48-40.37); LSMean difference = 31.2 (p = 1e-04, CI 16.49-45.9); LSMean difference = 28.9 (p = 1e-04, CI 14.24-43.52); LSMean difference = 23.1 (p = 0.0021, CI 8.46-37.66); LSMean difference = 32.1 (p = 1e-04, CI 17.42-46.71); LSMean difference = 31.3 (p = 1e-04, CI 16.73-45.91); LSMean difference = 41.8 (p = 1e-04, CI 26.95-56.68); LSMean difference = 25.6 (p = 8e-04, CI 10.77-40.43); LSMean difference = 31.3 (p = 1e-04, CI 16.75-45.94); LSMean difference = 29.4 (p = 1e-04, CI 14.91-43.97); LSMean difference = 20.2 (p = 0.0045, CI 6.31-34.06); LSMean difference = 30.6 (p = 1e-04, CI 16.68-44.49); LSMean difference = 29.1 (p = 1e-04, CI 15.14-42.98); LSMean difference = 40.1 (p = 1e-04, CI 25.96-54.26); LSMean difference = 24.4 (p = 7e-04, CI 10.28-38.42); LSMean difference = 26.7 (p = 2e-04, CI 1.78-40.55); LSMean difference = 23.4 (p = 0.001, CI 9.55-37.22); LSMean difference = 19.1 (p = 0.004, CI 6.13-32.11); LSMean difference = 23.8 (p = 4e-04, CI 10.8-36.83); LSMean difference = 27.2 (p = 1e-04, CI 14.1-40.24); LSMean difference = 35.6 (p = 1e-04, CI 22.34-48.88); LSMean difference = 20 (p = 0.0032, CI 6.76-33.19); LSMean difference = 24.1 (p = 3e-04, CI 11.02-37.13); LSMean difference = 23.1 (p = 5e-04, CI 10.17-36.08); LSMean difference = 17.6 (p = 0.0102, CI 4.2-31.04); LSMean difference = 25.9 (p = 2e-04, CI 12.42-39.29); LSMean difference = 25.8 (p = 2e-04, CI 12.29-39.33); LSMean difference = 36.3 (p = 1e-04, CI 22.58-49.98); LSMean difference = 20.6 (p = 0.0031, CI 7-34.29); LSMean difference = 22.9 (p = 9e-04, CI 9.43-36.38); LSMean difference = 22.8 (p = 9e-04, CI 9.42-36.19); LSMean difference = 13.8 (p = 0.0408, CI 0.58-26.97); LSMean difference = 20 (p = 0.0031, CI 6.77-33.21); LSMean difference = 22.1 (p = 0.0012, CI 8.8-35.4); LSMean difference = 29.9 (p = 1e-04, CI 16.39-43.42); LSMean difference = 14.9 (p = 0.0303, CI 1.42-28.32); LSMean difference = 19.6 (p = 0.004, CI 6.3-32.87); LSMean difference = 19.5 (p = 0.0038, CI 6.34-32.73); LSMean difference = 16 (p = 0.0137, CI 3.29-28.68); LSMean difference = 18.1 (p = 0.0052, CI 5.44-30.82); LSMean difference = 22.6 (p = 6e-04, CI 9.81-35.39); LSMean difference = 29.4 (p = 1e-04, CI 16.41-42.32); LSMean difference = 13.7 (p = 0.0378, CI 0.78-26.63); LSMean difference = 20.1 (p = 0.002, CI 7.31-32.85); LSMean difference = 17.4 (p = 0.0071, CI 4.77-30.09); LSMean difference = 20.7 (p = 0.002, CI 7.61-33.71); LSMean difference = 18.7 (p = 0.005, CI 5.68-31.79); LSMean difference = 20.2 (p = 0.0015, CI 7.77-32.65); LSMean difference = 25 (p = 1e-04, CI 12.41-37.57); LSMean difference = 29.8 (p = 1e-04, CI 17.12-42.49); LSMean difference = 19.6 (p = 0.0026, CI 6.9-32.21); LSMean difference = 23.4 (p = 3e-04, CI 10.92-35.94); LSMean difference = 21.7 (p = 6e-04, CI 9.34-34.14); LSMean difference = 19.3 (p = 0.0026, CI 6.78-31.83); LSMean difference = 20.8 (p = 0.0012, CI 8.29-33.33); LSMean difference = 25.1 (p = 1e-04, CI 12.48-37.82); LSMean difference = 4.9 (p = 0.5797, CI -12.43-22.19); LSMean difference = 6.2 (p = 0.4817, CI -11.1-23.47); LSMean differencce = 10.5 (p = 0.2358, CI -6.87-27.79); LSMean difference = 14.3 (p = 0.107, CI -3.11-31.77); LSMean difference = 6.7 (p = 0.4268, CI -9.94-23.43); LSMean difference = -0.9 (p = 0.9197, CI -17.81-16.08); LSMean difference = 0 (p = 0.9954, CI -16.77-16.87); LSMean difference = 0.4 (p = 0.9607, CI -17.28-18.17); LSMean difference = -3.9 (p = 0.6625, CI -21.33-13.59); LSMean difference = -0.1 (p = 0.9952, CI -17.81-17.7); LSMean difference = 7.6 (p = 0.4001, CI -10.16-25.36); LSMean difference = -2.7 (p = 0.751, CI -19.52-14.1). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 1.74 (p = 0.2251, CI 0.71-4.26); Odds Ratio (OR) = 3.57 (p = 0.0084, CI 1.39-9.2); Odds Ratio (OR) = 5.71 (p = 7e-04, CI 2.09-15.62); Odds Ratio (OR) = 5.11 (p = 0.0015, CI 1.87-14); Odds Ratio (OR) = 1.2 (p = 0.6976, CI 0.48-2.95); Odds Ratio (OR) = 4.57 (p = 0.0021, CI 1.73-12.05); Odds Ratio (OR) = 3.06 (p = 0.0171, CI 1.22-7.68); Odds Ratio (OR) = 1.86 (p = 0.2224, CI 0.69-5.04); Odds Ratio (OR) = 1.74 (p = 0.2716, CI 0.65-4.69); Odds Ratio (OR) = 4.49 (p = 0.0112, CI 1.41-14.32); Odds Ratio (OR) = 3.08 (p = 0.0461, CI 1.02-9.31); Odds Ratio (OR) = 1.63 (p = 0.3463, CI 0.59-4.47); Odds Ratio (OR) = 3.05 (p = 0.0419, CI 1.04-8.92); Odds Ratio (OR) = 1.68 (p = 0.2977, CI 0.63-4.46); Odds Ratio (OR) = 1.87 (p = 0.23, CI 0.67-5.21); Odds Ratio (OR) = 2.83 (p = 0.0655, CI 0.94-8.58); Odds Ratio (OR) = 3.79 (p = 0.0245, CI 1.19-12.11); Odds Ratio (OR) = 5.62 (p = 0.0129, CI 1.44-21.93); Odds Ratio (OR) = 2.37 (p = 0.1259, CI 0.79-7.15); Odds Ratio (OR) = 2.4 (p = 0.1015, CI 0.84-6.82); Odds Ratio (OR) = 4.48 (p = 0.0167, CI 1.31-15.33); Odds Ratio (OR) = 1.4 (p = 0.5232, CI 0.5-3.95); Odds Ratio (OR) = 2 (p = 0.2055, CI 0.68-5.82); Odds Ratio (OR) = 3 (p = 0.0658, CI 0.93-9.64); Odds Ratio (OR) = 7.34 (p = 0.0136, CI 1.51-35.75); Odds Ratio (OR) = 1.71 (p = 0.3238, CI 0.59-5); Odds Ratio (OR) = 5.86 (p = 0.0118, CI 1.48-23.21); Odds Ratio (OR) = 5.29 (p = 0.0163, CI 1.36-20.62); Odds Ratio (OR) = 1.32 (p = 0.6363, CI 0.42-4.18); Odds Ratio (OR) = 3.68 (p = 0.0722, CI 0.89-15.25); Odds Ratio (OR) = 2.19 (p = 0.3742, CI 0.39-12.26); Odds Ratio (OR) = 5.24 (p = 0.1436, CI 0.57-48.26); Odds Ratio (OR) = 5.57 (p = 0.1277, CI 0.61-50.77); Odds Ratio (OR) = 0.75 (p = 0.6689, CI 0.2-2.81); Odds Ratio (OR) = 1.2 (p = 0.8019, CI 0.29-4.95); Odds Ratio (OR) = 0.96 (p = 0.9591, CI 0.23-4.05); Odds Ratio (OR) = 2.33 (p = 0.3364, CI 0.42-13.06); Odds Ratio (OR) = 2.2 (p = 0.3698, CI 0.39-12.32); Odds Ratio (OR) = 4.92 (p = 0.1587, CI 0.54-45.01); Odds Ratio (OR) = 5.5 (p = 0.13, CI 0.61-50.06); Odds Ratio (OR) = 1.81 (p = 0.4152, CI 0.43-7.53); Odds Ratio (OR) = 0.97 (p = 0.9645, CI 0.27-3.5); Odds Ratio (OR) = 1.95 (p = 0.3884, CI 0.43-8.96); Odds Ratio (OR) = 2.62 (p = 0.267, CI 0.48-14.41); Odds Ratio (OR) = 1.26 (p = 0.7437, CI 0.31-5.1); Odds Ratio (OR) = 1.3 (p = 0.6848, CI 0.36-4.71); Odds Ratio (OR) = 2.35 (p = 0.2019, CI 0.63-8.73); Odds Ratio (OR) = 10.15 (p = 0.0337, CI 1.2-86.09); Odds Ratio (OR) = 2.25 (p = 0.2207, CI 0.61-8.24); Odds Ratio (OR) = 3.5 (p = 0.0849, CI 0.84-14.57); Odds Ratio (OR) = 3.47 (p = 0.0844, CI 0.84-14.24); Odds Ratio (OR) = 2.15 (p = 0.2383, CI 0.6-7.65); Odds Ratio (OR) = 2.55 (p = 0.1653, CI 0.68-9.58); Odds Ratio (OR) = 2.48 (p = 0.1836, CI 0.65-9.48); Odds Ratio (OR) = 8.3 (p = 0.0529, CI 0.97-70.8); Odds Ratio (OR) = 1.95 (p = 0.3197, CI 0.52-7.27); Odds Ratio (OR) = 5.88 (p = 0.0376, CI 1.11-31.25); Odds Ratio (OR) = 10.08 (p = 0.0343, CI 1.19-85.64); Odds Ratio (OR) = 1.58 (p = 0.4435, CI 0.49-5.09); Odds Ratio (OR) = 2.34 (p = 0.1805, CI 0.67-8.13); Odds Ratio (OR) = 3.54 (p = 0.0857, CI 0.84-14.95); Odds Ratio (OR) = 10.5 (p = 0.0316, CI 1.23-89.63); Odds Ratio (OR) = 1.81 (p = 0.3471, CI 0.52-6.27); Odds Ratio (OR) = 6.15 (p = 0.0313, CI 1.18-32.09); Odds Ratio (OR) = 12.49 (p = 0.0208, CI 1.47-106.3); Odds Ratio (OR) = 1.11 (p = 0.8669, CI 0.31-3.97); Odds Ratio (OR) = 1.34 (p = 0.6592, CI 0.37-4.89); Odds Ratio (OR) = 2.23 (p = 0.2923, CI 0.5-9.98); Odds Ratio (OR) = 5.78 (p = 0.1145, CI 0.65-51.04); Odds Ratio (OR) = 1.77 (p = 0.447, CI 0.4-7.78); Odds Ratio (OR) = 7.31 (p = 0.0753, CI 0.82-65.41); Odds Ratio (OR) = 6.85 (p = 0.0829, CI 0.78-60.24); Odds Ratio (OR) = 1 (p = 0.9978, CI 0.28-3.59); Odds Ratio (OR) = 1.68 (p = 0.4571, CI 0.43-6.65); Odds Ratio (OR) = 1.99 (p = 0.3681, CI 0.44-8.94); Odds Ratio (OR) = 6.12 (p = 0.1038, CI 0.69-54.38); Odds Ratio (OR) = 1.74 (p = 0.4639, CI 0.39-7.72); Odds Ratio (OR) = 7.15 (p = 0.077, CI 0.81-63.27); Odds Ratio (OR) = 1.01 (p = 0.9838, CI 0.26-4.01); Odds Ratio (OR) = 0.77 (p = 0.6995, CI 0.21-2.86); Odds Ratio (OR) = 1.12 (p = 0.8808, CI 0.26-4.71); Odds Ratio (OR) = 4.94 (p = 0.157, CI 0.54-45.13); Odds Ratio (OR) = 6.91 (p = 0.0861, CI 0.76-62.9); Odds Ratio (OR) = 7.21 (p = 0.0774, CI 0.8-64.66); Odds Ratio (OR) = 4.73 (p = 0.0389, CI 1.08-20.65); Odds Ratio (OR) = 1.81 (p = 0.3695, CI 0.5-6.57); Odds Ratio (OR) = 1.95 (p = 0.3501, CI 0.48-7.89); Odds Ratio (OR) = 2.49 (p = 0.2021, CI 0.61-10.14); Odds Ratio (OR) = 1.42 (p = 0.6201, CI 0.36-5.62); Odds Ratio (OR) = 13.71 (p = 0.0235, CI 1.42-132); Odds Ratio (OR) = 3.43 (p = 0.0929, CI 0.81-14.48); Odds Ratio (OR) = 0.99 (p = 0.982, CI 0.29-3.33); Odds Ratio (OR) = 1.55 (p = 0.4956, CI 0.44-5.41); Odds Ratio (OR) = 0.7 (p = 0.5708, CI 0.2-2.44); Odds Ratio (OR) = 2.55 (p = 0.1985, CI 0.61-10.61); Odds Ratio (OR) = 1.15 (p = 0.8368, CI 0.31-4.32); Odds Ratio (OR) = 3.18 (p = 0.1397, CI 0.68-14.76); Odds Ratio (OR) = 1.88 (p = 0.0366, CI 0.52-6.85); Odds Ratio (OR) = 0.84 (p = 0.7968, CI 0.23-3.05); Odds Ratio (OR) = 1.08 (p = 0.9074, CI 0.3-3.81); Odds Ratio (OR) = 0.41 (p = 0.1987, CI 0.1-1.6); Odds Ratio (OR) = 2.58 (p = 0.204, CI 0.6-11.18); Odds Ratio (OR) = 0.51 (p = 0.3318, CI 0.13-1.99). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 2.6 (p = 0.0429, CI 1.03-6.55); Odds Ratio (OR) = 2.81 (p = 0.0296, CI 1.11-7.12); Odds Ratio (OR) = 4.48 (p = 0.0032, CI 1.65-12.13); Odds Ratio (OR) = 7.11 (p = 6e-04, CI 2.31-21.9); Odds Ratio (OR) = 1.8 (p = 0.2073, CI 0.72-4.47); Odds Ratio (OR) = 3.54 (p = 0.0096, CI 1.36-9.2); Odds Ratio (OR) = 2.52 (p = 0.0462, CI 1.02-6.27); Odds Ratio (OR) = 2.26 (p = 0.1387, CI 0.77-6.63); Odds Ratio (OR) = 1.71 (p = 0.313, CI 0.6-4.84); Odds Ratio (OR) = 2.89 (p = 0.1507, CI 0.68-12.28); Odds Ratio (OR) = 5.92 (p = 0.0385, CI 1.1-31.94); Odds Ratio (OR) = 10.85 (p = 0.0299, CI 1.26-93.28); Odds Ratio (OR) = 1.19 (p = 0.8034, CI 0.3-4.74); Odds Ratio (OR) = 1.14 (p = 0.8532, CI 0.29-4.42); Odds Ratio (OR) = 1.11 (p = 0.8823, CI 0.28-4.41); Odds Ratio (OR) = 4.79 (p = 0.1651, CI 0.52-43.76); Odds Ratio (OR) = 6.36 (p = 0.1048, CI 0.68-59.55); Odds Ratio (OR) = 5.87 (p = 0.1168, CI 0.64-53.53); Odds Ratio (OR) = 1.31 (p = 0.6936, CI 0.35-4.95); Odds Ratio (OR) = 1.74 (p = 0.4315, CI 0.44-6.9); Odds Ratio (OR) = 1.19 (p = 0.7936, CI 0.31-4.53); Odds Ratio (OR) = 6.3 (p = 0.099, CI 0.71-56.03); Odds Ratio (OR) = 5.86 (p = 0.1128, CI 0.66-52.21); Odds Ratio (OR) = 7.36 (p = 0.0732, CI 0.83-65.38); Odds Ratio (OR) = 1.39 (p = 0.6559, CI 0.33-5.91); Odds Ratio (OR) = 0.8 (p = 0.7333, CI 0.21-2.96); Odds Ratio (OR) = 3.32 (p = 0.0392, CI 1.06-10.4); Odds Ratio (OR) = 5.7 (p = 0.0135, CI 1.43-22.71); Odds Ratio (OR) = 2.85 (p = 0.084, CI 0.87-9.36); Odds Ratio (OR) = 4.47 (p = 0.0163, CI 1.32-15.17); Odds Ratio (OR) = 1.41 (p = 0.5056, CI 0.52-3.84); Odds Ratio (OR) = 1.69 (p = 0.3358, CI 0.58-4.9); Odds Ratio (OR) = 3.05 (p = 0.0696, CI 0.91-10.18); Odds Ratio (OR) = 2.8 (p = 0.0794, CI 0.89-8.82); Odds Ratio (OR) = 7.32 (p = 0.0149, CI 1.48-36.28); Odds Ratio (OR) = 4.37 (p = 0.0377, CI 1.09-17.59); Odds Ratio (OR) = 3.32 (p = 0.0454, CI 1.03-10.77); Odds Ratio (OR) = 3.77 (p = 0.039, CI 1.07-13.26); Odds Ratio (OR) = 2.12 (p = 0.1947, CI 0.68-6.64); Odds Ratio (OR) = 1.79 (p = 0.2913, CI 0.61-5.25); Odds Ratio (OR) = 2.21 (p = 0.1665, CI 0.72-6.82); Odds Ratio (OR) = 13.41 (p = 0.0157, CI 1.63-110.3); Odds Ratio (OR) = 3.01 (p = 0.0846, CI 0.86-10.49); Odds Ratio (OR) = 5.42 (p = 0.0171, CI 1.35-21.75); Odds Ratio (OR) = 4.71 (p = 0.0262, CI 1.2-18.49); Odds Ratio (OR) = 1.88 (p = 0.2858, CI 0.59-5.95); Odds Ratio (OR) = 7.65 (p = 0.0155, CI 1.47-39.72); Odds Ratio (OR) = 2.66 (p = 0.1249, CI 0.76-9.31); Odds Ratio (OR) = 3.85 (p = 0.0616, CI 0.94-15.82); Odds Ratio (OR) = 8.32 (p = 0.0126, CI 1.58-43.9); Odds Ratio (OR) = 3.1 (p = 0.0853, CI 0.85-11.23); Odds Ratio (OR) = 2.56 (p = 0.1562, CI 0.7-9.35); Odds Ratio (OR) = 2.83 (p = 0.1297, CI 0.74-10.91); Odds Ratio (OR) = 2.34 (p = 0.2001, CI 0.64-8.55); Odds Ratio (OR) = 8.6 (p = 0.0495, CI 1-73.7); Odds Ratio (OR) = 2.86 (p = 0.1553, CI 0.67-12.2); Odds Ratio (OR) = 7.67 (p = 0.0199, CI 1.38-42.67); Odds Ratio (OR) = 5.28 (p = 0.0472, CI 1.02-27.34); Odds Ratio (OR) = 1.75 (p = 0.3736, CI 0.51-5.98); Odds Ratio (OR) = 2.06 (p = 0.2628, CI 0.58-7.26); Odds Ratio (OR) = 2.43 (p = 0.1998, CI 0.63-9.39); Odds Ratio (OR) = 0.94 (p = 0.9266, CI 0.24-3.74); Odds Ratio (OR) = 5.04 (p = 0.1518, CI 0.55-46.13); Odds Ratio (OR) = 4.69 (p = 0.1714, CI 0.51-42.91); Odds Ratio (OR) = 5.6 (p = 0.1299, CI 0.6-51.95); Odds Ratio (OR) = 2.75 (p = 0.2495, CI 0.49-15.44); Odds Ratio (OR) = 1.32 (p = 0.7065, CI 0.31-5.6); Odds Ratio (OR) = 1.26 (p = 0.7504, CI 0.3-5.24); Odds Ratio (OR) = 0.83 (p = 0.7862, CI 0.21-3.29); Odds Ratio (OR) = 4.98 (p = 0.155, CI 0.54-45.59); Odds Ratio (OR) = 4.7 (p = 0.1706, CI 0.51-42.96); Odds Ratio (OR) = 5.31 (p = 0.1415, CI 0.57-49.11); Odds Ratio (OR) = 5.67 (p = 0.1241, CI 0.62-51.74); Odds Ratio (OR) = 2.64 (p = 0.2169, CI 0.57-12.29); Odds Ratio (OR) = 1 (p = 0.9982, CI 0.28-3.6); Odds Ratio (OR) = 1.57 (p = 0.5364, CI 0.38-6.54); Odds Ratio (OR) = 5.68 (p = 0.121, CI 0.63-51.07); Odds Ratio (OR) = 7.65 (p = 0.0726, CI 0.83-70.58); Odds Ratio (OR) = 1.97 (p = 0.3034, CI 0.54-7.17); Odds Ratio (OR) = 1.01 (p = 0.9901, CI 0.28-3.6); Odds Ratio (OR) = 1.55 (p = 0.507, CI 0.42-5.68); Odds Ratio (OR) = 0.83 (p = 0.7927, CI 0.21-3.26); Odds Ratio (OR) = 1.71 (p = 0.4426, CI 0.44-6.69); Odds Ratio (OR) = 0.91 (p = 0.8925, CI 0.23-3.56); Odds Ratio (OR) = 1.79 (p = 0.4285, CI 0.42-7.52); Odds Ratio (OR) = 1.08 (p = 0.9, CI 0.31-3.72); Odds Ratio (OR) = 7.34 (p = 0.0749, CI 0.82-65.81); Odds Ratio (OR) = 4.01 (p = 0.053, CI 0.98-16.35); Odds Ratio (OR) = 2.32 (p = 0.2134, CI 0.62-8.72); Odds Ratio (OR) = 1.88 (p = 0.3688, CI 0.48-7.41); Odds Ratio (OR) = 4.61 (p = 0.0563, CI 0.96-22.11); Odds Ratio (OR) = 3.94 (p = 0.0935, CI 0.79-19.52); Odds Ratio (OR) = 3.71 (p = 0.0901, CI 0.81-16.93); Odds Ratio (OR) = 2.84 (p = 0.1366, CI 0.72-11.26); Odds Ratio (OR) = 1.19 (p = 0.7876, CI 0.34-4.08); Odds Ratio (OR) = 1.59 (p = 0.4658, CI 0.45-5.59); Odds Ratio (OR) = 0.9 (p = 0.8707, CI 0.25-3.2); Odds Ratio (OR) = 1.89 (p = 0.3584, CI 0.49-7.36); Odds Ratio (OR) = 3.13 (p = 0.1455, CI 0.67-14.57); Odds Ratio (OR) = 5.07 (p = 0.0661, CI 0.9-28.66). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 2.12 (p = 0.1114, CI 0.84-5.32); Odds Ratio (OR) = 4.69 (p = 0.0013, CI 1.83-12.04); Odds Ratio (OR) = 7.01 (p = 1e-04, CI 2.65-18.54); Odds Ratio (OR) = 4.96 (p = 0.001, CI 1.91-12.89); Odds Ratio (OR) = 1.25 (p = 0.6384, CI 0.49-3.22); Odds Ratio (OR) = 5.77 (p = 3e-04, CI 2.23-14.93); Odds Ratio (OR) = 4.15 (p = 0.0025, CI 1.65-10.45); Odds Ratio (OR) = 2.82 (p = 0.0279, CI 1.12-7.12); Odds Ratio (OR) = 3.36 (p = 0.0114, CI 1.31-8.61); Odds Ratio (OR) = 7.55 (p = 1e-04, CI 2.66-21.45); Odds Ratio (OR) = 6.41 (p = 5e-04, CI 2.25-18.26); Odds Ratio (OR) = 2.37 (p = 0.0695, CI 0.93-6.02); Odds Ratio (OR) = 4.83 (p = 0.0015, CI 1.83-12.77); Odds Ratio (OR) = 3.28 (p = 0.012, CI 1.3-8.28); Odds Ratio (OR) = 2.49 (p = 0.662, CI 0.94-6.57); Odds Ratio (OR) = 2.22 (p = 0.1019, CI 0.85-5.8); Odds Ratio (OR) = 5.44 (p = 0.0023, CI 1.83-16.18); Odds Ratio (OR) = 7.33 (p = 0.0015, CI 2.15-25.02); Odds Ratio (OR) = 10.16 (p = 0.0043, CI 2.07-49.9); Odds Ratio (OR) = 1.38 (p = 0.5571, CI 0.47-4.04); Odds Ratio (OR) = 2.13 (p = 0.1911, CI 0.69-6.59); Odds Ratio (OR) = 2.74 (p = 0.1101, CI 0.8-9.41); Odds Ratio (OR) = 6.86 (p = 0.0199, CI 1.36-34.74); Odds Ratio (OR) = 1.96 (p = 0.26, CI 0.61-6.33); Odds Ratio (OR) = 8.93 (p = 0.009, CI 1.73-46.19); Odds Ratio (OR) = 17.22 (p = 0.0089, CI 2.04-145.2); Odds Ratio (OR) = 1.07 (p = 0.8966, CI 0.36-3.19); Odds Ratio (OR) = 1.47 (p = 0.5031, CI 0.48-4.51); Odds Ratio (OR) = 2.03 (p = 0.2603, CI 0.59-6.92); Odds Ratio (OR) = 2.15 (p = 0.2569, CI 0.57-8.07); Odds Ratio (OR) = 9.32 (p = 0.0412, CI 1.09-79.44); Odds Ratio (OR) = 2.84 (p = 0.1201, CI 0.76-10.61); Odds Ratio (OR) = 1.67 (p = 0.3814, CI 0.53-5.23); Odds Ratio (OR) = 1.11 (p = 0.8549, CI 0.38-3.23); Odds Ratio (OR) = 2.77 (p = 0.1274, CI 0.75-10.24); Odds Ratio (OR) = 3.67 (p = 0.0703, CI 0.9-15.01); Odds Ratio (OR) = 2.41 (p = 0.1821, CI 0.66-8.76); Odds Ratio (OR) = 12.96 (p = 0.0187, CI 1.53-109.5); Odds Ratio (OR) = 4.18 (p = 0.0458, CI 1.03-17); Odds Ratio (OR) = 1.27 (p = 0.6806, CI 0.41-3.89); Odds Ratio (OR) = 1.15 (p = 0.809, CI 0.38-3.45); Odds Ratio (OR) = 2.22 (p = 0.2352, CI 0.6-8.26); Odds Ratio (OR) = 3.04 (p = 0.1231, CI 0.74-12.5); Odds Ratio (OR) = 2.8 (p = 0.16, CI 0.67-11.76); Odds Ratio (OR) = 6.13 (p = 0.0317, CI 1.17-32.11); Odds Ratio (OR) = 3.73 (p = 0.0709, CI 0.89-15.53); Odds Ratio (OR) = 1.6 (p = 0.4533, CI 0.47-5.41); Odds Ratio (OR) = 0.8 (p = 0.7053, CI 0.24-2.6); Odds Ratio (OR) = 1.84 (p = 0.3677, CI 0.49-6.99); Odds Ratio (OR) = 1.24 (p = 0.735, CI 0.35-4.4); Odds Ratio (OR) = 1.37 (p = 0.6443, CI 0.36-5.15); Odds Ratio (OR) = 1.58 (p = 0.4865, CI 0.43-5.76); Odds Ratio (OR) = 2.52 (p = 0.1628, CI 0.69-9.27); Odds Ratio (OR) = 0.79 (p = 0.6935, CI 0.24-2.57); Odds Ratio (OR) = 1.02 (p = 0.9753, CI 0.32-3.28); Odds Ratio (OR) = 0.81 (p = 0.7407, CI 0.23-2.81); Odds Ratio (OR) = 1.55 (p = 0.4929, CI 0.44-5.49); Odds Ratio (OR) = 0.88 (p = 0.8496, CI 0.25-3.15); Odds Ratio (OR) = 1.92 (p = 0.3248, CI 0.52-7.05); Odds Ratio (OR) = 2.03 (p = 0.2589, CI 0.59-6.92); Odds Ratio (OR) = 0.54 (p = 0.3318, CI 0.16-1.87); Odds Ratio (OR) = 0.89 (p = 0.8536, CI 0.26-3.01); Odds Ratio (OR) = 0.48 (p = 0.2817, CI 0.12-1.84); Odds Ratio (OR) = 0.59 (p = 0.4091, CI 0.17-2.07); Odds Ratio (OR) = 1.78 (p = 0.238, CI 0.68-4.66); Odds Ratio (OR) = 3.61 (p = 0.012, CI 1.33-9.81); Odds Ratio (OR) = 2.25 (p = 0.091, CI 0.88-5.77); Odds Ratio (OR) = 1.93 (p = 0.1926, CI 0.72-5.18); Odds Ratio (OR) = 2.29 (p = 0.1017, CI 0.85-6.15); Odds Ratio (OR) = 3.85 (p = 0.0153, CI 1.29-11.45); Odds Ratio (OR) = 7.52 (p = 0.0034, CI 1.95-28.98); Odds Ratio (OR) = 1.44 (p = 0.4539, CI 0.55-3.76); Odds Ratio (OR) = 3.03 (p = 0.0327, CI 1.1-8.4); Odds Ratio (OR) = 2.67 (p = 0.0555, CI 0.98-7.3); Odds Ratio (OR) = 1.64 (p = 0.3505, CI 0.58-4.67); Odds Ratio (OR) = 3.92 (p = 0.0265, CI 1.17-13.11); Odds Ratio (OR) = 4.77 (p = 0.0174, CI 1.32-17.32); Odds Ratio (OR) = 8.95 (p = 0.0075, CI 1.8-44.61); Odds Ratio (OR) = 2.46 (p = 0.1228, CI 0.78-7.68); Odds Ratio (OR) = 3.28 (p = 0.0431, CI 1.04-10.38); Odds Ratio (OR) = 2.7 (p = 0.0851, CI 0.87-8.35); Odds Ratio (OR) = 1.45 (p = 0.4726, CI 0.53-3.99); Odds Ratio (OR) = 2.29 (p = 0.1289, CI 0.79-6.67); Odds Ratio (OR) = 3.39 (p = 0.04, CI 1.06-10.84); Odds Ratio (OR) = 8.22 (p = 0.0097, CI 1.67-40.55); Odds Ratio (OR) = 1.97 (p = 0.226, CI 0.66-5.94); Odds Ratio (OR) = 8.63 (p = 0.0031, CI 2.07-35.96); Odds Ratio (OR) = 2.16 (p = 0.2447, CI 0.59-7.88); Odds Ratio (OR) = 1.64 (p = 0.4239, CI 0.49-5.55); Odds Ratio (OR) = 11.72 (p = 0.024, CI 1.38-99.35); Odds Ratio (OR) = 2.6 (p = 0.1457, CI 0.72-9.41); Odds Ratio (OR) = 1.08 (p = 0.9, CI 0.34-3.38); Odds Ratio (OR) = 1.19 (p = 0.7644, CI 0.39-3.64); Odds Ratio (OR) = 2.29 (p = 0.2245, CI 0.6-8.67); Odds Ratio (OR) = 5.28 (p = 0.0475, CI 1.02-27.4); Odds Ratio (OR) = 2.86 (p = 0.1445, CI 0.7-11.76); Odds Ratio (OR) = 12.03 (p = 0.023, CI 1.41-102.7); Odds Ratio (OR) = 3.51 (p = 0.0801, CI 0.86-14.36); Odds Ratio (OR) = 1.63 (p = 0.4152, CI 0.5-5.32); Odds Ratio (OR) = 1.7 (p = 0.3845, CI 0.51-5.65); Odds Ratio (OR) = 2.46 (p = 0.1864, CI 0.65-9.39); Odds Ratio (OR) = 3.06 (p = 0.01268, CI 0.73-12.86); Odds Ratio (OR) = 0.5 (p = 0.3147, CI 0.13-1.93); Odds Ratio (OR) = 0.89 (p = 0.8547, CI 0.24-3.24); Odds Ratio (OR) = 0.66 (p = 0.5023, CI 0.2-2.19). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 3.34 (p = 0.0148, CI 1.27-8.81); Odds Ratio (OR) = 5.05 (p = 0.0018, CI 1.83-13.94); Odds Ratio (OR) = 7.27 (p = 7e-04, CI 2.32-22.78); Odds Ratio (OR) = 3.11 (p = 0.0246, CI 1.16-8.35); Odds Ratio (OR) = 5.22 (p = 0.0016, CI 1.87-14.6); Odds Ratio (OR) = 2.25 (p = 0.0825, CI 0.9-5.62); Odds Ratio (OR) = 2.66 (p = 0.0542, CI 0.98-7.2); Odds Ratio (OR) = 2.38 (p = 0.0837, CI 0.89-6.33); Odds Ratio (OR) = 3.67 (p = 0.0131, CI 1.31-10.26); Odds Ratio (OR) = 9.34 (p = 0.0012, CI 2.41-36.19); Odds Ratio (OR) = 3.1 (p = 0.0359, CI 1.08-8.93); Odds Ratio (OR) = 5.86 (p = 0.0019, CI 1.91-17.92); Odds Ratio (OR) = 2.43 (p = 0.0715, CI 0.93-6.38); Odds Ratio (OR) = 2.89 (p = 0.0465, CI 1.02-8.2); Odds Ratio (OR) = 2.41 (p = 0.0602, CI 0.96-6.06); Odds Ratio (OR) = 4.88 (p = 0.001, CI 1.89-12.57); Odds Ratio (OR) = 5.24 (p = 6e-04, CI 2.03-13.51); Odds Ratio (OR) = 9.07 (p = 1e-04, CI 3.23-25.45); Odds Ratio (OR) = 2.06 (p = 0.1259, CI 0.82-5.22); Odds Ratio (OR) = 7.05 (p = 1e-04, CI 2.65-18.71); Odds Ratio (OR) = 3.51 (p = 0.007, CI 1.41-8.76); Odds Ratio (OR) = 3.15 (p = 0.0193, CI 1.2-8.23); Odds Ratio (OR) = 2.41 (p = 0.0839, CI 0.89-6.53); Odds Ratio (OR) = 3.56 (p = 0.0191, CI 1.23-10.28); Odds Ratio (OR) = 12.11 (p = 0.0019, CI 2.52-58.22); Odds Ratio (OR) = 2.76 (p = 0.0593, CI 0.96-7.9); Odds Ratio (OR) = 4.95 (p = 0.0048, CI 1.63-15.04); Odds Ratio (OR) = 2.75 (p = 0.0494, CI 1-7.57); Odds Ratio (OR) = 2.15 (p = 0.1887, CI 0.69-6.7); Odds Ratio (OR) = 3.06 (p = 0.0717, CI 0.91-10.7); Odds Ratio (OR) = 2.43 (p = 0.1419, CI 0.74-7.92); Odds Ratio (OR) = 14.37 (p = 0.0141, CI 1.71-120.6); Odds Ratio (OR) = 3.19 (p = 0.0775, CI 0.88-11.54); Odds Ratio (OR) = 3.55 (p = 0.0537, CI 0.98-12.86); Odds Ratio (OR) = 7.72 (p = 0.0144, CI 1.5-39.66); Odds Ratio (OR) = 1.29 (p = 0.666, CI 0.41-4.09); Odds Ratio (OR) = 1.16 (p = 0.7923, CI 0.37-3.62); Odds Ratio (OR) = 1.73 (p = 0.3796, CI 0.51-5.9); Odds Ratio (OR) = 4.2 (p = 0.0874, CI 0.81-21.73); Odds Ratio (OR) = 2.6 (p = 0.1925, CI 0.62-10.96); Odds Ratio (OR) = 3.99 (p = 0.0651, CI 0.92-17.38); Odds Ratio (OR) = 1.46 (p = 0.5361, CI 0.44-4.81); Odds Ratio (OR) = 1.33 (p = 0.6258, CI 0.42-4.17); Odds Ratio (OR) = 4.35 (p = 0.0283, CI 1.17-16.19); Odds Ratio (OR) = 2.21 (p = 0.1767, CI 0.7-6.96); Odds Ratio (OR) = 2.2 (p = 0.1675, CI 0.72-6.72); Odds Ratio (OR) = 1.84 (p = 0.2717, CI 0.62-5.49); Odds Ratio (OR) = 2.4 (p = 0.1367, CI 0.76-7.64); Odds Ratio (OR) = 13.53 (p = 0.0162, CI 1.62-113); Odds Ratio (OR) = 3.23 (p = 0.0765, CI 0.88-11.78); Odds Ratio (OR) = 7.8 (p = 0.0061, CI 1.79-33.87); Odds Ratio (OR) = 5.4 (p = 0.0181, CI 1.33-21.85); Odds Ratio (OR) = 1.63 (p = 0.3925, CI 0.53-4.99); Odds Ratio (OR) = 1.66 (p = 0.374, CI 0.54-5.12); Odds Ratio (OR) = 2.33 (p = 0.1753, CI 0.69-7.93); Odds Ratio (OR) = 12.85 (p = 0.0195, CI 1.51-109.5); Odds Ratio (OR) = 2.29 (p = 0.1932, CI 0.66-8.02); Odds Ratio (OR) = 1.32 (p = 0.6275, CI 0.43-4.06); Odds Ratio (OR) = 2.21 (p = 0.2212, CI 0.62-7.9); Odds Ratio (OR) = 11.13 (p = 0.028, CI 1.3-95.49); Odds Ratio (OR) = 4.88 (p = 0.0589, CI 0.94-25.32); Odds Ratio (OR) = 3.63 (p = 0.0799, CI 0.86-15.39); Odds Ratio (OR) = 2.91 (p = 0.1112, CI 0.78-10.87); Odds Ratio (OR) = 1.41 (p = 0.5529, CI 0.45-4.39); Odds Ratio (OR) = 1.87 (p = 0.3268, CI 0.53-6.55); Odds Ratio (OR) = 10.02 (p = 0.0343, CI 1.19-84.66); Odds Ratio (OR) = 9.45 (p = 0.0391, CI 1.12-79.82); Odds Ratio (OR) = 13.31 (p = 0.0187, CI 1.54-115.1); Odds Ratio (OR) = 2.6 (p = 0.1475, CI 0.71-9.47); Odds Ratio (OR) = 2.19 (p = 0.2161, CI 0.63-7.55); Odds Ratio (OR) = 1.79 (p = 0.3478, CI 0.53-6.04); Odds Ratio (OR) = 2.22 (p = 0.2269, CI 0.61-8.14); Odds Ratio (OR) = 4.66 (p = 0.0683, CI 0.89-24.35); Odds Ratio (OR) = 7.11 (p = 0.0228, CI 1.31-38.49); Odds Ratio (OR) = 3.95 (p = 0.062, CI 0.93-16.72); Odds Ratio (OR) = 2.18 (p = 0.2251, CI 0.62-7.67); Odds Ratio (OR) = 2.76 (p = 0.0959, CI 0.84-9.11); Odds Ratio (OR) = 1.62 (p = 0.3886, CI 0.54-4.85); Odds Ratio (OR) = 3 (p = 0.0864, CI 0.85-10.52); Odds Ratio (OR) = 14.22 (p = 0.0145, CI 1.69-119.5); Odds Ratio (OR) = 13.08 (p = 0.018, CI 1.56-110); Odds Ratio (OR) = 18.53 (p = 0.008, CI 2.14-160.6); Odds Ratio (OR) = 5.07 (p = 0.0236, CI 1.24-20.65); Odds Ratio (OR) = 1.59 (p = 0.4303, CI 0.5-5.07); Odds Ratio (OR) = 1.18 (p = 0.7908, CI 0.35-3.99); Odds Ratio (OR) = 1.84 (p = 0.3735, CI 0.48-7.06); Odds Ratio (OR) = 2.49 (p = 0.1856, CI 0.64-9.64); Odds Ratio (OR) = 2.67 (p = 0.01798, CI 0.64-11.2); Odds Ratio (OR) = 3.19 (p = 0.1101, CI 0.77-13.22); Odds Ratio (OR) = 2.99 (p = 0.106, CI 0.79-11.31); Odds Ratio (OR) = 1.47 (p = 0.5258, CI 0.45-4.86); Odds Ratio (OR) = 1.1 (p = 0.8746, CI 0.34-3.5); Odds Ratio (OR) = 0.82 (p = 0.7434, CI 0.24-2.77); Odds Ratio (OR) = 1.9 (p = 0.3211, CI 0.53-6.8); Odds Ratio (OR) = 1.51 (p = 0.533, CI 0.41-5.48); Odds Ratio (OR) = 3 (p = 0.1119, CI 0.77-11.64); Odds Ratio (OR) = 1.76 (p = 0.354, CI 0.53-5.85); Odds Ratio (OR) = 0.65 (p = 0.5076, CI 0.19-2.29); Odds Ratio (OR) = 0.71 (p = 0.5801, CI 0.21-2.41); Odds Ratio (OR) = 0.48 (p = 0.2785, CI 0.13-1.82); Odds Ratio (OR) = 0.69 (p = 0.5656, CI 0.19-2.45); Odds Ratio (OR) = 0.73 (p = 0.6445, CI 0.19-2.81); Odds Ratio (OR) = 1.27 (p = 0.7363, CI 0.32-4.99); Odds Ratio (OR) = 0.56 (p = 0.3455, CI 0.17-1.86). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 4.12 (p = 0.0034, CI 1.6-10.62); Odds Ratio (OR) = 6.55 (p = 2e-04, CI 2.45-17.47); Odds Ratio (OR) = 4.9 (p = 0.0014, CI 1.85-12.98); Odds Ratio (OR) = 2.26 (p = 0.0872, CI 0.89-5.74); Odds Ratio (OR) = 3.19 (p = 0.0131, CI 1.28-7.98); Odds Ratio (OR) = 2.6 (p = 0.0386, CI 1.05-6.43); Odds Ratio (OR) = 3.11 (p = 0.0191, CI 1.2-8.05); Odds Ratio (OR) = 2.84 (p = 0.0291, CI 1.11-7.26); Odds Ratio (OR) = 6.09 (p = 4e-04, CI 2.23-16.58); Odds Ratio (OR) = 7.24 (p = 3e-04, CI 2.49-21.02); Odds Ratio (OR) = 2.22 (p = 0.0992, CI 0.86-5.72); Odds Ratio (OR) = 5.66 (p = 6e-04, CI 2.11-15.16); Odds Ratio (OR) = 3.74 (p = 0.006, CI 1.46-9.59); Odds Ratio (OR) = 2.01 (p = 0.1472, CI 0.78-5.14); Odds Ratio (OR) = 1.57 (p = 0.3698, CI 0.59-4.22); Odds Ratio (OR) = 4.58 (p = 0.0059, CI 1.55-13.53); Odds Ratio (OR) = 3.32 (p = 0.0241, CI 1.17-9.44); Odds Ratio (OR) = 1.38 (p = 0.5308, CI 0.5-3.77); Odds Ratio (OR) = 1.09 (p = 0.8603, CI 0.41-2.9); Odds Ratio (OR) = 3.73 (p = 0.0264, CI 1.17-11.95); Odds Ratio (OR) = 4.6 (p = 0.0188, CI 1.29-16.42); Odds Ratio (OR) = 1.17 (p = 0.7642, CI 0.42-3.27); Odds Ratio (OR) = 4.91 (p = 0.0101, CI 1.46-16.53); Odds Ratio (OR) = 2.88 (p = 0.0572, CI 0.97-8.55); Odds Ratio (OR) = 1.19 (p = 0.7348, CI 0.44-3.2); Odds Ratio (OR) = 2.2 (p = 0.1397, CI 0.77-6.25); Odds Ratio (OR) = 4.07 (p = 0.0231, CI 1.21-13.64); Odds Ratio (OR) = 4.54 (p = 0.0196, CI 1.27-16.15); Odds Ratio (OR) = 1.16 (p = 0.7703, CI 0.42-3.24); Odds Ratio (OR) = 3.83 (p = 0.0222, CI 1.21-12.12); Odds Ratio (OR) = 2.77 (p = 0.0668, CI 0.93-8.21); Odds Ratio (OR) = 1.18 (p = 0.7533, CI 0.43-3.22); Odds Ratio (OR) = 1.67 (p = 0.3325, CI 0.59-4.73); Odds Ratio (OR) = 2.71 (p = 0.0899, CI 0.86-8.57); Odds Ratio (OR) = 3.31 (p = 0.0642, CI 0.93-11.79); Odds Ratio (OR) = 1.34 (p = 0.5964, CI 0.46-3.89); Odds Ratio (OR) = 4.43 (p = 0.0224, CI 1.23-15.91); Odds Ratio (OR) = 1.72 (p = 0.3139, CI 0.6-4.96); Odds Ratio (OR) = 1.3 (p = 0.6343, CI 0.45-3.76); Odds Ratio (OR) = 1.27 (p = 0.6557, CI 0.45-3.61); Odds Ratio (OR) = 3.66 (p = 0.0516, CI 0.99-13.51); Odds Ratio (OR) = 4.38 (p = 0.04, CI 1.07-17.91); Odds Ratio (OR) = 1.37 (p = 0.5825, CI 0.44-4.24); Odds Ratio (OR) = 7.46 (p = 0.0152, CI 1.47-37.83); Odds Ratio (OR) = 2.3 (p = 0.1565, CI 0.73-7.3); Odds Ratio (OR) = 1.45 (p = 0.4932, CI 0.5-4.25); Odds Ratio (OR) = 1.11 (p = 0.8504, CI 0.39-3.12); Odds Ratio (OR) = 3.07 (p = 0.0759, CI 0.89-10.61); Odds Ratio (OR) = 3.69 (p = 0.0477, CI 1.01-13.46); Odds Ratio (OR) = 2.47 (p = 0.1448, CI 0.73-8.36); Odds Ratio (OR) = 5.54 (p = 0.0173, CI 1.35-22.71); Odds Ratio (OR) = 2.57 (p = 0.1101, CI 0.81-8.17); Odds Ratio (OR) = 1.32 (p = 0.6022, CI 0.46-3.78); Odds Ratio (OR) = 1.31 (p = 0.6128, CI 0.46-3.73); Odds Ratio (OR) = 2.82 (p = 0.1001, CI 0.82-9.68); Odds Ratio (OR) = 4.95 (p = 0.0255, CI 1.22-20.12); Odds Ratio (OR) = 2.42 (p = 0.1521, CI 0.72-8.1); Odds Ratio (OR) = 9.37 (p = 0.0071, CI 1.84-47.69); Odds Ratio (OR) = 2.52 (p = 0.115, CI 0.8-7.93); Odds Ratio (OR) = 1.14 (p = 0.8101, CI 0.4-3.22); Odds Ratio (OR) = 1.49 (p = 0.4663, CI 0.51-4.33); Odds Ratio (OR) = 3.8 (p = 0.0453, CI 1.03-14.01); Odds Ratio (OR) = 3.36 (p = 0.0659, CI 0.92-12.21); Odds Ratio (OR) = 1.83 (p = 0.3117, CI 0.57-5.86); Odds Ratio (OR) = 6.02 (p = 0.0129, CI 1.46-24.73); Odds Ratio (OR) = 4.12 (p = 0.0303, CI 1.14-14.83); Odds Ratio (OR) = 1.94 (p = 0.2772, CI 0.59-6.42); Odds Ratio (OR) = 0.96 (p = 0.9432, CI 0.29-3.16); Odds Ratio (OR) = 2.08 (p = 0.2577, CI 0.59-7.36); Odds Ratio (OR) = 2.55 (p = 0.1496, CI 0.71-9.12); Odds Ratio (OR) = 2.05 (p = 0.2874, CI 0.55-7.67); Odds Ratio (OR) = 2.26 (p = 0.1981, CI 0.65-7.78); Odds Ratio (OR) = 3.35 (p = 0.0531, CI 0.98-11.43); Odds Ratio (OR) = 0.72 (p = 0.5858, CI 0.22-2.35); Odds Ratio (OR) = 0.68 (p = 0.5122, CI 0.21-2.16); Odds Ratio (OR) = 0.55 (p = 0.3415, CI 0.16-1.89); Odds Ratio (OR) = 0.87 (p = 0.8263, CI 0.25-2.98); Odds Ratio (OR) = 0.86 (p = 0.8085, CI 0.24-3.03); Odds Ratio (OR) = 1.3 (p = 0.6745, CI 0.38-4.43); Odds Ratio (OR) = 1.08 (p = 0.9019, CI 0.34-3.45); Odds Ratio (OR) = 0.62 (p = 0.4425, CI 0.18-2.1); Odds Ratio (OR) = 0.54 (p = 0.3106, CI 0.17-1.77); Odds Ratio (OR) = 0.32 (p = 0.0912, CI 0.08-1.2); Odds Ratio (OR) = 0.7 (p = 0.5681, CI 0.2-2.41); Odds Ratio (OR) = 0.58 (p = 0.4261, CI 0.15-2.21); Odds Ratio (OR) = 0.82 (p = 0.7514, CI 0.24-2.82); Odds Ratio (OR) = 0.52 (p = 0.2712, CI 0.16-1.67); Odds Ratio (OR) = 3.99 (p = 0.0093, CI 1.41-11.35); Odds Ratio (OR) = 4.66 (p = 0.0035, CI 1.66-13.09); Odds Ratio (OR) = 8.48 (p = 1e-04, CI 3.01-23.9); Odds Ratio (OR) = 7.57 (p = 2e-04, CI 2.65-21.59); Odds Ratio (OR) = 2.13 (p = 0.1664, CI 0.73-6.22); Odds Ratio (OR) = 5.39 (p = 0.0012, CI 1.94-14.96); Odds Ratio (OR) = 9.85 (p = 1e-04, CI 3.49-27.86); Odds Ratio (OR) = 2.73 (p = 0.0334, CI 1.08-6.89); Odds Ratio (OR) = 2.05 (p = 0.1284, CI 0.81-5.15); Odds Ratio (OR) = 3.55 (p = 0.0117, CI 1.32-9.5); Odds Ratio (OR) = 4.24 (p = 0.0067, CI 1.49-12.03); Odds Ratio (OR) = 1.47 (p = 0.4088, CI 0.59-3.71); Odds Ratio (OR) = 3.09 (p = 0.0194, CI 1.2-7.96); Odds Ratio (OR) = 2.64 (p = 0.0423, CI 1.03-6.73); Odds Ratio (OR) = 1.86 (p = 0.2151, CI 0.7-4.99); Odds Ratio (OR) = 2.71 (p = 0.0531, CI 0.99-7.42); Odds Ratio (OR) = 4.11 (p = 0.0118, CI 1.37-12.34); Odds Ratio (OR) = 16.28 (p = 6e-04, CI 3.29-80.46). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 4.4 (p = 0.002, CI 1.72-11.29); Odds Ratio (OR) = 2.76 (p = 0.0291, CI 1.11-6.86); Odds Ratio (OR) = 4.3 (p = 0.0037, CI 1.6-11.54); Odds Ratio (OR) = 3.95 (p = 0.0057, CI 1.49-10.48); Odds Ratio (OR) = 6.03 (p = 3e-04, CI 2.26-16.13); Odds Ratio (OR) = 6.42 (p = 3e-04, CI 2.37-17.39); Odds Ratio (OR) = 2.11 (p = 0.141, CI 0.78-5.73); Odds Ratio (OR) = 5.85 (p = 4e-04, CI 2.2-15.55); Odds Ratio (OR) = 5.5 (p = 6e-04, CI 2.08-14.54); Odds Ratio (OR) = 4.09 (p = 0.0037, CI 1.58-10.57); Odds Ratio (OR) = 4.31 (p = 0.0026, CI 1.67-11.16); Odds Ratio (OR) = 6.26 (p = 2e-04, CI 2.63-16.6); Odds Ratio (OR) = 9.4 (p = 1e-04, CI 3.23-27.34); Odds Ratio (OR) = 2.64 (p = 0.0431, CI 1.03-6.76); Odds Ratio (OR) = 3.96 (p = 0.0063, CI 1.48-10.61); Odds Ratio (OR) = 3.11 (p = 0.0202, CI 1.19-8.11); Odds Ratio (OR) = 4.1 (p = 0.0044, CI 1.55-10.84); Odds Ratio (OR) = 9.21 (p = 2e-04, CI 2.89-29.38); Odds Ratio (OR) = 2.43 (p = 0.0706, CI 0.93-6.37); Odds Ratio (OR) = 8.2 (p = 1e-04, CI 2.79-24.08); Odds Ratio (OR) = 3.24 (p = 0.0146, CI 1.26-8.32); Odds Ratio (OR) = 2.37 (p = 0.0816, CI 0.9-6.24); Odds Ratio (OR) = 2.25 (p = 0.093, CI 0.87-5.81); Odds Ratio (OR) = 2.81 (p = 0.365, CI 1.07-7.39); Odds Ratio (OR) = 4.93 (p = 0.0042, CI 1.65-14.73); Odds Ratio (OR) = 2.17 (p = 0.1577, CI 0.74-6.37); Odds Ratio (OR) = 2.73 (p = 0.0488, CI 1.01-7.41); Odds Ratio (OR) = 3.85 (p = 0.0075, CI 1.43-10.36); Odds Ratio (OR) = 2.2 (p = 0.0984, CI 0.86-5.59); Odds Ratio (OR) = 1.89 (p = 0.2226, CI 0.68-5.29); Odds Ratio (OR) = 2.16 (p = 0.1467, CI 0.76-6.08); Odds Ratio (OR) = 2.74 (p = 0.0705, CI 0.92-8.19); Odds Ratio (OR) = 26.62 (p = 0.0025, CI 3.16-223.9); Odds Ratio (OR) = 2.75 (p = 0.0757, CI 0.9-8.4); Odds Ratio (OR) = 2.16 (p = 0.1608, CI 0.74-6.34); Odds Ratio (OR) = 2.96 (p = 0.0693, CI 0.92-9.53); Odds Ratio (OR) = 9.57 (p = 0.0063, CI 1.89-48.39); Odds Ratio (OR) = 2.25 (p = 0.1637, CI 0.72-7.05); Odds Ratio (OR) = 3.57 (p = 0.0326, CI 1.11-11.47); Odds Ratio (OR) = 2.24 (p = 0.1455, CI 0.76-6.67); Odds Ratio (OR) = 2.08 (p = 0.1951, CI 0.69-6.32); Odds Ratio (OR) = 5.66 (p = 0.0045, CI 1.71-18.74); Odds Ratio (OR) = 2.63 (p = 0.0771, CI 0.9-7.67); Odds Ratio (OR) = 2.03 (p = 0.1856, CI 0.71-5.81); Odds Ratio (OR) = 1.31 (p = 0.5973, CI 0.48-3.54); Odds Ratio (OR) = 2.57 (p = 0.0935, CI 0.85-7.77); Odds Ratio (OR) = 5.52 (p = 0.0157, CI 1.38-22.1); Odds Ratio (OR) = 2.08 (p = 0.1963, CI 0.68-6.32); Odds Ratio (OR) = 1.56 (p = 0.4097, CI 0.54-4.53); Odds Ratio (OR) = 2.29 (p = 0.1554, CI 0.73-7.22); Odds Ratio (OR) = 4.22 (p = 0.044, CI 1.04-17.14); Odds Ratio (OR) = 2.23 (p = 0.1928, CI 0.67-7.47); Odds Ratio (OR) = 4.67 (p = 0.0222, CI 1.25-17.47); Odds Ratio (OR) = 1.58 (p = 0.4075, CI 0.54-4.65); Odds Ratio (OR) = 5.31 (p = 0.0085, CI 1.53-18.43); Odds Ratio (OR) = 2.21 (p = 0.1433, CI 0.76-6.38); Odds Ratio (OR) = 4.75 (p = 0.0306, CI 1.16-19.52); Odds Ratio (OR) = 10.1 (p = 0.0059, CI 1.92-52.29); Odds Ratio (OR) = 1.65 (p = 0.3659, CI 0.56-4.93); Odds Ratio (OR) = 1.15 (p = 0.7878, CI 0.41-3.24); Odds Ratio (OR) = 3.26 (p = 0.0635, CI 0.94-11.38); Odds Ratio (OR) = 14.62 (p = 0.0137, CI 1.73-123.3); Odds Ratio (OR) = 2.64 (p = 0.1004, CI 0.83-8.43); Odds Ratio (OR) = 2.11 (p = 0.1837, CI 0.7-6.36); Odds Ratio (OR) = 1.33 (p = 0.5929, CI 0.47-3.75); Odds Ratio (OR) = 1.93 (p = 0.2588, CI 0.62-6.07); Odds Ratio (OR) = 2.91 (p = 0.1069, CI 0.79-10.62); Odds Ratio (OR) = 5.6 (p = 0.0186, CI 1.33-23.47); Odds Ratio (OR) = 2.37 (p = 0.1434, CI 0.75-7.56); Odds Ratio (OR) = 2.2 (p = 0.167, CI 0.72-6.75); Odds Ratio (OR) = 1.16 (p = 0.781, CI 0.41-3.28); Odds Ratio (OR) = 2.27 (p = 0.1682, CI 0.71-7.26); Odds Ratio (OR) = 5.22 (p = 0.0215, CI 1.28-21.39); Odds Ratio (OR) = 2.84 (p = 0.0938, CI 0.84-9.66); Odds Ratio (OR) = 8.02 (p = 0.0125, CI 1.57-41.08); Odds Ratio (OR) = 3.29 (p = 0.0761, CI 0.88-12.23); Odds Ratio (OR) = 4.02 (p = 0.0305, CI 1.14-14.16); Odds Ratio (OR) = 3.42 (p = 0.0501, CI 1-11.68); Odds Ratio (OR) = 2.61 (p = 0.1212, CI 0.78-8.77); Odds Ratio (OR) = 1.13 (p = 0.8332, CI 0.35-3.68); Odds Ratio (OR) = 1.66 (p = 0.4285, CI 0.48-5.76); Odds Ratio (OR) = 1.4 (p = 0.5761, CI 0.43-4.58); Odds Ratio (OR) = 0.64 (p = 0.454, CI 0.2-2.04); Odds Ratio (OR) = 0.57 (p = 0.3732, CI 0.17-1.96); Odds Ratio (OR) = 1.59 (p = 0.4665, CI 0.46-5.5); Odds Ratio (OR) = 1.46 (p = 0.5634, CI 0.41-5.25); Odds Ratio (OR) = 1.65 (p = 0.4297, CI 0.48-5.7); Odds Ratio (OR) = 0.98 (p = 0.9789, CI 0.31-3.14); Odds Ratio (OR) = 0.81 (p = 0.7357, CI 0.24-2.7); Odds Ratio (OR) = 0.46 (p = 0.1977, CI 0.14-1.5); Odds Ratio (OR) = 0.52 (p = 0.3203, CI 0.14-1.88); Odds Ratio (OR) = 1.02 (p = 0.9739, CI 0.3-3.44); Odds Ratio (OR) = 1.33 (p = 0.6714, CI 0.36-4.97); Odds Ratio (OR) = 7.69 (p = 0.0129, CI 1.54-38.41); Odds Ratio (OR) = 7.12 (p = 0.0168, CI 1.42-35.61); Odds Ratio (OR) = 9.95 (p = 0.0058, CI 1.94-50.97); Odds Ratio (OR) = 2.08 (p = 0.1934, CI 0.69-6.26); Odds Ratio (OR) = 2.01 (p = 0.2181, CI 0.66-6.12); Odds Ratio (OR) = 1.58 (p = 0.4116, CI 0.53-4.71); Odds Ratio (OR) = 2.98 (p = 0.0954, CI 0.83-10.74); Odds Ratio (OR) = 2.98 (p = 0.111, CI 0.78-11.38); Odds Ratio (OR) = 2.44 (p = 0.1642, CI 0.69-8.55); Odds Ratio (OR) = 2.19 (p = 0.1976, CI 0.66-7.24); Odds Ratio (OR) = 0.75 (p = 0.6375, CI 0.22-2.52); Odds Ratio (OR) = 0.54 (p = 0.298, CI 0.17-1.71). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 4.89 (p = 0.0103, CI 1.46-16.4); Odds Ratio (OR) = 7.19 (p = 0.0011, CI 2.2-23.48); Odds Ratio (OR) = 11.06 (p = 1e-04, CI 3.41-35.86); Odds Ratio (OR) = 10.48 (p = 1e-04, CI 3.18-34.55); Odds Ratio (OR) = 2.46 (p = 0.1571, CI 0.71-8.55); Odds Ratio (OR) = 7.14 (p = 0.001, CI 2.21-23.04); Odds Ratio (OR) = 7.35 (p = 8e-04, CI 2.29-23.61); Odds Ratio (OR) = 2.78 (p = 0.0342, CI 1.08-7.18); Odds Ratio (OR) = 2.98 (p = 0.0231, CI 1.16-7.66); Odds Ratio (OR) = 4.12 (p = 0.0032, CI 1.6-10.55); Odds Ratio (OR) = 3.89 (p = 0.0059, CI 1.48-10.22); Odds Ratio (OR) = 1.76 (p = 0.2471, CI 0.68-4.59); Odds Ratio (OR) = 2.66 (p = 0.0381, CI 1.05-6.7); Odds Ratio (OR) = 3.34 (p = 0.0113, CI 1.31-8.48); Odds Ratio (OR) = 2.56 (p = 0.0486, CI 1.01-6.52); Odds Ratio (OR) = 2.71 (p = 0.035, CI 1.07-6.87); Odds Ratio (OR) = 4.24 (p = 0.0027, CI 1.65-10.9); Odds Ratio (OR) = 4.68 (p = 0.002, CI 1.76-12.47); Odds Ratio (OR) = 2.41 (p = 0.0686, CI 0.94-6.19); Odds Ratio (OR) = 4.02 (p = 0.0034, CI 1.58-10.21); Odds Ratio (OR) = 2.9 (p = 0.0222, CI 1.16-7.22); Odds Ratio (OR) = 2.28 (p = 0.0876, CI 0.89-5.84); Odds Ratio (OR) = 2.72 (p = 0.0345, CI 1.08-6.88); Odds Ratio (OR) = 2.76 (p = 0.0319, CI 1.09-6.99); Odds Ratio (OR) = 5.27 (p = 0.0013, CI 1.92-14.47); Odds Ratio (OR) = 1.91 (p = 0.1751, CI 0.75-4.87); Odds Ratio (OR) = 4.46 (p = 0.0019, CI 1.73-11.5); Odds Ratio (OR) = 2.79 (p = 0.0284, CI 1.11-6.97); Odds Ratio (OR) = 1.72 (p = 0.265, CI 0.66-4.45); Odds Ratio (OR) = 2.1 (p = 0.1238, CI 0.82-5.38); Odds Ratio (OR) = 3.22 (p = 0.0219, CI 1.18-8.74); Odds Ratio (OR) = 5.46 (p = 0.0022, CI 1.84-16.16); Odds Ratio (OR) = 1.82 (p = 0.223, CI 0.69-4.77); Odds Ratio (OR) = 5.05 (p = 0.0018, CI 1.83-13.97); Odds Ratio (OR) = 3.17 (p = 0.0205, CI 1.19-8.42); Odds Ratio (OR) = 1.44 (p = 0.4628, CI 0.54-3.81); Odds Ratio (OR) = 1.51 (p = 0.4015, CI 0.58-3.92); Odds Ratio (OR) = 5.39 (p = 0.0031, CI 1.76-16.47); Odds Ratio (OR) = 4.15 (p = 0.0115, CI 1.38-12.5); Odds Ratio (OR) = 1.81 (p = 0.2513, CI 0.66-4.98); Odds Ratio (OR) = 3.94 (p = 0.0099, CI 1.39-11.14); Odds Ratio (OR) = 3.19 (p = 0.0242, CI 1.16-8.74); Odds Ratio (OR) = 2.07 (p = 0.1518, CI 0.77-5.6); Odds Ratio (OR) = 1.95 (p = 0.1811, CI 0.73-5.17); Odds Ratio (OR) = 3.88 (p = 0.015, CI 1.3-11.55); Odds Ratio (OR) = 5.28 (p = 0.0046, CI 1.67-16.68); Odds Ratio (OR) = 1.58 (p = 0.3788, CI 0.57-4.34); Odds Ratio (OR) = 2.82 (p = 0.0424, CI 1.04-7.7); Odds Ratio (OR) = 3.69 (p = 0.0139, CI 1.3-10.43); Odds Ratio (OR) = 1.67 (p = 0.3057, CI 0.63-4.42); Odds Ratio (OR) = 1.55 (p = 0.3717, CI 0.59-4.02); Odds Ratio (OR) = 3.32 (p = 0.0252, CI 1.16-9.5); Odds Ratio (OR) = 3.56 (p = 0.0235, CI 1.19-10.69); Odds Ratio (OR) = 1.25 (p = 0.658, CI 0.46-3.39); Odds Ratio (OR) = 4.58 (p = 0.0061, CI 1.54-13.62); Odds Ratio (OR) = 3.7 (p = 0.0149, CI 1.29-10.61); Odds Ratio (OR) = 0.95 (p = 0.9282, CI 0.35-2.62); Odds Ratio (OR) = 0.87 (p = 0.7902, CI 0.33-2.35); Odds Ratio (OR) = 2.22 (p = 0.1603, CI 0.73-6.74); Odds Ratio (OR) = 2.55 (p = 0.1144, CI 0.8-8.14); Odds Ratio (OR) = 0.75 (p = 0.5903, CI 0.26-2.13); Odds Ratio (OR) = 3.89 (p = 0.029, CI 1.15-13.16); Odds Ratio (OR) = 2.12 (p = 0.1721, CI 0.72-6.26); Odds Ratio (OR) = 1.83 (p = 0.2439, CI 0.66-5.09); Odds Ratio (OR) = 1.18 (p = 0.7402, CI 0.44-3.19); Odds Ratio (OR) = 3.17 (p = 0.0422, CI 1.04-9.63); Odds Ratio (OR) = 5.44 (p = 0.0061, CI 1.62-18.27); Odds Ratio (OR) = 1.71 (p = 0.3191, CI 0.59-4.92); Odds Ratio (OR) = 5.91 (p = 0.0037, CI 1.78-19.66); Odds Ratio (OR) = 4.02 (p = 0.0139, CI 1.33-12.2); Odds Ratio (OR) = 1.59 (p = 0.3757, CI 0.57-4.42); Odds Ratio (OR) = 1.21 (p = 0.7087, CI 0.45-3.28); Odds Ratio (OR) = 2.53 (p = 0.1083, CI 0.81-7.88); Odds Ratio (OR) = 3.21 (p = 0.0473, CI 1.01-10.14); Odds Ratio (OR) = 1.89 (p = 0.2481, CI 0.64-5.6); Odds Ratio (OR) = 5.84 (p = 0.0066, CI 1.64-20.89); Odds Ratio (OR) = 3.06 (p = 0.0466, CI 1.02-9.18); Odds Ratio (OR) = 0.92 (p = 0.8769, CI 0.34-2.53); Odds Ratio (OR) = 1.37 (p = 0.5448, CI 0.49-3.82); Odds Ratio (OR) = 1.57 (p = 0.4125, CI 0.53-4.64); Odds Ratio (OR) = 3.36 (p = 0.05, CI 1-11.3); Odds Ratio (OR) = 1.32 (p = 0.6167, CI 0.45-3.87); Odds Ratio (OR) = 4 (p = 0.0233, CI 1.21-13.26); Odds Ratio (OR) = 2.68 (p = 0.0803, CI 0.89-8.09); Odds Ratio (OR) = 2.64 (p = 0.1274, CI 0.76-9.18); Odds Ratio (OR) = 1.05 (p = 0.9445, CI 0.29-3.71); Odds Ratio (OR) = 1.69 (p = 0.4204, CI 0.47-6.03); Odds Ratio (OR) = 2.78 (p = 0.1315, CI 0.74-10.49); Odds Ratio (OR) = 3.24 (p = 0.0944, CI 0.82-12.87); Odds Ratio (OR) = 1.99 (p = 0.2801, CI 0.57-6.89); Odds Ratio (OR) = 2.44 (p = 0.1524, CI 0.72-8.3); Odds Ratio (OR) = 1.38 (p = 0.6129, CI 0.4-4.75); Odds Ratio (OR) = 0.63 (p = 0.4617, CI 0.18-2.18); Odds Ratio (OR) = 0.74 (p = 0.6519, CI 0.2-2.7); Odds Ratio (OR) = 0.84 (p = 0.8011, CI 0.22-3.18); Odds Ratio (OR) = 1.95 (p = 0.3254, CI 0.51-7.41); Odds Ratio (OR) = 2 (p = 0.273, CI 0.58-6.94); Odds Ratio (OR) = 1.31 (p = 0.6601, CI 0.39-4.41); Odds Ratio (OR) = 0.74 (p = 0.6588, CI 0.2-2.76); Odds Ratio (OR) = 0.52 (p = 0.3257, CI 0.14-1.92); Odds Ratio (OR) = 0.42 (p = 0.2229, CI 0.1-1.69); Odds Ratio (OR) = 0.43 (p = 0.2425, CI 0.1-1.77); Odds Ratio (OR) = 0.97 (p = 0.9672, CI 0.23-4.11); Odds Ratio (OR) = 1.43 (p = 0.5838, CI 0.4-5.09); Odds Ratio (OR) = 0.95 (p = 0.9361, CI 0.28-3.24). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 1.56 (p = 0.36, CI 0.6-4.03); Odds Ratio (OR) = 2.05 (p = 0.1394, CI 0.79-5.32); Odds Ratio (OR) = 2.7 (p = 0.0522, CI 0.99-7.36); Odds Ratio (OR) = 3.97 (p = 0.0119, CI 1.63-11.61); Odds Ratio (OR) = 2.07 (p = 0.1474, CI 0.77-5.53); Odds Ratio (OR) = 5.08 (p = 0.0026, CI 1.76-14.67); Odds Ratio (OR) = 2.11 (p = 0.1263, CI 0.81-5.51); Odds Ratio (OR) = 1.83 (p = 0.2327, CI 0.68-4.95); Odds Ratio (OR) = 1.95 (p = 0.2045, CI 0.7-5.44); Odds Ratio (OR) = 2.54 (p = 0.0958, CI 0.85-7.62); Odds Ratio (OR) = 1.7 (p = 0.321, CI 0.6-4.85); Odds Ratio (OR) = 3.75 (p = 0.0199, CI 1.23-11.39); Odds Ratio (OR) = 2.26 (p = 0.1219, CI 0.8-6.36); Odds Ratio (OR) = 1.72 (p = 0.2975, CI 0.62-4.76); Odds Ratio (OR) = 1.75 (p = 0.2763, CI 0.64-4.8); Odds Ratio (OR) = 2.33 (p = 0.1235, CI 0.79-6.82); Odds Ratio (OR) = 4.24 (p = 0.019, CI 1.27-14.19); Odds Ratio (OR) = 1.98 (p = 0.2213, CI 0.66-5.93); Odds Ratio (OR) = 5.88 (p = 0.005, CI 1.71-20.25); Odds Ratio (OR) = 2.39 (p = 0.1053, CI 0.83-6.85); Odds Ratio (OR) = 2.39 (p = 0.0991, CI 0.85-6.72); Odds Ratio (OR) = 1.93 (p = 0.2056, CI 0.7-5.32); Odds Ratio (OR) = 5.15 (p = 0.0095, CI 1.49-17.13); Odds Ratio (OR) = 2.34 (p = 0.1254, CI 0.79-6.94); Odds Ratio (OR) = 3.66 (p = 0.0402, CI 1.06-12.63); Odds Ratio (OR) = 1.59 (p = 0.4547, CI 0.47-5.42); Odds Ratio (OR) = 1.71 (p = 0.4008, CI 0.49-5.99); Odds Ratio (OR) = 2.55 (p = 0.1535, CI 0.71-9.22); Odds Ratio (OR) = 7.19 (p = 0.0055, CI 1.79-28.95); Odds Ratio (OR) = 2.19 (p = 0.2116, CI 0.64-7.5); Odds Ratio (OR) = 2.34 (p = 0.1668, CI 0.7-7.83); Odds Ratio (OR) = 2.32 (p = 0.1824, CI 0.67-7.98); Odds Ratio (OR) = 0.85 (p = 0.797, CI 0.25-2.9); Odds Ratio (OR) = 0.78 (p = 0.7065, CI 0.21-2.85); Odds Ratio (OR) = 1.08 (p = 0.9126, CI 0.29-3.93); Odds Ratio (OR) = 2.82 (p = 0.1282, CI 0.74-10.7); Odds Ratio (OR) = 2.03 (p = 0.2661, CI 0.58-7.04); Odds Ratio (OR) = 5.35 (p = 0.0044, CI 1.69-16.96); Odds Ratio (OR) = 8.65 (p = 2e-04, CI 2.79-26.83); Odds Ratio (OR) = 10.82 (p = 1e-04, CI 3.49-33.54); Odds Ratio (OR) = 10.01 (p = 1e-04, CI 3.2-31.29); Odds Ratio (OR) = 2.51 (p = 0.1266, CI 0.77-8.15); Odds Ratio (OR) = 5.72 (p = 0.0024, CI 1.85-17.66); Odds Ratio (OR) = 7.93 (p = 3e-04, CI 2.59-24.26); Odds Ratio (OR) = 3.11 (p = 0.0217, CI 1.18-8.17); Odds Ratio (OR) = 4.63 (p = 0.0021, CI 1.75-12.25); Odds Ratio (OR) = 4.72 (p = 0.0016, CI 1.8-12.37); Odds Ratio (OR) = 4.8 (p = 0.0018, CI 1.79-12.86); Odds Ratio (OR) = 2.69 (p = 0.0467, CI 1.01-7.14); Odds Ratio (OR) = 4.7 (p = 0.0016, CI 1.8-12.28); Odds Ratio (OR) = 2.98 (p = 0.0234, CI 1.16-7.65); Odds Ratio (OR) = 2.88 (p = 0.0294, CI 1.11-7.46); Odds Ratio (OR) = 3.74 (p = 0.0068, CI 1.44-9.73); Odds Ratio (OR) = 4.35 (p = 0.0025, CI 1.68-11.29); Odds Ratio (OR) = 5.82 (p = 6e-04, CI 2.13-15.92); Odds Ratio (OR) = 2.53 (p = 0.0572, CI 0.97-6.61); Odds Ratio (OR) = 6.03 (p = 3e-04, CI 2.28-15.97); Odds Ratio (OR) = 2.55 (p = 0.046, CI 1.02-6.38); Odds Ratio (OR) = 2.03 (p = 0.1406, CI 0.79-5.23); Odds Ratio (OR) = 2.97 (p = 0.0234, CI 1.16-7.63); Odds Ratio (OR) = 2.82 (p = 0.0302, CI 1.1-7.22); Odds Ratio (OR) = 5.23 (p = 0.0016, CI 1.87-14.63); Odds Ratio (OR) = 1.82 (p = 0.2105, CI 0.71-4.64); Odds Ratio (OR) = 4.17 (p = 0.0033, CI 1.61-10.81); Odds Ratio (OR) = 2.1 (p = 0.1087, CI 0.85-5.21); Odds Ratio (OR) = 2.12 (p = 0.1359, CI 0.79-5.7); Odds Ratio (OR) = 3.35 (p = 0.0258, CI 1.16-9.69); Odds Ratio (OR) = 4.77 (p = 0.0076, CI 1.51-15.04); Odds Ratio (OR) = 2.36 (p = 0.1088, CI 0.83-6.75); Odds Ratio (OR) = 4.89 (p = 0.0045, CI 1.64-14.62); Odds Ratio (OR) = 2.74 (p = 0.0493, CI 1-7.5); Odds Ratio (OR) = 2.99 (p = 0.0376, CI 1.06-8.41); Odds Ratio (OR) = 2.53 (p = 0.0723, CI 0.92-6.94); Odds Ratio (OR) = 3.11 (p = 0.0396, CI 1.06-9.17); Odds Ratio (OR) = 6.18 (p = 0.0031, CI 1.85-20.67); Odds Ratio (OR) = 2.41 (p = 0.1044, CI 0.83-6.96); Odds Ratio (OR) = 5.47 (p = 0.0029, CI 1.78-16.75); Odds Ratio (OR) = 3.01 (p = 0.0364, CI 1.07-8.45); Odds Ratio (OR) = 1.26 (p = 0.6396, CI 0.47-3.37); Odds Ratio (OR) = 1.47 (p = 0.4378, CI 0.55-3.91); Odds Ratio (OR) = 3.17 (p = 0.0407, CI 1.05-9.57); Odds Ratio (OR) = 5.47 (p = 0.0059, CI 1.63-18.3); Odds Ratio (OR) = 3.85 (p = 0.023, CI 1.2-12.3); Odds Ratio (OR) = 7.36 (p = 0.0015, CI 2.14-25.29); Odds Ratio (OR) = 3.45 (p = 0.0248, CI 1.17-10.16); Odds Ratio (OR) = 2.37 (p = 0.1091, CI 0.82-6.83); Odds Ratio (OR) = 1.71 (p = 0.3054, CI 0.61-4.75); Odds Ratio (OR) = 2.48 (p = 0.1129, CI 0.81-7.61); Odds Ratio (OR) = 3.28 (p = 0.0432, CI 1.04-10.37); Odds Ratio (OR) = 3.77 (p = 0.0315, CI 1.13-12.6); Odds Ratio (OR) = 4.26 (p = 0.0147, CI 1.33-13.64); Odds Ratio (OR) = 3.18 (p = 0.0405, CI 1.05-9.59); Odds Ratio (OR) = 1.4 (p = 0.5238, CI 0.5-3.93); Odds Ratio (OR) = 1.73 (p = 0.306, CI 0.6-4.97); Odds Ratio (OR) = 1.64 (p = 0.3747, CI 0.55-4.86); Odds Ratio (OR) = 3.49 (p = 0.0443, CI 1.03-11.8); Odds Ratio (OR) = 2.49 (p = 0.1269, CI 0.77-8.06); Odds Ratio (OR) = 1.22 (p = 0.7457, CI 0.36-4.09); Odds Ratio (OR) = 1.73 (p = 0.4095, CI 0.47-6.41); Odds Ratio (OR) = 1.04 (p = 0.9571, CI 0.28-3.77); Odds Ratio (OR) = 0.9 (p = 0.8827, CI 0.23-3.59); Odds Ratio (OR) = 0.69 (p = 0.5944, CI 0.17-2.74); Odds Ratio (OR) = 2.74 (p = 0.1647, CI 0.66-11.39); Odds Ratio (OR) = 2.07 (p = 0.2684, CI 0.57-7.48); Odds Ratio (OR) = 1.48 (p = 0.5338, CI 0.43-5.07). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 0.67 (p = 0.7899, CI 0.04-12.34); Odds Ratio (OR) = 0.86 (p = 0.9186, CI 0.05-14.73); Odds Ratio (OR) = 2.19 (p = 0.5303, CI 0.19-25.46); Odds Ratio (OR) = 5.85 (p = 0.1149, CI 0.65-52.66); Odds Ratio (OR) = 9.07 (p = 0.0442, CI 1.06-77.71); Odds Ratio (OR) = 3.53 (p = 0.2851, CI 0.35-35.68); Odds Ratio (OR) = 4.22 (p = 0.2073, CI 0.45-39.48); Odds Ratio (OR) = 3.68 (p = 0.27, CI 0.36-37.16); Odds Ratio (OR) = 3.41 (p = 0.2982, CI 0.34-34.27); Odds Ratio (OR) = 12.3 (p = 0.0204, CI 1.47-102.6); Odds Ratio (OR) = 11.1 (p = 0.027, CI 1.31-93.74); Odds Ratio (OR) = 2.22 (p = 0.5224, CI 0.19-25.68); Odds Ratio (OR) = 4.92 (p = 0.1635, CI 0.52-46.35); Odds Ratio (OR) = 10.97 (p = 0.0266, CI 1.32-91.15); Odds Ratio (OR) = 2.69 (p = 0.4299, CI 0.23-31.21); Odds Ratio (OR) = 4.87 (p = 0.1667, CI 0.52-45.84); Odds Ratio (OR) = 8.11 (p = 0.0592, CI 0.92-71.35); Odds Ratio (OR) = 18.28 (p = 0.007, CI 2.21-151.2); Odds Ratio (OR) = 3.79 (p = 0.2594, CI 0.37-38.32); Odds Ratio (OR) = 8.14 (p = 0.0589, CI 0.92-71.67); Odds Ratio (OR) = 10.08 (p = 0.0338, CI 1.19-85.2); Odds Ratio (OR) = 0.76 (p = 0.7756, CI 0.12-4.88); Odds Ratio (OR) = 1.08 (p = 0.9246, CI 0.2-5.74); Odds Ratio (OR) = 5.42 (p = 0.0177, CI 1.34-21.93); Odds Ratio (OR) = 5.38 (p = 0.0178, CI 1.34-21.65); Odds Ratio (OR) = 1.17 (p = 0.8564, CI 0.22-6.2); Odds Ratio (OR) = 2.52 (p = 0.2202, CI 0.58-11); Odds Ratio (OR) = 2.37 (p = 0.2498, CI 0.55-10.25); Odds Ratio (OR) = 8.22 (p = 0.0576, CI 0.93-72.29); Odds Ratio (OR) = 3.34 (p = 0.3065, CI 0.33-33.59); Odds Ratio (OR) = 19.9 (p = 0.0056, CI 2.4-165.1); Odds Ratio (OR) = 25.05 (p = 0.0027, CI 3.05-205.5); Odds Ratio (OR) = 3.61 (p = 0.2762, CI 0.36-36.51); Odds Ratio (OR) = 6.93 (p = 0.0851, CI 0.77-62.69); Odds Ratio (OR) = 17.02 (p = 0.0081, CI 2.09-138.7); Odds Ratio (OR) = 6.37 (p = 0.0995, CI 0.7-57.62); Odds Ratio (OR) = 5.76 (p = 0.1184, CI 0.64-51.8); Odds Ratio (OR) = 26.54 (p = 0.0023, CI 3.23-218.3); Odds Ratio (OR) = 19.09 (p = 0.0062, CI 2.31-157.9); Odds Ratio (OR) = 7.49 (p = 0.0695, CI 0.85-65.87); Odds Ratio (OR) = 8.64 (p = 0.052, CI 0.98-75.98); Odds Ratio (OR) = 22.3 (p = 0.0036, CI 2.75-180.6); Odds Ratio (OR) = 4.66 (p = 0.0676, CI 0.89-24.23); Odds Ratio (OR) = 4.14 (p = 0.0903, CI 0.8-21.38); Odds Ratio (OR) = 15.46 (p = 7e-04, CI 3.18-75.14); Odds Ratio (OR) = 10.94 (p = 0.0032, CI 2.22-53.77); Odds Ratio (OR) = 3.04 (p = 0.2031, CI 0.55-16.85); Odds Ratio (OR) = 4.13 (p = 0.0972, CI 0.77-22.1); Odds Ratio (OR) = 11.04 (p = 0.0027, CI 2.3-53.06); Odds Ratio (OR) = 3.06 (p = 0.1306, CI 0.72-13.02); Odds Ratio (OR) = 4.83 (p = 0.0248, CI 1.22-19.1); Odds Ratio (OR) = 7.14 (p = 0.0054, CI 1.79-28.53); Odds Ratio (OR) = 10.01 (p = 0.001, CI 2.55-39.36); Odds Ratio (OR) = 1.21 (p = 0.8271, CI 0.23-6.45); Odds Ratio (OR) = 3.27 (p = 0.1089, CI 0.77-13.95); Odds Ratio (OR) = 5.58 (p = 0.0138, CI 1.42-21.93); Odds Ratio (OR) = 2.4 (p = 0.1987, CI 0.63-9.15); Odds Ratio (OR) = 1.8 (p = 0.3984, CI 0.46-7.02); Odds Ratio (OR) = 3.92 (p = 0.0402, CI 1.06-14.45); Odds Ratio (OR) = 8.05 (p = 0.001, CI 2.32-27.95); Odds Ratio (OR) = 0.84 (p = 0.8287, CI 0.17-4.08); Odds Ratio (OR) = 2.93 (p = 0.1083, CI 0.79-10.92); Odds Ratio (OR) = 6.03 (p = 0.0043, CI 1.76-20.66); Odds Ratio (OR) = 3.23 (p = 0.1126, CI 0.76-13.79); Odds Ratio (OR) = 2.9 (p = 0.1479, CI 0.69-12.3); Odds Ratio (OR) = 10.49 (p = 0.001, CI 2.59-42.46); Odds Ratio (OR) = 13.01 (p = 2e-04, CI 3.31-51.14); Odds Ratio (OR) = 2.91 (p = 0.1483, CI 0.68-12.41); Odds Ratio (OR) = 4.03 (p = 0.0557, CI 0.97-16.84); Odds Ratio (OR) = 6.47 (p = 0.0072, CI 1.66-25.28); Odds Ratio (OR) = 1.02 (p = 0.9715, CI 0.32-3.24); Odds Ratio (OR) = 1.49 (p = 0.472, CI 0.5-4.39); Odds Ratio (OR) = 2.35 (p = 0.1262, CI 0.79-7.05); Odds Ratio (OR) = 3.07 (p = 0.0396, CI 1.05-8.92); Odds Ratio (OR) = 0.66 (p = 0.5137, CI 0.19-2.29); Odds Ratio (OR) = 2.25 (p = 0.137, CI 0.77-6.58); Odds Ratio (OR) = 1.39 (p = 0.5526, CI 0.47-4.07). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 8.83 (p = 0.0469, CI 1.03-75.68); Odds Ratio (OR) = 4.44 (p = 0.1924, CI 0.47-41.87); Odds Ratio (OR) = 7.54 (p = 0.068, CI 0.86-66); Odds Ratio (OR) = 15.95 (p = 0.0095, CI 1.97-129.4); Odds Ratio (OR) = 3.68 (p = 0.269, CI 0.36-37.21); Odds Ratio (OR) = 10.28 (p = 0.0321, CI 1.22-86.53); Odds Ratio (OR) = 14.48 (p = 0.0131, CI 1.75-119.7); Odds Ratio (OR) = 25.22 (p = 0.0025, CI 3.11-204.6); Odds Ratio (OR) = 4.65 (p = 0.1788, CI 0.49-43.72); Odds Ratio (OR) = 35.99 (p = 8e-04, CI 4.41-293.5); Odds Ratio (OR) = 12.67 (p = 0.0192, CI 1.51-106.1); Odds Ratio (OR) = 16.92 (p = 0.0089, CI 2.03-141); Odds Ratio (OR) = 24.96 (p = 0.0025, CI 3.09-201.6); Odds Ratio (OR) = 3.03 (p = 0.091, CI 0.84-10.94); Odds Ratio (OR) = 3.96 (p = 0.0296, CI 1.15-13.67); Odds Ratio (OR) = 8.23 (p = 9e-04, CI 2.38-28.44); Odds Ratio (OR) = 2.05 (p = 0.1981, CI 0.69-6.08); Odds Ratio (OR) = 5.28 (p = 0.0029, CI 1.76-15.78); Odds Ratio (OR) = 5.95 (p = 0.0011, CI 2.03-17.4); Odds Ratio (OR) = 0.96 (p = 0.9511, CI 0.29-3.23); Odds Ratio (OR) = 1.76 (p = 0.3241, CI 0.57-5.45); Odds Ratio (OR) = 3.9 (p = 0.0111, CI 1.36-11.16); Odds Ratio (OR) = 2.51 (p = 0.1375, CI 0.74-8.48); Odds Ratio (OR) = 3.02 (p = 0.067, CI 0.93-9.83); Odds Ratio (OR) = 7.57 (p = 9e-04, CI 2.29-25.04); Odds Ratio (OR) = 9.42 (p = 2e-04, CI 2.91-30.49); Odds Ratio (OR) = 2.75 (p = 0.0982, CI 0.83-9.14); Odds Ratio (OR) = 2.6 (p = 0.1233, CI 0.77-8.8); Odds Ratio (OR) = 4.63 (p = 0.0091, CI 1.46-14.64); Odds Ratio (OR) = 1.03 (p = 0.962, CI 0.34-3.1); Odds Ratio (OR) = 1.63 (p = 0.3527, CI 0.58-4.59); Odds Ratio (OR) = 3.04 (p = 0.0394, CI 1.06-8.76); Odds Ratio (OR) = 3.36 (p = 0.0224, CI 1.19-9.53); Odds Ratio (OR) = 1.16 (p = 0.7891, CI 0.39-3.44); Odds Ratio (OR) = 2.48 (p = 0.0851, CI 0.88-6.99); Odds Ratio (OR) = 1.74 (p = 0.2885, CI 0.63-4.83); Odds Ratio (OR) = 0.78 (p = 0.8611, CI 0.05-13.3); Odds Ratio (OR) = 1.48 (p = 0.7549, CI 0.13-17.42); Odds Ratio (OR) = 2.07 (p = 0.5658, CI 0.17-24.66); Odds Ratio (OR) = 1.83 (p = 0.6319, CI 0.15-21.86); Odds Ratio (OR) = 1.09 (p = 0.9526, CI 0.06-18.96); Odds Ratio (OR) = 0.94 (p = 0.9671, CI 0.06-16.04); Odds Ratio (OR) = 3.16 (p = 0.3289, CI 0.31-31.87); Odds Ratio (OR) = 3.26 (p = 0.3157, CI 0.32-32.71); Odds Ratio (OR) = 1 (p = 0.991, CI 0.06-16.83); Odds Ratio (OR) = 2.26 (p = 0.5139, CI 0.2-26.12); Odds Ratio (OR) = 3.32 (p = 0.3079, CI 0.33-33.45); Odds Ratio (OR) = 14.39 (p = 0.0134, CI 1.74-119.1); Odds Ratio (OR) = 4.98 (p = 0.1606, CI 0.53-46.9); Odds Ratio (OR) = 6.69 (p = 0.0854, CI 0.77-58.35); Odds Ratio (OR) = 6.07 (p = 0.1082, CI 0.67-54.72); Odds Ratio (OR) = 7.22 (p = 0.0737, CI 0.83-63.04); Odds Ratio (OR) = 11.98 (p = 0.0217, CI 1.44-99.74); Odds Ratio (OR) = 19.24 (p = 0.0058, CI 2.36-157.1); Odds Ratio (OR) = 10.33 (p = 0.032, CI 1.22-87.31); Odds Ratio (OR) = 11.24 (p = 0.0251, CI 1.35-93.33); Odds Ratio (OR) = 1.43 (p = 0.6154, CI 0.35-5.83); Odds Ratio (OR) = 2.37 (p = 0.1906, CI 0.65-8.63); Odds Ratio (OR) = 3.67 (p = 0.045, CI 1.03-13.07); Odds Ratio (OR) = 7.19 (p = 0.0017, CI 2.1-24.66); Odds Ratio (OR) = 1.8 (p = 0.3939, CI 0.47-6.97); Odds Ratio (OR) = 2.06 (p = 0.2869, CI 0.55-7.74); Odds Ratio (OR) = 2.41 (p = 0.1817, CI 0.66-8.8); Odds Ratio (OR) = 11.41 (p = 0.0256, CI 1.35-96.77); Odds Ratio (OR) = 13.65 (p = 0.0153, CI 1.65-112.8); Odds Ratio (OR) = 21.76 (p = 0.0042, CI 2.64-179.2); Odds Ratio (OR) = 35.75 (p = 8e-04, CI 4.39-291.5); Odds Ratio (OR) = 6.45 (p = 0.0967, CI 0.71-58.21); Odds Ratio (OR) = 8.3 (p = 0.0564, CI 0.94-72.95); Odds Ratio (OR) = 23.63 (p = 0.003, CI 2.93-190.5); Odds Ratio (OR) = 9.72 (p = 0.0384, CI 1.13-83.68); Odds Ratio (OR) = 13.65 (p = 0.0153, CI 1.65-112.9); Odds Ratio (OR) = 30.55 (p = 0.0015, CI 3.72-250.6); Odds Ratio (OR) = 8.54 (p = 7e-04, CI 2.46-29.63); Odds Ratio (OR) = 1.76 (p = 0.4152, CI 0.45-6.86); Odds Ratio (OR) = 3.29 (p = 0.07, CI 0.91-11.93); Odds Ratio (OR) = 5.83 (p = 0.0048, CI 1.71-19.84); Odds Ratio (OR) = 2.44 (p = 0.1497, CI 0.72-8.23); Odds Ratio (OR) = 3.05 (p = 0.0608, CI 0.95-9.77); Odds Ratio (OR) = 5.99 (p = 0.0028, CI 1.85-19.34); Odds Ratio (OR) = 7.84 (p = 5e-04, CI 2.45-25.13); Odds Ratio (OR) = 1.15 (p = 0.8393, CI 0.3-4.39); Odds Ratio (OR) = 4.01 (p = 0.0215, CI 1.23-13.1); Odds Ratio (OR) = 4.42 (p = 0.0112, CI 1.4-13.94); Odds Ratio (OR) = 1.71 (p = 0.3498, CI 0.55-5.29). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 2.9 (p = 0.0214, CI 1.17-7.18); Odds Ratio (OR) = 3.67 (p = 0.0049, CI 1.48-9.09); Odds Ratio (OR) = 3.36 (p = 0.0078, CI 1.38-8.22); Odds Ratio (OR) = 2.28 (p = 0.0727, CI 0.93-5.63); Odds Ratio (OR) = 2.94 (p = 0.0199, CI 1.19-7.29); Odds Ratio (OR) = 4.21 (p = 0.0034, CI 1.61-11.01); Odds Ratio (OR) = 6.26 (p = 7e-04, CI 2.16-18.26); Odds Ratio (OR) = 2.02 (p = 0.1206, CI 0.83-4.92); Odds Ratio (OR) = 3.58 (p = 0.007, CI 1.42-9.03); Odds Ratio (OR) = 3.41 (p = 0.0088, CI 1.36-8.54); Odds Ratio (OR) = 1.41 (p = 0.4485, CI 0.58-3.4); Odds Ratio (OR) = 2.92 (p = 0.0255, CI 1.14-7.47); Odds Ratio (OR) = 4.18 (p = 0.0066, CI 1.49-11.75); Odds Ratio (OR) = 4.46 (p = 0.0061, CI 1.53-13.01); Odds Ratio (OR) = 2.22 (p = 0.0879, CI 0.89-5.57); Odds Ratio (OR) = 2.68 (p = 0.0389, CI 1.05-6.83); Odds Ratio (OR) = 2.62 (p = 0.0446, CI 1.02-6.73); Odds Ratio (OR) = 1.11 (p = 0.8196, CI 0.45-2.72); Odds Ratio (OR) = 2 (p = 0.145, CI 0.79-5.1); Odds Ratio (OR) = 4.08 (p = 0.0114, CI 1.37-12.11); Odds Ratio (OR) = 3.29 (p = 0.0307, CI 1.12-9.71); Odds Ratio (OR) = 1.29 (p = 0.5921, CI 0.51-3.24); Odds Ratio (OR) = 2.69 (p = 0.0502, CI 1-7.26); Odds Ratio (OR) = 3.31 (p = 0.0224, CI 1.18-9.25); Odds Ratio (OR) = 1.18 (p = 0.7225, CI 0.47-2.93); Odds Ratio (OR) = 2.43 (p = 0.0762, CI 0.91-6.48); Odds Ratio (OR) = 1.1 (p = 0.8485, CI 0.4-3.04); Odds Ratio (OR) = 2.16 (p = 0.1652, CI 0.73-6.42); Odds Ratio (OR) = 1.94 (p = 0.2244, CI 0.67-5.65); Odds Ratio (OR) = 1.85 (p = 0.2097, CI 0.71-4.84); Odds Ratio (OR) = 1.53 (p = 0.3708, CI 0.6-3.92); Odds Ratio (OR) = 2.66 (p = 0.0704, CI 0.92-7.66); Odds Ratio (OR) = 7.21 (p = 0.004, CI 1.88-27.73); Odds Ratio (OR) = 2.04 (p = 0.1625, CI 0.75-5.55); Odds Ratio (OR) = 4.59 (p = 0.0093, CI 1.46-14.5); Odds Ratio (OR) = 4.44 (p = 0.0103, CI 1.42-13.87); Odds Ratio (OR) = 1.89 (p = 0.1965, CI 0.72-4.95); Odds Ratio (OR) = 2.69 (p = 0.0549, CI 0.98-7.42); Odds Ratio (OR) = 3.01 (p = 0.0503, CI 1-9.09); Odds Ratio (OR) = 7.03 (p = 0.0046, CI 1.82-27.1); Odds Ratio (OR) = 2.46 (p = 0.0866, CI 0.88-6.88); Odds Ratio (OR) = 5.96 (p = 0.0045, CI 1.74-20.4); Odds Ratio (OR) = 3.59 (p = 0.0207, CI 1.22-10.62); Odds Ratio (OR) = 1.86 (p = 0.2127, CI 0.7-4.91); Odds Ratio (OR) = 2.04 (p = 0.1521, CI 0.77-5.43); Odds Ratio (OR) = 5.12 (p = 0.0098, CI 1.48-17.7); Odds Ratio (OR) = 7.08 (p = 0.0047, CI 1.82-27.5); Odds Ratio (OR) = 2 (p = 0.1817, CI 0.72-5.51); Odds Ratio (OR) = 6.09 (p = 0.0042, CI 1.77-20.95); Odds Ratio (OR) = 6.09 (p = 0.0039, CI 1.78-20.74); Odds Ratio (OR) = 1.23 (p = 0.7025, CI 0.42-3.57); Odds Ratio (OR) = 1.03 (p = 0.9599, CI 0.36-2.97); Odds Ratio (OR) = 1.02 (p = 0.9671, CI 0.34-3.1); Odds Ratio (OR) = 1.47 (p = 0.506, CI 0.47-4.54); Odds Ratio (OR) = 1.67 (p = 0.3842, CI 0.53-5.31); Odds Ratio (OR) = 1.44 (p = 0.5021, CI 0.49-4.23); Odds Ratio (OR) = 0.42 (p = 0.1349, CI 0.14-1.31); Odds Ratio (OR) = 0.57 (p = 0.3191, CI 0.19-1.71); Odds Ratio (OR) = 0.3 (p = 0.0623, CI 0.09-1.06); Odds Ratio (OR) = 0.47 (p = 0.1958, CI 0.15-1.48); Odds Ratio (OR) = 0.62 (p = 0.4353, CI 0.19-2.05); Odds Ratio (OR) = 1.02 (p = 0.9729, CI 0.31-3.31); Odds Ratio (OR) = 0.64 (p = 0.4211, CI 0.22-1.89); Odds Ratio (OR) = 6.02 (p = 0.0018, CI 1.95-18.64); Odds Ratio (OR) = 8.28 (p = 2e-04, CI 2.7-25.42); Odds Ratio (OR) = 10.92 (p = 1e-04, CI 3.53-33.74); Odds Ratio (OR) = 12.18 (p = 1e-04, CI 3.91-37.89); Odds Ratio (OR) = 2.1 (p = 0.2244, CI 0.64-6.92); Odds Ratio (OR) = 8.58 (p = 2e-04, CI 2.77-26.53); Odds Ratio (OR) = 8.25 (p = 2e-04, CI 2.71-25.13); Odds Ratio (OR) = 3.04 (p = 0.0149, CI 1.24-7.45); Odds Ratio (OR) = 4.65 (p = 0.0011, CI 1.85-11.73); Odds Ratio (OR) = 6.36 (p = 1e-04, CI 2.46-16.45); Odds Ratio (OR) = 6.87 (p = 1e-04, CI 2.56-18.46); Odds Ratio (OR) = 2.18 (p = 0.0897, CI 0.89-5.34); Odds Ratio (OR) = 3.46 (p = 0.007, CI 1.42-8.53); Odds Ratio (OR) = 3.75 (p = 0.0041, CI 1.52-9.23); Odds Ratio (OR) = 2.77 (p = 0.0254, CI 1.13-6.78); Odds Ratio (OR) = 4 (p = 0.0032, CI 1.59-10.04); Odds Ratio (OR) = 6.25 (p = 2e-04, CI 2.37-16.51); Odds Ratio (OR) = 8.78 (p = 1e-04, CI 3-25.7); Odds Ratio (OR) = 3.51 (p = 0.0252, CI 1.17-10.53); Odds Ratio (OR) = 2.98 (p = 0.049, CI 1-8.87); Odds Ratio (OR) = 1.97 (p = 0.1773, CI 0.74-5.3); Odds Ratio (OR) = 2.62 (p = 0.0609, CI 0.96-7.16); Odds Ratio (OR) = 2.11 (p = 0.1364, CI 0.79-5.61); Odds Ratio (OR) = 1.36 (p = 0.5268, CI 0.53-3.51); Odds Ratio (OR) = 2.02 (p = 0.1645, CI 0.75-5.46); Odds Ratio (OR) = 3.92 (p = 0.0215, CI 1.22-12.57); Odds Ratio (OR) = 3.04 (p = 0.06, CI 0.95-9.69); Odds Ratio (OR) = 1.25 (p = 0.6503, CI 0.47-3.32); Odds Ratio (OR) = 2.7 (p = 0.0683, CI 0.93-7.88); Odds Ratio (OR) = 2.83 (p = 0.0618, CI 0.95-8.44); Odds Ratio (OR) = 1.34 (p = 0.5621, CI 0.5-3.63); Odds Ratio (OR) = 1.92 (p = 0.2182, CI 0.68-5.4); Odds Ratio (OR) = 3.11 (p = 0.06, CI 0.95-10.15); Odds Ratio (OR) = 4.6 (p = 0.029, CI 1.17-18.12); Odds Ratio (OR) = 1.26 (p = 0.681, CI 0.42-3.83); Odds Ratio (OR) = 1.31 (p = 0.6346, CI 0.43-4.04); Odds Ratio (OR) = 1.16 (p = 0.7929, CI 0.38-3.57); Odds Ratio (OR) = 1.13 (p = 0.8188, CI 0.39-3.28); Odds Ratio (OR) = 0.88 (p = 0.8226, CI 0.3-2.6); Odds Ratio (OR) = 0.94 (p = 0.9088, CI 0.32-2.72); Odds Ratio (OR) = 0.75 (p = 0.6189, CI 0.24-2.35); Odds Ratio (OR) = 1.3 (p = 0.6463, CI 0.42-4.03). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 5.75 (p = 0.0012, CI 1.99-16.62); Odds Ratio (OR) = 8.86 (p = 1e-04, CI 3.06-25.68); Odds Ratio (OR) = 11.55 (p = 1e-04, CI 3.94-33.85); Odds Ratio (OR) = 13.55 (p = 1e-04, CI 4.55-40.38); Odds Ratio (OR) = 2.9 (p = 0.0555, CI 0.98-8.61); Odds Ratio (OR) = 7.98 (p = 1e-04, CI 2.75-23.18); Odds Ratio (OR) = 8.07 (p = 1e-04, CI 2.81-23.19); Odds Ratio (OR) = 4.55 (p = 0.0012, CI 1.82-11.39); Odds Ratio (OR) = 5.25 (p = 5e-04, CI 2.06-13.43); Odds Ratio (OR) = 5.62 (p = 3e-04, CI 2.2-14.39); Odds Ratio (OR) = 8.42 (p = 1e-04, CI 2.99-23.74); Odds Ratio (OR) = 2.74 (p = 0.0277, CI 1.12-6.7); Odds Ratio (OR) = 4.15 (p = 0.0022, CI 1.66-10.32); Odds Ratio (OR) = 3.06 (p = 0.0314, CI 1.26-7.41); Odds Ratio (OR) = 3.92 (p = 0.0041, CI 1.54-9.97); Odds Ratio (OR) = 4.19 (p = 0.0028, CI 1.64-10.74); Odds Ratio (OR) = 4.96 (p = 0.0011, CI 1.9-12.98); Odds Ratio (OR) = 8.79 (p = 1e-04, CI 2.86-26.99); Odds Ratio (OR) = 4.09 (p = 0.0036, CI 1.59-10.57); Odds Ratio (OR) = 4.52 (p = 0.0018, CI 1.75-11.67); Odds Ratio (OR) = 2.76 (p = 0.0243, CI 1.14-6.68); Odds Ratio (OR) = 2.33 (p = 0.077, CI 0.91-5.96); Odds Ratio (OR) = 2.61 (p = 0.0451, CI 1.02-6.69); Odds Ratio (OR) = 3.36 (p = 0.0165, CI 1.25-9.04); Odds Ratio (OR) = 5.28 (p = 0.0037, CI 1.72-16.23); Odds Ratio (OR) = 2.29 (p = 0.0812, CI 0.9-5.82); Odds Ratio (OR) = 2.46 (p = 0.0577, CI 0.97-6.22); Odds Ratio (OR) = 2.33 (p = 0.0706, CI 0.93-5.85); Odds Ratio (OR) = 2.7 (p = 0.0404, CI 1.04-7); Odds Ratio (OR) = 4.3 (p = 0.0054, CI 1.54-11.99); Odds Ratio (OR) = 3.37 (p = 0.0186, CI 1.22-9.27); Odds Ratio (OR) = 6.58 (p = 0.0023, CI 1.96-22.14); Odds Ratio (OR) = 3.63 (p = 0.0118, CI 1.33-9.93); Odds Ratio (OR) = 5.57 (p = 0.002, CI 1.88-16.53); Odds Ratio (OR) = 2.71 (p = 0.043, CI 1.03-7.14); Odds Ratio (OR) = 1.81 (p = 0.2197, CI 0.7-4.66); Odds Ratio (OR) = 2.08 (p = 0.1341, CI 0.8-5.42); Odds Ratio (OR) = 3.69 (p = 0.0196, CI 1.23-11.05); Odds Ratio (OR) = 4.79 (p = 0.0121, CI 1.41-16.26); Odds Ratio (OR) = 2.06 (p = 0.1511, CI 0.77-5.56); Odds Ratio (OR) = 4.94 (p = 0.0068, CI 1.55-15.68); Odds Ratio (OR) = 2.49 (p = 0.0741, CI 0.91-6.79); Odds Ratio (OR) = 1.7 (p = 0.2772, CI 0.65-4.43); Odds Ratio (OR) = 2.55 (p = 0.0705, CI 0.92-7.02); Odds Ratio (OR) = 3.88 (p = 0.022, CI 1.22-12.39); Odds Ratio (OR) = 4.33 (p = 0.0196, CI 1.27-14.82); Odds Ratio (OR) = 3.09 (p = 0.0433, CI 1.03-9.24); Odds Ratio (OR) = 3.15 (p = 0.0355, CI 1.08-9.2); Odds Ratio (OR) = 1.63 (p = 0.3238, CI 0.62-4.28); Odds Ratio (OR) = 1.68 (p = 0.3208, CI 0.6-4.68); Odds Ratio (OR) = 1.9 (p = 0.2281, CI 0.67-5.4); Odds Ratio (OR) = 3.18 (p = 0.0566, CI 0.97-10.46); Odds Ratio (OR) = 2.39 (p = 0.1491, CI 0.73-7.78); Odds Ratio (OR) = 2.32 (p = 0.1477, CI 0.74-7.23); Odds Ratio (OR) = 3.24 (p = 0.0532, CI 0.98-10.64); Odds Ratio (OR) = 2.22 (p = 0.1616, CI 0.73-6.76); Odds Ratio (OR) = 1.5 (p = 0.432, CI 0.55-4.11); Odds Ratio (OR) = 1.9 (p = 0.2231, CI 0.68-5.35); Odds Ratio (OR) = 3.88 (p = 0.0347, CI 1.1-13.64); Odds Ratio (OR) = 4.59 (p = 0.0291, CI 1.17-18.07); Odds Ratio (OR) = 1.82 (p = 0.2805, CI 0.61-5.38); Odds Ratio (OR) = 3.1 (p = 0.0602, CI 0.95-10.11); Odds Ratio (OR) = 1.41 (p = 0.5087, CI 0.51-3.88); Odds Ratio (OR) = 2.26 (p = 0.1224, CI 0.8-6.38); Odds Ratio (OR) = 1.85 (p = 0.228, CI 0.68-5.02); Odds Ratio (OR) = 2.07 (p = 0.1835, CI 0.71-6.02); Odds Ratio (OR) = 5.85 (p = 0.0107, CI 1.51-22.69); Odds Ratio (OR) = 2.94 (p = 0.0576, CI 0.97-8.96); Odds Ratio (OR) = 9.68 (p = 0.0047, CI 2-46.77); Odds Ratio (OR) = 2.89 (p = 0.0569, CI 0.97-8.64); Odds Ratio (OR) = 2.35 (p = 0.1078, CI 0.83-6.68); Odds Ratio (OR) = 2.6 (p = 0.0772, CI 0.9-7.47); Odds Ratio (OR) = 2.36 (p = 0.1311, CI 0.77-7.22); Odds Ratio (OR) = 5.64 (p = 0.01255, CI 1.45-21.96); Odds Ratio (OR) = 4.97 (p = 0.0128, CI 1.41-17.54); Odds Ratio (OR) = 6.32 (p = 0.0079, CI 1.62-24.63); Odds Ratio (OR) = 2.9 (p = 0.0572, CI 0.97-8.67); Odds Ratio (OR) = 3.33 (p = 0.0284, CI 1.14-9.79); Odds Ratio (OR) = 2.58 (p = 0.0705, CI 0.92-7.22); Odds Ratio (OR) = 4.81 (p = 0.0136, CI 1.38-16.77); Odds Ratio (OR) = 9.96 (p = 0.0043, CI 2.06-48.29); Odds Ratio (OR) = 2.66 (p = 0.076, CI 0.9-7.83); Odds Ratio (OR) = 5.75 (p = 0.0059, CI 1.65-20); Odds Ratio (OR) = 4.22 (p = 0.0143, CI 1.33-13.35); Odds Ratio (OR) = 1.82 (p = 0.2779, CI 0.62-5.35); Odds Ratio (OR) = 1.18 (p = 0.7559, CI 0.41-3.41); Odds Ratio (OR) = 1.07 (p = 0.905, CI 0.35-3.23); Odds Ratio (OR) = 2.05 (p = 0.2163, CI 0.66-6.38); Odds Ratio (OR) = 2.24 (p = 0.1713, CI 0.7-7.14); Odds Ratio (OR) = 1.63 (p = 0.3981, CI 0.52-5.09); Odds Ratio (OR) = 1.02 (p = 0.9692, CI 0.35-2.96); Odds Ratio (OR) = 1.77 (p = 0.2978, CI 0.6-5.22); Odds Ratio (OR) = 1.11 (p = 0.8525, CI 0.38-3.18); Odds Ratio (OR) = 0.67 (p = 0.5028, CI 0.21-2.13); Odds Ratio (OR) = 1.53 (p = 0.4594, CI 0.5-4.73); Odds Ratio (OR) = 2.56 (p = 0.1124, CI 0.8-8.17); Odds Ratio (OR) = 1.75 (p = 0.3415, CI 0.55-5.58); Odds Ratio (OR) = 1.65 (p = 0.3635, CI 0.56-4.83); Odds Ratio (OR) = 0.73 (p = 0.5716, CI 0.24-2.2); Odds Ratio (OR) = 0.69 (p = 0.5028, CI 0.23-2.05); Odds Ratio (OR) = 0.6 (p = 0.3982, CI 0.18-1.98); Odds Ratio (OR) = 0.93 (p = 0.93, CI 0.3-2.87); Odds Ratio (OR) = 2.12 (p = 0.2364, CI 0.61-7.32); Odds Ratio (OR) = 1.25 (p = 0.7095, CI 0.39-4.04); Odds Ratio (OR) = 0.75 (p = 0.6011, CI 0.26-2.2). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 3.05 (p = 0.1938, CI 0.57-16.35); Odds Ratio (OR) = 6.97 (p = 0.0162, CI 1.43-33.91); Odds Ratio (OR) = 2.35 (p = 0.0768, CI 0.91-6.05); Odds Ratio (OR) = 2.91 (p = 0.00251, CI 1.14-7.39); Odds Ratio (OR) = 5.99 (p = 2e-04, CI 2.3-15.57); Odds Ratio (OR) = 7.29 (p = 1e-04, CI 2.7-19.71); Odds Ratio (OR) = 2.14 (p = 0.1144, CI 0.83-5.5); Odds Ratio (OR) = 2.06 (p = 0.1341, CI 0.8-5.3); Odds Ratio (OR) = 4.43 (p = 0.0017, CI 1.75-11.22); Odds Ratio (OR) = 2.06 (p = 0.1488, CI 0.77-5.5); Odds Ratio (OR) = 3.99 (p = 0.0043, CI 1.54-10.3); Odds Ratio (OR) = 5.53 (p = 5e-04, CI 2.1-14.57); Odds Ratio (OR) = 14.54 (p = 1e-04, CI 4.85-43.58); Odds Ratio (OR) = 2.96 (p = 0.0262, CI 1.14-7.68); Odds Ratio (OR) = 5.07 (p = 9e-04, CI 1.95-13.19); Odds Ratio (OR) = 5.33 (p = 6e-04, CI 2.06-13.8); Odds Ratio (OR) = 1.52 (p = 0.3673, CI 0.61-3.75); Odds Ratio (OR) = 2.02 (p = 0.1207, CI 0.83-4.91); Odds Ratio (OR) = 5.01 (p = 0.0011, CI 1.9-13.21); Odds Ratio (OR) = 9.19 (p = 1e-04, CI 3.08-27.38); Odds Ratio (OR) = 2.38 (p = 0.0594, CI 0.97-5.86); Odds Ratio (OR) = 2.47 (p = 0.05, CI 1-6.09); Odds Ratio (OR) = 3.22 (p = 0.0123, CI 1.29-8.03); Odds Ratio (OR) = 1.76 (p = 0.2243, CI 0.71-4.37); Odds Ratio (OR) = 2.13 (p = 0.0976, CI 0.87-5.24); Odds Ratio (OR) = 6.09 (p = 4e-04, CI 2.25-16.44); Odds Ratio (OR) = 9.13 (p = 1e-04, CI 3.04-27.4); Odds Ratio (OR) = 2.06 (p = 0.1237, CI 0.82-5.17); Odds Ratio (OR) = 2.94 (p = 0.0226, CI 1.16-7.41); Odds Ratio (OR) = 3.55 (p = 0.0069, CI 1.42-8.91); Odds Ratio (OR) = 1.9 (p = 0.1666, CI 0.76-4.75); Odds Ratio (OR) = 2.7 (p = 0.0317, CI 1.09-6.67); Odds Ratio (OR) = 5.28 (p = 0.0011, CI 1.94-14.39); Odds Ratio (OR) = 8.45 (p = 1e-04, CI 2.81-25.46); Odds Ratio (OR) = 2.1 (p = 0.1142, CI 0.84-5.27); Odds Ratio (OR) = 2.91 (p = 0.025, CI 1.14-7.39); Odds Ratio (OR) = 3.08 (p = 0.0166, CI 1.23-7.75); Odds Ratio (OR) = 1.27 (p = 0.6033, CI 0.52-3.11); Odds Ratio (OR) = 2.05 (p = 0.117, CI 0.84-5.02); Odds Ratio (OR) = 2.69 (p = 0.04, CI 1.05-6.91); Odds Ratio (OR) = 5.61 (p = 0.002, CI 1.88-16.72); Odds Ratio (OR) = 1.35 (p = 0.5177, CI 0.54-3.37); Odds Ratio (OR) = 1.79 (p = 0.2117, CI 0.72-4.48); Odds Ratio (OR) = 2.62 (p = 0.0426, CI 1.03-6.67); Odds Ratio (OR) = 1.54 (p = 0.3508, CI 0.62-3.82); Odds Ratio (OR) = 1.42 (p = 0.4431, CI 0.58-3.45); Odds Ratio (OR) = 4.27 (p = 0.005, CI 1.55-11.78); Odds Ratio (OR) = 5.47 (p = 0.0023, CI 1.84-16.3); Odds Ratio (OR) = 1.31 (p = 0.5663, CI 0.52-3.32); Odds Ratio (OR) = 2.64 (p = 0.0461, CI 1.02-6.83); Odds Ratio (OR) = 2.5 (p = 0.0552, CI 0.98-6.38); Odds Ratio (OR) = 1.95 (p = 0.1536, CI 0.78-4.88); Odds Ratio (OR) = 1.69 (p = 0.2575, CI 0.68-4.2); Odds Ratio (OR) = 3.73 (p = 0.0096, CI 1.38-10.11); Odds Ratio (OR) = 8.48 (p = 3e-04, CI 2.69-26.76); Odds Ratio (OR) = 2.18 (p = 0.1047, CI 1.48-10.35); Odds Ratio (OR) = 3.91 (p = 0.006, CI 1.48-10.35); Odds Ratio (OR) = 2.64 (p = 0.0414, CI 1.04-6.71); Odds Ratio (OR) = 2.31 (p = 0.0809, CI 0.9-5.89); Odds Ratio (OR) = 1.74 (p = 0.2377, CI 0.69-4.34); Odds Ratio (OR) = 4.21 (p = 0.0087, CI 1.44-12.34); Odds Ratio (OR) = 6 (p = 0.0022, CI 1.9-18.94); Odds Ratio (OR) = 1.4 (p = 0.4788, CI 0.55-3.55); Odds Ratio (OR) = 3.98 (p = 0.0074, CI 1.45-10.94); Odds Ratio (OR) = 3.26 (p = 0.0187, CI 1.22-8.75); Odds Ratio (OR) = 1.57 (p = 0.3443, CI 0.62-4); Odds Ratio (OR) = 1.66 (p = 0.2867, CI 0.65-4.22); Odds Ratio (OR) = 5.12 (p = 0.0044, CI 1.66-15.78); Odds Ratio (OR) = 5.58 (p = 0.0038, CI 1.74-17.87); Odds Ratio (OR) = 2.09 (p = 0.1424, CI 0.78-5.6); Odds Ratio (OR) = 3.32 (p = 0.0191, CI 1.22-9.07); Odds Ratio (OR) = 3.15 (p = 0.0244, CI 1.16-8.56); Odds Ratio (OR) = 2.63 (p = 0.1462, CI 0.71-9.67); Odds Ratio (OR) = 1.26 (p = 0.7403, CI 0.32-4.97); Odds Ratio (OR) = 2.35 (p = 0.2144, CI 0.61-9.07); Odds Ratio (OR) = 1.74 (p = 0.4321, CI 0.44-6.96); Odds Ratio (OR) = 2.53 (p = 0.1778, CI 0.66-9.75); Odds Ratio (OR) = 1.21 (p = 0.8016, CI 0.28-5.2); Odds Ratio (OR) = 2.62 (p = 0.1486, CI 0.71-9.64); Odds Ratio (OR) = 0.51 (p = 0.2881, CI 0.15-1.77); Odds Ratio (OR) = 0.36 (p = 0.1217, CI 0.1-1.31); Odds Ratio (OR) = 0.36 (p = 0.1027, CI 0.07-1.28); Odds Ratio (OR) = 0.18 (p = 0.0428, CI 0.03-0.94); Odds Ratio (OR) = 0.72 (p = 0.5943, CI 0.21-2.44); Odds Ratio (OR) = 0.94 (p = 0.928, CI 0.27-3.28); Odds Ratio (OR) = 0.94 (p = 0.916, CI 0.3-2.94); Odds Ratio (OR) = 0.43 (p = 0.2262, CI 0.11-1.69); Odds Ratio (OR) = 0.48 (p = 0.2682, CI 0.13-1.75); Odds Ratio (OR) = 0.4 (p = 0.2344, CI 0.09-1.81); Odds Ratio (OR) = 0.22 (p = 0.0835, CI 0.04-1.22); Odds Ratio (OR) = 0.72 (p = 0.6322, CI 0.19-2.72); Odds Ratio (OR) = 0.65 (p = 0.4845, CI 0.2-2.17); Odds Ratio (OR) = 14.37 (p = 8e-04, CI 3.04-67.96); Odds Ratio (OR) = 16.02 (p = 5e-04, CI 3.39-75.68); Odds Ratio (OR) = 3.02 (p = 0.1971, CI 0.56-16.17); Odds Ratio (OR) = 4.31 (p = 0.0811, CI 0.83-22.27); Odds Ratio (OR) = 11.44 (p = 0.0021, CI 2.43-53.94); Odds Ratio (OR) = 2.11 (p = 0.137, CI 0.79-5.64); Odds Ratio (OR) = 3.2 (p = 0.0181, CI 1.22-8.4); Odds Ratio (OR) = 6.43 (p = 2e-04, CI 2.43-17.05); Odds Ratio (OR) = 6.08 (p = 3e-04, CI 2.26-16.31); Odds Ratio (OR) = 1.65 (p = 0.3241, CI 0.61-4.49); Odds Ratio (OR) = 1.85 (p = 0.2249, CI 0.68-5.03); Odds Ratio (OR) = 3.53 (p = 0.0096, CI 1.36-9.18). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 6.78 (p = 0.0181, CI 1.39-33.1); Odds Ratio (OR) = 9.97 (p = 0.0039, CI 2.1-47.48); Odds Ratio (OR) = 21.2 (p = 1e-04, CI 4.51-99.65); Odds Ratio (OR) = 23.97 (p = 1e-04, CI 5.09-112.9); Odds Ratio (OR) = 3.17 (p = 0.1766, CI 0.59-16.87); Odds Ratio (OR) = 7.68 (p = 0.0116, CI 1.58-37.43); Odds Ratio (OR) = 12.74 (p = 0.0013, CI 2.71-59.81); Odds Ratio (OR) = 2.82 (p = 0.0359, CI 1.07-7.43); Odds Ratio (OR) = 5.8 (p = 4e-04, CI 2.2-15.33); Odds Ratio (OR) = 7.13 (p = 1e-04, CI 2.68-18.98); Odds Ratio (OR) = 6.84 (p = 1e-04, CI 2.53-18.46); Odds Ratio (OR) = 2.04 (p = 0.154, CI 0.76-5.47); Odds Ratio (OR) = 3.84 (p = 0.0065, CI 1.46-10.12); Odds Ratio (OR) = 3.9 (p = 0.0052, CI 1.5-10.14); Odds Ratio (OR) = 3.68 (p = 0.0064, CI 1.44-9.39); Odds Ratio (OR) = 5.86 (p = 3e-04, CI 2.26-15.21); Odds Ratio (OR) = 6.42 (p = 1e-04, CI 2.47-16.69); Odds Ratio (OR) = 8.21 (p = 1e-04, CI 3.01-22.42); Odds Ratio (OR) = 3.12 (p = 0.0171, CI 1.22-7.97); Odds Ratio (OR) = 4.38 (p = 0.002, CI 1.71-11.18); Odds Ratio (OR) = 3.97 (p = 0.0034, CI 1.58-9.99); Odds Ratio (OR) = 2.63 (p = 0.0399, CI 1.05-6.59); Odds Ratio (OR) = 5.76 (p = 3e-04, CI 2.23-14.84); Odds Ratio (OR) = 4.05 (p = 0.0031, CI 1.6-10.23); Odds Ratio (OR) = 9.82 (p = 1e-04, CI 3.41-28.28); Odds Ratio (OR) = 3.96 (p = 0.0036, CI 1.57-10.01); Odds Ratio (OR) = 4.79 (p = 9e-04, CI 1.89-12.11); Odds Ratio (OR) = 3.33 (p = 0.0091, CI 1.35-8.21); Odds Ratio (OR) = 1.78 (p = 0.2043, CI 0.73-4.34); Odds Ratio (OR) = 4.7 (p = 0.0012, CI 1.84-12.01); Odds Ratio (OR) = 3.77 (p = 0.0058, CI 1.47-9.7); Odds Ratio (OR) = 8.07 (p = 2e-04, CI 2.73-23.83); Odds Ratio (OR) = 2.88 (p = 0.0221, CI 1.16-7.12); Odds Ratio (OR) = 4 (p = 0.0034, CI 1.58-10.13); Odds Ratio (OR) = 3.22 (p = 0.0123, CI 1.29-8.04); Odds Ratio (OR) = 1.56 (p = 0.3291, CI 0.64-3.78); Odds Ratio (OR) = 3.27 (p = 0.0118, CI 1.3-8.21); Odds Ratio (OR) = 3.93 (p = 0.0058, CI 1.49-10.4); Odds Ratio (OR) = 5.98 (p = 0.0012, CI 2.03-17.65); Odds Ratio (OR) = 2.13 (p = 0.1043, CI 0.85-5.32); Odds Ratio (OR) = 5.01 (p = 0.0015, CI 1.85-13.54); Odds Ratio (OR) = 2.33 (p = 0.0658, CI 0.95-5.73); Odds Ratio (OR) = 2.02 (p = 0.1253, CI 0.82-4.98); Odds Ratio (OR) = 5.01 (p = 0.0013, CI 1.88-13.34); Odds Ratio (OR) = 3.66 (p = 0.0096, CI 1.37-9.75); Odds Ratio (OR) = 6.06 (p = 0.0012, CI 2.04-17.96); Odds Ratio (OR) = 2.75 (p = 0.0344, CI 1.08-7.02); Odds Ratio (OR) = 4.07 (p = 0.0045, CI 1.55-10.72); Odds Ratio (OR) = 2.24 (p = 0.081, CI 0.91-5.55); Odds Ratio (OR) = 2.29 (p = 0.0761, CI 0.92-5.7); Odds Ratio (OR) = 3.66 (p = 0.0078, CI 1.41-9.51); Odds Ratio (OR) = 2.99 (p = 0.0253, CI 1.15-7.82); Odds Ratio (OR) = 6.23 (p = 0.0017, CI 1.99-19.55); Odds Ratio (OR) = 1.55 (p = 0.3512, CI 0.62-3.87); Odds Ratio (OR) = 2.77 (p = 0.0352, CI 1.07-7.13); Odds Ratio (OR) = 2.36 (p = 0.0704, CI 0.93-5.97); Odds Ratio (OR) = 1.94 (p = 0.1651, CI 0.76-4.93); Odds Ratio (OR) = 2.21 (p = 0.0964, CI 0.87-5.62); Odds Ratio (OR) = 3.12 (p = 0.0276, CI 1.13-8.59); Odds Ratio (OR) = 4.99 (p = 0.006, CI 1.58-15.7); Odds Ratio (OR) = 2.03 (p = 0.1556, CI 0.76-5.39); Odds Ratio (OR) = 3.33 (p = 0.0202, CI 1.21-9.18); Odds Ratio (OR) = 1.83 (p = 0.2063, CI 0.72-4.67); Odds Ratio (OR) = 2.7 (p = 0.0383, CI 1.06-6.92); Odds Ratio (OR) = 3.46 (p = 0.0118, CI 1.32-9.1); Odds Ratio (OR) = 2.96 (p = 0.0314, CI 1.1-7.97); Odds Ratio (OR) = 6.8 (p = 0.001, CI 2.17-21.34); Odds Ratio (OR) = 2.24 (p = 0.0956, CI 0.87-5.8); Odds Ratio (OR) = 4.8 (p = 0.0027, CI 1.72-13.4); Odds Ratio (OR) = 2.41 (p = 0.066, CI 0.94-6.14); Odds Ratio (OR) = 2.32 (p = 0.0853, CI 0.89-6.05); Odds Ratio (OR) = 3.49 (p = 0.0159, CI 1.26-9.62); Odds Ratio (OR) = 3.27 (p = 0.0303, CI 1.12-9.53); Odds Ratio (OR) = 4.84 (p = 0.0071, CI 1.54-15.28); Odds Ratio (OR) = 2.6 (p = 0.0621, CI 0.95-7.09); Odds Ratio (OR) = 4.2 (p = 0.0081, CI 1.45-12.15); Odds Ratio (OR) = 2.64 (p = 0.0533, CI 0.99-7.09); Odds Ratio (OR) = 1.71 (p = 0.2666, CI 0.66-4.42); Odds Ratio (OR) = 2.44 (p = 0.0754, CI 0.91-6.52); Odds Ratio (OR) = 3.27 (p = 0.0313, CI 1.11-9.64); Odds Ratio (OR) = 5.76 (p = 0.0056, CI 1.67-19.88); Odds Ratio (OR) = 2.58 (p = 0.0736, CI 0.91-7.28); Odds Ratio (OR) = 3.51 (p = 0.0184, CI 1.24-10); Odds Ratio (OR) = 2.18 (p = 0.1187, CI 0.82-5.81); Odds Ratio (OR) = 3.8 (p = 0.0299, CI 1.14-12.69); Odds Ratio (OR) = 1.4 (p = 0.5989, CI 0.4-4.89); Odds Ratio (OR) = 2.61 (p = 0.1337, CI 0.74-9.14); Odds Ratio (OR) = 1.62 (p = 0.4605, CI 0.45-5.89); Odds Ratio (OR) = 4.48 (p = 0.0188, CI 1.28-15.65); Odds Ratio (OR) = 1.44 (p = 0.5854, CI 0.39-5.42); Odds Ratio (OR) = 2.32 (p = 0.1768, CI 0.68-7.86); Odds Ratio (OR) = 0.89 (p = 0.8426, CI 0.29-2.78); Odds Ratio (OR) = 0.54 (p = 0.3017, CI 0.17-1.73); Odds Ratio (OR) = 0.72 (p = 0.5958, CI 0.21-2.43); Odds Ratio (OR) = 0.23 (p = 0.0515, CI 0.05-1.01); Odds Ratio (OR) = 0.98 (p = 0.9734, CI 0.31-3.11); Odds Ratio (OR) = 0.85 (p = 0.7969, CI 0.25-2.93); Odds Ratio (OR) = 0.78 (p = 0.6637, CI 0.25-2.4); Odds Ratio (OR) = 1.53 (p = 0.4921, CI 0.45-5.15); Odds Ratio (OR) = 1.09 (p = 0.891, CI 0.33-3.64); Odds Ratio (OR) = 0.68 (p = 0.5881, CI 0.16-2.78); Odds Ratio (OR) = 0.11 (p = 0.0523, CI 0.01-1.02); Odds Ratio (OR) = 1.6 (p = 0.4646, CI 0.46-5.61); Odds Ratio (OR) = 1.43 (p = 0.5806, CI 0.4-5.14); Odds Ratio (OR) = 0.94 (p = 0.922, CI 0.28-3.12). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 1.08 (p = 0.9587, CI 0.06-17.98); Odds Ratio (OR) = 1.02 (p = 0.9895, CI 0.06-16.89); Odds Ratio (OR) = 7.24 (p = 0.0736, CI 0.83-63.32); Odds Ratio (OR) = 7.08 (p = 0.0767, CI 0.81-61.78); Odds Ratio (OR) = 3.51 (p = 0.288, CI 0.35-35.49); Odds Ratio (OR) = 1.96 (p = 0.5894, CI 0.17-22.47); Odds Ratio (OR) = 2.45 (p = 0.3093, CI 0.44-13.78); Odds Ratio (OR) = 3.31 (p = 0.1606, CI 0.62-17.58); Odds Ratio (OR) = 11.92 (p = 0.0019, CI 2.5-56.87); Odds Ratio (OR) = 14.4 (p = 8e-04, CI 3.02-68.73); Odds Ratio (OR) = 0.86 (p = 0.8803, CI 0.11-6.55); Odds Ratio (OR) = 2.98 (p = 0.2096, CI 0.54-16.46); Odds Ratio (OR) = 7.69 (p = 0.011, CI 1.6-37.11); Odds Ratio (OR) = 3.09 (p = 0.0845, CI 0.86-11.11); Odds Ratio (OR) = 2.83 (p = 0.1094, CI 0.79-10.13); Odds Ratio (OR) = 8.97 (p = 4e-04, CI 2.68-30.07); Odds Ratio (OR) = 7.11 (p = 0.0016, CI 2.1-24.09); Odds Ratio (OR) = 1.71 (p = 0.4375, CI 0.44-6.64); Odds Ratio (OR) = 3.02 (p = 0.0898, CI 0.84-10.85); Odds Ratio (OR) = 6.32 (p = 0.0027, CI 1.9-21.06); Odds Ratio (OR) = 2.44 (p = 0.1242, CI 0.78-7.64); Odds Ratio (OR) = 2.66 (p = 0.0815, CI 0.88-8.03); Odds Ratio (OR) = 6.21 (p = 9e-04, CI 2.11-18.27); Odds Ratio (OR) = 5.28 (p = 0.0027, CI 1.78-15.64); Odds Ratio (OR) = 1.35 (p = 0.6267, CI 0.41-4.46); Odds Ratio (OR) = 2.77 (p = 0.0709, CI 0.92-8.38); Odds Ratio (OR) = 4.62 (p = 0.0049, CI 1.59-13.59); Odds Ratio (OR) = 1.5 (p = 0.5107, CI 0.45-4.98); Odds Ratio (OR) = 2.37 (p = 0.1297, CI 0.78-7.22); Odds Ratio (OR) = 7.04 (p = 5e-04, CI 2.34-21.22); Odds Ratio (OR) = 8.5 (p = 1e-04, CI 2.82-25.63); Odds Ratio (OR) = 1.84 (p = 0.299, CI 0.58-5.81); Odds Ratio (OR) = 2.38 (p = 0.1355, CI 0.76-7.42); Odds Ratio (OR) = 5.17 (p = 0.0028, CI 1.76-15.14); Odds Ratio (OR) = 1.2 (p = 0.7422, CI 0.41-3.47); Odds Ratio (OR) = 2.44 (p = 0.075, CI 0.91-6.52); Odds Ratio (OR) = 6 (p = 6e-04, CI 2.16-16.67); Odds Ratio (OR) = 7.63 (p = 1e-04, CI 2.69-21.65); Odds Ratio (OR) = 1.12 (p = 0.8405, CI 0.38-3.23); Odds Ratio (OR) = 1.3 (p = 0.6257, CI 0.45-3.79); Odds Ratio (OR) = 3.92 (p = 0.006, CI 1.48-10.36); Odds Ratio (OR) = 1.74 (p = 0.3556, CI 0.54-5.68); Odds Ratio (OR) = 3.67 (p = 0.019, CI 1.24-10.9); Odds Ratio (OR) = 9.9 (p = 1e-04, CI 3.2-30.68); Odds Ratio (OR) = 14.81 (p = 1e-04, CI 4.67-47.05); Odds Ratio (OR) = 2.13 (p = 0.1936, CI 0.68-6.67); Odds Ratio (OR) = 3.39 (p = 0.0335, CI 1.1-10.47); Odds Ratio (OR) = 6.18 (p = 9e-04, CI 2.1-18.17); Odds Ratio (OR) = 0.9 (p = 0.833, CI 0.34-2.39); Odds Ratio (OR) = 1.56 (p = 0.341, CI 0.62-3.91); Odds Ratio (OR) = 3.71 (p = 0.0075, CI 1.42-9.69); Odds Ratio (OR) = 4.86 (p = 0.002, CI 1.78-13.26); Odds Ratio (OR) = 0.78 (p = 0.6216, CI 0.29-2.1); Odds Ratio (OR) = 1.43 (p = 0.4615, CI 0.55-3.71); Odds Ratio (OR) = 2.84 (p = 0.0281, CI 1.12-7.19); Odds Ratio (OR) = 0.88 (p = 0.8028, CI 0.33-2.35); Odds Ratio (OR) = 1.21 (p = 0.6846, CI 0.48-3.07); Odds Ratio (OR) = 3.31 (p = 0.0149, CI 1.26-8.67); Odds Ratio (OR) = 5.64 (p = 9e-04, CI 2.03-15.65); Odds Ratio (OR) = 0.79 (p = 0.6434, CI 0.29-2.15); Odds Ratio (OR) = 1.41 (p = 0.4784, CI 0.54-3.69); Odds Ratio (OR) = 2.2 (p = 0.0955, CI 0.87-5.55); Odds Ratio (OR) = 1.06 (p = 0.9082, CI 0.4-2.79); Odds Ratio (OR) = 1.25 (p = 0.6478, CI 0.48-3.21); Odds Ratio (OR) = 3.65 (p = 0.0104, CI 1.35-9.82); Odds Ratio (OR) = 6.66 (p = 4e-04, CI 2.34-18.94); Odds Ratio (OR) = 0.91 (p = 0.856, CI 0.34-2.45); Odds Ratio (OR) = 1.6 (p = 0.3319, CI 0.62-4.17); Odds Ratio (OR) = 2.34 (p = 0.0747, CI 0.92-5.95); Odds Ratio (OR) = 1.06 (p = 0.8986, CI 0.41-2.76); Odds Ratio (OR) = 0.98 (p = 0.9712, CI 0.38-2.53); Odds Ratio (OR) = 3.31 (p = 0.091, CI 1.22-8.98); Odds Ratio (OR) = 5.68 (p = 0.0011, CI 2.01-16.06); Odds Ratio (OR) = 0.91 (p = 0.8466, CI 0.35-2.39); Odds Ratio (OR) = 2.03 (p = 0.1409, CI 0.79-5.21); Odds Ratio (OR) = 2.08 (p = 0.1212, CI 0.82-5.25); Odds Ratio (OR) = 1.48 (p = 0.4269, CI 0.56-3.88); Odds Ratio (OR) = 1.34 (p = 0.5454, CI 0.52-3.49); Odds Ratio (OR) = 2.62 (p = 0.0595, CI 0.96-7.15); Odds Ratio (OR) = 4.58 (p = 0.0041, CI 1.62-12.98); Odds Ratio (OR) = 0.77 (p = 0.6121, CI 0.28-2.13); Odds Ratio (OR) = 1.8 (p = 0.2329, CI 0.68-4.75); Odds Ratio (OR) = 2.28 (p = 0.0891, CI 0.88-5.9); Odds Ratio (OR) = 0.55 (p = 0.6857, CI 0.03-9.97); Odds Ratio (OR) = 1.56 (p = 0.7291, CI 0.12-19.71); Odds Ratio (OR) = 0.82 (p = 0.8951, CI 0.05-14.41); Odds Ratio (OR) = 1.66 (p = 0.6865, CI 0.14-19.74); Odds Ratio (OR) = 1.17 (p = 0.9132, CI 0.07-20.24); Odds Ratio (OR) = 1.38 (p = 0.7982, CI 0.12-16.59); Odds Ratio (OR) = 1.17 (p = 0.9029, CI 0.09-15.57); Odds Ratio (OR) = 0.69 (p = 0.7971, CI 0.04-11.94). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week. Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15. Description: The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).. Parameters: Odds Ratio (OR) = 2.97 (p = 0.1318, CI 0.72-12.19); Odds Ratio (OR) = 5.99 (p = 0.0093, CI 1.56-23.04); Odds Ratio (OR) = 10.13 (p = 6e-04, CI 2.69-38.22); Odds Ratio (OR) = 15.63 (p = 1e-04, CI 4.11-59.4); Odds Ratio (OR) = 2.53 (p = 0.2054, CI 0.6-10.64); Odds Ratio (OR) = 2.8 (p = 0.1592, CI 0.67-11.72); Odds Ratio (OR) = 6.31 (p = 0.007, CI 1.66-24.07); Odds Ratio (OR) = 3.39 (p = 0.0392, CI 1.06-10.85); Odds Ratio (OR) = 4.49 (p = 0.0096, CI 1.44-13.96); Odds Ratio (OR) = 10.11 (p = 1e-04, CI 3.28-31.16); Odds Ratio (OR) = 11.76 (p = 1e-04, CI 3.75-36.9); Odds Ratio (OR) = 2.11 (p = 0.2217, CI 0.64-7.03); Odds Ratio (OR) = 4.26 (p = 0.0131, CI 1.36-13.38); Odds Ratio (OR) = 2.13 (p = 0.1334, CI 0.79-5.74); Odds Ratio (OR) = 3.39 (p = 0.012, CI 1.31-8.77); Odds Ratio (OR) = 1.84 (p = 0.2443, CI 0.66-5.1); Odds Ratio (OR) = 4.6 (p = 0.0022, CI 1.73-12.25); Odds Ratio (OR) = 6.6 (p = 4e-04, CI 2.35-18.58); Odds Ratio (OR) = 12.17 (p = 1e-04, CI 4.05-36.63); Odds Ratio (OR) = 1.7 (p = 0.3101, CI 0.61-4.71); Odds Ratio (OR) = 3.65 (p = 0.0116, CI 1.34-10); Odds Ratio (OR) = 4.15 (p = 0.0045, CI 1.56-11.05); Odds Ratio (OR) = 1.55 (p = 0.3505, CI 0.62-3.88); Odds Ratio (OR) = 2.28 (p = 0.0739, CI 0.92-5.62); Odds Ratio (OR) = 3.19 (p = 0.0163, CI 1.24-8.2); Odds Ratio (OR) = 8.49 (p = 1e-04, CI 2.81-25.64); Odds Ratio (OR) = 0.9 (p = 0.8358, CI 0.35-2.35); Odds Ratio (OR) = 2.18 (p = 0.1006, CI 0.86-5.52); Odds Ratio (OR) = 2.53 (p = 0.0484, CI 1.01-6.34); Odds Ratio (OR) = 1.24 (p = 0.6492, CI 0.5-3.08); Odds Ratio (OR) = 1.74 (p = 0.223, CI 0.71-4.27); Odds Ratio (OR) = 3.43 (p = 0.0126, CI 1.3-9.02); Odds Ratio (OR) = 5.56 (p = 0.0014, CI 1.94-15.98); Odds Ratio (OR) = 0.7 (p = 0.4713, CI 0.27-1.83); Odds Ratio (OR) = 2.02 (p = 0.1397, CI 0.79-5.12); Odds Ratio (OR) = 1.75 (p = 0.2272, CI 0.71-4.34); Odds Ratio (OR) = 1.83 (p = 0.2024, CI 0.72-4.64); Odds Ratio (OR) = 1.9 (p = 0.1716, CI 0.76-4.79); Odds Ratio (OR) = 3.2 (p = 0.0199, CI 1.2-8.51); Odds Ratio (OR) = 8.45 (p = 2e-04, CI 2.8-25.54); Odds Ratio (OR) = 1.47 (p = 0.4243, CI 0.57-3.77); Odds Ratio (OR) = 1.99 (p = 0.1507, CI 0.78-5.09); Odds Ratio (OR) = 2.6 (p = 0.0449, CI 1.02-6.6); Odds Ratio (OR) = 1.68 (p = 0.2759, CI 0.66-4.24); Odds Ratio (OR) = 1.9 (p = 0.17, CI 0.76-4.78); Odds Ratio (OR) = 3.47 (p = 0.0153, CI 1.27-9.51); Odds Ratio (OR) = 6.04 (p = 9e-04, CI 2.08-17.53); Odds Ratio (OR) = 1.27 (p = 0.6228, CI 0.5-3.23); Odds Ratio (OR) = 2.62 (p = 0.046, CI 1.02-6.76); Odds Ratio (OR) = 2.07 (p = 0.1215, CI 0.82-5.23); Odds Ratio (OR) = 4.45 (p = 0.1933, CI 0.47-42.25); Odds Ratio (OR) = 5.61 (p = 0.124, CI 0.62-50.44); Odds Ratio (OR) = 14.16 (p = 0.014, CI 1.71-117.2); Odds Ratio (OR) = 17.5 (p = 0.0075, CI 2.15-142.7); Odds Ratio (OR) = 1.98 (p = 0.5853, CI 0.17-22.96); Odds Ratio (OR) = 5 (p = 0.1596, CI 0.53-47.05); Odds Ratio (OR) = 6.48 (p = 0.0908, CI 0.74-56.51); Odds Ratio (OR) = 5.39 (p = 0.0031, CI 1.76-16.46); Odds Ratio (OR) = 2.15 (p = 0.1485, CI 0.76-6.1); Odds Ratio (OR) = 3.54 (p = 0.0128, CI 1.31-9.56); Odds Ratio (OR) = 6.5 (p = 3e-04, CI 2.37-17.81); Odds Ratio (OR) = 6.42 (p = 3e-04, CI 2.32-17.77); Odds Ratio (OR) = 1.87 (p = 0.2354, CI 0.67-5.26); Odds Ratio (OR) = 2.41 (p = 0.0894, CI 0.87-6.65); Odds Ratio (OR) = 3.23 (p = 0.0201, CI 1.2-8.67); Odds Ratio (OR) = 2.1 (p = 0.1614, CI 0.74-5.94); Odds Ratio (OR) = 3.57 (p = 0.0123, CI 1.32-9.66); Odds Ratio (OR) = 6.08 (p = 6e-04, CI 2.17-17.03); Odds Ratio (OR) = 9.82 (p = 1e-04, CI 3.4-28.36); Odds Ratio (OR) = 2.08 (p = 0.1609, CI 0.75-5.81); Odds Ratio (OR) = 2.42 (p = 0.093, CI 0.86-6.79); Odds Ratio (OR) = 4.02 (p = 0.0063, CI 1.48-10.91); Odds Ratio (OR) = 1.76 (p = 0.2621, CI 0.65-4.74); Odds Ratio (OR) = 3.55 (p = 0.0092, CI 1.37-9.21); Odds Ratio (OR) = 5.69 (p = 7e-04, CI 2.09-15.48); Odds Ratio (OR) = 8.85 (p = 1e-04, CI 3.08-25.43); Odds Ratio (OR) = 1.5 (p = 0.4259, CI 0.55-4.08); Odds Ratio (OR) = 1.75 (p = 0.247, CI 0.68-4.48); Odds Ratio (OR) = 1.83 (p = 0.2072, CI 0.72-4.66); Odds Ratio (OR) = 2.57 (p = 0.0621, CI 0.95-6.94); Odds Ratio (OR) = 5.67 (p = 0.0016, CI 1.93-16.69); Odds Ratio (OR) = 1.47 (p = 0.4372, CI 0.56-3.84); Odds Ratio (OR) = 2.18 (p = 0.11, CI 0.84-5.66); Odds Ratio (OR) = 2.55 (p = 0.0533, CI 0.99-6.59); Odds Ratio (OR) = 4.68 (p = 0.1769, CI 0.5-44); Odds Ratio (OR) = 2.26 (p = 0.4942, CI 0.22-23.53); Odds Ratio (OR) = 12.82 (p = 0.0214, CI 1.46-112.7); Odds Ratio (OR) = 1.93 (p = 0.6013, CI 0.16-22.99); Odds Ratio (OR) = 8.6 (p = 0.0537, CI 0.97-76.58); Odds Ratio (OR) = 3.8 (p = 0.2662, CI 0.36-39.91); Odds Ratio (OR) = 1.51 (p = 0.7431, CI 0.13-17.84); Odds Ratio (OR) = 3.53 (p = 0.2829, CI 0.35-35.22); Odds Ratio (OR) = 2.12 (p = 0.5311, CI 0.2-22.29); Odds Ratio (OR) = 4.71 (p = 0.1857, CI 0.47-46.83); Odds Ratio (OR) = 1.02 (p = 0.9879, CI 0.06-17.5); Odds Ratio (OR) = 4.57 (p = 0.1853, CI 0.48-43.19); Odds Ratio (OR) = 4.43 (p = 0.217, CI 0.42-46.93); Odds Ratio (OR) = 0.74 (p = 0.8354, CI 0.04-12.62). Non-inferiority type: SUPERIORITY.
Study: A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Summary: To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

Detailed Description: NA

Results: Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 6. Time frame: Baseline, Month 6. Description: Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).. Parameters: LS Mean Difference = -0.1 (p = 0.84, CI -1.3-1). Non-inferiority type: NON_INFERIORITY.
Study: A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Summary: The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Detailed Description: This is a multi-centre, multi-country, double-blind, randomised, placebo-controlled Phase 2b study. The study will have a single-blind run-in period and will be adaptive with respect to the number of subjects recruited into each dose group. Four doses of BAY3427080 (40 mg once a day, 80 mg once a day, 120 mg once a day and 160 mg once a day) will be investigated and compared to placebo, in five parallel groups. Subjects will participate in the study for a total of approximately 19 weeks, comprising a screening period of 1 week, a 14 week treatment period, and then a final follow up visit 4 weeks after the end of the treatment period. There will be a total of 8 visits whilst participating in the study. Subjects will record their hot flashes in an electronic diary during the screening period to establish eligibility and throughout the study after randomisation.

Results: Outcome: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12. Time frame: From baseline to Week 12. Description: Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.. Parameters: Difference in LS means = -1.67 (p = 0.2097, CI -4.28--0.95); Difference in LS means = -0.77 (p = 0.6369, CI -3.97-2.44); Difference in LS means = -2.95 (p = 0.0116, CI -5.22--0.67); Difference in LS means = -1.78 (p = 0.1346, CI -4.12-0.56). Non-inferiority type: SUPERIORITY. Outcome: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4. Time frame: From baseline to Week 4. Description: Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.. Parameters: Difference in LS means = 1.29 (p = 0.3682, CI -4.11-1.53); Difference in LS means = -1.52 (p = 0.1946, CI -3.83-0.78); Difference in LS means = -3.93 (p = 2e-04, CI -5.94--1.92); Difference in LS means = -2.63 (p = 0.0115, CI -4.66--0.6). Non-inferiority type: SUPERIORITY. Outcome: Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12. Time frame: From baseline to Week 12. Description: Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).. Parameters: Difference in LS means = -0.09 (p = 0.5511, CI -0.39-0.21); Difference in LS means = 0.16 (p = 0.3822, CI -0.2-0.52); Difference in LS means = -0.15 (p = 0.2606, CI -0.41-0.11); Difference in LS means = -0.27 (p = 0.0479, CI -0.53-0). Non-inferiority type: SUPERIORITY. Outcome: Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4. Time frame: From baseline to Week 4. Description: Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).. Parameters: Difference in LS means = -0.05 (p = 0.7033, CI -0.3-0.2); Difference in LS means = -0.14 (p = 0.3724, CI -0.45-0.17); Difference in LS means = -0.19 (p = 0.0896, CI -0.41-0.03); Difference in LS means = -0.19 (p = 0.09, CI -0.41-0.03). Non-inferiority type: SUPERIORITY.
Study: A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

Summary: The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.

Detailed Description: This is a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Eligible subjects will be stratified by natural or surgical menopause and randomized (1:1) to receive 3 single injections, 28-days apart, of either G-CSF or placebo.

This study will consist of a 14-21 day screening period. Subjects enrolled will be given three single 1.0 mL subcutaneous (SC) injections (repeated 28-days apart), in the outer area of either upper arm, of either G-CSF or placebo (sterile physiological saline) at Baseline, Day 28 and Day 56. Subjects will be followed for 12 weeks and will complete hot flash diary entries every day for the duration of treatment. Safety will be assessed by adverse events, clinical laboratory tests (clinical chemistry and complete blood count with differential) and vital signs. A follow-up phone call will occur 60 days after the last dose of study drug.

Eligibility will be assessed via physical examination, clinical laboratory testing, vital signs.

Subjects will receive a diary in which to record daily hot flashes symptoms during the duration of the screening period. Subjects must have at least 14 days of hot flash recordings to participate in the study. The diary will be reviewed by study site staff on Baseline (Day 0) to confirm study eligibility.

During the treatment period, subjects will return to the study site at Days 1, 21, 28, 29, 49, 56, 57, and 84 for assessments.

The follow-up phone call will occur approximately 60 days following the last dose of study drug.

Results: Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0. Time frame: Baseline and day 1. Description: Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 0. Blood samples were collected 24 hours after adminstration of G-CSF on day 0.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28. Time frame: Baseline and day 29. Description: Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 28. Blood samples were collected 24 hours after adminstration of G-CSF on day 28.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.. Time frame: Baseline and day 57. Description: Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 56. Blood samples were collected 24 hours after adminstration of G-CSF on day 56.. Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo). Time frame: Baseline and day 84. Description: Change from baseline in white blood cell counts on day 84. Blood samples were collected 24 hours after adminstration of G-CSF on day 84.. Parameters: NA = NA (p = 0.199, CI NA-NA); NA = NA (p = 0.189, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12. Time frame: Baseline and week 12. Description: CDS (Composite Daily Hot Flash Severity) was calculated as follows:

\[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.333, CI NA-NA); NA = NA (p = 0.014, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4. Time frame: Baseline and week 4. Description: CDS (Composite Daily Hot Flash Severity) was calculated as follows:

\[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.501, CI NA-NA); NA = NA (p = 0.37, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12. Time frame: Baseline and week 12. Description: HFSS (Daily Hot Flash Severity Score) was calculated as follows:

\[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.032, CI NA-NA); NA = NA (p = 0.077, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4. Time frame: Baseline and week 4. Description: HFSS (Daily Hot Flash Severity Score) was calculated as follows:

\[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.124, CI NA-NA); NA = NA (p = 0.175, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12. Time frame: Baseline and week 12. Description: The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.232, CI NA-NA); NA = NA (p = 0.085, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4. Time frame: Baseline and week 4. Description: The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.398, CI NA-NA); NA = NA (p = 0.391, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Net Change in FSS Score at 12 Weeks. Time frame: Baseline and week 12. Description: Fatigue Severity Scale (FSS) of Sleep Disorders. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a short questionnaire (10 questions) that requires the subject to rate level of fatigue. The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms. Each statement is read and the corresponding number from 1 to 7 is circled. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. (Maximum bother = 70; No bother = 0). Parameters: NA = NA (p = 0.406, CI NA-NA); NA = NA (p = 0.494, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Net Change in HFRDIS Score. Time frame: Baseline and week 12. Description: The Hot Flash Related Daily Interference Scale (HFRDIS) measures (as a score of 0 to 10) the effect of hot flashes on overall quality of life and on nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relations with others, sexuality, and enjoyment of life. The 10 answers are added up to get a total score. HFRDIS Score (Maximum Bothersomness = 100; No Bothersomeness = 0). The higher the score, the more bothersome the symptoms.. Parameters: NA = NA (p = 0.289, CI NA-NA); NA = NA (p = 0.338, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Net Change in HFSS at 12 Weeks in Demographic Subgroups. Time frame: Baseline and Week 12. Description: HFSS (Daily Hot Flash Severity Score) was calculated as follows:

\[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received. Parameters: NA = NA (p = 0.147, CI NA-NA); NA = NA (p = 0.16, CI NA-NA); NA = NA (p = 0.152, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Net Change in ISI Score at 12 Weeks. Time frame: Baseline and week 12. Description: The Insomnia Severity Index has seven questions. For each question, most bothersome = 4; not bothersome = 0. The seven answers are added up to get a total score. Total score categories: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe). Parameters: NA = NA (p = 0.393, CI NA-NA); NA = NA (p = 0.365, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Net Change in MENQOL VMS Score. Time frame: Baseline and week 12. Description: Menopause-specific Quality of Life (MENQOL) Questionnaire. The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). MENQOL VMS refers to the answers to items 1-3 where 6 = most bothersome and 0 = least bothersome). (Maximum bothersomeness = 18; No bothersomeness = 0). Parameters: NA = NA (p = 0.286, CI NA-NA); NA = NA (p = 0.107, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change in M+S at 12 Weeks in Demographic Subgroups. Time frame: Baseline and Week 12. Description: The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.. Parameters: NA = NA (p = 0.047, CI NA-NA); NA = NA (p = 0.139, CI NA-NA); NA = NA (p = 0.395, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Summary: The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.

Detailed Description: This was an open-label, single-arm study of postmenopausal women with osteoporosis treated with 80 micrograms (g) abaloparatide for 3 months. Transiliac bone biopsies were taken at 3 months after quadruple fluorochrome labeling. The treatment duration of 3 months was determined to be the optimal time when biochemical markers of bone turnover peak and are predictive of subsequent changes in bone mineral density (BMD).

The main study was conducted for a 3-month treatment period with a 1-month follow up. A sub-study was conducted at 1 site to collect peripheral quantitative computed tomography (pQCT) data. Study treatment for participants in the sub-study was extended for an additional 3 months of study drug administration for a total of 6 months of treatment.

Results: Outcome: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3. Time frame: Baseline (Day 1), Month 3. Description: Change in dynamic histomorphometry indices was assessed in the cancellous envelope.. Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: OTHER.
Study: Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

Summary: Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.

Detailed Description: Despite decades of clinical research, depression continues to affect 20.9 million Americans each year and remains the leading cause of disability worldwide. Women are twice as likely as men to experience depression, and depression symptoms are particularly common during periods of hormone change. Depression risk increases 14-fold in the two years surrounding menopause, suggesting that hormone changes may cause depression during this time. Past research has shown that estrogen, in particular, plays an important role in depression during the transition to menopause ("the perimenopause") for the following reasons: 1) depression begins when estrogen levels plummet, 2) estrogen therapy reduces depression symptoms, and 3) when perimenopausal women who were treated with estrogen are taken off of estrogen (without their knowledge), their depression returns. Despite clear evidence that estrogen plays a role in depression during the perimenopause (DPM), the investigators don't know how estrogen affects the brain, which is important for developing effective medications to treat DPM and also for determining which patients are most likely to benefit from medication that replaces the estrogen lost during menopause (estrogen replacement therapy).

The investigator received a grant from the National Institutes of Health, which received preliminary support from the Foundation of Hope, to characterize the effect of estrogen replacement therapy on the brain in women with DPM and women without depression ("controls"). The brain pathway affected most by depression is the neural reward circuit, which consists of a number of different brain regions that act in concert to determine a person's response to rewards. Activity in the neural reward circuit depends on estrogen levels and is reduced in people with depression. The investigator's NIH-funded study will be the first to examine how the neural reward circuit is affected by DPM and estrogen replacement therapy. While estrogen replacement therapy acts as an antidepressant, many women elect not to take estrogen and many physicians discourage its use because of the risk of long-term negative health effects, including breast and uterine cancer. A new FDA-approved compound, Duavee, combines estrogen with another medication, bazedoxifene, which protects against breast and uterine cancer while reducing hot flashes. Duavee may therefore be more acceptable to women with DPM and their doctors than estrogen replacement therapy. However, the effects of Duavee on depression and the neural reward circuit have never been tested, and one can't infer that estrogen will have the same antidepressant effects in the presence of bazedoxifene (which partially blocks the effects of estrogen in certain tissues).

The purpose of the proposed project is to 1) test the antidepressant effects of Duavee, and 2) quantify the effects of Duavee on the neural reward circuit. The investigators expect that Duavee will reduce symptoms of depression and increase activity in the neural reward circuit. In this study, the investigators will recruit medically healthy, unmedicated women with DPM and administer Duavee for 3 weeks (a duration that has been shown in previous studies of estrogen replacement to be sufficient for treating depression). Eligibility will be assessed by an initial telephone screen and confirmed by a gynecologic exam, laboratory testing, and an interview about their current and past depression symptoms. Only women with depression that began during the menopause transition (i.e., when they started skipping periods) will be enrolled. Both before and after treatment, women will have a fMRI brain scan to determine the effects of the medication on the neural reward circuit. During the 3-week treatment, women will come into the clinic to have their blood drawn, refill their medication, and answer questions about their mood and menopause symptoms.This study is important because untreated DPM contributes to cardiac deaths. Many women are afraid to use estrogen replacement therapy because of the long-term risk of cancer and yet refuse to take antidepressants for fear of side effects and stigma. Because Duavee addresses the main potential problems of estrogen replacement therapy, this research stands to revolutionize treatment for DPM. The use of estrogen replacement therapy to treat DPM is a relatively new area of research and one of great importance given the large and increasing number of women who enter the perimenopause each year and are potentially at risk for depression. Women with DPM seek treatment from gynecologists, psychiatrists, and general practitioners, yet there is neither consensus nor practical guidelines for preventing and treating DPM.

Specific Aims: The investigators currently are assessing the neural reward system in subjects with perimenopausal major depressive disorder (PM-MDD) and those without depression ("controls") using functional magnetic resonance imaging (fMRI) at baseline and following estrogen replacement therapy (ERT). The Foundation of Hope (FOH) award will allow us to add a Tissue Selective Estrogen Complex (TSEC) treatment condition in a separate group of PM-MDD. The investigators' central hypothesis is that the neural reward system is hypoactive in PM-MDD, and the antidepressant effects of a three-week TSEC intervention will be associated with increased activity in the neural reward system, assessed using functional magnetic resonance imaging (fMRI). The investigators will test the hypothesis by executing the following aims: Aim 1: Determine the extent to which TSEC reduces anhedonia and other depressive symptoms in PM-MDD. Anhedonia and other depressive symptoms will be assessed at baseline and following TSEC administration. The investigators also will compare the effects of TSEC and ERT in PM-MDD. Hypothesis 1: Women PM-MDD will report a significant reduction in depressive symptoms following TSEC administration, and the degree of symptom improvement will be associated with the change in frontostriatal responsivity to reward. Aim 2: Quantify the effect of TSEC on the neural reward system in PM-MDD. The investigators will use fMRI at baseline and following TSEC treatment in PM-MDD to probe frontostriatal reward circuitry. The investigator will also compare the effects of TSEC and ERT in PM-MDD. Hypothesis 2: PM-MDD will show increased activation of the frontostriatal circuit in response to reward following TSEC administration (compared with baseline).

Results: Outcome: Change in Frontostriatal Reactivity to Reward During MID fMRI Task. Time frame: Baseline to 3 weeks. Description: The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during "win" and "lose" conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more "active" or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner.. Parameters: NA = NA (p = 0.53, CI NA-NA). Non-inferiority type: NON_INFERIORITY. Outcome: Depressive Symptoms as Measured by the MASQ-AD. Time frame: Baseline, week 2, week 3, week 4 (post treatment). Description: The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome.. Parameters: GLM = -5.8 (p = 0.001, CI NA-NA). Non-inferiority type: NON_INFERIORITY.
Study: The Effect of a Multivitamin in the Treatment of Memory Loss in Postmenopausal Women

Summary: Complaints about memory loss are very common in women in the menopausal transition period. The effectiveness of estrogen replacement therapy in cognitive improvement is controversial. Partial positive results were obtained in some studies with regard to memory improvement, so far no standard treatment considered effective in these cases. Effective pharmacological approaches to the treatment of memory loss associated with menopause are an unmet medical need. Cogmax is a multivitamin and mineral supplement that contains numerous key elements for cognitive function, and may be a safe therapeutic option in these cases.

The multicenter, non-comparative (single-arm) phase IV clinical trial will be conducted with 80 female participants aged 45 to 60 years and menopausal memory loss complaint.

After 3 months of using multivitamin and mineral supplement, memory and attention will be reevaluated through specific questionnaire and the Stroop Test Victoria version.

Detailed Description: This multicenter, non-comparative phase IV clinical trial will be conducted at brazilian clinical trial centers under the auspices of Eurofarma Laboratories S.A. Recruitment for the study will begin after the relevant ethical and regulatory approvals and will have an estimated duration of 4 months.

The study will include 80 female participants aged between 45 and 60 years and menopausal memory complaints who consent to participate in the study by signing the informed consent form.

To be included, participants must meet all inclusion criteria and none of the exclusion criteria. Each participant will initially complete a selection period with a maximum duration of 14 days for evaluation of eligibility. Participants will then be treated with Cogmax in the dosage of two capsules per day for 12 weeks.

Results: Outcome: Change From Baseline of the Score Number Relative to the Self-efficacy Factor, Consisting of Average Scores on the Domains Capacity, Control and Change of the Meta-memory in Adulthood Questionnaire - Portuguese Reduced Version. Time frame: 12 weeks after the start of the treatment (Baseline). Description: The primary outcome measure will evaluate the change from baseline in the score relative to the self-efficacy factor (SEF), consisting of arithmetic average on the domains capacity, control and change of the Meta-memory in Adulthood Questionnaire - Portuguese reduced version (MIAr) SEF final - SEF baseline  0 (no improvement in the measured memory capacity between the initial and final evaluations) SEF final - SEF baseline \> 0 (improvement in the memory capacity measured between the initial and final evaluations)

The arithmetic average on the domains capacity, control and change range from 1 (worse) to 5 (better).. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: OTHER.
Study: Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Summary: This study was conducted to assess if there were any clinically meaningful differences in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, or immunogenicity between GP2411 (proposed biosimilar denosumab) and EU-authorized Prolia (denosumab).

Detailed Description: This was an international, multicenter, randomized, double-blind, parallel-group study with a total duration of up to 83 weeks.

The study comprised a screening period of up to 5 weeks to assess a subject's eligibility and two treatment periods: Treatment Period 1 (TP1) from Day 1 to Week 52 and Treatment Period 2 (TP2) from Week 52 to Week 78.

Women with postmenopausal osteoporosis (PMO) were randomized on Day 1 in a 1:1 ratio to receive either two 60 mg subcutaneous (s.c.) doses at 26-week intervals of GP2411 (proposed biosimilar denosumab) or EU-Prolia (EU-authorized Prolia) during TP1. At Week 52, participants in the EU-Prolia group were re-randomized 1:1 to either continue with a third dose of EU-Prolia or switch to GP2411 for TP2. Participants in the GP2411 group continued the treatment with a third dose of GP2411 in TP2. The End of Study was achieved at Week 78.

Results: Outcome: Area Under the Effect-time Curve (AUEC) of Percentage Change From Baseline in Serum CTX Concentrations After First Dose - Pharmacodynamic Analysis Set. Time frame: Baseline (pre-dose Day 1), up to Week 26. Description: Carboxy-terminal crosslinked telopeptides of type I collagen (CTX) is a bone resorption biomarker. Serum CTX concentration-time data were analyzed by non-compartmental methods. The AUEC of baseline corrected serum CTX concentrations (% change from baseline) was calculated using the linear trapezoidal method. Values below the lower limit of quantification (LLOQ) were imputed with the actual value for the LLOQ.. Parameters: Geometric mean ratio = 1 (p = NA, CI 0.98-1.01); Geometric mean ratio = 1 (p = NA, CI 0.98-1.01). Non-inferiority type: EQUIVALENCE. Outcome: Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf) of Denosumab After First Dose. Time frame: Baseline (pre-dose Day 1), up to Week 26. Description: Serum denosumab concentration-time data were analyzed by non-compartmental methods. Missing denosumab serum concentrations or concentrations below the LLOQ were not imputed and handled as missing values, except for the pre-dose sample which were treated as zero. The linear-up log-down trapezoidal method was used for the AUCinf calculation.. Parameters: Geometric mean ratio = 0.99 (p = NA, CI 0.93-1.05). Non-inferiority type: EQUIVALENCE. Outcome: Maximum Observed Serum Concentration (Cmax) of Denosumab After First Dose. Time frame: Baseline (pre-dose Day 1), up to Week 26. Description: Serum denosumab concentration-time data were analyzed by non-compartmental methods. Missing denosumab serum concentrations or concentrations below the LLOQ were not imputed and handled as missing values, except for the pre-dose sample which were treated as zero.. Parameters: Geometric mean ratio = 0.97 (p = NA, CI 0.92-1.03). Non-inferiority type: EQUIVALENCE. Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52 - Per-Protocol Set. Time frame: Baseline (screening), up to Week 52. Description: Bone density measurements were performed by dual energy X-ray absorptiometry (DXA). Lumbar spine scan included L1 through L4 vertebrae. All DXA scans were submitted to a central imaging vendor for analysis. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in LS-BMD for all post-baseline time points up to Week 52. Values at Week 52 were estimated from the model and are presented in the table.. Parameters: Mean Difference (Final Values) = -0.145 (p = NA, CI -0.798-0.509). Non-inferiority type: EQUIVALENCE. Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52 - TP1 Full Analysis Set. Time frame: Baseline (screening), up to Week 52. Description: Bone density measurements were performed by DXA. Lumbar spine scan included L1 through L4 vertebrae. All DXA scans were submitted to a central imaging vendor for analysis. A MMRM was fitted to the changes from baseline in LS-BMD for all post-baseline time points up to Week 52. Missing values were assumed to be missing at random (MAR) using the MMRM model. Values at Week 52 were estimated from the model and are presented in the table.. Parameters: Mean Difference (Final Values) = -0.177 (p = NA, CI -0.83-0.475). Non-inferiority type: EQUIVALENCE.
Study: Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods

Summary: Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.It has been suggested that the transport of cGMP to oocyte via gap junctions causes a continuous increase in cyclic adenosine monophosphate (cAMP) levels within the oocyte. An important role of increased cAMP levels in oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid (DNA) studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after Luteinizing hormone(LH) / human chorionic(hCG) stimulation. Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG (9).

Detailed Description: In this prospective study, 60 patients are planned to recruite. Group 1 consists of 20 healthy reproductive aged women between 18-40 years old, with regular menstruation. Group 2 will include 20 patients in perimenopausal time period between 40-49 ages and in group 3 there will be20 postmenopausal women.

Age, gravida, parity and body mass index (BMI) data of all patients will be recorded. BMI is calculated by dividing the body weight in kilograms by the square of the height in meters. All patients will go under ultrasound examination by the same clinician (ACO). The number of antral follicles in group 1 and group 2 will be recorded. In addition, on the 2nd or 3rd day of menstruation, serum FSH, LH and E2 data of the patients in group 1 and 2 will be recorded.

For the last 6 months, patients with drug use that may affect menstruation like oral contraceptives, patients with cardiac or renal disease and therefore drug use, causes of infertility other than unexplained infertility, history of ovarian surgery, presence of polycystic ovary syndrome, and patients with irregular menstruation will be excluded for the study. In addition, patients with renal, cardiac, central nervous system and endocrine diseases will be excluded.

Morning fasting venous blood samples will be taken from the patients on the 2nd or 3rd day of the menstruation for group 1 and 2. All blood samples will be centrifuged on the day of collection and separated serum samples and will be kept at -80 degrees until the day of CNP test. Serum CNP levels of the patients will be analyzed by an enzyme-linked immunosorbent (ELISA) assay for human CNP in accordance with the manufacturer's instructions (SEA721Hu, ELISA Kit for Human CNP, Wuhan USCN Business Co., Ltd., Cloud-Clone Corp., CCC, USA).

Data will be analyzed using Statistical Package for Social Sciences software (SPSS v15, SPSS Inc, Chicago, IL, USA). The variables will be investigated using visual and analytical methods (histograms, homogeneity of variances test, Kolmogorov-Simirnov/Shapiro-Wilk's test) to determine whether or not they are normally distributed. Patient demographics and CNP values will be presented as median  interquartile range. Gravida and parity will be demonstrated by frequency distribution. The correlation coefficients and their significance will be calculated using the Spearman test. P-values less than 0.05 will be regarded as statistically significant.

Results: Outcome: Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2. Time frame: Second or Third Day of Menstruation. Description: Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2. Time frame: Second or Third Day of Menstruation. Description: Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2. Time frame: Second or Third Day of Menstruation. Description: Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Serum C Type Natriuretic Peptide Levels. Time frame: Second or Third Day of Menstruation. Description: The comparison of serum levels of C type natriuretic peptide among different age groups. Parameters: NA = NA (p = 0.017, CI NA-NA). Non-inferiority type: OTHER.
Study: Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Summary: A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).

Detailed Description: This study aims to evaluate the non-inferiority of abaloparatide-sMTS 300 micrograms (mcg) compared to abaloparatide-SC 80 mcg based on lumbar spine bone mineral density (BMD) at 12 months and to evaluate the safety and tolerability of abaloparatide-sMTS in the treatment of postmenopausal women with osteoporosis.

Results: Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12. Time frame: Baseline, Month 12. Description: Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory.. Parameters: Least Squares Means (LSM) Difference = -3.721 (p = NA, CI -5.0089--2.4331). Non-inferiority type: NON_INFERIORITY.
Study: Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

Summary: Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role in the regulation of bone homeostasis in periodontal disease-induced bone resorption. The Wnt / -catenin signal is controlled by physiological antagonists, including dickkopf released from osteocytes-associated protein 1 (DKK-1) and sclerostin (SOST). Thus, Wnt inhibitors SOST and DKK-1 affect bone mass changes. Bisphosphonates used in osteoporous treatment are selective inhibitors of bone resorption. In the serum of postmenopausal osteoporotic women treated with bisphosphonate, short-term and decreased DKK-1 level during the treatment, and increased SOST in the late period were reported. Increased bone formation after bisphosphonate treatment in postmenopausal osteoporotic patients has been associated with increased serum SOST level. The aim of our study is to investigate the effect of bisphosphonate in patients with post-menopausal osteoporosis on the bone demolition metabolism in periodontally healthy and periodontally diseased tooth regions and gingival health with the clinical data by investigating the SOST and DDK-1 molecules that play role in bone destruction mechanism.

Detailed Description: This study aims to reveal the effect of initial periodontal treatment together with bisphosphonate on sclerostin (SOST) and dickkopf-related protein-1 (DKK-1) in gingival crevicular fluid (GCF) of patients with osteoporosis.

Clinical recordings and GCF were obtained from postmenopausal women; with chronic periodontitis and those using bisphosphonate (Group A, n=12), with chronic periodontitis and otherwise healthy (Group B, n=10), without chronic periodontitis and those using bisphosphonate (Group C, n=11), systemically and periodontally healthy controls (Group D, n=10) at the baseline.

GCF sampling were recorded and repeated at the 6th and 12th months in Group A, B and C. SOST and DKK-1 values were measured by ELISA.

Results: Outcome: Dkk-1 Values for 12th Month. Time frame: 12 months. Description: levels of dickkopf-related protein-1 in 12th month. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Dkk-1 Values for 6th Month. Time frame: 6 months. Description: levels of dickkopf-related protein-1 in 6th month. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Sost Values for 12th Month. Time frame: 12 month. Description: levels of sclerostin in 12th month. Parameters: NA = NA (p = 0.05, CI NA-NA). Non-inferiority type: OTHER. Outcome: Sost Values for 6th Month. Time frame: 6 months. Description: levels of sclerostin in 6th month. Parameters: Mean Difference (Final Values) = 0.01 (p = 0.01, CI NA-NA). Non-inferiority type: OTHER.
Study: A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Summary: The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia (denosumab)

Detailed Description: This is a multinational, multicenter, randomized, double-blind study to demonstrate similar efficacy and safety of TVB-009 compared to Prolia administered subcutaneously at doses of 60 mg every 26 weeks. Approximately 326 postmenopausal women with osteoporosis will be randomized to receive either TVB-009 or Prolia. At week 52, patients in the Prolia arm will be re-randomized 1:1 to either continue with a third dose of Prolia or transition to TVB-009 and receive a single dose of TVB-009 in the transition period to assess immunogenicity and safety after a transition from Prolia to TVB-009. The total treatment duration for each patient is 78 weeks.

Results: Outcome: Percent Change From Baseline in LS-BMD at Week 52. Time frame: Baseline and week 52. Description: Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52. Parameters: Mean Difference (Net) = 0.21 (p = NA, CI -0.73-1.15). Non-inferiority type: EQUIVALENCE. Outcome: Percent Change From Baseline in sCTX-1 at Week 26. Time frame: Baseline and week 26. Description: Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26. Parameters: Mean Difference (Net) = 9.07 (p = NA, CI -0.14-18.29). Non-inferiority type: EQUIVALENCE.
Study: A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

Summary: This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis

Detailed Description: This is a double-blind, randomized, active-controlled, Phase 3 study to evaluate the efficacy, PK, PD, and safety including immunogenicity of CT-P41 compared with US-licensed Prolia in postmenopausal women with osteoporosis. All patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin D from randomization to EOS visit and the data will be collected via patient's diary.

Results: Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS). Time frame: baseline (screening), Week 52 predose. Description: Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor. To evaluate the difference between 2 groups in the primary efficacy endpoint, the percent change from baseline in BMD for lumbar spine (L1 to L4) by DXA at Week 52 was analyzed using an analysis of covariance (ANCOVA) model coupled with multiple imputation assuming the data to be missing at random (MAR).. Parameters: Mean Difference (Final Values) = -0.19 (p = NA, CI -0.76-0.38). Non-inferiority type: EQUIVALENCE.
Study: A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

Summary: The primary objective of this study is to demonstrate equivalent efficacy of the proposed biosimilar denosumab FKS518 to US-licensed Prolia in women with postmenopausal osteoporosis (PMO).

Detailed Description: NA

Results: Outcome: Percentage Change From Baseline in LS-BMD by DXA. Time frame: Baseline and Week 52. Description: Bone density was measured at the lumbar spine from L1 through L4. Per FDA request for this study, data were analyzed by non-inferiority and non-superiority analyses. Decreased BMD is associated with risk of fracture.. Parameters: Mean Difference (Final Values) = 0.46 (p = NA, CI -0.05-0.96). Non-inferiority type: NON_INFERIORITY. Outcome: Percentage Change From Baseline in LS-BMD by DXA. Time frame: Baseline and Week 52. Description: Bone density was measured at the lumbar spine from L1 through L4. Per FDA request for this study, data were analyzed by non-inferiority and non-superiority analyses. Decreased BMD is associated with risk of fracture.. Parameters: Mean Difference (Final Values) = 0.69 (p = NA, CI 0.19-1.2). Non-inferiority type: OTHER.
Study: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Summary: The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts

Detailed Description: This is a retrospective observational cohort study using healthcare administrative claims data from the USA.

This study will use anonymized patient claims data from PRA's Symphony Health Patient Source Integrated Dataverse (IDV) database including the enhanced hospital data. Data are routinely collected in healthcare encounters from all available healthcare sites (inpatient hospital, outpatient hospital, physician office, pharmacy, etc.) for all types of provided services including specialty, preventive care, and office-based treatments.

The patients for inclusion in the study analyses will be identified based on the prescribed anabolic therapy filled (ABL or TPTD). The identification period (May 1, 2017 to June 30, 2019) was chosen to coincide with the date of the FDA approval of ABL in the USA.

Results: Outcome: Number of Participants With Composite Endpoint of Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or In-hospital Cardiovascular Death. Time frame: From index date up to 19 months. Description: Cardiovascular safety was evaluated based only on events occurring from the beginning of the index period through 19 months. The date of the first prescription claim for either abaloparatide or teriparatide during the identification period was considered the index date. Cardiovascular events (MI and stroke) were defined as the first post-index incidence recorded on a hospital claim or physician claim. A validated claims-based algorithm was used to identify deaths, based on hospital discharge status, that are likely to be caused by cardiovascular events. Patients were followed for up to 18 months while on treatment plus 30 days follow-up, or until their first cardiovascular event (MI or stroke) or hospital death, whichever came first.. Parameters: Hazard Ratio (HR) = 1.08 (p = NA, CI 0.89-1.3). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With a Composite Endpoint of Nonfatal MI, Nonfatal Stroke, Heart Failure or In-hospital Cardiovascular Death. Time frame: From index date up to 19 months. Description: Cardiovascular safety was evaluated based only on events occurring from the beginning of the index period through 19 months. The date of the first prescription claim for either abaloparatide or teriparatide during the identification period was considered the index date. Cardiovascular events (MI, stroke, and heart failure) were defined as the first post-index incidence recorded on a hospital claim or physician claim. A validated claims-based algorithm was used to identify deaths, based on hospital discharge status, that are likely to be caused by cardiovascular events. Patients were followed for up to 18 months while on treatment plus 30 days follow-up, or until their first cardiovascular event (MI, stroke, or heart failure) or hospital death, whichever came first.. Parameters: Hazard Ratio (HR) = 1.08 (p = NA, CI 0.95-1.22). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With a Nonvertebral Fracture. Time frame: From index date up to 19 months. Description: A nonvertebral fracture is any fragility fracture at the hip, pelvis, femur, ankle, shoulder (including shoulder, humerus, clavicle), radius/ulna, wrist, or tibia/fibula. The date of the first prescription claim for either abaloparatide or teriparatide during the identification period was considered the index date. A claims-based algorithm with high specificity for fracture site was used to identify osteoporosis related fractures. Patients were followed for up to 18 months after their index date, plus 30 days follow-up or until their first nonvertebral fracture event or hospital death, whichever came first.. Parameters: Hazard Ratio (HR) = 0.94 (p = NA, CI 0.81-1.1). Non-inferiority type: NON_INFERIORITY.
Study: Comparative Efficacy and Safety Study of RGB-14-P and Prolia in Women With Postmenopausal Osteoporosis

Summary: This study will be conducted to assess the efficacy, pharmacodynamic (PD), safety, tolerability, and immunogenicity of RGB -14- P compared to US-licensed Prolia in participants with postmenopausal osteoporosis, in a comparative manner.

Detailed Description: This is a randomized, double-blind, multicentre, multiple fixed-dose, 2-arm parallel-group study that includes 2 periods as:

1. Main period (52 weeks), consists of Treatment Period 1 (26 weeks) and Treatment Period 2 (26 weeks). On Day 1 of Treatment Period 1, prior to dosing, participants will be randomized in a 1:1 ratio to receive either RGB-14-P or Prolia.
2. Transition Period: consists of Treatment Period 3 (26 weeks). On Day 1 of Treatment Period 3 (Week 52), a subset of participants who received Prolia during the Main Period will be re-randomized 1:1 to receive either a dose RGB-14-P or Prolia in a double-blinded manner. A subset of participants continuing in the Transition Period who received RGB-14-P during the Main Period will continue to receive a dose of RGB-14- P but will also follow the randomization procedure to maintain blinding.

All participants will receive the study drugs on 2 occasions (Weeks 0 and 26), on Day 1 of Treatment Periods 1 and 2. Participants continuing to the Transition Period will receive the study drugs on a third-occasion (Week 52), Day 1 of Treatment Period 3. One Treatment Period will take 6 months (26 weeks, 183 days).

Results: Outcome: %CfB in Lumbar Spine BMD. Time frame: Weeks 26 and 78. Description: %CfB in lumbar spine BMD was assessed.. Parameters: Estimated Difference = 0.03 (p = 0.929, CI -0.703-0.769). Non-inferiority type: OTHER. Outcome: %CfB in Total Hip BMD. Time frame: Weeks 26, 52 and 78. Description: %CfB in total hip BMD was assessed.. Parameters: Estimated difference = -0.31 (p = 0.199, CI -0.792-0.165); Estimated difference = -0.16 (p = 0.543, CI -0.68-0.358). Non-inferiority type: OTHER. Outcome: Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX). Time frame: Week 26. Description: The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.. Parameters: Geometric mean ratio = 1.01 (p = 0.494, CI 0.978-1.046). Non-inferiority type: OTHER. Outcome: Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD). Time frame: Week 52. Description: Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.. Parameters: Estimated Difference = 0.18 (p = NA, CI -0.465-0.826). Non-inferiority type: NON_INFERIORITY. Outcome: Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD). Time frame: Week 52. Description: Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.. Parameters: Estimated Difference = 0.55 (p = NA, CI -0.099-1.191). Non-inferiority type: SUPERIORITY.
Study: MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

Summary: As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

Detailed Description: The purpose of this research study is to:

1. Investigate how women randomly assigned to visit MyMenoPlan use the website (time spent on website, treatment and symptom page views, use of interactive tools, and use of the MyMenoPlan tool).
2. Compare the ratings of women randomly assigned to MyMenoPlan to those randomly assigned to other menopause websites for perceived quality of information, readability, self-efficacy, and credibility of these online menopause resources.

Results: Outcome: Credibility. Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Description: This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree) scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (credibility).

Items:

1. The information is credible.
2. The information is trustworthy.. Parameters: NA = NA (p = 0.45, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Perceived Quality of Information. Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Description: This 7-item, 5-point Likert scale (1- Strongly disagree to 5 - Strongly agree) is adapted from the Post-Study System Usability Questionnaire (PSSUQ) in Lewis (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (perceived quality of information).

Items:

1. Reading the information made me feel in more control of my perimenopause/menopause.
2. The information on the website(s) was helpful to me.
3. I found the information I was looking for.
4. The information answered my questions about perimenopause/menopause.
5. I liked the website (s).
6. I would have liked more in-depth information. (reverse-coded)
7. The website(s) were fairly comprehensive about perimenopause /menopause.. Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Readability. Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Description: This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree)scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (readability).

Items:

1. The information I read was clear.
2. The information I read was easy for me to understand.. Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Self-Efficacy for Managing Menopause Symptoms. Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Description: This is a newly developed Likert scale (1- Strongly disagree to 5 - Strongly agree) for assessing participants' beliefs in their own abilities in managing menopausal symptoms. The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (self-efficacy).

Items:

1. If I want to, I am certain I could figure out the treatments or coping strategies that would work best for me.
2. I feel I could treat or cope with my symptoms of perimenopause/menopause if I want to.. Parameters: NA = NA (p = 0.22, CI NA-NA). Non-inferiority type: SUPERIORITY.
Study: A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia [EU-sourced] in Postmenopausal Osteoporosis.

Summary: This was a randomized, double-blind, parallel, multicenter, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 versus Prolia in postmenopausal women with osteoporosis

Detailed Description: The study was planning to randomise approximately 528 postmenopausal women with osteoporosis aged 55 and 80 years old with a Bone Mineral Density (BMD) consistent with T-score of  -2.5 and  -4 at the lumbar spine or total hip as measured by DXA during the Screening Period. Screening evaluations were to be completed within 28 days prior to randomisation.

On Day 1, 528 eligible postmenopausal women with osteoporosis were to be randomised in a 2:1:1 ratio to receive MB09-MB09 (Arm 1), Prolia-MB09 (Arm 2), or Prolia-Prolia (Arm 3) using an Interactive Response Sys-tem (IRT).

During the Main Treatment Period, subjects received one subcutaneous injection (60 mg/mL) of study drug on Day 1 and at Month 6. At Month 12, after all efficacy and safety assessments have been performed, the subject were to be enter the Transition/Safety Follow Up Period and were to receive the third dose of study drug. Subjects assigned to the MB09 MB09 arm (Arm 1) received MB09 on Day 1, at Month 6 and at Month 12. Subjects assigned to the Prolia MB09 arm (Arm 2) received EU-Prolia on Day 1 and at Month 6, and MB09 at Month 12. Subjects assigned to the Prolia-Prolia arm (Arm 3) received EU-Prolia on Day 1, at Month 6, and at Month 12. All subjects were to be followed up to Transition Period Month 6.

All subjects received daily supplementation of calcium and vitamin D.

Results: Outcome: Efficacy: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52 - Full Analysis Set (FAS). Time frame: Baseline (screening), up to Week 52. Description: Difference in means (MB09-Prolia) in the %CfB in lumbar spine BMD after 12 months in postmenopausal women with osteoporosis treated with SC denosumab injections every 6 months. This included all subjects and data records irrespective of failed eligibility criteria, receipt of prohibited medications, discontinued treatment for any reason, had errors or deviations in dosing, or receipt of both doses. Estimation was via Multiple Imputation (MI) and ANCOVA on the FAS. Since the retrieved dropout rate was low, a treatment-failure (TF) penalty was applied to the imputed values at Month 12 for those subjects who received only one dose of the study treatment to centre the distribution of each subject's %CfB values around their baseline level. Bone density measurements were performed by DXA. All DXA scans were submitted to a central imaging vendor for analysis.. Parameters: Mean Difference (Final Values) = 0.03 (p = NA, CI -0.69-0.74). Non-inferiority type: EQUIVALENCE. Outcome: Efficacy: Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (LS-BMD) at 52 Weeks - Modified Full Analysis Set (mFAS). Time frame: Baseline (Screening), up to Week 52. Description: To demonstrate equivalent efficacy of MB09 to EU Prolia in postmenopausal women with osteoporosis in terms of lumbar spine BMD at Week 52 (Month 12). The main analysis method was on the mFAS using a mixed model for repeated measures (MMRM) fitted to the composite %CfB lumbar spine BMD at Month 6 and Month 12, without any imputation of missing data. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor.. Parameters: Mean Difference (Final Values) = 0.2 (p = NA, CI -0.51-0.91). Non-inferiority type: EQUIVALENCE. Outcome: Pharmacodynamics: %CfB Area Under the Percent Inhibition Curve From Time Zero to 6 Months (AUIC0-6 Months) in sCTX - on mFAS. Time frame: Baseline (pre-dose Day 1), up to Month 6.. Description: AUIC0-6 months = Area under the inhibition curve for % change from baseline sCTX concentrations from time zero to 6 months. Parameters: Ratio of Geometric means = 99.13 (p = NA, CI 96.31-102.02). Non-inferiority type: EQUIVALENCE. Outcome: Pharmacodynamics: Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (sCTX) Area Under the Effect Curve From Zero to 6 Months (AUEC0-6 Months) After First Dose - Modified Full Analysis Set (mFAS). Time frame: Baseline (pre-dose Day 1), up to Month 6.. Description: Geometric meant (geometric CV%) sCTX Area under the effect curve from zero to 6 months (AUEC0-6 months) after first dose in postmenopausal women with osteoporosis treated with SC denosumab injections every 6 months assuming all women received their first denosumab dose without any errors in dosing and without receipt of any prohibited therapies or other osteoporosis medications up to 6 months after first dose.. Parameters: Ratio of Geometric means = 99.91 (p = NA, CI 91.99-108.52). Non-inferiority type: EQUIVALENCE. Outcome: Pharmacokinetics: Maximum Observed Serum Concentration (Cmax) of Denosumab After First Dose Study Treatment (Pharmacokinetic Parameter Analysis Set). Time frame: Baseline (pre-dose Day 1), up to Month 6. Description: To assess the PK profile of MB09 compared with EU-Prolia following the first dose, maximum Observed Serum Concentration (Cmax) of Denosumab After First Dose study treatment (Pharmacokinetic Parameter Analysis Set).. Parameters: LS Geometric Mean Ratio = 104.13 (p = NA, CI 98.83-109.71). Non-inferiority type: EQUIVALENCE. Outcome: Pharmacokinetics: To Assess the PK Profile of MB09 Compared With EU Prolia (AUC0-6 Months) Following the First Dose. Time frame: Baseline (pre-dose Day 1), up to Month 6.. Description: Area under the concentration-time curve from time zero to 6 months analysed on the log scale by ANCOVA. The model will include treatment and stratification variables (baseline BMD T-score at the lumbar spine ( -3.0 and \> -3.0 SD), body mass index (\< 25 and  25 kg/m2), age at study entry ( 55 to \< 68 years versus  68 to  80 years) and prior bisphosphonate medication use at study entry (prior use of bisphosphonates versus no prior bisphosphonate use as fixed effects. The estimated mean difference with 95% CI will be back-transformed to give the ratio of geometric means (MB09/EU-Prolia) with 95% CI following the first dose in the Main Treatment Period.. Parameters: LS Geometric Mean Ratio = 106.06 (p = NA, CI 99.84-112.66). Non-inferiority type: EQUIVALENCE.
